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Summary / Abstract 
“Films” or “Oral films” in the US Pharmacopeia monograph are simply defined as single or 
multi-layer thin sheets with or without drug substance (DS) to be placed in oral cavity. In 
turn, the European Pharmacopeia adds it as innovative and new dosage form. The oral films 
are generally prepared by solvent-casting or extrusion, being designed for fast or delayed 
disintegration and may allow gastrointestinal or mucosal absorption. These differences can 
be achieved through the modification of the base formulation. This justifies the growing 
interest of many companies in the development of this dosage form in a perspective of a 
versatile drug delivery technology. There are also many advantages of this recent and 
convenient dosage form that also contributed for its rapid growth in the drug delivery 
market. Also, the clear success of several companies in the field roused the interest of 
exploring and developing our own conception and technological platform.  
An extensive revision of the literature was initially performed in order to gather information 
about this recent dosage form that allowed the further development of a new and versatile 
oral film technological platform. This information has been summarized and critically 
exposed in an extensive literature review divided in two different parts, which covers areas 
ranging from oral film development appearance to their growth and sustainability on the 
market.  
The output of this broad literature examination led to some considerations and orientations 
in the experimental part of the thesis. Marketed oral films were deeply analysed and 
characterized to develop experimental knowledge and suitable quality and process 
parameters. This work was based on specific statistical tools, as Design of Experiments 
platforms and Chemometrics analysis. Simultaneously, a wide polymeric screening was 
performed and 3 new technological platforms were developed, but only the most promising 
was fully optimized. Once more, this was based on particular tools and systematic 
approaches that allowed controlling and improving the quality of the product, as Quality by 
Design concept. This quality and regulatory trend associated with the novelty, particular 
processing and multicomponent composition unleashed the need of establishing 
development guidance. Therefore, a quality target product profile (QTPP) was delineated 
and critical quality attributes (CQAs) stablished to further identify appropriate critical 
process parameters (CPPs) to function as criterion in new oral film formulations 
development.  
2 
The majority of the fast disintegrating oral films for, commonly designated by orodispersible 
films (ODFs) are generally based on hydrophilic polymers. This characteristic is usually 
associated with lower stability, undesirable texture and appearance, especially when 
exposed to ordinary environment conditions. Considering this aspect and the intellectual 
property landscape, more stable and robust oral films, were explored, screened and 
developed. Consequently, oral films based on hydrophobic polymers with a fast 
disintegration were obtained, which led to a patent application grounded by the polymer 
nature differentiation, novelty and outcoming advantages.  
Finally, two different DS (Pramipexole and ND drug) were incorporated in the developed and 
optimized ODF, and a small scale-up was performed. Almost 90% of individuals with 
Parkinson Disease (PD) and more than 33% of Neurodegenerative Disease (ND) patients may 
develop or already suffer from dysphagia. Pramipexole ODF and ND drug ODF with 
hydrophobic polymeric matrices, including PVAc, polyvinyl alcohol, triethyl citrate and 
sodium carboximethylcellulose were developed. The ND drug ODF development was further 
performed in a larger scale and following Good Manufacturing Practices (GMP) to obtain 
enough samples to delineate a suitable stability study and lately a bioavailability comparison 
between ND drug ODF / ND drug capsules (reference product). This approach would function 
as a proof-of-concept for later scale-up studies. Additionally, research and development 
challenges and the main issues of the slight scale transposition (manufacturing process and 
liquid mixture processability) were reported and analysed in a short revision, gathering 
experimental experience with focused literature examination.  
In this thesis, several ODFs were developed and characterized, but importantly some critical 
knowledge and innovation was generated. For instance, was shown that it is possible to 
develop ODFs based on hydrophobic polymers without compromising the fast 
disintegration, breaking an important paradigm in the ODF research field. It was also 
demonstrated that different characterization techniques and alternative methods of 
analysis may be very helpful in oral films’ development. Another important goal was the 
conceptual development of a Pramipexole ODF and a relatively stable ND drug ODF that 
materialize an unmet need of PD and ND therapy, mostly associated to swallowing issues of 
the drug dosage forms available in the market.  
  
3 
Key words 
Oral Films; Orodispersable films; Solvent casting; Quality by Design; Design of Experiments; 
Chemometrics; Hydrophobic polymers;   
 
  
4 
Resumo 
A forma farmacêutica Película (do inglês “Films”) é definida genericamente nas 
Farmacopeias como uma fina folha composta por uma ou várias camadas com ou sem 
fármaco, que se destina a ser colocado na cavidade oral. Estas películas são geralmente 
preparadas por técnicas como solvent-casting ou extrusão, podendo ser preparadas com o 
objetivo de apresentarem desintegração rápida ou lenta e / ou permitirem uma absorção 
gastrointestinal ou através mucosa oral do fármaco. Estas diferenças podem ser alcançadas 
por uma simples modificação da composição da formulação base. Esta versatilidade 
associada a outras vantagens conhecidas como a portabilidade e facilidade de administração 
justificam o elevado interesse de muitas empresas no desenvolvimento desta forma 
farmacêutica. Foram estes os motivos que conduziram ao interesse em explorar o 
conhecimento em torno das películas orodispersíveis. 
Inicialmente, foi efetuada uma revisão bibliográfica aprofundada de forma a reunir 
informação que permitisse o desenvolvimento de uma Película nova e inovadora. Esta 
informação foi sumariada e criticamente discutida num artigo de revisão dividido em duas 
partes, descortinando-se desde o seu desenvolvimento primordial até ao seu crescimento e 
sustentabilidade de mercado. 
Esta extensa avaliação conduziu e confluiu para importantes orientações do trabalho 
experimental. Películas disponíveis comercialmente foram analisadas e caracterizadas para 
desenvolver conhecimento experimental e parâmetros adequados de processo e qualidade 
do produto. Este trabalho teve como base ferramentas estatísticas específicas como 
Desenho de Experiências e Quimiometria. Paralelamente, foi efetuada uma triagem a 
inúmeros polímeros e 3 novas películas foram desenvolvidas. Mas apenas uma, a que 
apresentou resultados mais promissores, foi optimizada. Esta optimização foi efetuada com 
base em instrumentos e abordagens sistemáticas que permitissem o controlo e 
melhoramento da qualidade do produto, como o conceito Quality by Design). Esta tendência 
regulamentar e de qualidade associada à novidade, processo de fabrico peculiar e 
composição complexa, desencadeou a necessidade de estabelecer linhas de orientação ou 
directrizes para o seu desenvolvimento. Assim, o perfil de qualidade do produto alvo foi 
delineado e os atributos críticos de qualidade estabelecidos para poder definir os 
parâmetros críticos de processo e servirem como critério de qualidade e aceitação no 
desenvolvimento de novas películas. 
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A maioria das películas com rápida desintegração, normalmente designadas por películas 
orodispersíveis (do inglês “Orodispersible Films”) são constituídas por polímeros hidrofílicos. 
Esta característica costuma estar associada a baixa estabilidade e originar texturas e 
aparências pouco apelativas e indesejáveis, especialmente quando expostos às condições 
ambientais. Assim, e considerando o panorama de propriedade intelectual existente na 
área, películas mais estáveis e robustas foram selecionadas e preparadas. 
Consequentemente, películas orodispersíveis compostas por polímeros hidrofóbicos foram 
desenvolvidas, contribuindo para uma aplicação de patente, baseada na novidade dos 
polímeros utilizados e como solução alternativa para colmatar necessidades tecnológicas e 
terapêuticas. 
Finalmente, 2 fármacos diferentes foram incorporados na película orosdispersível 
desenvolvida e optimizada, e uma pequena transposição de escala foi também efetuada. 
Aproximadamente 90% de Doentes de Parkinson (DP) e cerca de 33% de doentes com 
Doença Neurodegenerativa (DN) apresentam ou irão desenvolver disfagia (problemas de 
deglutição). As películas orodispersíveis desenvolvidas, uma com Pramipexole (tratamento 
na DP) e outra com fármaco para tratamento de DN, são constituídas por uma matriz 
hidrofóbica, incluindo acetato de polivinilo, alcóol polivinilico, trietilcitrato e 
caraboximetilcelulose sódica. A película orodispersível para tratamento de DN foi ainda 
preparada numa escala ligeiramente superior de acordo com as Boas Práticas de Fabrico, de 
forma a obter amostras suficientes para delinear um estudo de estabilidade adequado e 
posteriormente efectuar um estudo de biodisponibilidade comparativa entre películas 
orodispersíveis e as cápsulas de fármaco para DN disponíveis no mercado (produto de 
referência). Esta abordagem servirá essencialmente como prova de conceito para testes 
posteriores de transposição de escala para um nível comercial. Em termo de conclusão, foi 
ainda elaborada uma pequena revisão que foca os desafios técnicos encontrados durante o 
processo de investigação e desenvolvimento e transposição de escala; a qual reúne 
informação da experiência prática, suportada com consulta bibliográfica, sugerindo 
igualmente possíveis alternativas e soluções para os problemas apontados. 
Esta tese inclui o desenvolvimento e caracterização de inúmeras películas orodispersíveis, 
mas permitiu também gerar conhecimento relevante e inovação. Foi demonstrado que é 
possível desenvolver películas orodispersíveis constituídas essencialmente por uma matriz 
hidrofóbica sem comprometer a sua rápida desintegração, destronando um forte paradigma 
desta área de investigação. Foram ainda elucidadas e sugeridas diferentes técnicas de 
caracterização e métodos de análise alternativos que podem ser úteis no desenvolvimento 
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desta forma farmacêutica. Para além disso, foram ainda desenvolvidas películas 
orodispersíveis de Pramipexole e películas orodispersíveis para tratamento de DN que 
poderão vir a colmatar as necessidades dos doentes com DP e DN, maioritariamente 
associadas a problemas de deglutição das formas farmacêuticas atualmente disponíveis. 
 
Palavras Chave 
Películas; Películas orodispersíveis; Solvent casting; Quality by Design; Desenho de 
Experiências; Quimiometria; Polímeros Hidrofóbicos;  
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Aims of the thesis and motivation 
Drug delivery (DD) is a fast growing and highly dynamic segment in the pharmaceutical and 
biotechnology industry. Pharmaceutical companies are continuously pursuing innovative 
dosage forms due to the fact that DD technologies are a strategic tool for expanding markets 
and indications, contributing for extending product life-cycles, generating newer market 
opportunities and increase the competitive edge and product differentiation. Formulation 
development is important not only for new chemical entities but also for the improvement 
of the DD of existing drugs, aiming to improve pharmacoeconomics of drugs (e.g. reducing 
adverse effects, improving therapy, safety, efficacy, convenience and compliance). 
Additionally, the oral route administration remains the most preferred by the general 
population, representing the larger market slice. Therefore, the main goal of this project was 
the development of a novel and versatile oral fast-dissolving system; namely an oral film 
drug delivery system designed to dissolve in the mouth within a few seconds after 
administration. In addition, this development would generate valuable intellectual property 
to be patentable and allow grant of marketing exclusivity.  
The specific aims of the project were: 
 To select the most appropriate excipients / ingredients for formulating orodispersible 
films (ODFs) with the following properties: fast disintegration, high stability, 
transportability, ease of handling and administration, no water necessary for 
administration, accuracy of dosage and a pleasant taste. 
 To develop a basic understanding of the interplay between the ODFs’ components 
and processing conditions on the final product performance (critical quality 
attributes, CQAs): physical and mechanical properties, content uniformity, stability, 
disintegration and dissolution. 
 To develop and implement effective and efficient manufacturing technology, with 
special concern to critical process parameters (CPPs). 
 To assure consistency of the manufacturing processes through the: identification and 
quantification of critical process parameters; characterization of variability; 
definition of design space; understanding and control over the formulation and 
manufacturing variables. 
 Develop in-house expertise and process know-how of a novel drug delivery 
technology. 
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The importance of innovation and new products conception has been increasing in recent 
years, and the need to generate new technologies is the main core for the business growth. 
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Outline of the thesis  
The present thesis is based on four main parts:  
 Introduction to the Oral Films concept – Chapter I 
 Oral Films Characterization and Critical Quality attributes outline - Chapter II 
 Hydrophobic polymers for oral films: Development and Optimization of novel 
formulations– Chapter III 
 Product formulation overview and development of an Orodispersible Film (ODF) with 
a Neurodegenerative Disorder drug – Chapter IV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - Overview: outline of thesis. 
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Oral films are basically a complex polymeric matrix, usually in a stamp shape, which may be 
used efficiently as drug release platforms. Oral films are relatively recent dosage forms, 
especially in the pharmaceutical market, in which the first Rx product was only introduced 
in 2010. Although the recent inclusion of this dosage form in the European Pharmacopeia 
some research work has been done in the field during the last years.  
Chapter I was dedicated to an exhaustive literature revision with an overall examination of 
the main points of oral film development through their growth and sustainability on the 
market. This chapter is divided in two different parts: Chapter I.1 and I.2. The first part is 
dedicated to the galenical development and quality attributes of the oral films (Chapter I.1), 
while the second part is focused on the main technological platforms developed, intellectual 
property and market outlook (Chapter I.2).  
In Chapter I.1 we may find important information to start the development of a new oral 
film technological platform. Briefly, oral films are composed by complex polymeric matrices 
with several components but, generally based on hydrophilic polymers. Both natural (e.g. 
modified celluloses, modified starches) and synthetic polymers (e.g. polyvinyl alcohol, 
polyvinylpyrrolidone) are used; and their inherent characteristics (e.g. molecular weight 
(Mw), degree of substituents), proportions and processing particularities are optimized in 
order to achieve the desired final product properties. So, a basic understanding of polymers 
chemistry properties and type are critical for a successful formulation development and 
quality control. Additional excipients may be added in an attempt to design a suitable 
product, fitting the quality target product profile (QTTP) that may depend on the drug 
substance and therapeutic indication. These substances include plasticizers, sweeteners, 
flavours, colourants, stabilizers, fillers, saliva stimulating agents, buffer systems and others. 
Although there are several works dedicated to the subject, much work still needs to be done 
related with the definition of suitable methods for the oral films characterization, quality 
control and oral films specifications. Therefore, this substantial lack of guidance had lead 
during the past few years to intensive and somehow scattered work and methods 
development, always in attempt to hamper the flaw. The two main techniques used to 
prepare oral films are solvent casting and hot melt extrusion, but in the past few years some 
developments and innovative techniques emerged, such as casting and extrusion variants 
and more inventive methods, such as rolling and printing techniques. Chapter I.1 also 
discriminates oral films evaluation and characterization procedures developed along the 
years. These may include techniques appropriated for formulation research and 
development, such as morphological characterization (scanning electron microscopy, near-
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infrared chemical imaging) as well as product performance techniques (tensile strength, 
based on DIN EN ISO 527 or puncture tests; disintegration by thermomechanical analysis, 
contact angle measurement, petri-dish method; and dissolution profile, through fiber-optic 
sensor, USP apparatus V, or common and adapted dissolution apparatus). 
Chapter I.2 is more centered in the marketing outlook and future prospective. The 
continuous growing number of patent applications highlights the high competitiveness and 
fast-evolution of oral films development. More than 132 patent families have been identified 
and at least 30 companies/institutions are developing these technological platforms. The 
main players in this field are MonoSol Rx, Kyukyu Pharmaceuticals Co.LTD, LTS Lohmann 
Therapy-Systems AG, Labtec Pharma SA and Hexal AG. Composition patents are the larger 
slice in the overall patents filled, claiming the technology composition but essentially the 
film-forming polymer(s), crucial for the matrix formation. The most patented polymers are 
polysaccharides, including starch, cellulose and its derivatives. Process patents have also 
some relevance, but only a few are restricted to a specific drug, therapy or method of use. 
Generally, the referred top player companies follow a similar business pattern: an innovative 
and versatile technological platform is developed (e.g. oral film placebo) and several drug 
candidates are evaluated and considered to be incorporated in oral film. Additionally, 
partnerships establishment between oral film developers/manufacturers and other 
pharmaceutical companies researching new chemical entities, developing novel uses for 
existing drugs (repurposing) or companies looking for innovative formulations for their drugs 
(life-cycle management) is common. The most prominent oral film technological platforms 
are the Monosol Pharmfilm®, with nine products on the market, Labtec / APR Rapidfilm®, 
with four marketed oral films, and KyuKyu Rapid Dissolving Film technology, with at least six 
available films. 
In order to gain some practical experience to be able to develop new and inventive oral films’ 
formulations, marketed oral films were fully analysed and characterized and these results 
are included in Chapter II. Therefore, a basic understanding of the interplay between the 
main components of the formulation, possible interactions between them and their effect 
in oral films properties, was achieved through the study of two marketed films (Chapter II.1 
and II.2). This selection was based on their composition, the Listerine Pocket Packs™ 
composed by Pullulan, described as the most suitable film-forming polymer for oral films 
technology, and GAS-X ThinStrips®, composed by more than 50% (%w/w) of drug substance 
(Simethicone). These oral films were evaluated regarding their residual water content (Rwc), 
disintegration time (Dt), chemical, thermal and mechanical properties. Reconstituted 
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formulations of both were also prepared based on Design of Experiments (DoE) software. 
The data was analysed using statistical DoE specific platforms and other multivariate 
analyses based on Chemometrics fundamentals (Principal component analysis (PCA) and 
Partial Least Squares regression (PLS)). This type of analysis was very useful to establish a 
rational understanding that would be harder to find using other common approaches. The 
PCA allowed a graphical plot differentiation between FTIR spectra differences: all the 
reconstituted formulations are very different from each other and particularly dissimilar 
from the commercial formulation. In turn, by PLS analysis the effect of each excipient in the 
final polymer matrix was highlighted: pullulan, the sweeteners, propylene glycol and 
menthol have a high influence in the mechanical and thermal properties, whereas the 
cellulose Mw affects mainly the Rwc and Dt, and simethicone may greatly affect the oral 
films thermal properties (Chapter II.1).  
An extensive thermo-mechanical characterization of GAS-X® and Listerine® marketed films 
and in-house prepared formulations were performed by TGA, DSC and DMTA. Briefly, GAS-
X® films are thermally more stable than Listerine®, evidenced in TGA profiles, whereas DSC 
and DMTA analyses add complementary information about polymer chains nature and their 
influence on oral films performance. There is a high impact of the composition on the 
thermal properties of the oral films, underlining the importance of thermal techniques in 
the development of this innovative oral dosage. In fact, it was verified and showed that a 
deep understanding of the mechanical and thermal properties of oral films is very important 
to develop fundamental knowledge that may be critical to better formulate these polymeric 
matrices platforms (Chapter II.2).  
Allied to these techniques, the statistical tools employed in this study enabled the 
development of extensive knowledge about the system and the identification of the 
influence of each excipient in the final product properties as well as the identification of the 
major interactions in the polymeric matrix. These tools and concepts were recently 
introduced in the pharmaceutical field by the quality by design (QbD) approach. This is a 
systematic approach that allows building and improving the quality of the product. It is 
supported by simple quality concepts as the QTPP that describes the desired product 
performance by stablishing critical quality attributes (CQAs) and identifying critical process 
parameters (CPPs). Therefore, another approach was to reach essential information about a 
clear definition of oral films CQAs, through the analysis of several suitable marketed films. 
Despite oral films’ complexity it was possible to outline suitable acceptance criteria for the 
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identified CQAs that can work as a reference in the development of new oral film 
formulations (Chapter II.3). 
Chapter III is focused in the preparation of a novel and versatile oral films technological 
platform. Generally, available oral films are in their majority based on hydrophilic polymers. 
Additionally these are commonly design for fast oral disintegration, receiving the common 
designation of orodispersible films (ODFs). However, the ODF hydrophilic nature is 
frequently related with lower stability, undesirable texture (sticky) and appearance, 
particularly after exposed to ordinary environments. Therefore in an attempt to circumvent 
this limitation and considering the intellectual property survey, innovative ODFs were 
studied and developed. Subsequently, ODFs with a hydrophobic core but with fast 
disintegration were prepared: polyvinyl acetate (PVAc), methacrylate copolymer and shellac 
based films (Chapter III.1). The QbD approach was applied to screen the three different 
formulations based on the previous CQAs established and selection of appropriate CPPs 
(percentage of the different excipients and plasticizer type). This study lead to a patent 
application entitled “Orodispersible films”. Briefly, three different formulations generically 
composed by a hydrophobic polymer (PVAc, methacrylate copolymer and shellac), a 
stabilizer (polyvinylalcohol (PVA) or hydroxypropylcellulose (HPMC)), a disintegrant 
(carboxymethylcellulose sodium (NaCMC)) and a plasticizer were developed. These 
formulations (hydrophobic film-forming polymer) allowed obtaining ODFs with suitable 
mechanical properties and higher resistance to moisture conditions without compromising 
the rapid disintegration time. Additionally, with this study it was also found that the same 
component may behave differently depending on the system: NaCMC and PVA affect 
differently the mechanical properties of different matrices (Chapter III.1).  
The second approach of the formulation development was to prepare an optimized ODF, 
with suitable performance and capable of incorporating a DS (Chapter III.2). The PVAc 
formulation demonstrated during the preliminary tests more promising results: easiness to 
manufacture and best product performance. Therefore, this formulation was selected to 
further optimization based on a QbD approach. In summary, three different screening / 
optimization studies were completed: evaluation of the plasticizer type influence, 
optimization study to obtain a pleasant and moisture resistant polymeric matrix and 
determination of the capability to incorporate a drug substance (Pramipexole). The 
formulations were characterized regarding their mechanical properties, residual water 
content, disintegration time, contact angle, organoleptic and appearance characteristics in 
attempt to find a suitable ODF that meets the CQAs defined, varying the same CPPs of the 
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formulation screening (percentage of the different excipients and plasticizer type). It was 
possible to find a binary taste-masking system, based on a flavour and a sweetener, which 
allowed obtaining pleasant ODFs. Additionally, it was shown that the incorporation of a drug 
substance as well as the plasticization effect may be critical for the overall performance and 
stability of the ODF, and depends on their structure and concentration. An ODF with suitable 
characteristics, very fast oral disintegration, easy to handle and manufacture, pleasant taste 
and appearance and likely to become appropriate for drug delivery, was developed (Chapter 
III.2).  
The previous work gave important evidences on the viability of the new technological 
platform. Afterwards, this was used to incorporate other drug substances directed to 
therapies with an urgent need of easy to swallow formulations (Chapter IV).  
Neurodegenerative Disorder (ND) is a degenerative neurologic disorder, in which more than 
33% of the patients have chewing or swallowing problems, and some may also develop 
permanent dysphagia. Currently, there is no cure for this ND only disease-modifying 
treatments. The first-line disease modifying drugs include interferons, glatiramer acetate 
and a ND drug as the first oral treatment alternative. ND drug is an oral sphingosine 
phosphate receptor modulator marketed in the form of a capsule, which may became a 
problem in an advanced disease course. Hence, a ND drug ODF may become an alternative 
to the conventional dosage form available and improve patients’ compliance. ND drug ODF 
with a hydrophobic polymeric matrix, including PVAc, PVA, triethyl citrate and NaCMC was 
prepared. Exhaustive preliminary tests were performed in an attempt to stabilize the ND 
drug in the polymeric structure due to its high reactivity and instability. The process to 
prepare the ODFs was found to deeply influence the DS stability and a structured and 
organized procedure needed to be followed. A suitable ODF for fast oral disintegration was 
developed and is likely to become an appropriate and convenient option for oral ND therapy, 
avoiding the swallowing issues associated with the disease (Chapter IV.1).  
Finally, the second part of Chapter IV, reports the main problems found in the slight scale-
up used to prepare sufficient samples for suitable stability study and a proof of concept 
clinical trial. This small scale transposition was performed according to the Good 
Manufacturing Practices (GMP). Critical issues involving solvent casting (manufacturing 
process) and liquid mixture processability transposition were identified and surpassed 
during the process. These challenges were reported and analysed in a short revision that 
gathered the practical and experimental experience developed with a focus on literature 
examination (Chapter IV.2). From the industry perspective, the concern of having research 
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and development equipment similar to the industrial production facilitates the scale 
transposition. Furthermore, QbD also arises as a conception that favoured the scale-up 
process by the overall system knowledge. A better understanding and advances in quality, 
scale up issues, and regulations is important to design and direct efforts for new products 
development. Firstly, it is important to define the compositional and process variables, the 
CPPs, which may influence and interfere with the process and product attributes, the CQAs. 
It is also important to have defined assays that may allow us to evaluate these parameters, 
namely in vitro tests. These are the main factors that if correctly applied proved to lead to 
an efficient and successful oral films scale transposition. 
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Chapter I 
Introduction to the Oral Films concept 
 
This chapter is an overview of the state of the art with regard to Oral Films. This literature 
review points out the different types of Oral Films, describes and explores the oral film 
technology from its main component to the new and possible market applications, 
highlighting all the critical and important points of its development. This revision intends to 
highlight the current status in the Oral films field but simultaneously reveal the main flaws 
and indicating some suggestions and possible future prospections. 
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Oral films: Current status and future perspectives  
I — Galenical development and quality attributes 
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1. Introduction 
A thin film that readily dissolves in the oral cavity is commonly referred as orodispersible 
film by the European Medicines Agency (EMA) (Hoffmann et al., 2011) or simply soluble film 
by the FDA (Food and Drug Administration, 2013). Although, oral films initially appeared as 
innovative breath freshening formulations, it rapidly evolved to give response to different 
market needs, namely an easy-to-carry and easy-to-swallow drug delivery system.  
The oral films are essentially complex polymeric matrices that may be used efficiently as 
drug release platforms. These polymeric matrices may be composed by several components 
in order to achieve well-designed drug-delivery platforms, but usually hydrophilic polymers 
are its main core. The polymers early entered into the pharmaceutical and biomedical 
industries as essential components of the formulations and their range of applicability easily 
spread to several areas, from packaging material to the most sophisticated drug delivery 
systems and devices. The basic understanding of the role of polymers as excipients, meaning 
as ingredients in drug products, is critical for formulation development and quality control. 
Additionally, the knowledge of polymers’ basic concepts, as chemistry, properties and types 
may be critical to develop new or improve conventional drug delivery systems.  
Both natural and synthetic polymers can be used in orodispersible dosage forms. The oral 
films are basically a polymeric matrix which may vary on its composition in order to achieve 
the desired final product properties. There are several characteristics, such as 
mucoadhesiveness, disintegration time, % of drug load, mechanical / handling properties 
(among others) which may be fine-tuned by adjusting the type, amount or grade of the 
polymers. Additionally, other components may be added in order design the final product 
according to the target product profile, depending on the drug substance and therapeutic 
indication. Some of these substances include plasticizers, sweeteners, flavours, colourants, 
stabilizers, fillers, saliva stimulating agents, buffer systems and others.  
Oral films emerged as a very promising and prominent pharmaceutical dosage form in a field 
subdued to tablets and capsules. The state of the art was also diffused and restrained about 
the matter until Dixit et al. in 2009 pledge us with a comprehensive overview of the subject, 
which may probably functioned as a catalyst for several research works. Currently, several 
original works and patents can be found in literature, but considerable efforts still need to 
be carried out to optimize the performance of the films (Cilurzo et al., 2008; Dinge and 
Nagarsenker, 2008; Zerbe et al., 2003). Regarding the pharmaceutical field, there is still a 
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considerable lack of guidance for the manufacture, characterization and quality control of 
the oral films.  
This review highlights the essential points of oral films development from their appearance 
through their market growth and formulation key points. To facilitate the readers 
understanding, the review is divided in two distinct parts. The first part is focused in the 
galenical development and quality attributes of the oral films whereas the second part 
covers technological platforms, Intellectual Property protection and a market outlook.  
 
2. Miscellaneous terms 
Thin-film, oral film, wafer, oral strip, orodispersible film, oral thin film, oral soluble film, 
dissofilms, buccal soluble film, mucoadhesive film, buccal film, transmucosal film, are some 
of the innumerous terms that can be found in literature. Although, the terms seem to be 
easily differentiated, their meaning can sometimes be misinterpreted and misunderstood. 
The oral films were recently introduced in the “Oromucosal Preparations” monograph of the 
European Pharmacopeia (Ph. Eur. 7.4) with the subchapter “Orodispersible films” whereas 
the mucoadhesive buccal films are included in the “Mucoadhesive preparations” (Hoffmann 
et al., 2011). These terms and designations should be carefully read and interpreted to avoid 
possible misinterpretations.  
Orodispersible films should not be confused with buccal films, which should not also be 
narrowed to the mucoadhesive films designation. 
 
3. Orodispersible films 
Non-adhesive fast dissolving films are normally composed by low molecular weight (Mw) 
(approx. between 1.000 to 9.000 Da) hydrophilic polymers. The majority of the 
orodispersible films are not necessarily designed to be mucoadhesive, but they may exhibit 
some degree of mucoadhesiveness, due to the inherent characteristics of the polymers used. 
This mucoadhesion may also vary depending on the chemical properties and Mw of the film-
forming polymer used, as discussed later in this review. However, the Mw of the most 
common polymers used for this formulation type is usually below 200,000 Da (Myers and 
Dadey, 2014). Additionally, these films are intended to exhibit a fast disintegration in the 
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oral cavity, be swallowed and absorbed to the systemic circulation in the gastro-intestinal 
tract. Actually, this is somehow explicit in both official definitions: “single- or multilayer 
sheets of suitable materials, to be placed in the mouth where they disperse rapidly” (Ph. Eur. 
7.4, “Orodispersible films”) and a “thin layer or coating which is susceptible to being 
dissolved when in contact with a liquid” (FDA, dosage form) (Food and Drug Administration, 
2013; Hoffmann et al., 2011). Clearly, the high exposition of the drug substance in the oral 
cavity may influence its absorption through the oral mucosa, but certainly this fact is not the 
main purpose of the fast dissolving oral films. Indeed, this aspect may lead to another 
controversial issue, the urgent need of new regulations for oral films, aiming to establish 
adequately the product differentiation and to eliminate the idea that oral films compete 
directly with the generics. Additionally, according with the previous, being develop as a 
generic would not be an easy task due to the interference in the Bioavailability and 
Bioequivalence Studies (BDBE) related with a possible super-bioavailability and 
consequently, the failure of these tests. In this case the higher bioavailability may be related 
with the fast availability of the drug and consequently some oral adsorption. However, if the 
reference product is already an orodispersible formulation, as the orodispersible tablets, this 
issue is easily surpassed, being the recent marketed generic oral films good examples. 
 
4. Buccal films 
The buccal films are intended to deliver drug substances through the oral mucosa. This goal 
might be more complex than it seems, since a higher residence time in mouth is far from 
being the only determining factor. The oral mucosa drug saturation should also be 
considered, and the one-way absorption should be kept in mind to avoid minimize inter and 
intra –individual variability. Consequently, multilayer films also appear as a new designation 
for the buccal films. The advantages of this drug delivery system are very significant. The oral 
cavity presents many advantages to drug delivery beyond its good acceptably by the 
patients. The oral mucosa, generally divided in sublingual, gingival, buccal and soft palatal 
mucosa, is relatively permeable allowing systemic transmucosal drug delivery (Figure 2). For 
instance drugs that can be rapidly absorbed via buccal delivery do not pass the 
gastrointestinal tract, which may subject the drug to degradation from stomach acid, bile 
and other first pass metabolism. As a result, these thin films have the potential to fasten the 
drug onset of action, to lower the drug strength and enhance the efficacy and safety profile 
of some drugs. Curiously, the European and USA definition is more consensual regarding 
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these pharmaceutical dosage form - buccal films. In the European Pharmacopeia they are 
included in the mucoadhesive preparations, referred as buccal films and defined as “single-
or multilayer sheets that adhere to the buccal mucosa and may dissolve” (Figure 3). FDA 
does not have so clear definition or designation for these films, but buccal soluble film or 
buccal film, may be acceptable designations if Onsolis® submission is taken as an example. 
 
 
Figure 2 - Different local application sites of the oral films. Depending on the type of film the site of 
application may vary. 
 
Finally, it is important to consider that additional designations may be used to specify and 
differentiate the oral film platform technology developed by each company. For example 
there are also references of some double- or multi- layer orodispersible films and sublingual 
orodispersible films (Breitenbach et al., 2014; Myers and Dadey, 2014). 
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Figure 3 - Simplified scheme with the different terminologies. 
 
5. Why oral films? Particular features for patients 
and companies 
The design of an oral formulation is generally based on two critical factors, drug therapy and 
the target population. However, the choice of the type of pharmaceutical dosage form may 
become very difficult when specific target groups include very young children, from birth to 
8 - 10 years of age, and geriatric population. Regarding the paediatric segment the major 
challenge involves the development of a specific type of dosage form suitable for children 
of all ages. Additionally, for both population groups the size of the dosage form can also be 
a challenge, essentially due to swallowing issues. The swallowing process involves 
synchronized actions of several nerves and muscles. It is assumed that a safe swallowing is 
an ability developed since the 12 years-old (Stegemann et al., 2012; Zajicek et al., 2013). 
Generally, the swallowing function underlay an aging process, then, some malfunctions may 
be age-related, normally called as presbyphagia, but also may be due to pathological 
conditions, usually referred as dysphagia (Stegemann et al., 2012). These conditions are 
directly related with patients’ drug therapy adherence which had led to the huge concern in 
the development of patient-centered formulations. Therefore, liquid or orally disintegrating 
dosage forms have been the most preferred and exploited for these population segments. 
Hence, the oral films appeared as a suitable alternative to patients with swallowing 
difficulties and also as a more suitable and convenient dosage form when compared to the 
conventional oral dosage forms.  
ORAL FILMS 
Mucoadhesive 
Oral absorption 
Fast onset action 
ORAL-MUCOSA FILMS 
Sublingual Buccal Palatal 
GI absortion  
ORODISPERSIBLE 
FILM 
Mw polymer > 
9kDa 
Non-
mucoadhesive  
ORODISPERSIBLE 
FILMS 
Mw polymer 1 
to 9 kDa 
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5.1. Advantages for patients 
In fact, orodispersible films promote patient compliance due to its appellative form and 
inherent ease administration (Dixit and Puthli, 2009). These overall characteristics are 
especially important for young and elderly patients when proper and complete dosing can 
be difficult. Additionally, the drug delivery for these groups sometimes needs to be 
individualized / patient-tailored and may require special delivery devices. Nevertheless, this 
dosage form can also be beneficial for drugs with small therapeutic windows and for those 
that need precise dose adaptation in phases of initial dose monitoring; allowing the 
development of tailored therapeutic drug targets that otherwise may not be possible in 
conventional formulations. Furthermore, the oral films can be useful for bedridden and non-
cooperative patients since they are easily administrated and hardly spited out.  
 
5.2. Advantages over other oral dosage forms 
There are also other advantages of the oral films when compared with conventional oral 
delivery forms. The orodispersible films are a fast dissolving dosage form more stable and 
resistant in comparison to some orodispersible tablets (ODTs), which are fragile and brittle. 
Oral films tend to be flexible and portable, whereas ODTs demand special package for 
transportation. On the other hand, liquid dosage forms are considered very flexible and an 
alternative to overcome swallowing issues but they are usually associated to some 
limitations. Generally, liquids should be accurately measured by the care-giver and carefully 
shaken before administration. The amount of volume is also an important consideration 
since small amounts may lead to inaccurate measures whereas large amounts may 
contribute to diminish the adherence of the patients. On contrary, oral films enable 
improved dosing accuracy once every strip is manufactured to contain a precise amount of 
the drug. Additionally, depending on the package device is also possible to achieve high dose 
flexibility, as an electronic tape dispenser can be used that allows to dispense individual 
strips with adjustable doses simply by controlling an electronic system with a display 
(Wening and Breitkreutz, 2010). As previously referred, oral films are an easy portable 
dosage form in contrast to the large liquid bottles and measuring devices that are 
inconvenient to transport. Besides that, it is also important to consider the poor stability of 
the liquid formulations, especially the aqueous-based mixtures, that in opposition to the 
majority of the oral films formulations require the addition of several substance to extend 
their shelf-life (Hoffmann et al., 2011).  
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5.3. Market advantages 
From the market perspective new drug delivery technologies offer the opportunity to extend 
revenue life cycles for pharmaceutical companies whose drug patent is about to expire and 
will soon be vulnerable to generic competition. Moreover, the grant of marketing exclusivity 
to the new dosage form would help to enlarge the revenue. This type of formulation may 
also be designed to discourage common methods of tampering associated with misuse and 
abuse of some prescription drugs (IBISWorld, 2015). 
Considering oral films as novel dosage form for drugs already in the market, with a different 
pharmacokinetic profile, the approval process should be a New Drug Application (NDA) 
505(b)(2) for FDA approval, or an Abridged Application, Directive 2001/83/EC, for European 
Marketing Authorization approval. In this case, especially for the USA market clinical studies 
would be essential for the FDA granting three marketing exclusivity (3-5 years) (Barei et al., 
2013; Dixit and Puthli, 2009).  
 
5.4. Clinical advantages 
From the clinical point of view, some oral films may improve the oral bioavailability of drugs 
with extensive first pass metabolism, by promoting the absorption of the drug substance 
through the oral mucosa reducing the dose necessary to achieve the therapeutic action, 
which may contribute also to a reduction of the side effects (Dixit and Puthli, 2009). 
Nevertheless, this absorption route may also be advantageous in drug therapies where a fast 
onset action is essential. 
 
5.5. Major limitations 
The most common limitations of the oral films are related to their instability in environments 
with high relative humidity, and the small drug dose that can be incorporated, essentially 
due to its small size, low weight and thin form. However, some companies had managed to 
develop oral film technology platforms that can incorporate more than 50% of drug 
substance (DS) per film weight (GAS-X Strips ®). There are also some types of drugs that 
should not be selected to incorporate in this pharmaceutical form, such as drugs that are 
unstable at buccal pH and that may irritate the oral mucosa (Dixit and Puthli, 2009). 
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Another critical issue is taste-masking since the dosage form is in direct contact with the oral 
mucosa and may remain in the mouth for long periods of time.  
 
6. Polymers in oral films: the key component 
Orodispersible films are basically a polymeric matrix which may be composed by one or 
more polymers with different physicochemical and functional properties. There are several 
characteristics that may be controlled depending on the type or grade of polymers: 
mucoadhesiveness, disintegration time, drug loading capacity, mechanical strength, 
elasticity, handling properties and others.  
The selection of the polymer (or mixtures) for the development of oral film matrices is a 
critical step and may vary taking into account the desired target product profile. Hydrophilic 
polymers have been extensively studied and tested for this application. 
Table 1, presents a summary of the most widely used polymers in the oral films preparation. 
Some chemical critical aspects that should be taken in consideration during formulation are 
revised hereinafter. 
 
6.1. Celluloses 
Celluloses, namely cellulose derivatives are widely used. Among those, hydroxypropyl 
methylcellulose (HPMC) is one of the most used. HPMC is a partly O-methylated and O-(2-
hydroxypropylated) cellulose which is available in several grades that differ on their Mw and 
the amount of substituent groups on the anhydroglucose units (Rowe et al., 2009). The 
average number of methoxyl and hydroxypropyl groups attached to the ring, usually 
designated by degree of substitution (DS), influences greatly the oral film properties. There 
are some references that highlight how these structural and chemical differences may 
contribute to the final product properties, especially concerning the drug substance release 
and mechanical and thermal properties. Briefly, hydroxypropyl group, -OCH2CH(OH)CH3 is 
relatively hydrophilic group contributing to the rate of hydration, whereas the methoxyl 
group is more hydrophobic. Therefore, polymeric matrices with high hydroxypropoxyl / 
methoxyl ratio may easily establish a gel barrier (Dow, 2006) This characteristic in polymeric 
film matrices was found important in the dissolution profile and drug substance release. 
HPMC grades with higher hydroxypropoxyl / methoxyl ratio were found to delay the release 
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of the DS from the oral film matrix due to the formation of a thick matrix gel upon contact 
with the dissolution or biologic media (ElMeshad and El Hagrasy, 2011). Regarding the 
mechanical properties of the polymeric matrices it is described that methoxyl substitution 
degree along with the HPMC grade intrinsic viscosity has a remarkable influence. In general, 
HPMC grades with high viscosity and methoxyl content tend to produce more resistant, stiff 
and extensible polymeric matrices. High viscosity is possibly associated to higher branching 
and /or higher Mw related with physical entanglement due to longer chains. This 
phenomenon may increase the input strength required to disrupt the primary chain 
interactions (higher tensile strength). In turn, higher methoxyl substitution degrees may lead 
to an anchoring effect on HPMC chains provided by their larger dimensions compared to the 
original hydroxyl groups that may also contribute to high tensile strength. The Young’s 
modulus seems not to be significantly affected by methoxyl substitution degree. Concerning 
the thermal characteristics of the HPMC films, the polarity of the polymer chains conferred 
by the methoxyl content apparently affects the glass transition temperature (Tg). HPMC 
grades with lower amount of methoxyl groups present lower polarity that contributes to the 
reduction of the free space between the polymer chains. The increasing proximity of the 
polymeric chains will strengthen the secondary interactions between them, which increases 
the energy required for chain mobility (Otoni et al., 2014). 
Additionally, the rearrangement of the methoxyl groups during the film formation could also 
diminish the polymer inter- and intra-chain hydrogen interactions, thereby suppressing 
possible hydrophilic hydroxypropyl group actions, which may affect the final product 
characteristics (Gustafsson et al., 1999). 
There are several HPMC grades available and as discussed above their selection should not 
be random, but evaluated according to the desired product profile. Essentially, there are 2 
types of HPMC that are widely used in the oral films formulation, which according to Dow 
Chemicals grade classification are HPMC type K and E. The HPMC type K contains 22% 
methoxyl, or a methoxyl DS of 1.4, and 8.1% hydroxypropyl, or a hydroxypropyl DS of 0.21, 
whereas HPMC type E has 29% methoxyl, or a methoxyl DS of 1.9, and 8.9% hydroxypropyl, 
or a hydroxypropyl DS of 0.23 (Dow, 2002, 2006). The HPMC K is often used as polymeric 
matrix but mainly for controlled and / or delayed release of the drug substance (ElMeshad 
and El Hagrasy, 2011; Kumria et al., 2013; Repka et al., 2005; Wen and Park, 2011), whereas 
HPMC type E is amply described in literature as film-forming polymer. The E3, E5 and E15 
are referred, tested and used intensively, essentially due to their low viscosity and optimal 
Tg for suitable oral film matrices, 160⁰C, 170⁰C and 175⁰C, respectively. The major difference 
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between these grades are the polymer chain length, which together with the increasing 
number of their designation is associated with the increase in the HPMC’s Mw (e.g. Mw 
HPMC E3 < Mw HPMC E5< Mw HPMC E15< Mw HPMC 50). It is reported that low 
concentration’s solutions of E3 and E5 may lead to thin, brittle and non-peelable films. These 
properties can be ameliorated with the increase of these polymers’ concentration, but the 
films are still referred as tacky (Mahesh A, 2010). Therefore, combinations of the different 
grades are preferred, especially mixtures with higher HPMCs’ Mw (Schobel and Vangala, 
2010). Mixtures with other polymers are also described. HPMC E15 is found to have suitable 
film former properties when mixed with synthetic polymers, as polyvinyl alcohol (PVA) and 
polyvinylpyrrolidone (PVP). Also, good film former properties can be achieved when HPMC 
is blended with microcrystalline cellulose and plasticizers, such as PEG 400 and glycerol 
(Kulkarni AS, 2010). HPMC was also blended with a cationic copolymer based on 
dimethylaminoethyl methacrylate, butyl methacrylate and methyl methacrylate (Eudragit® 
E PO), contributing to the formation of films with better clarity and flexibility (Sharma R, 
2007). On the other hand, HPMC - Maltodextrin blends, with higher Maltodextrins’ 
concentration, allowed to obtain thin, fast-disintegrating, sweeter and tastier films (Kunte 
and Tandale, 2010).  
It is demonstrated that HPMC origins films with optimal properties depending on its 
concentration and different blends. This fact is probably the reason why different authors 
are not consensual regarding the most suitable HPMC to obtain thin films with optimal 
characteristics. Additionally, it was shown that the drug substance may also have an 
important impact in the final film properties; some found that HPMC E3 was the most 
suitable grade to the manufacture cetirizine films (Mishra R), whereas others preferred the 
E5 to prepare triclosan films (Dinge and Nagarsenker, 2008). It is also described that the 
mechanical properties of the polymeric matrices are greatly affected by the different grades, 
and generally, the maximum puncture strength increase with Mw, E3 < E5 < E15 < E50 
(Dahiya et al., 2009).  
Hydroxypropyl Cellulose (HPC) is another cellulose derivative where some of the hydroxyl 
groups of the cellulose have been hydroxypropylated forming –OCH2CH(OH)CH3 groups 
(Rowe R, 2009). HPC has been used as film former due to its good properties to origin films 
with proper mechanical properties (Alanazi et al., 2007; Bunnelle et al., 2005). HPC films 
have good carrying capacity, reasonable clarity and moderate bioadhesive properties 
associated with HPC’s swelling capacity (Alanazi et al., 2007; Dahiya M, 2009). An evident 
advantage of the use of this cellulose is the wide range of solubility (Rowe R, 2009), which 
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allows a flexible selection of the solvent according to the drug solubility (Yasuda et al., 2011). 
Interestingly, it is reported that when a combination of HPCs (Klucels EF - Mw 80.000, and 
KlucelX GF - Mw 300.000) is used to replace synthetic polymers (PVA and PVP) or HPMC in a 
polymer matrix with modified starch (Maltrin M100, Maltrin M180, Maltrin's QD M550, and 
Maltrin's QD M600 or Pure-Cote B792) the solubility properties of the films tend to improve 
(Zerbe and Al-Khalil, 2003). 
Carboxymethylcellulose (CMC) is another cellulose derivative that in opposition to the 
previous non-ionic polymers is an anionic linear polysaccharide, produced by reacting 
cellulose with sodium monochloroacetate under controlled conditions (Baldwin et al., 1994). 
CMC, also known as cellulose gum, is an important industrial polymer with a wide range of 
applications, essentially due to its low cost. In the pharmaceutical field it has a prominent 
value as thickener and it is ideal for applications requiring a fast dissolving base. It is 
commercially available with a wide DS range, between 0.4 and 1.5. The DS value of CMC has 
an important impact on the film-forming solutions properties, since higher DS values are 
directly related with a decrease in the interchain interactions due to the increase 
substitution of the hydroxyl sites (Baldwin et al., 1994). CMC had proven to be useful for the 
preparation of optimal polymeric matrices, produces films with excellent clarity and with the 
ability of carrying a wide range of active components. CMC oral films with optimal 
characteristics to be used in oral health biotherapy had also been prepared (Saha et al., 
2013). In the preparation of buccal mucoadhesive films it was shown that sodium CMC 
improved the residence time of HPC and sodium alginate films (Nappinnai et al., 2008). It is 
also reported that CMC has a good compatibility with starch forming single-phase of 
polymeric matrix films with improved mechanical and barrier properties (Lu et al., 2009; 
Tongdeesoontorn et al., 2011). However, some authors showed that HPMC based films are 
tougher, more elastic and bioadhesive in vivo than sodium CMC based films (Peh and Wong, 
1999).  
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6.2. Starch 
Among all natural biopolymers, starch was always considered one of the most promising 
polymers for this application, due to its wide availability, biodegradability and low cost (Mali 
S, 2010; Xie et al., 2012). However, pure starch films are usually brittle and tacky. Native 
starch generally contains 75% of amylopectin and 25% of amylose, a combination that for 
this application is associated with a lack of strength, water resistibility, thermal stability and 
processability difficulties (Koch K, 2009; Xie et al., 2012). Therefore, to obtain oral film 
matrices with optimal properties native starch should be blended with other polymers. The 
process issues are essentially related with the difficulty of dissolving native starch in water, 
due to its high molecular size and strong hydrogen bonding. In fact, to dissolve starch, low 
concentrations and high temperatures need to be used, which is not economically 
favourable. Thus, in order to overcome this disadvantage and also improve the product 
performance, several starch derivatives have been developed and are currently available on 
the market. Examples of modified starches applied to oral films are hydrolysed starches, 
such as Maltodextrins (MDX) (e.g. MALTRIN®, from Grain Processing Corporation), 
hydroxypropyl starches (e.g. Lycoat ®, from Roquette), pre-gelatinized starches (e.g. 
INSTANT PURE-COTE® by Grain Processing Corporation (GPC)) and others, such as Pullulan. 
In fact, Maltodextrins have been used blended with other polymers to improve the overall 
properties of the film, as already discussed, but also as sole film forming polymer (Cilurzo et 
al., 2011; Cilurzo et al., 2010; Cilurzo et al., 2008; Cilurzo et al., 2012). Chemically, MDX is a 
mixture of polymers that consists in D-glucose units, with a dextrose equivalent (DE) lower 
than 20, and are prepared by the partial hydrolysis of a food-grade starch (Rowe R, 2009). 
MDX origins good quality films (Shamekh et al., 2002) with fast disintegration and low 
dissolution time (<45 seconds) (Cilurzo et al., 2010; Cilurzo et al., 2012). Low DE MDXs offer 
higher viscosity and better film formation than higher DE MDXs. It is also referred that low 
DE MDXs present an improvement on flexibility and reduced cracking compared to modified 
starch-based films (Chapdelaine et al., 2003). In turn, when blended with microcrystalline 
cellulose (MC) tends to form non-sticky and smooth polymeric matrices (Cilurzo et al., 2008). 
Similarly, Lycoat® can also be used as sole film forming polymer with excellent functionality. 
Although, it is easily dispersed in cold water, it is suggested the treatment at 70⁰C in order 
to improve its film forming ability. In addition, by contrast with native starch solutions, 
Lycoat® cooked solutions can be immediately cooled down, since the gelation and 
retrogradation would not be probable to happen due to the high stability of the 
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hydroxypropylated starch molecules (Parissaux X, 2007). Compared with HPMC, 
hydroxyethyl cellulose and polyvinyl alcohol, Lycoat® showed faster dissolution time, 
moderate moisture uptake and satisfactory mechanical properties (El-Setouhy and Abd El-
Malak, 2010). 
The pre-gelatinized starch is a chemically and/or mechanically processed starch, 
commercially available in fully or partially pre-gelatinized grades. The first is easily soluble in 
cold water, whereas partial pre-gelatinization produces a starch with soluble (gelatinized) 
but also insoluble fractions (Cunningham; Rowe et al., 2009). The knowledge of these 
differences is critical to obtain formulations with the desired disintegration times.  
INSTANT PURE-COTE® is a pre-gelatinized starch, marketed by GPC, with good film-forming 
capabilities. This polymer origins clear, strong and flexible films using a 15 to 20% solution 
by solvent-casting process (Business Wire, 2010). GPC offers a broad range of modified 
starches for pharmaceutical applications including also the PURE-COTE® a corn starch 
specifically modified to produce clear, flexible, fast drying and tasteless oral polymer 
matrices (Fadden et al., 2006; GPC, 2014; Kulkarni et al., 2006).  
Pullulan, is a modified starch composed by glucose units in maltotriose units connected by 
glycosidic bonds. Pullulan have both suitable processing and film-forming properties that 
turn it into one of the preferred polymers to be used in the preparation of oral polymeric 
matrices. It is easily soluble in hot or cold water, and forms a clear and viscous solution that 
origins smooth, transparent and stable films. Pullulan is obtained from a fermentation 
process of yeast, the Aureobasidium pullulans, thus, its low availability results in a high cost 
product (Prajapati et al., 2013). Therefore, Pullulan is usually blended with other compatible 
polymers that are more abundant and less expensive. For example, other modified starches 
may be used in combination with Pullulan, to decrease the overall cost. In fact, 50 to 80% of 
Pullulan can be replaced by starch or modified starch without the loss of its required 
properties as a good film-former (Dixit and Puthli, 2009). Sodium alginate and CMC, can also 
be used with the same purpose since they are compatible. In fact, the formation of hydrogen 
bonds between the COO groups of alginate and CMC with the –OH groups of Pullulan may 
synergistically enhance the material properties of the resulting film (Dahiya M, 2009; Tong 
Q, 2008). In addition, it is also reported that Pullulan – HPMC blends, with a HPMC content 
above 50%, a miscible composition is obtained, and the final polymeric matrix presents 
improved thermal and mechanical properties (Prasad P, 2008). 
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The mechanical properties of Pullulan films prepared at various temperatures were also 
studied. Generally, films prepared at low temperatures are stiffer and more flexible than 
films prepared at higher temperatures that are brittle and do not have a clear plastic 
deformation. The Pullulan based films usually present a fast disintegration time (Kawahara 
M, 2003). 
 
6.3. Semi-synthetic, synthetic and others 
There are others natural or semi-synthetic polymers that have been tested as polymeric 
matrices for drug delivery application, such as: rosin and rosin derivatives, gelatin, sodium 
alginate, pectin and others (Fulzele S, 2002; Galgatte et al., 2013). Gelatin has excellent 
properties as film former, but the high viscosity during the processing difficult the handling 
and limits its applicability in films formulations. On the other hand, the pectin usage 
limitation is more related with the final product characteristics rather than the 
manufacturing process. Pectin is a natural polymer obtained from citrus fruits and apples, 
with a good film forming capacity. Pectin based films have optimal capacity to carry drug 
substances (Galgatte et al., 2013), but tend to dissolve slowly. This is related with pectin’s 
strong mucoadhesive properties, which is not very useful for fast dissolving films. Thus, 
modified pectins had also been produced and tested to obtain films with fast dissolution 
rates (Puri and Zielinski, 2007). 
The synthetic polymers have been also intensively explored as film-formers, but the majority 
converge to PVA, PVP (Alanazi et al., 2007) and methacrylate polymers (Kulkarni AS, 2010).  
PVA is a water soluble polymer prepared by partial or complete hydrolysis of polyvinyl 
acetate that has been successfully used as main film-former polymer (Horstmann and Laux, 
2004; Leichs et al., 2008). It is also available a polyvinyl alcohol-g-polyethylene glycol 
copolymer (PVA–g-PEG), Kollicoat® IR, composed by 75% PVA and 25% PEG units. There are 
considerable advantages of this copolymer compared to pristine PVA. Regarding the 
manufacturing process, it is important to consider that PVA is only completely solubilized in 
hot water and the increase of the PVA hydrolysis is directly proportional to the temperature 
needed to PVA complete dissolution. In opposition, Kollicoat® IR is freely soluble in water 
and the presence of the PEG spares the addition of plasticizers to the formulation, 
simplifying the processability. Additionally, it was shown that the higher ability of Kollicoat® 
IR to form very flexible films with higher elongation at break values when compared with 
cellulose derivatives based films. This is probably due to the PVA moiety, combined to the 
32 
plasticizing and surfactant properties of the PEG moiety (Bougaret et al., 2009; Mura et al., 
2010).  
PVP or Povidone is a polymer with linear 1-vinyl-2-pyrrolidinone groups that is available with 
different molecular weights (Rowe et al., 2009). In general, PVP is described as a good film 
former (Alanazi et al., 2007; Asari et al., 2011; Centers for Disease Control Prevention, 2009; 
Chu et al., 2012; El-Setouhy and Abd El-Malak, 2010), but some authors described PVP as a 
polymer with very poor film forming capacity, which may be improved to an average film 
former polymer when blended with PVA or HPMC, resulting in transparent and fast 
disintegration films (Kulkarni AS, 2010). This discrepancy may be due to the different PVP’s 
Mw used in the different studies. PVP has been widely explored as film former because it is 
an edible polymer that rapidly dissolves in mouth. It is sufficiently soluble in both water and 
organic solvents enabling the use of the most appropriate solvent during the process and 
manufacture depending on the drug substance. However, PVP exhibits higher hygroscopicity 
than HPC, which justify the preference of some authors for this cellulosic derivative polymer 
(Asari et al., 2011). It is reported that PVP K90 (about Mw 750.000) blended with Ethyl 
Cellulose and HPC origins films with increased flexibility and softer and tougher properties. 
It was also verified that the PVP addition, contributes to an increase of the film’s swelling 
rate and extent which results in higher barrier effects that decrease the drug substance 
diffusion. It is also described that PVP may augment significantly the bioadhesive strength 
probably due to hydrogen bonding and Van der Wall forces (Alanazi et al., 2007). PVP K90 
based films may also present fast disintegration time depending on the formulation 
composition. However, it is reported that HPMC-PVP K90 based films, when compared with 
HPMC-MDX and HPMC-PVA blends, had lower dissolution rate, probably due to the 
viscoelastic properties of PVP K90 (El-Setouhy and Abd El-Malak, 2010). It is also 
demonstrated that different ratios of PVP - alginate blends can be used to control the drug 
release: higher amount of PVP contributes to smaller dissolution times whereas higher Mw 
PVP origins films with increased drug release lags (Chu et al., 2012). 
Polyethylene Oxide (PEO) is another synthetic polymer that has been used as main film 
forming polymer for the preparation of oral films due to its peculiar characteristics (Bruce 
and Manning, 2011; Chen M, 2006; Myers, 2008; Myers et al., 2011). PEO is a non-ionic 
hydrophilic PEG with high molecular weight that is commercially known by POLYOX™. 
Interestingly, PEO can be used as self-plasticizing polymer matrix, due to its low Tg, about -
67°C (Dahiya M, 2009), especially for Mw ranging from ~100kDa (Polyox WSR N-10) to 
~4,000kDa (Polyox WSR 301). This feature eliminates the need of an additional plasticizer in 
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the oral films formulation, allowing a higher drug load due to the smaller number of 
excipients (56% by weight of the film) (Myers, 2008). PEOs with higher Mw, as Polyox WSR 
Coagulant or WSR 303, may be preferentially used to increase the mucoadhesiveness of the 
films (Myers, 2008; Rowe et al., 2009). 
PEO based films are described as films with good resistance to tearing, minimal or no curling, 
and fast dissolution rate (Yang et al., 2006). Additionally, it is reported the dissolution time 
for different POLYOX grades, as expected, increases with the Mw: N-10 (Mw=100kDa) < N-
80 (Mw=200kDa) < N-750 (Mw=300 kDa) < WSR 205 (Mw=600 kDa). In fact, POLYOX N-10, 
N-80 present disintegration times lower than Pullulan films, whereas POLYOX WSR 205 and 
N-750 have dissolution times similar to the Pullulan films. The same authors also reported 
that PEO based films have a pleasant mouth feel, without a sticky feeling or formation of a 
highly viscous gel in the mouth. However, the puncture strength of POLYOX N-750 is 
reported to be 3,000 kg/m2, slightly lower when compared with some available commercial 
Pullulan based films (about 10,000 kg/m2) (Chen M, 2006). The desirable characteristics of 
the resulting oral film can be designed by using different PEOs’ grades and concentrations. 
On this matter, it is possible to balance the tear resistance, dissolution rate, and adhesion 
tendencies of film compositions combining low Mw PEO from 50% to 75%, with a higher Mw 
PEO and / or with a cellulosic polymer, as HPC or HPMC (Yang et al., 2006). 
There are several polymers that are continuously being explored to develop these matrices 
for drug delivery. The innumerous types of polymers, the different polymer grades, and the 
several possible polymer-polymer blend ratios result in an exponential number of possible 
formulations and a wide range of final product characteristics. Therefore, it is crucial to have 
a deep understanding of the system under development to avoid undesired and unexpected 
product profiles. 
Although, polymers are the main oral films component, additional excipients may be 
required in order tailor the target product profile. These excipients include plasticizers, 
sweeteners, flavour, colourants, stabilizers, fillers, saliva stimulating agents, buffer systems 
and others.  
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Table 1 - Most widely used polymers in oral films formulations. 
(Alanazi et al., 2007; Bunnelle et al., 2005; Rowe R, 2009; Yasuda et al., 2011; Zerbe and Al-Khalil, 2003); (Baldwin et al., 1994; Saha et al., 2013); (Lu et al., 2009; Nappinnai et al., 2008; Peh and Wong, 1999; Tongdeesoontorn et al., 2011); (Koch K, 
2009; Mali S, 2010; Xie et al., 2012); (Chapdelaine et al., 2003; Cilurzo et al., 2010; Cilurzo et al., 2008; Cilurzo et al., 2012; Shamekh et al., 2002); (El-Setouhy and Abd El-Malak, 2010; Parissaux X, 2007); (Business Wire, 2010; Cunningham; Fadden et al., 
2006; GPC, 2014; Kulkarni et al., 2006); (Dahiya M, 2009; Dixit and Puthli, 2009; Kawahara M, 2003; Tong Q, 2008)  
Class Polymer Polymer ID
Chemical 
features to 
consider
Examples Characteristics Application References
Several Mw 
Good drug loading 
capacity
Klucels EF 
Degree of 
substitution
Swelling 
properties
Moderate bioadhesiveness KlucelX GF
Allows a flexible selection of 
the solvent according to the 
drug solubility
Simplified processability
Higher DS values
Decrease in the interchain 
interactions due to the 
increase substitution of the 
hydroxyl sites
(Baldwin et al., 1994; 
Saha et al., 2013) 
Sodium CMC improved 
the residence time of 
HPC and sodium 
alginate films
Good compatibility with 
starch forming single-
phase  polymeric matrix 
films with improved 
mechanical and barrier 
properties
Generally 
contains 75% of 
amylopectin 
and 25% of 
amylose 
High molecular 
size 
Strong hydrogen 
bonding
Higher viscosity Fast disintegration 
Better film formation
Blended with 
microcrystalline 
cellulose (MC) tends to 
form non-sticky and 
smooth polymeric 
matrices
Hydrolysis 
degree
Fast dissolution time
Substituent 
type
Moderate moisture 
uptake 
Substitution 
degree
Satisfactory 
mechanical 
properties
Insoluble fractions
INSTANT PURE-
COTE®
Clear, strong and 
flexible films 
Critical to produce 
formulations with the desired 
disintegration time
PURE-COTE®
Clear, flexible, fast 
drying and tasteless 
oral polymer matrices
Too expensive
50 to 80% of Pullulan can be 
replaced by starch or 
modified starch
Smooth, transparent 
and stable films
Blended with Sodium 
alginate and / or CMC, 
may synergistically 
enhance the properties 
of the film 
Films prepared at 
low temperatures
Stiffer and more flexible
Films with fast 
disintegration
Pullulan – HPMC films, 
have improved thermal 
and mechanical 
properties 
Higher 
temperatures 
Brittle and do not have a clear 
plastic deformation
(Lu et al., 2009; 
Nappinnai et al., 
2008; Peh and Wong, 
1999; 
Tongdeesoontorn et 
al., 2011)
Formulation Impact
Celluloses
HPC
Used to replace 
synthetic polymers or 
HPMC in a polymer 
matrix with modified 
starch to improve 
solubility
(Alanazi et al., 2007; 
Bunnelle et al., 2005; 
Rowe R, 2009; Yasuda 
et al., 2011; Zerbe 
and Al-Khalil, 2003)
Wide range of 
solubility
CMC
DS range, 
between 0.4 
and 1.5
Swelling 
properties
Mucoadhesive preparations NaCMC
Films with excellent 
clarity and with the 
ability of carrying a 
wide range of DS
Starch
Native starch
Lack of strength, water 
resistibility, thermal stability 
and processability difficulties
Hydrolyzed 
substituted 
starches
Hydroxypropylate
d starch molecules
High stability
Pullulan
(Koch K, 2009; Mali S, 
2010; Xie et al., 2012)
Maltodextrins
D-glucose units, 
with a dextrose 
equivalent (DE)
Low DE MDXs MALTRIN®
(Chapdelaine et al., 
2003; Cilurzo et al., 
2010; Cilurzo et al., 
2008; Cilurzo et al., 
2012; Shamekh et al., 
2002)
(Dahiya M, 2009; 
Dixit and Puthli, 
2009; Kawahara M, 
2003; Tong Q, 2008)
Lycoat® 
(hydroxyprop
ylated pea 
starch)
(El-Setouhy and Abd El-
Malak, 2010; 
Parissaux X, 2007)
Pre-gelatinized 
starch
Fully or partially 
pre-gelatinized 
grades
Partially pre-
gelatinized grades
(Business Wire, 2010; 
Cunningham; Fadden 
et al., 2006; GPC, 
2014; Kulkarni et al., 
2006)
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7. Mucoadhesion: a polymeric inner property? 
Although the mucoadhesion concept appeared early during the eighties, it was only ten 
years later that improved mucoadhesive polymers were introduced in the pharmaceutical 
field (Laffleur, 2014). There are several theories that may explain the bioadhesion process, 
but none is able to explain the overall mechanism. The wetting theory is one of the oldest 
theories and involves notions of thermodynamic work and contact angle. Briefly, the 
bioadhesion in this theory is defined as the surface tension of the two adherent phases 
subtracted by their apparent interfacial tensions. On the other hand, the diffusion theory is 
related with the possible relation between the polymeric chains with the glycoprotein mucin 
chains. According to this theory depending on the depth of the contact, semi-permanent 
bonds, between the substrate and polymer adhesive chains, may occur. Therefore, the 
diffusion coefficient may be influenced by the polymer’s Mw and cross-link density. Other 
theories are associated with attractive forces mediated by electrons transference 
(electrostatic theory) or by chemisorption due to the formation of van der Waal’s, hydrogen 
and hydrophobic bonding (adsorption theory) and / or fracture strength (fracture theory). 
Nevertheless, the polymers may be categorized according to the binding type to the mucosa 
(Laffleur, 2014).  
 
7.1. Ionic polymers 
The bioadhesive polymers tend to adhere to the biological substrates mostly by 
interpenetration followed by secondary non-covalent bonding. These secondary 
interactions are usually hydrogen bonds between the charged polymers’ chains with the 
oligosaccharide side chains of the mucus proteins. Some of the most effective anionic 
polymers are the polyacrylates (Carbopols) and carboxymethyl celluloses (CMC) (Andrews 
et al., 2009; Laffleur, 2014; Morales and McConville, 2011). Carbopols are synthetic high-
molecular-weight polymer cross-linked with either allyl sucrose or allyl ethers of 
pentaerythritol, which present a rapid, high, and stable swelling and good mucoadhesive 
properties. The NaCMC is also used but normally in combination with other polymers to 
increase the bioadhesive performance of the oral films. Hydroxyethyl cellulose (HEC) based 
films generally present high swelling properties and rapid erosion but exhibit poor 
mucoadhesive properties, therefore NaCMC can be added to enhance this property. The 
referred mucoadhesive polymers are included in the so called first-generation and have 
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been intensively used. Their bioadhesion properties come essentially from the H-bonds with 
their carboxyl functional groups. In addition, the sulfate groups are also characterized by 
their bioadhesion due to anionic non-covalent and H-bonds. These functional groups are 
characteristic of the Carrageenans, a gum polymer widely used. There are several types of 
carrageenan but Carrageenan k, is the most mentioned for the oral films development. This 
is a strongly gelling polymer with small but stable swelling characteristics and moderate 
mucoadhesive properties (Andrews et al., 2009; Laffleur, 2014; Morales and McConville, 
2011; Preis et al., 2013; Woertz et al., 2013) (Figure 4).  
Additionally, cationic polymers can naturally be used as bioadhesive materials since they 
tend to interact with the anionic substructures present in the mucus, such as sialic acid 
groups. Chitosan is among all cationic polymers one of the most widely used and tested for 
biomedical and pharmaceutical applications (Dash et al., 2011; Jayakumar et al., 2010). 
Chitosan is a natural polysaccharide comprising copolymers of glucosamine and N-
acetylglucosamine presenting a high to moderate swelling and mucoadhesive properties 
(Laffleur, 2014; Morales et al., 2013; Rowe et al., 2009) (Figure 4). 
Regarding amphiphilic polymers, non-covalent bonds can also be established. The cationic 
structures adhere to the mucosa by interacting with negatively charged substructures of the 
mucus, whereas the anionic parts interact with the oral mucosa essentially through 
hydrogen bonds.  
 
7.2. Neutral polymers 
Non-ionic polymers can also present bioadhesive properties through non-covalent 
interactions with the surrounding fluids. For instance, the mucoadhesiveness of PEO and 
Polycarbophil polymers would be promoted by the high entanglement level of their polymer 
chains followed by possible hydrogen bonds formation (Zhu et al., 2013) (Figure 4).  
The concept of chain entanglement emerged early during the nineties in attempt to explain 
the mechanical properties of amorphous polymers above the Tg. The evidence of its 
existence is mainly based in the mechanical properties behaviour of the materials. The 
entangling interactions might be simply resumed as an ability of the molecules to slip to 
different equilibrium positions promoting somehow temporary links of physical interlocking, 
distinct from the permanent chemical linkages (Graessley, 1974).  
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The length and flexibility nature of the polymeric chains may allow the rearrangement 
through loops that might offer high resistance to deformation for a while, but would 
eventually slip or be removed and reformed by random thermal motion. Additionally, most 
prominent effects were observed at high polymer concentrations and Mw, with low crosslink 
densities and large primary chain lengths (Graessley, 1974). 
After the polymer matrix-substrate contact the interpenetration of the polymer chains with 
the mucus glycoproteins may induce the chain interlocking or physical entanglement, which 
would be associated with possible conformational changes and followed by secondary 
chemical interactions. 
The mucoadhesiveness measured by rheology comparing different non-ionic polymers, 
showed that, although weak, the HPMC adhesiveness was superior to the MC. The same 
authors also reported that PEO with low Mw, inferior to 4000kDa, do not present significant 
mucoadhesiveness (Madsen et al., 1998). 
PEO are polymers with long linear chains in which their length is directly related with de Mw. 
Low Mw PEOs may not be so favourable to form entanglement conformations able to 
promote mucoadhesion. Regarding the celluloses, it is also valid the unfavourable 
conformation for entanglement that is probably more related with the stiffness of their 
backbone as a result of their inherent chemical nature. The cellulosic anhydroglucose ring is 
empirically more rigid than the long linear chains of ethylene oxide oligomers (PEO). 
Furthermore, despite the physical interlocking of the chains, secondary chemical bonds (as 
hydrogen bonds) may be formed and would contribute to strengthen the links. Therefore, 
between the celluloses, the high density of available hydrogen bonding groups may 
contribute to stronger interactions of the polymer chains with the mucin glycoproteins. 
Nevertheless, the celluloses tested by the authors have significant different viscosities (MC 
with 4000 cp and HPMC 80000–120000cP, 2% solutions (Dow, 2002) indicative of very 
distinct Mw, which may turn this mucoadhesiveness comparison unreliable regarding the 
different type of cellulose.  
Other assays with neutral polymers, dextran and PEO, reforced that mucoadhesion could be 
increased by the polymer concentration, is hardly affected by the pH and may be reduced 
by the molecular branching and short linear polymer chains (Hassan and Gallo, 1990; 
Nakamura et al., 1996). 
These studies highlight the existence of physical chain entanglement between the polymer 
chains and glycoproteins and their relevance in the mucoadhesion.  
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Furthermore, it is important to consider that besides the importance of this mechanism to 
explain the mucoadhesiveness of the neutral polymers, it may also be relevant in the ionic 
polymers (Madsen et al., 1998). In fact, the chain entanglement is also described for charged 
polymers, as poly (acrylic acids). Depending on the polymer chain lengths the entanglement 
may also favour the chemical reactions between ionic polymers and the mucin proteins as 
well as to other secondary chemical bonds.  
Moreover, the high Mw Poly(methacrylate) with effective entanglement chains exhibit a 
very poor bioadhesive properties in its non-ionic form, which may only be mitigated when 
its salt form is used (Cilurzo et al., 2003). Though, the non-covalent adhesive bonds of non-
ionic polymers are usually weaker than the non-covalent bonds established by charged 
polymers (anionic or cationic). 
 
7.3. Thiomers 
The majority of the polymers referred are essentially water-soluble and their 
bioadhesiveness to the mucous membrane arises from their non-covalent bonds after 
hydration. This property has been widely explored in pharmaceutical technology for several 
years, but only during the 90s real ‘pharmaceutical glue’ excipients had been developed. In 
fact, a clear distinction can be found in literature, a first generation including the mucous-
non-covalent-bond polymers and a second generation comprising mucous-covalent-bond 
polymers. These polymers commonly called thiomers are capable of forming covalent bonds, 
mainly based on thiol /disulfide exchange reactions. The thiol groups of the polymers bond 
covalently to the cysteine-rich subdomains of the mucus layer by the formation of disulfide 
bonds (Figure 4). There are several anionic and cationic thiolated polymers that have already 
been synthesized: polycarbophil-cysteine, poly(acrylic acid)-cysteine, alginate-cysteine, 
chitosan-4-thio-butylamidine, chitosan-thioglycolic acid, chitosan-2-mercaptoethylamine 
(Andrews et al., 2009; Bernkop-Schnurch and Steininger, 2000; Laffleur, 2014). 
It is reported that these thioled polymers present improved mucoadhesion characteristics 
compared to the unmodified counterparts. In addition, a new type of thiomers has been 
recently developed, the preactivated thiomers, which have better mucoadhesive properties 
and higher stability: chitosan-thioglycolic acid mercaptonicotin amide, pectin-cysteine-
mercaptonicotinic acid and chitosan-4-thiobutylamidine-mercaptonicotinamide.  
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Generally, these second generation mucoadhesive polymers are usually less sensitive to 
ionic and pH changes and the disulfide bonds may facilitate controlled drug diffusion due to 
the higher rigidity and cross-linking. Therefore, these polymers may be preferred to develop 
modified profile release drug delivery systems whereas the first-generation polymers are 
preferable to fast onset drug release (Andrews et al., 2009; Bernkop-Schnurch and 
Steininger, 2000; Laffleur, 2014). 
Although many researches have been performed in this area, the application of thiomers in 
oral films has not been explored to the best of our knowledge. In table 2 it is summarized 
some of the research work performed with thiomers. There is a wide range of drug delivery 
systems developed and studied but for buccal or oral delivery, but it is mainly related to 
tablets. Regarding the first generation thiomers, their usage in the oral films development 
may also be challenging due to their inherent instability. Thiomers are unstable in aqueous 
solutions with pH ≥ 5 due to the oxidation of the thiol groups. It is also advisable the 
production and storage under inert conditions, light and oxygen protection, to avoid thiomer 
formulations instability. However, the second generation thiomers are more stable in 
solutions and in a broader pH range (Bonengel and Bernkop-Schnurch, 2014; Ijaz and 
Bernkop-Schnurch, 2015). Nevertheless, the inclusion of these components in 
pharmaceutical dosage forms may be still restricted to some applications due to regulatory 
(e.g. safety assays, registration) and process-production scale-up issues (Ijaz and Bernkop-
Schnurch, 2015). Currently, there are only clinical trials for ocular application of chitosan-N-
acetylcysteine conjugate (Bonengel and Bernkop-Schnurch, 2014; Garhofer and Medical 
University of Vienna, 2010, 2012; Ijaz and Bernkop-Schnurch, 2015) and hyaluronic thiomer 
(Croma-Pharma GmbH, 2013). 
Additionally, the inclusion of these compounds in the oral films, especially in buccal films, 
may also be used as permeation enhancers and protein /peptides stabilizers as already 
explored by others (Bernkop-Schnurch and Thaler, 2000; Hornof and Bernkop-Schnürch, 
2002; Kast et al., 2003; Leitner et al., 2004). 
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Table 2 - Summary of some of the research work performed with the thiomers. 
(Hoyer et al., 2009) (Bernkop-Schnurch and Steininger, 2000) (Werle et al., 2009) (Hornof et al., 2003) (Bernkop-Schnurch et 
al., 2003) (Guggi et al., 2004; Leitner et al., 2003) (Aher and Nair, 2014) (Bernkop-Schnurch et al., 2001) (Jindal et al., 2010; 
Roldo et al., 2004) (Liu et al., 2014) (Bernkop-Schnurch et al., 2005)(Bonengel and Bernkop-Schnurch, 2014; Ijaz and Bernkop-
Schnurch, 2015) (Hauptstein et al., 2013) (Hauptstein et al., 2014)  
Drug Delivery type Dosage form Drug substance Reference
Buccal Tablets Rifampicin
(Bernkop-
Schnurch and 
Steininger, 2000)
Oral Liposomes
(Werle et al., 
2009)
Ocular Inserts Diclofenac salts
(Hornof et al., 
2003)
Ocular Microparticles Bromelain
(Bernkop-
Schnurch et al., 
2003) 
Tablets
(Guggi et al., 2004; 
Leitner et al., 
2003)
Ocular Bilayer inserts Gatifloxacin
(Aher and Nair, 
2014) 
Oral Tablets
(Bernkop-
Schnurch et al., 
2001) 
Oral Tablets
Tramadol 
hydrochloride
Oral Tablet
In situ gel-
forming system
Protein (Liu et al., 2014)
Oral Tablets Peptide
(Bernkop-
Schnurch et al., 
2005)
Chitosan-N-
acetylcysteine 
conjugate 
Ocular
Lacrimera® eye 
drops
Dry eye 
syndrome
(Bonengel and 
Bernkop-
Schnurch, 2014; 
Ijaz and Bernkop-
Schnurch, 2015) 
Oral Minitablets Rosuvastatin 
(Hauptstein et al., 
2013) 
Calcium
Lidocaine
(Hoyer et al., 
2009)
Poly(acrylic acid)-
cysteine
Alginate-cysteine
Chitosan-4-thio-
butylamidine
Thiomers
Polycarbophil-
cysteine
Buccal
Patch
Four layered 
(Jindal et al., 
2010; Roldo et al., 
2004) 
Preactivated 
thiomers
Pectin-cysteine-
mercaptonicotinic 
acid Buccal Gel delivery
(Hauptstein et al., 
2014) 
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Figure 4 - Bioadhesive interactions. Simplified oral mucosa representation: sub-mucosa with nerves 
and blood vessels, lamina propria, essentially with connective tissue and with some blood vessels, 
basement membrane usually a single cell layer lying in the interface of the epithelium and lamina 
propria; a simplified oral epithelium only for representative purposes; and a mucus layer with mucin 
and glycoproteins. The mucoadhesiveness of the polymers to the oral mucosa may be explained by 
the non-covalent and covalent bonds, depending on the polymers’ functional groups.  
 
In general, any polymer is capable of establishing electrostatic interactions presenting some 
degree of bioadhesive properties. Additionally, the majority of polymers used to prepare 
oral film matrices are rich in hydroxyl groups, which can easily interact with the biological 
subtracts through H-bonds. This is associated with the natural mucoadhesion of the majority 
of the hydrophilic polymers used to prepare these platforms. Furthermore, some of these 
polymers can also be used as adjuvants or modifiers to improve or diminish film’s 
mucoadhesive characteristics. Polymers with small but stable swelling properties 
characterized by very poor mucoadhesion, such as Agar (hydrophilic colloidal 
polysaccharide) or Acacia (complex and loose aggregate of sugars and hemicelluloses) can 
be used to decrease matrices bioadhesion. Another example is the Poly-D,L (lactide-co-
glycolide) (PLGA), a synthetic copolymer of lactide and glycolide PLGA, that can be added to 
the polymeric matrix to confer hydrophobicity to diminish the swelling of other polymers 
and / or to obtain a prolonged drug release (Cavallari et al., 2013; Dott et al., 2013; Jones et 
al., 2014; Perugini P, 2003; Rana and Murthy, 2013; Shen et al., 2014).  
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8. Polymer selection 
As discussed on previous sections, the polymer selection during the formulation 
development of polymeric matrices may be critical and some points should be considered. 
Several examples were given related the ability of the polymer to affect the mechanical and 
texture properties of the films and also their influence on the drug release. On the other 
hand, the inclusion of the drug substance in the polymer matrix may also affect significantly 
the mechanical properties of the film. Depending on the chemical structure of the DS and 
the % of drug load the DS may easily interpose between the polymer chains, interfering with 
the polymer intermolecular bonds. This effect may allow the polymer to move more freely, 
resulting in matrices with higher flexibility due to a reduction on the elastic modulus and 
tensile strength parameters (Alanazi et al., 2007). In fact, depending on the drug, the effects 
may be different, for example, chlorpheniramine maleate has a higher plasticizer effect on 
HPC based films than indomethacin. Nevertheless this plasticizing effect may also have direct 
impact in the oral film manufacture, due to chemical modifications of the mixture 
properties, such as reducing the softening temperature (Low et al., 2013). 
Aesthetic and performance characteristics should also be considered during the selection of 
the polymer. This dosage form is for oral administration and may have some residence time 
in the oral mucosa. Therefore, polymers that may become unpleasant should be avoided. 
Therefore some aspects as taste masking, physical appearance and mouth feel should be 
considered. The hydrophilic polymers are the major choice for the preparation of oral film 
matrix so the film may smoothly and softly dissolve in the oral cavity. Polymers or 
combinations that tend to form pastes should be avoided since it may become unpleasant. 
Regarding the manufacturing process, properties such as good wetting, spreadability, 
sufficient peel, shear and tensile strengths, should also be taken in consideration.  
The mechanical properties of the polymeric matrix are also critical. An ideal oral film should 
be flexible, elastic and robust enough to resist to handling, transportation and the stress 
from mouth activities. Generally, low-molecular-weight polymers dissolve quicker, but 
polymers with higher molecular mass origin films with better mechanical properties. 
Additionally, the polymer should be preferentially ready-to-use, not toxic or irritant to the 
oral mucosa and ideally not very expensive. Therefore, a mixture of polymers is preferable 
used, instead of a one-polymer-based- film, in attempt to improve and optimize the final 
polymeric matrix characteristics. 
  
 43 
9. Critical quality attributes (CQA) 
There are general critical quality attributes of the oral films that should be considered during 
their development. These properties are obviously inherent to the formulation but also 
significantly influenced by the manufacturing process. Hereinafter, are described briefly 
some of the most common quality attributes that should be considered during the oral film 
development. 
 
9.1. Physical strength 
Appropriate physical strength, is one of the most evident CQA of the oral films. The product 
should have suitable mechanical properties so it can be easily manufactured, packaged and 
handled without damage or break. However, there are no guidelines with the description of 
the most adequate properties, methods and ranges that should be studied. However, in 
literature there is a general consensus about the main properties that should be tested: 
elongation at break, young’s modulus and tensile strength (Cao et al., 2009; Dixit and Puthli, 
2009; Preis et al., 2014). The literature review highlighted the difficulty of stablishing strict 
ranges for these parameters (Preis et al., 2014) and a wide variation may be appropriate 
depending on the polymeric matrix under development. In fact, the appropriate value for 
the mechanical strength may vary significantly depending on the polymeric matrix and 
method of manufacture (Nair et al., 2013). 
An appropriate balance should be found between these properties. The oral film should be 
malleable so it can be handled without break but not too flexible that extends easily and 
deforms during cutting or packaging processes. It should present enough tension so it can 
be pulled out from the pouch, rolled up after casting, pealed from the release liner, but not 
too much that may difficult the cutting process. Nevertheless, the mechanical evaluation is 
particularly important during the product life-time but also for up-scale manufacturing 
process, since all the process from coiling to the packaging demands robustness (Preis et al., 
2013).  
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9.2. Stability 
It is important that the product has the ability to maintain its suitable properties over time, 
so physical and chemical stability are assured. These characteristics depend on the polymeric 
matrix and possibly on the manufacturing process. Thus, suitable stability and screening 
tests should be planned and performed during the development stage. However, proper 
approaches that may also guarantee the product stability are well-controlled manufacturing 
conditions, and the selection of an adequate packaging material in an early-development-
stage.  
Regarding the chemical stability, it is important to consider the polymeric matrix 
characteristics. The complexity of these matrices is sometimes underestimated and careful 
attention should be taken during its development. Although the majority of the reaction / 
interactions need high temperatures to take place, it is found in literature hypothesis of 
some reactions that may occur at room temperature in polymeric film matrices (Koo et al., 
2011; Ortega-Toro et al., 2014). Nevertheless, there are excipients that may inadvertently 
function as reaction catalysers, compromising the product stability.  
Importantly, it is also to assure the drug substance stability incorporated in the polymeric 
matrix. Although the stability of some drug substances is well known, the change of the 
pharmaceutical form may interfere with it. The Suboxone® sublingual film is a good example, 
in which Naloxone may be more easily oxidized in the film compared to the sublingual tablets 
available. Therefore, the shelf-life is limited to 12 months if the storage temperature is 
reduced from 30⁰C to 25⁰C (Australian Government et al., 2011). 
The thermal stability of the product should also be considered since it may influence its long 
term stability, its storage conditions and possible restrictions. 
 
9.3.  Appearance 
The appearance of the films is another relevant CQA. The size and the shape should be 
carefully studied and selected depending on the strength and application site. This has 
special importance for sublingual formulations which have a small available area to adhere. 
Moreover, the buccal films, which generally tend to be placed in the mouth for long periods 
of time, should also have suitable dimensions to be comfortable for the patient. 
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9.4. Drug release profile 
The target drug release profile delivery should be defined early in the development based 
on the target product profile. The most reliable tests available to this evaluation are the 
disintegration time and the dissolution profile. Depending on the product, it may be 
intended to have a bioequivalent oral dosage form or other specific drug-delivery type (e.g. 
extended or fast release, mucosa or gastrointestinal absorption).  
It is also important to consider that according to the FDA guidance a fast disintegration time 
in vitro should be less than 30s (Food and Drug Administration, 2008).  
 
9.5. Residual water content 
The residual water content of the films is critical and should also be strictly defined for each 
specific formulation, since it may influence significantly any of the properties described. It is 
also crucial to monitor and control the room conditions during production (temperature and 
relative humidity), and an appropriate primary packaging material should be provided to 
avoid water transferences between the product and the surrounding room.  
An excess or deficit of water content may affect the mechanical properties of the polymeric 
matrix. The water molecules may interpose in the polymer chains functioning as a plasticizer, 
so the loss of water content, may contribute for brittle polymeric matrices. In turn, an excess 
of water absorption by the polymeric matrix may originate sticky films that may adhere to 
the patient fingers and / or packaging material.  
Moreover, the interposition of the water molecules in the polymeric chains may also 
influence the disintegration / dissolution of the films. The loss of water molecules would 
contribute to thigh the polymeric chain links, turning difficult the water penetration and 
therefore the disintegration time.  
Furthermore, the free water in the film may also interfere with the stability of the drug 
substance incorporated and / or with the excipients. 
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9.6. Organoleptic characteristics 
The oral films have a relatively high surface area in contact with the oral mucosa, which 
makes important to focus some of the development efforts in the formulation of a pleasant 
and palatable system. Generally, the disagreeable taste is related with the drug substance 
characteristics (bitterness, particle size / shape, solubility, ionization) and strength in the oral 
film (Gala and Chauhan, 2014). Therefore, depending on these properties is important to 
define an efficient strategy to assure an agreeable taste, aftertaste and mouthfeel. 
Another important point to consider is the target market, since there may be regional and / 
or aged group preferences. Different consumers have different preferences and should be 
captivated by different and independent ways. From the formulation point of view it is 
important to consider the regional and aged group tastes. For example, children generally 
prefer fruit and / or sweetener flavours, while adults tend to prefer slightly acid flavours and 
older people frequently prefer mint or wine flavoured products. Even so, it is important to 
notice that even flavours’ children preferences may vary from country to country and may 
depend on social and cultural factors (Marriott et al., 2010; Taylor and Linforth, 2010; WHO 
Expert Committee, 2012). Curiously, even for animals’ medicine market is important to 
record that the choice of the flavour and colour may have impact in the acceptance of the 
medicine. Actually, these animals’ preferences can be surprising. Regarding colours, it is 
known that iguanas and emus are attracted to red and yellow, respectively. About the 
flavours, horses may prefer banana instead of apple or molasses, some ferrets may be fond 
of bubble-gum and rabbits and guinea pigs may prefer pina-colada flavour (Slade, 2012). 
Despite that, the appropriate choice of flavour is mainly affected by the taste sensation 
conferred by the drug substance, and the flavours or their combination should mask any 
bitterness, providing a good balance of acid, salty or sour taste, and covering any unpleasant 
aftertaste. 
 
9.7. Dose uniformity 
The individual weight of the films and the dosage uniformity must be also controlled during 
the process. It is also important to have a deep knowledge of the process and the product 
so slightly adjustments may be performed during manufacturing if necessary.  
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9.8. Others 
Additional attributes may also be considered depending on the type of the oral film to 
develop. For example, adhesion or mucoadhesion tests, for buccal and / or sublingual films 
and pH values measurements, when the drug absorption or stability depends on it. 
Moreover the pH assays may also be important to predict possible mucosa irritation, since 
acidic or alkaline pH may cause some discomfort, and the surface pH should be ideally close 
to neutral (Kunte and Tandale, 2010). 
The CQA must be defined in the beginning of the development according to the target 
product profile. Moreover, due to the sensitivity / complexity of the product other 
properties / process parameters involved in the oral films formulation and manufacturing 
must not be discarded (release liner and packaging material properties). A helpful way to 
define efficiently the quality attributes of the oral film under development is to consider the 
quality target product profile and (if possible) previous knowledge of the product and 
manufacturing process. This should be followed by an appropriate quality risk management 
to evaluate and highlight the critical and potential attributes that would affect the quality of 
the drug product (Food and Drug Administration, 2009). 
 
10. Manufacturing processes overview: from the 
conventional to the innovative 
The two main techniques used to prepare oral films are solvent casting (Cilurzo et al., 2011; 
El-Setouhy and Abd El-Malak, 2010; Garsuch and Breitkreutz, 2010; Kunte and Tandale, 
2010; Mashru et al., 2005; Mura et al., 2010; Nishimura et al., 2009; Perumal et al., 2008) 
and hot melt extrusion (Cilurzo et al., 2008; Cilurzo et al., 2012; Low et al., 2013) (Figure 5). 
However, during the past few years some developments and innovative techniques have 
emerged. Some variants of these manufacturing methods of casting and extrusion have also 
been described and used alone or in combination, such as semisolid casting and solid-
dispersion extrusion (Nagaraju et al., 2013). Inventive manufacturing processes as the rolling 
(Nagaraju et al., 2013; Preis et al., 2013) or printing (Preis et al., 2013).methods have also 
been described. The first involves essentially the preparation of a pre-mix with a further 
addition of the drug substance, and the resulting matrix is passed through a metering roller. 
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The printing method consists literally in printing the drug substance on a placebo oral film 
with specific techniques (Preis et al., 2013).  
 
10.1. Conventional methods 
The solvent-casting method consists essentially in an aqueous or hydro-alcoholic mixture of 
excipients and drug substance(s) that is casted onto a surface, dried, and cut into a desirable 
size. On the other hand, hot-melt extrusion consists simply in shaping an adequate mixture 
of polymer(s), other excipients and drug substance(s) into a film by melting all the 
components (Mishra and Amin, 2011). Both techniques allow the preparation of films with 
good characteristics, but generally the solvent casting method is the most widely used, 
probably due to the special equipment required and high costs associated to the hot melt 
extrusion method (Dixit and Puthli, 2009).  
Regarding the variant methods referred previously, the semisolid casting consists in a gel 
mass casted using heat controlled drums and obtained by the addition of an acid insoluble 
polymer to the main liquid mixture in a preferential ratio of 1:4. In turn, the solid dispersion 
extrusion consists essentially in the dispersion of a drug substance dissolved in an 
appropriate solvent and its incorporation into polyethylene glycol (PEG) melted. However, 
the drug substance or the solvent used to dissolve it should be insoluble in polyethylene 
glycol.  
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Figure 5 - Most common techniques to prepare oral films. Solvent casting technique (left) and Hot-melt-extrusion method (right). 
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10.2. Innovative methods 
An inventive manufacturing processes is the rolling method which involves the preparation 
of a pre-mix with a further addition of the drug substance, and the resulting matrix is passed 
through a metering roller (Nagaraju et al., 2013).  
Another, are the drug printing technologies methods, that seemed to be highly flexible and 
cost-effective (Preis et al., 2013) (Figure 6). 
Printing technologies are widely used in the pharmaceutical industry to identify or label the 
pharmaceutical dosage forms, especially for personalization purposes to be readily 
identified and to avoid counterfeit production. However, instead of merely printing some 
identification characters, this technology early started to be adapted to the drug load of 
pharmaceutical dosage forms. During the 80’s, Anhauser, Klein and Nick et al. used screen 
printing and pad printing to load transdermal patches with drug substances (Janssen et al., 
2013) (Figure 6 C, D). Nevertheless, for large production scale, these methods are essentially 
limited by the low speed production. Later, the inkjet printing started to be explored as a 
safe and accurate method to produce dosage forms with potent or low-dose drugs. 
GlaxoSmithKline (GSK) has a GMP Pilot machine since 2005, based on this innovative 
technology, the Liquid Dispensing Technology, used as a new tablet-manufacturing process 
that delivers microgram doses with unparalleled precision. GSK is the owner of all 
intellectual property for this technology until 2028, which was also rewarded in 2012 with a 
Health and Safety Award by IChmE (IChemE Advancing chemical engineering worldwide, 
2012; Richardson and Wilson, 2013). The application of this technology to oral films is not 
yet much explored. Nevertheless, during 2011, based on printable medicines and with the 
idea of printing a drug substance onto a carrier (such as a paper strip that can be then 
inserted into a capsule for an easy administration), a revolutionary concept was established: 
personalized medicines (Khinast et al., 2011). Although, some references to this concept 
have emerged in the last years (Buanz et al., 2011; Niklas Sandler, 2011), there is still no 
reference to the industrial application of these methods for the production of oral films.  
GSK technology may achieve a medium output of 20,000 tablets per hour. However, it has 
no direct correlation with oral films manufacturing production, and some authors consider 
that inkjet printing is still not suitable for high-throughput industrial production (Figure 6B). 
Therefore, another printing technology is suggested to be more feasible for oral films 
industrial production, the flexographic printing technology (Janssen et al., 2013) (Figure 6A). 
The flexographic printing is a rotary printing process in which the ink (drug substance 
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solution or suspension) is metered by an anilox roller then transferred to printing cylinder 
that prints the drug-free-film after unrolling the daughter roll. On the other hand, the drop 
deposition of the DS solution or suspension with the ink-jet printing may be challenging 
considering that it is important to avoid the film disintegration or rupturing and 
simultaneously maintaining the oral film’s fast dissolving properties (Janssen et al., 2013).
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Figure 6 - Printing techniques. Representation of the 4 main printing techniques used in oral films preparation. The two top figures are simplified schemes of possible printing 
industrial techniques applied to the oral films, flexoprinting (A) and inkjet (B) printing. The two bottom pictures represent two simpler printing methods the pad (C) and screen 
printing (D).
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In theory, any of the printing methods mentioned above would contribute to a more 
homogeneous distribution and accurate dosage of the drug substance within the film, which 
by the conventional methods is very challenging. Moreover, dose accuracy and uniform 
distribution of the drug substance in the films normally depends on the coating mass 
properties, like viscosity or density, which in turn are affected by the characteristics and 
amount of the processed drug substances. On this matter, with the conventional methods 
the formulations have often to be adjusted for each drug substance and dosage strength 
(Janssen et al., 2013). Hence, the application of these technologies could streamline all the 
manufacturing process and shorten the time to the market. 
In summary, printing drug substances on dosage forms are nowadays a reality and its 
application in oral films has opened a new world of opportunities when referring to 
personalized and individualized medicines.  
 
11. Characterization methods 
Several efforts have been made to develop suitable techniques for oral films evaluation and 
characterization, considering their particular characteristics. There are critical parameters 
that should be evaluated for the quality control of the films. Despite the lack of guidance, 
the European Pharmacopeia refers the need of a “suitable mechanical strength to resist 
handling without being damaged” and an appropriate dissolution method “to demonstrate 
the appropriate release of the active substance”. However, it is advisable to evaluate other 
critical properties, usually also referred as critical quality attributes that are referred 
hereinafter.  
 
11.1. Mechanical properties 
The variety of dimensions of commercially available oral films difficult the standardization 
of specific evaluation techniques. The most referred is the determination of mechanical 
properties based on ASTM or DIN-ISO guidelines, namely DIN EN ISO 527 for foil materials 
and ASTM D882-01 for tensile properties of thin plastic sheeting. This method consists in the 
fixation of the sample between two clamps and pull until breaking (Preis et al., 2014). The 
main limitations of this approach is the unresponsiveness of the apparatus and the 
preferential use of bone shapes samples to assure that the forces are centred in the middle 
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of the specimen, which does not match the common small rectangular format (about 2 to 8 
cm2) of the oral films (Garsuch and Breitkreutz, 2009). More suitable methods were 
developed as the puncture test with a cylindrical probe with a plane flat-faced surface using 
Texture Analyzer equipment. The probe with the flat face surface allows retrieving the area 
directly affected by the strain (Preis et al., 2014). 
 
11.2. Dissolution 
The dissolution method is also critical, especially concerning the apparatus and media 
selection. Despite the simple orientation of the Pharmacopeia description, it is important to 
consider that this assay should be representative and an approach to predict the in vivo 
behaviour.  
The majority of the methods described do not mimic the physiological conditions 
satisfactorily, regarding the dissolution method conditions and apparatus (Garsuch and 
Breitkreutz, 2009; Xia et al., 2015). Another point to consider is the type of oral film to test, 
which may include different challenges and limitations. Briefly, the major restrictions in the 
oral films dissolution methods are the in vivo small volume dissolution, the short residence 
time in mouth (specially fast dissolving films), mucosal absorption (buccal films), 
composition (e.g. adhesive compounds) and incomplete dissolution (sometimes a complete 
disintegration is preferred instead of a complete dissolution). 
Generally, the apparatus selection would be based on two different assumptions: 
orodispersible dosage forms (e.g. orodispersible tablets) or transdermal dosage forms, 
which commonly uses accessories to lock the dosage form in the bottom of the vessel. The 
paddle apparatus (USP type II) is more used (Arun Arya, 2010; Cilurzo et al., 2010; Gohel et 
al., 2009; Gupta M.M et al., 2011; Kunte and Tandale, 2010; Liew et al., 2012; Nishimura et 
al., 2009; Shimoda et al., 2009) than the basket apparatus (USP type I) (Cilurzo et al., 2010; 
El-Setouhy and Abd El-Malak, 2010; Mahesh A, 2010; Sri et al., 2012). But, due to the 
limitations of both methods, many researchers have suggested the use of modified 
apparatus (Dinge and Nagarsenker, 2008; Garsuch and Breitkreutz, 2009; Xia et al., 2015). 
The majority of the modifications consisted in dissolution media volume reduction (usually 
including the vessel type modification), stirring accessory modifications (Dinge and 
Nagarsenker, 2008; Sharma R, 2007; Xia et al., 2015) and type of dissolution medium, such 
as simulated artificial saliva (Arya et al., 2010; Gohel et al., 2009; Gupta et al., 2011).  
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Additionally, Gursuch et al. presented a fibre-optic sensor system to overcome the shorter 
intervals sampling collection (lower than 30s) and the filters clog in apparatus with modified 
sample withdraw (Garsuch and Breitkreutz, 2009). In fact, fast orodispersible films usually 
exhibit a rapid disintegration / dissolution, becoming sometimes hard to obtain suitable 
dissolution profiles with the conventional (manual or automated) sampling collection. 
Although the online measurement may surge as a suitable alternative for fast dissolvable 
dosage forms, some points should be considered. The majority of the online fibre optic 
sensor systems currently available usually use UV spectroscopy, which becomes unviable if 
there is similar absorption spectrum between drug substance and any other compound of 
the formulation.  
The selection of the correct apparatus and possible adaptive accessories should also be 
carefully chosen. One-layer fast dissolving films should have both surfaces in contact with 
the dissolution media, but in multi-layer films this choice may not be the most appropriate. 
Furthermore, the adhesion of some components of the formulation may also origin trapped 
disintegrated masses on the accessory / sinker / basket used, resulting in irreproducible 
dissolution profiles.  
Another approach is the usage of the paddle over disk apparatus (USP type V). This 
dissolution apparatus was used in the development of Zuplenz® along with a gastric pH 
dissolution media. This may be justified since the primary objective of this fast dissolving film 
is to disintegrate fast in the mouth to be readily swallowed with the saliva (Warren and 
Balerna, 2010). 
Finally, there are many critical points to consider in the development of the dissolution 
method and many options are available due to the nonspecific or inexistence of 
pharmacopeia guidance. However, the method choice should be well grounded and 
justified.  
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Table 3 - Summary of the dissolution methods currently used to test oral films. 
(Par Pharmaceutical, 2010)(Shimoda et al., 2009) (El-Setouhy and Abd El-Malak, 2010) (Nishimura et al., 2009) (Cilurzo et al., 2010) (Gohel et al., 2009) (Arun Arya, 2010) (Mahesh A, 2010) (Kunte and 
Tandale, 2010) (Gupta M.M et al., 2011) (Liew et al., 2012) (Cilurzo et al., 2011) (Sri et al., 2012) (Dinge and Nagarsenker, 2008) (Sharma R, 2007) (Xia et al., 2015)  
Sampling Details
900 mL 
0.1N HCl
37.0⁰C ± 0.5⁰C
900 mL of phosphate 
solution (pH 1.2)
37.0⁰C ± 0.5⁰C
50 rpm
USP type I
400 ml freshly distil led 
water, 37±0.5°C 100 rpm
2, 4, 6, 8, and 10 
min
(El -Setouhy and 
Abd El -Malak, 
2010) 
10 mL
 from 2 min to 
120 min
USP type II
300 mL freshly deionized 
water, 37±1°C 
50 rpm
(Ci lurzo et a l ., 
2010)
300 ml distil led water or 
simulated saliva (pH 6.8) or 
5 ml 
900 mL of simulated gastric 
fluid (pH 1.2) 
0-, 1-, 2-, 3-, 5-, 
10-, and 20-
minute
37°C ± 0.5°C
Simulated saliva 
(phosphate buffer pH 6.4)
37±0.5°C. 
300 ml 
Simulated saliva 
(phosphate buffer pH 6.8) 
or 
900 ml of simulated gastric 
fluid (0.1N HCl)
37 ± 0.5°C
900 mL 
phosphate buffer pH 6.6
37±0.5°C
simulated saliva 
(phosphate buffer pH 6.8)
900 ml phosphate buffer 
saline (pH6.8) 
37⁰C,
900 mL 3 mL
0.1 M HCl 
1, 3, 5, 10, 20 
and 30 min
37.0±0.5°C
500 mL
deionized water
37 ±1⁰C
900 ml 
buffer pH 6.8
37⁰C ± 1⁰C
20 ml 4 ml 
Phosphate buffer pH 6.4
7, 14, 21, 28, 35 
and 42 min 
1000 ml
Distil led water
37.0±0.5°C
100 ml 30rpm 
Distil led water 50 rpm 
 100 rpm.
Apparatus Reference
USP type V 50 rpm
10 minute 
intervals
(Par 
Pharmaceutica l , 
2010)
Dissolution Media Stirring
Ten-mill i l iter 
aliquot from 2 
min to 60 min
(Shimoda et a l ., 
2009)
900 mL of phosphate 
solution (pH 1.2), 37 ± 0.5 C 
50 rpm
(Nishimura et 
a l ., 2009)
USP type II 50 rpm
Simulated saliva:12 mM 
KH2PO4, 40 mM NaCl, 1.5 mM 
CaCl2 and NaOH to pH 6.8)
(Gohel  et a l ., 
2009)
USP type II (Arun Arya, 2010) 
USP type II (?) 50 rpm 1 to 30 min
(Kunte and 
Tandale, 2010)
USP type I 50 rpm. 5 mL 
(Mahesh A, 
2010)
USP type II 50 rpm
1, 2, 3, 4, 5, 10, 
15, 20 and 30 
minute
(Gupta  M.M et 
a l ., 2011)
USP type II 50 rpm Reposition 
(Liew et a l ., 
2012)
(Sharma R, 2007)
USP type I 25 rpm
(Ci lurzo et a l ., 
2011)
USP type I 5 ml Media reposition (Sri  et a l ., 2012)
Third method apparatus 
Chinese Pharmacopeia 
(CP 2010, appendix XD 
modified
Autosampling
Film samples were 
sandwiched between two 
pieces of a sieve mesh and 
fixed in the right and vertical 
position 
(Xia  et a l .)
Method
Media reposition, fi lm was 
placed with the help of forceps 
in a 50 ml glass beaker 
Without the basket attached 
with a shaft.
Each fi lm is attached to a 
glass slide (with glue) that 
remains  in the bottom of the 
vessel 
Simulated saliva: 2.38 g 
Na2HPO4, 0.19 g KH2PO4, and 
8.00 g NaCl per l iter adjusted 
with phosphoric acid to pH 
6.8).
JP15 paddle apparatus
JP15 paddle apparatus
Modified USP-XXIII 
type1 apparatus
100 rpm
(Dinge and 
Nagarsenker, 
2008)
Modified USP XXIII 
apparatus (paddle over 
disk)
100 rpm 5 ml
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11.3. Mucoadhesiveness 
There are no mucoadhesion methods described in any Pharmacopeia. Also, it is complex to 
define an appropriate method considering the numerous approaches available in literature, 
the lack of correlation between in vivo and in vitro tests and the challenge to found intact 
and fresh buccal mucosa (Nair et al., 2013; Preis et al., 2013). Nair et al. recently compiled 
the most used in vitro techniques to evaluate the buccal films with a short but relevant 
section of mucoadhesive studies (Nair et al., 2013). 
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12. Conclusion 
The flexibility of this dissolvable film technology platform offers future potential for 
expanded applications across different delivery routes in multiple pharmaceutical, 
biopharmaceutical, and medical markets. It also provides an opportunity to extend revenue 
life cycles for existing drugs whose patent is expiring and will soon be vulnerable to generic 
competition. In other words, oral films allow the lifecycle management of the products. 
Additionally, the majority of the manufacturing approaches used are well understood and 
easily controlled, prompting a robust and efficient development from bench to market. 
There are some important issues that should be taken in consideration regarding the oral 
films development, manufacturing and marketing. During the development the critical 
quality attributes should be well-stablished to prevent unfortunate and uncontrolled events. 
Despite the complexity of the formulation and process, a deep knowledge of the system may 
be sufficient to control and surpass some inevitable and unpredictable proceedings.  
Finally, it is important that the combination of thin film technology with the selected drug 
substance gain wide consumer acceptance and pave the way for other medicines to move 
to this portable, exceptionally convenient pharmaceutical form.  
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1. Introduction 
The oral route remains the most preferred for the general population (Rosen and Abribat, 
2005). It is easier, non-invasive, convenient and flexible, and generally oral formulations 
have a lower cost of production for the pharmaceutical companies. These facts justify why 
the oral delivery market holds 52% of the market share remaining the largest sector in the 
overall drug delivery market (GBI Research, 2010; Research Report, 2013; Vasisht and Finn, 
2008). Although the majority of drugs are administered in the form of tablets and capsules, 
several groups of patients have serious swallowing difficulties. It is estimated that almost 
28% of the general population have frequent problems in swallowing medicines that is often 
the cause of poor patient compliance (Schiele et al., 2013). This is commonly associated to 
dangerous tablets and capsules’ modifications, such as splitting or crushing, related with 
dosage inaccuracy and drug therapy inefficiency or overdosing (Stegemann et al., 2012). In 
order to overcome these issues, fast dissolving delivery systems are gaining considerable 
attention. Among them, oral films have emerged and have been dragged by this urgent 
market need. 
There is no strong evidence or consensus about the date for the first reference of 
orodispersible delivery systems (Bala et al., 2013) but the most likely pioneer in the 
conception of orodispersible films was Deadman Frederic in 1960s (Hoffmann et al., 2011). 
Nevertheless, it remained just a concept until 2001 when Pfizer introduced in the market 
the major orodispersible film blockbuster, the Listerine® Pocket Packs® (Levinson, 2012).  
There is an evident trend that the pharmaceutical field is moving from the conventional and 
traditional to the innovative and patient-centred developments. There is also an increase 
demand of the authorities for knowledge, in order to improve the quality of the products, 
and the optimization and lean of the resources.  
This section of the review highlights the Intellectual Property developed in this field, looking 
over the major players in the area, their platform technologies and all the commercial 
evolution through a summary market outlook and trends.  
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2. Intellectual Property 
The drug delivery technology is an area with extensive intellectual property protection which 
is extremely important and required considering the high competitiveness of this fast-
evolving field. There are a considerable number of institutions developing oral films, which 
can be easily confirmed by the constant growing number of patent applications. In fact, the 
increasing number of patents filled each year is impressive and more than 132 patent 
families have been identified and at least 30 companies / institutions are developing these 
technological platforms (Evalueserve, 2011). Until 2011, the majority of the patents were 
filled in the US and Japan, by the top players such as MonoSol and Kyukyu Pharmaceuticals 
Co. LTD, with Europe gaining some ground in the recent years with LTS Lohmann Therapy-
Systems (LTS), Labtec Pharma, Hexal Pharmaceuticals and others. Additionally, LTS and 
MonoSol are clearly the major players with a broader technology coverage concerning the 
intellectual property, highlighting the diversified and fuelled research of these companies in 
the field (Evalueserve, 2011). At the moment according to the recent published Root Analysis 
report, MonoSol is the most prominent player in the oral thin films, with nine products 
already on the market based on its own technology (Ryoo et al., 2012). 
Regarding intellectual property protection, an exhaustive search in free patent databases 
(google patents, Espacenet, WIPO) reveals that the composition patents are the larger slice 
in the overall patents filled. Among them, few are restricted to a specific therapy or drug 
substance, and the majority is therapeutically broader and focused in the composition of the 
technology, claiming essentially the film forming polymer(s), crucial for the matrix 
formation. The process patents have also some relevance, but only a few are restricted to a 
specific drug, therapy or method of use.  
The most patented polymers are polysaccharides, including starch, cellulose and its 
derivatives (Figure 7). As already described in the part 1 of this review, these are two large 
groups of polymers that can be subdivided into subclasses according to the modifications 
and substituents added to the native natural polymer backbones.  
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Figure 7 - Overall Scenario of polymers usage. The Polysaccharide group comprises starch derivatives, 
pectin, gums, dextrans and alginates; other polymers group includes polyvinyl and polyethylene glycol 
polymers and co-polymers; the proteins groups consists of soy proteins, casein, zein, collagen and 
others; the acrylates groups refers mainly to methacrylate and polyacrylic polymers. 
 
The use of the majority of hydrophilic polymers in formulations of oral films is already 
protected by several patents, restricting the possibility of developing formulations that do 
not infringe existing patents and capable of being protected by new ones. During the last 
years the development of new polymers suitable to this technological platform was scarce, 
leading to an increasing number of process patent applications, and patent formulations 
related with specific drug substances or therapies. 
Furthermore, the difficulty in innovating in the formulation composition due to the small 
number of suitable excipients had probably contributed to new directions in this research 
field, such as  the development of new manufacturing processes (Breitenbach et al., 2013; 
Janssen et al., 2013) (see part 1 review), or the usage of oral films as drug delivery systems 
for biotechnology products (e.g. vaccines and insulin) (Cohen et al., 2012; Fierce Drug 
Delivery, 2012; Pulliam, 2012; Warren, 2012). 
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3. Technological platforms 
The majority of the top player companies referred above followed a similar pattern. 
Generally, a new and innovative technological platform is developed (like an oral film 
placebo) and then several drug candidates are evaluated and considered to be incorporated 
in the film. Obviously, this strategy implies necessarily the development of a versatile oral 
film platform, which in turn may suffer some modifications depending on the drug substance 
characteristics and the desired final dosage form performance.  
Furthermore, it is common in this market segment the establishment of partnerships 
between oral film developers / manufacturers and other pharmaceutical companies 
researching new chemical entities, developing novel uses for existing drugs (repurposing) or 
companies looking for innovative formulations for their drugs (life-cycle management). This 
strategy is beneficial to share fixed expenses associated with the product licensing and 
marketing (Belanger et al., 2009). Therefore, two different major players may be 
distinguished in this field: the oral film platform developers, usually the technology owners, 
and the marketing partners.  
Several oral film platforms have been already developed, the majority is listed on Table 4 
and some are revised herein. 
 
3.1. Pharmfilm®  
MonoSol, one of the pioneer companies in the oral film industry owns a protected drug 
delivery technology, PharmFilm®. MonoSol’s film technology is supposed to be more stable 
and robust than other conventional dosage forms with a loading capacity up to 80 mg. The 
Pharmfilm® is a polymeric matrix based on polyethylene oxide and hydroxypropylmethyl 
cellulose, which normally is related with fast dissolution rates and rapid drug absorption 
(Morales and McConville, 2011). However, MonoSol claims that this technological platform 
can be used for either fast dissolving system or buccal delivery. In fact, ondansetron 
hydrochloride had been successfully incorporated into the PharmFilm® technology as fast-
dissolving system and others drug substances such as montelukast sodium, rizatriptan, 
escitalopram oxalate, donezepil hydrochloride and epinephrine are being considered or 
under development as oral quick release formulations (Dixit and Puthli, 2009; MonoSol Rx, 
2008; Monosol Rx LLC, 2013; NASDAQ OMX, 2013; PRNewswire, 2011; Reuters, 2014). 
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Additionally, as previously referred, the Pharmfilm® technology is also available as a slower 
release sublingual formulation (Suboxone® sublingual film) (Monosol Rx LLC, 2013).  
Moreover, MonoSol has established strategic partnerships to develop biotechnology 
sublingual and buccal films based on PharmaFilm® technology, such as anti-diabetic oral 
films or films to deliver a vaccine for universal flu. Together with Midatech, MonoSol has 
developed Nanoinsulin (insulin gold nanoparticles, MidaForm insulin) to incorporate in the 
MonoSol's PharmaFilm® buccal film technology, for the potential treatment of diabetes. In 
the beginning of 2013, this investigational medicinal product was listed as being in clinical 
development. Nevertheless, another buccal PharmaFilm® loaded with MidaForm 
nanoparticles, containing insulin and GLP-1, is also in preclinical development 
(FierceDrugDelivery, 2012; Monosol Rx LLC, 2013; PRNewswire, 2013).  
MonoSol in association with BiondVax Pharmaceuticals is developing a sublingual film 
formulation for vaccination, with the Multimeric-001 (M-001), for the potential prevention 
of universal influenza infection. It is expected that this type of formulation will allow the 
stability of the vaccine at room temperature (Reuters, 2012; Warren, 2012).  
 
3.2. RapidFilm®  
RapidFilm® is another patented technology developed by Labtec GmBH. The Rapidfilm® is a 
fast dissolving thin film based on water soluble polymers, non-mucoadhesive, which can vary 
from single to multilayer design system. This oral film platform is based in a PVA-Starch 
mixture plasticized with a medium Mw PEG. The composition used allows its fast dissolution 
rate when in contact with the oral mucosa (Leichs et al., 2008). It is claimed that RapidFilm® 
can accommodate up to 30 mg of the drug substances (Dixit and Puthli, 2009; tesa Labtec 
GmbH, 2015). The ondansetron Rapidfilm® was the first Rx oral film approval worldwide, but 
at the moment, there are at least three more Rapidfilm® products in the European market 
(APR Pharma, 2014) (see table 4).  
 
3.3. VersaFilm™ 
VersaFilm™ technology was developed and patented by IntelGenx Technologies Corp. 
Initially developed as an edible film for the instant delivery of savoury flavours to food 
substrates, VersaFilm™ is now used as a system of choice for indications requiring an 
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immediate onset of action. Thus, the company advances that VersaFilm™’s disintegration 
time may be wrought from 30 seconds to 10 minutes, and it can be sublingual, depending 
on the intended application. The maximum drug load claimed is around 40mg. According to 
IntelGenx pipeline there are several drug substances in consideration or being incorporated 
in the Versafilm™ technology. However, only one has recently received a complete response 
letter from FDA, the rizatriptan VersaFilm™, an oral quick release film for migraine, 
developed together with RedHill Biopharma Ltd (IntelGenx and Biopharma, 2014; IntelGenX 
Corp., 2006).  
 
3.4. Orally and Adhesive Disintegrating Films 
KyuKyu Pharmaceuticals Co. LTD is a Japanese company that also has its own oral film 
platform technology. Actually, KyuKyu have 2 different technologies the “Orally 
Disintegrating Film”, which dissolves in 10 to 30 seconds and the “Adhesive and 
Disintegrating Film” that adheres to the oral mucosa and the disintegration time can vary 
between 30 minutes and 8 hours (KyuKyu Pharmaceuticals Co.). KyuKyu presents a large 
pipeline with several oral dispersible films in the market, mainly in the Asian market. 
Recently, it started to develop buccal films for the treatment of cancer-related pain and 
nicotine dependence. In collaboration with Nippon Kayaku, a buccal formulation of fentanyl 
is being developed and a phase II trial is being conducted (Pharma & MedTech Business 
Intelligence, 2009). Regarding to the nicotine mucoadhesive disintegrating film, it was in the 
fourth quarter of 2013 listed as being in lead optimization. 
 
3.5. SmartFilm® 
Seoul Pharma has developed the SmartFilm® technology, an oral film with a high loading 
dose capacity, over 140 mg, capable of incorporating both hydrophilic and hydrophobic 
drugs, with unique taste masking technology and an eco-friendly manufacturing process 
(aqueous solution based). This South Korean pharmaceutical company launched Vultis® in 
the Korea market in 2012, a 140.45mg film formulation of sildenafil citrate. At the end of the 
same year, Seoul Pharma licensed it out to Pfizer which rebranded it as (Thomson Reuters 
Cortellis, 2013a, 2013b). The Sildenafil SmartFilm® technology is a fast dissolving film 
composition that uses a combination of magnesium oxide and sodium hydroxide to mask 
the bitter taste of the drug substance. Seoul Pharma is currently seeking and researching 
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other molecules to incorporate in its own oral film technology (Jeon et al., 2012; Jeong et 
al., 2013; Seoul Pharma, 2012). 
 
3.6. BEMA® 
BioDelivery Sciences International owns the worldwide rights of BEMA®, bio-erodible 
mucoadhesive, drug delivery technology. This drug delivery technology consists in a 
bioerodible polymer film which adheres quickly to the oral mucosa (less than 5 seconds) with 
a backing layer that assures the unidirectional diffusion of the drug substance. This 
multilayer buccal film technology can rapidly deliver a dose of drug across the oral mucosa 
and is completely dissolved within 15 to 30 minutes. The BEMA® technology may be 
developed to incorporate several drug substances, especially if a quick onset of action is 
required, the oral administration dose is not optimal (low oral bioavailability) or if parental 
administration is not an option (BioDelivery Sciences International, 2014b). Onsolis®, 
fentanyl buccal film, was the first product developed and marketed based on BEMA®’s 
technology, for the management of cancer pain in opioid-tolerant adults. It was launched in 
2009 (HighbeamBusiness, 2009), but by March 2012, the Onsolis® production had been 
temporarily closed in the US, due to FDA concerns regarding the manufacturing process 
(Pešić, 2010). In January 2014, it was announced that the re-launch of the product is planned 
to occur in the second half of 2014 (PR Newswire, 2014; PRWeb, 2012). In Europe, the 
product was approved in October 2010 as Breakyl® (Raleigh, 2010). Currently the BEMA® 
technology is being applied to improve the delivery of other therapies, as the opioid 
dependence with Bunavail™, previously referred. The base formulation of the BEMA® layers 
is very similar. Both the active and the backing layer are composed by hydroxypropyl 
cellulose, hydroxyethyl cellulose, but the active layer presents additional mucoadhesive 
polymers, as polycarbophil and carboxymethylcellulose sodium. Interestingly the sweetener 
and flavour are only present in the backing layer (DataPharm, 2015; Morales and McConville, 
2011). 
 
3.7. Bio-FX® Fast-Onset Oral-Cavity ODF 
Another technology platform is the Bio-FX® Fast-Onset Oral-Cavity ODF from NAL 
Pharmaceuticals Ltd. Briefly, it is an oral film formulated with a Bio-FX® absorption enhancer 
system, which increases the absorption of the drug substances through the oral mucosa with 
the aim to improve the oral bioavailability of drugs by avoiding the first-pass metabolism 
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and gastrointestinal degradation. This technology also incorporates a especial designed 
taste-masking system to improve taste and mouthfeel (NAL Pharma, 2014). Currently, there 
are no available products on the market with this technology, but several are under 
development. 
 
3.8. Quicksol® 
Quicksol® technology is the oral film platform from SK Chemicals that can accommodate a 
wide variety of drug substances. According to the company’s pipeline, several drug 
substances were loaded, but only two are already on the market, Montfree (Montelukast) 
ODF and Mvix-S (Mirodenafil) ODF (SK Chemicals, 2014). Mvix-S is a thin, light and portable 
50 mg oral film, available since January 2012, with a mirodenafil rate absorption 16.7% 
higher than Mvix tablet. Additionally, 15 days after its launch, Mvix-S sold over 1 billion units 
(SK Chemicals, 2012). 
 
3.9. Fast-onset sublingual bilayer film 
Cynapsus developed a fast-onset sublingual bilayer film of apomorphine, the APL-130277. 
The apomorphine in its neutral form (which may permit its fast mucosal absorption) is easily 
oxidized making difficult its incorporation in a film. Therefore, the apomorphine non-neutral 
form is loaded in one film layer, and a neutralizing agent is incorporated in other film layer, 
physically separated from each other. The neutralizing agent’s layer dissolves quickly upon 
contact with saliva, allowing a fast reaction with the drug substance for a rapidly absorption. 
Clinical trials demonstrated that the maximum blood levels were reached within 20 minutes 
of administration, in the majority of subjects, and that it has a good local tolerability (no 
irritation). The submission of a FDA 505(b) (2) NDA is expected to 2016, since Cynapsus 
estimate to complete efficacy and safety studies by the end of 2014 and 2015, respectively. 
This sublingual formulation had already proved to work in the most severe cases of 
Parkinson’s disease. Moreover, it may also present patient benefits and competitive 
advantages over the subcutaneous injection available and the inhaled and pulmonary 
approaches that are still in early development stages. According to their patent application 
the main polymer may be a cellulose, as HEC and / or a modified starch as maltodextrins, or 
even a mixture thereof (Cynapsus, 2014).  
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3.10. Biodegradable transmucosal film 
In the first quarter of 2005, Auxilium Pharmaceuticals had licensed an oral drug delivery 
system, based on the PharmaForm technology after their drug delivery platform acquisition. 
This platform is a biodegradable transmucosal film that adheres to the upper gum, 
preferentially above the back molar, and after that it completely dissolves. PharmaForm 
technology may allow a more effective delivery of the substances through a higher rate of 
drug absorption, contributing to achieve the same therapeutic levels with lower doses when 
compared with the conventional dosage form, shorter onset of action, reduction of first pass 
metabolism and probably less frequent dosing. Auxilium was using this technology platform 
to incorporate drug substances for the treatment of overactive bladder, management of 
pain and androgen replacement therapy. According to the company information, the 
overactive bladder transmucosal film candidate was supposed to be moving to phase II 
studies, after being demonstrated that oxybutynin could be administered using the 
transmucosal film, but no development has been recently reported. Similarly, Fentanyl 
Pharmaform film, which was in phase I development in 2011, has no recent updated 
information. Regarding to testosterone transmucosal film (TestoFilm), it was in a phase III 
trial in the beginning of 2006. However, in the last quarter of the same year Auxilium 
discontinued the development claiming that the formulation would not be commercially 
viable (Auxilium Pharmaceuticals, 2005a, 2005b).  
 
3.11. Eluting Bandage Platform 
Pharmedica has an innovative and patented oral film platform, the Eluting Bandage 
Platform. This is a multiple characteristic platform that can be used as single or multiple 
layer, with fast or slow disintegration time and for combined or protective treatment. Eluting 
Bandage Platform is a multi-purpose and multi-functional device that can be used for a large 
range of products, from fresh breathers to prescription products. Pharmedica was 
developing oral formulations of insulin for the potential treatment of diabetes which had a 
launch predicted date for 2013. However, no more information is available, but according to 
the company's website the insulin, together with cannabinoids, is still listed as a potential 
product for the Eluting Bandage platform (PharMedica Ltd, 2014). 
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3.12. XgelTM 
XgelTM film’s technology is the basis of Meldex International intellectual property, used in all 
its film systems: SoluleavesTM, FoamburstTM and WafertabTM. Soluleaves™ platform can be 
designed for fast dissolving release or to adhere to the oral mucosa for a slow release of the 
drug substance. The Foamburst™ is a variant of the previous technology where an inert gas 
is passed during the film’s manufacture resulting in a honeycomb structure that controls the 
dissolution rate of the drug substance contributing to a novel mouth sensation. In turn, the 
Wafertab™ platform is prepared from a placebo XgelTM film in which the drug substance is 
added afterwards, thus preventing its exposure to unnecessary heat and moisture. This 
technology allows the manufacture of unstable drugs and the preparation of multilayer films 
(Arun Arya, 2010; Dixit and Puthli, 2009). In 2007, Meldex was developing nicotine 
SoluleavesTM, but no recent development has been reported. According to the patent 
information this is a cellulose derivative based film (Zbygniew and John, 2006). 
 
3.13. ThinsolTM 
BioEnvelop (or Paladin Labs) has also its own patented technology, the ThinsolTM, an oral 
film based on enzymatically digested carboxymethylcellulose. This platform is a fast 
dissolving film (from five to 30 seconds) that allows a drug loading up to 60% and can be 
used to incorporate heat sensitive drugs, since it can be dried at low temperatures(Dixit and 
Puthli, 2009; Megget, 2007; ODFPharma inc., 2011; Paladin Labs Inc, 2007). 
Interestingly, the NeuroHealing Pharmaceuticals Inc. developed an intra-oral slow dissolving 
mucoadhesive thin film based on the original formulation of Listerine Pocket Packs®. This 
modified oral film was developed to incorporate 1mg of tropicamide for sialorrhea 
treatment. In fact, this buccal film platform, designated by the code name NH004, has two 
main modifications: additional mucoadhesive properties and a slower dissolution capability. 
Therefore the NH004 easily adheres to the oral mucosa to dissolve slowly, over a period of 
60-90 minutes, so the drug can be absorbed locally near the submandibular salivary gland 
(Neurohealing Pharmaceuticals, 2012). Currently a phase II clinical trial is being conducted 
in order to evaluate the safety and efficacy of tropicamide thin films in hypersalivation 
Parkinson's patients treatment (NeuroHealing Pharmaceuticals Inc, 2013).  
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3.14. Schmelzfilmen 
The “Schmelzfilmen”, or melting film, was developed by Hexal and has currently four 
marketed products: olanzapine, sildenafil, donepezil and risperidone (LTS Lohmann 
Therapie-Systeme AG, 2014; Medicines and Healthcare products Regulatory Agency, 2013; 
Siebenand, 2010). Although there are some composition variations between the four 
formulations, they are mainly cellulose based films. The olanzapine oral film commercially 
available presents Ethylcellulose as main film forming polymer, plasticized with 
dibutylsebacate, and apparently according to the patent claims the HPMC is essentially used 
as gelling agent, although the amounts described may indicate that it can also be used as a 
film-forming polymer (Heads of Medicines Agencies, 2014; Klokkers et al., 2007; Krekeler 
and Neumann, 2012; Medicines and Healthcare products Regulatory Agency, 2011, 2013). 
 
3.15. Others 
Additionally, other attention-grabbing technology is Nutra3 Complex®, a fast dissolving strip 
with a high loading capacity around 250 mg per film. Unfortunately, there are no recent 
reports regarding this product (PR Newswire, 2010). 
Also, FFT Medical presented its own transmucosal drug delivery technology based on a 
alginate polymeric film, the FFT trans-mucosal film. The company claims that this technology 
allows delivering a wide variety of substances by a rapid and consistent absorption through 
the oral mucosa surface directly into the bloodstream. They also refer that the drug 
dissolution is performed in a controlled rate to avoid the release to the saliva (Cohen et al., 
2012). 
Additional information about these technology platforms and others are summarized in 
table 4. 
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Table 4 - Oral Films’ technology platforms, their owners or developers, related patents and associated marketed products.* – means that there is no specific 
information about the designation and /or status of the technology / product. (Spence Leung et al., 2001; Susan Banbury and MacGregor, 2011) (IntelGenx and Biopharma, 2014; IntelGenX Corp., 2006; Paiement et al., 2011) (Belanger et al., 2009; Dixit and Puthli, 2009; Genevieve; et al., 2009; Labs and INC., 2007; Megget K, 2007; ODFPharma inc., 
2011) (Bogue et al., 2012a; Bogue et al., 2012b; Dadey and Schobel, 2013; Dixit and Puthli, 2009; FierceDrugDelivery, 2012; Fuisz and Fuisz, 2012; Mickle, 2013; Mickle, 2008; MonoSol and Rx, 2008; Monosol Rx LLC, 2013; NASDAQ and OMX, 2013; PRNewswire, 2011c; Reuters, 2014; Susan Banbury and MacGregor, 2011; Yang and Fuisz, 2003; Yang et al., 2004, 2006) (APR Pharma, 2012) (Awamura et al., 2005; Awamura et al., 2010; Awamura et al., 2011; Furusawa, 2005; Intelligence, 2009; Ishise and Nishikawa, 2013; KyuKyu 
Pharmaceuticals Co.) (Awamura and Sawai, 2003)  
Brand name / 
Designation
Owner / Originator 
Company
Patent
Active Companies / 
Partner / Distributor
Commercial products Drug substance Phase / Status
Oral Film 
Type
Polymer Ref.
US-07407669 B2 Pfizer
Listerine ® Pocket 
Packs®
Launched
McNeil-PPC Sudafed PE™ Phenylephrine Discontinued
McNeil-PPC Benadryl ®
Diphemhydrami
ne hcL
Discontinued
GlaxoSmithKline
NiQuitin Strips 2.5mg 
Oral Film
Nicotine Launched
RedHill Biopharma Rizatriptan film Approved by FDA dispers ible
US-20110136815 Tadalafil film
Phase 2 Clinical 
Pilot study planed 
for Q1 2014
dispers ible
INT0020 
Insomnia
Phase 2 Clinical dispers ible
INT-0022; anti-
psychotic agent
Phase 2 Clinical dispers ible
INT-0023 - 
Allergy
Phase 1 Clinical dispers ible
INT-0025 -  
Prostate 
hyperplasia
Phase 1 Clinical dispers ible
INT0031 Benign 
Prostatic
Hyperplasia
INT0030 – Animal 
health Vetafilm
Pilot study dispers ible
INT0036 - CNS Discovery dispers ible
Paladin Labs WO-2009055923
BioEnvelop's™
U.S. patent No. 
7,824,588
Polyethylene 
oxide and 
HPMC
WO-2011017483
Chloraseptic® Benzocaine Discontinued dispers ible
Little cold sore throat 
strip 
(Pectin) + 
Ascorbic acid
Discontinued dispers ible
WO-2013019187 
WO-2008098151
KemPharm's
Methylphenidat
e prodrug + 
ligand
Discovery dispers ible
WO-2012040262 MonoSol Rx LLC
Montelukast 
Sodium 
Clinical dispers ible
MonoSol Rx LLC
Diphenhydramin
e hydrochloride
* dispers ible
MonoSol Rx LLC Escitalopram
No Development 
Reported
dispers ible
MonoSol Rx LLC Rizatriptan Discovery dispers ible
MonoSol Rx LLC Epinephrine
No Development 
Reported
dispers ible
WO-2013026002 MonoSol Rx LLC Testosterone Discovery
WO-2012177326
Midatech MidaSol 
Therapeutics
Insulin 
nanoparticles 
(MidaForm 
insulin)
Phase 1 Clinical buccal
BiondVax Multimeric-001 Discovery dispers ible
WO-2004066986  
WO-2006031209; 
WO-03030881; WO-
2012040262
MonoSol Rx LLC; Vestiq 
Pharmaceuticals Inc
Zuplenz®
Ondansetron  
Hydrochloride
Launched dispers ible
MonoSol/Midatech GLP-1 peptides Discovery buccal (APR Pharma, 2012) 
WO-2010023874
Kyukyu Pharmaceutical 
Co Ltd
Loperamide Launched dispers ible
Kyukyu Pharmaceutical 
Co Ltd; Maruho Co.,Ltd.
Olopatadine  
Hydrochloride OD Film
Olopatadine  
Hydrochloride
Discovery dispers ible
WO-2013121663
Kyukyu Pharmaceutical 
Co Ltd;  Elmed Eisai 
co.,ltd.
Donepezil 
Hydrochloride OD film
Donepezil 
Hydrochloride
Launched dispers ible
Mochida Pharmaceutical 
Co Ltd
Zolpidem Tartrate OD 
Film
Zolpidem 
Tartrate
Launched dispers ible
Mochida Pharmaceutical 
Co Ltd
Loratadine OD Film Loratadine Launched dispers ible
Teva Pharma Japan Inc. Waplon
Triamcinolone 
Acetonide
dispers ible
US 20040126330 A1
WO-03026654
Kyukyu Pharmaceutical 
Co Ltd; Nippon Kayaku 
Co Ltd
Fentanyl Phase 2 Clinical buccal
WO-2005117803; 
WO-2011108643; 
MOCHIDA 
PHARMACEUTICAL 
Rapid 
Dissolving Film
Kyukyu 
Pharmaceutical Co Ltd
Kyukyu Pharmaceutical 
Co Ltd; 
Adhesive and 
Disintegrating 
Film (ADF)
Kyukyu Pharmaceutical 
Co Ltd
(Awamura and 
Sawai, 2003) 
Launched dispers ible
(Awamura et al., 
2005; Awamura et 
al., 2010; Awamura et 
al., 2011; Furusawa, 
2005; Intelligence, 
2009; Ishise and 
Nishikawa, 2013; 
KyuKyu 
Pharmaceuticals 
Co.) 
Launched dispers ible
Sennosides Discontinued
Nicotine Discovery buccal
Voglibose OD Film Voglibose
Amlodipine OD Film
Amlodipine 
Besilate
VersaFilm™
Intelgenx Technology 
Corp.
 
(IntelGenx and 
Biopharma, 2014; 
IntelGenX Corp., 
2006; Paiement et 
al., 2011) 
(Bogue et al., 2012a; 
Bogue et al., 2012b; 
Dadey and Schobel, 
2013; Dixit and Puthli, 
2009; 
FierceDrugDelivery, 
2012; Fuisz and 
Fuisz, 2012; M ickle, 
2013; M ickle, 2008; 
M onoSol and Rx, 
2008; M onosol Rx 
LLC, 2013; NASDAQ 
and OM X, 2013; 
PRNewswire, 2011c; 
Reuters, 2014; Susan 
Banbury and 
M acGregor, 2011; 
Yang and Fuisz, 
2003; Yang et al., 
2004, 2006)
Reckitt Benckiser 
Pharmaceuticals
Suboxone® Sublingual 
Film
Buprenorphine 
Hydrochloride + 
Launched dispers ible
Prestige Brands
Pharmfilm ® MonoSol Rx LLC
C.B. Fleet Company
Pedia Lax® Quick 
Dissolve Strips
Buccal Wafer LTS Lohman dispers ible
(Spence Leung et al., 
2001; Susan Banbury 
and M acGregor, 
2011) 
dispers ible
(Belanger et al., 
2009; Dixit and 
Puthli, 2009; 
Genevieve; et al., 
2009; Labs and INC., 
2007; M egget K, 
2007; ODFPharma 
inc., 2011) 
Thinsol™
Pilot study dispers ible
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Table 4 - Oral Films’ technology platforms, their owners or developers, related patents and associated marketed products.* – means that there is no specific 
information about the designation and /or status of the technology / product. (Susan Banbury and MacGregor, 2011) (Dixit and Puthli, 2009; Leichs et al., 2008; Press Release, 2009, 2013; Reiner et al., 2010) (Breitenbach and Schwier, 2012a; 
Press Release, 2012) (Breitenbach and Schwier, 2012b)(Breitenbach A et al., 2010) (Pharmazie, 2010)(A et al., 2003; BioDelivery Sciences International, 2014a; Vasisht and Finn, 2008) (Richard and W, 2005)(Dixit and Puthli, 2009)(Auxilium Pharmaceuticals, 2005a; Mao et al., 2010; Zeng and Eleuterius, 2009)(Dixit and 
Puthli, 2009; Zbygniew and John, 2006) (Chu et al., 2012; Pharma, 2014)  
Patent
Active Companies / 
Partner / Distributor
Commercial products Drug substance Phase / Status
Oral Film 
Type
Polymer Ref.
Gas-X® Simethicone Launched dispers ible PVA
Theraflu®Thin Strips® 
Dextromethorph
an
Discontinued dispers ible Starch
Triaminic® Thin Strips® Phenylephrine Discontinued dispers ible
Medium 
MwPEG
WO-2008040534;  
WO-2009043588
Norgine (Europe and 
Middle East, Africa and 
Australasia) /
Setofilm® / dispers ible
SciClone 
Pharmaceuticals, Inc 
Ondansetron 
Rapidfilm® /
dispers ible
Takeda Canada (Canada) 
/
Ondissolve™ dispers ible
Monosol RX § dispers ible
WO-2011124570
APR Applied Pharma 
Research SA; MonoSol Rx 
LLC; tesa Labtec GmbH
Zolmitriptan ODF 
RapidFilm®
Zolmitriptan Launched dispers ible
(Breitenbach and 
Schwier, 2012a; 
Press Release, 
2012)
Aripiprazole ODF Aripiprazole
No Development 
Reported
dispers ible
WO-2012110222
APR Applied Pharma 
Research SA; tesa Labtec 
GmbH
Olanzapine ODF Olanzapine Registered dispers ible
(Breitenbach and 
Schwier, 2012b)
WO-2009043588;  
EP-02213278
APR Applied Pharma 
Research SA; Ferrer 
Internacional SA; tesa 
Labtec GmbH
Donepezil ODF Donepezil Registered dispers ible
(Breitenbach A et al., 
2010) 
WO-2007009801
Olanzapin HEXAL® SF 
Schmelzfilm
Olanzapine Launched orodispers ible
Ethylcel lulos
e
WO-2007009800 Anti-migraine * HPMC
WO-2010115724
Aripiprazole HEXAL® SF 
Schmelzfilm
Aripiprazole * orodispers ible
Hexal Risperidon HEXAL® SF Risperidon Launched orodispers ible
Sandoz Donepezil-HCl Hexal®SF Donepezil Launched orodispers ible
WO-2012055947
SildeHEXAL SF  
(Tornetis)
Sildenafil Launched orodispers ible
Backing layer 
– HPC, HEC
WO-03086345
WO-2008011194; 
Active layer – 
polycarbophi
WO-2007070632
BioDelivery Sciences 
International Inc
BEMA® Granisetron Granisetron Discovery Buccal
WO-2013096811; 
WO-2010008863
Endo Pharmaceuticals BEMA® Buprenorphine Buprenorphine Phase 3 clinical Buccal
BUNAVAIL™
Buprenorphine + 
Naloxone 
NDA submitted to 
FDA on July  2013
Buccal
WO2005016321
BioDelivery Sciences 
International Inc
BEMA® Triptan Triptan Discovery Buccal
(Richard and W, 
2005)
Arius Pharmaceuticals 
Inc
BEMA® Zolpidem Zolpidem
No Development 
Reported
Buccal
dispers ible
(Dixit and Puthli, 
2009)
WO-2010002418 Rotavax™ Rotavirus
phase II clinical 
trials (May 2013)
Buccal
Testosterone Discontinued Buccal
Oxybutynin
No Development 
Reported
Buccal
WO-2009151574 Fentanyl
No Development 
Reported
Buccal
WO-2006114604 
(A3)
Cel lulose 
derivative
Selegiline Discovery
Rizatriptan 
Benzoate
Phase 1 Clinical
Nicotine Discovery
Levocetirizine Discovery
Zolmitriptan Discovery
Sumatriptan Discovery
Sildenafil citrate Phase 1 Clinical
Tadalafil Discovery
Montelukast Discovery
Fentanyl Discovery
Cetirizine HCl Discovery
Donezepil Discovery
Zolmitriptan Discovery
(Pharmazie, 2010)
Novartis Consumer 
Health
(Susan Banbury and 
M acGregor, 2011)
Ondansetron  
Hydrochloride
Launched
(Dixit and Puthli, 
2009; Leichs et al., 
2008; Press 
Release, 2009, 2013; 
Reiner et al., 2010) 
Meldex International Nicotine
(Auxilium 
Pharmaceuticals, 
2005a; M ao et al., 
2010; Zeng and 
Eleuterius, 2009)
KunWha Pharmaceutical 
Co Ltd; Meda AB; TTY 
Biopharm Co Ltd
Onsolis®
dispers ible
(Chu et al., 2012; 
Pharma, 2014) 
Fentanyl Launched Buccal
(A et al., 2003; 
B ioDelivery 
Sciences 
International, 2014a; 
Vasisht and Finn, 
2008) 
Buccal
(Dixit and Puthli, 
2009; Zbygniew and 
John, 2006)
No Development 
Reported
WO-2010062688
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Table 4 - Oral Films’ technology platforms, their owners or developers, related patents and associated marketed products.* – means that there is no specific 
information about the designation and /or status of the technology / product. (Choi et al., 2013; Jeong et al., 2013; Lee, 2013; SK Chemicals, 2014; Thomson Reuters Cortellis, 2013a, b) (Choi et al., 2013; Lee, 2013; SK Chemicals, 2014) (Astra 
Zeneca, 2012; AstraZeneca, 2012) (Neurohealing Pharmaceuticals, 2012; NeuroHealing Pharmaceuticals Inc, 2013; Ron et al., 2006) (PharMedica Ltd, 2014; Ron, 2012) (Cynapsus, 2014; Giovinazzo et al., 2012; John; et al., 2010) (Repka M A, 2003)  (PRNewswire, 2011a)  (PRNewswire, 2011b)  (T; et al., 2010)  (Jun and 
Jung, 2012)  (Kim, 2014) (Jeon et al., 2012; Yoo et al., 2013; Yoon, 2013)  (PR Newswire, 2012) (Cohen et al., 2012; Puri and Zielinski, 2007; Ryoo et al., 2012) (Wood et al., 2013) (Pulliam, 2012) (Ryoo et al., 2012)  
Brand name / 
Designation
Owner / Originator 
Company
Patent
Active Companies / 
Partner / Distributor
Commercial products Drug substance Phase / Status
Oral Film 
Type
Polymer Ref.
WO-2013129889 Pfizer Inc Vultis® Sildenafil citrate Launched dispers ible
SPO-1202  Attention 
deficit hyperactivity 
disorder
Discovery
SPO-1201  Depression Discovery
SPO-1113  
Schizophrenia
Discovery
SPO-1108  Asthma Discovery
SPO-1112 - Dementia Discovery
WO-2013100564 Montelukast
Launched (Korea)  
Initiated EU 
development
dispers ible
WO-2013085276
Mirodenafil 
hydrochloride
Launched dispers ible
Orally Rapid 
Disintegration 
Film
AstraZeneca plc Anastrozole ODF Anastrozole
Phase 1 Clinical 
completed
dispers ible
(Astra Zeneca, 2012; 
AstraZeneca, 2012)
WO/2012/104834 Insulin
No Development 
Reported
Buccal
Cannabinoids
No Development 
Reported
Buccal
Fast-onset 
sublingual 
bilayer film
Cynapsus 
Therapeutics
WO-2012083269;  
WO-2010144817
Cynapsus Therapeutics APL-130277 Apomorphine Phase 1 Clinical
dispers ible bi -
layer 
subl ingual
Cel lulose 
(HEC?) and / 
or modified 
s tarch (MDX)
(Cynapsus, 2014; 
Giovinazzo et al., 
2012; John; et al., 
2010)
Transmucosal 
Matrix Patch
ElSohly 
Laboratories, Inc
Dronabinol Discovery buccal (Repka M  A, 2003) 
Midazolam maleate
No Development 
Reported
dispers ible (PRNewswire, 2011a) 
Naloxone
No Development 
Reported
Subl ingual (PRNewswire, 2011b) 
WO-2010151020 (T; et al., 2010) 
WO-2012121461 Montelukast sodium Pre-registration dispers ible (Jun and Jung, 2012) 
WO-2014025206 Aripiprazole (Kim, 2014)
WO-2013002578 Clomipramine Pre-registration dispers ible
Tadalafil Clinical dispers ible
Donepezil Clinical dispers ible
WO-2012108738
CTC Bio Inc; Dong Kook 
Pharmaceutical Co Ltd; 
Huons Co Ltd; Jeil 
Pharmaceutical Co Ltd; 
Jin Yang Pharm Co Ltd; 
KunWha Pharmaceutical 
Co Ltd
Sildenafil Launched dispers ible
Artesunate
and
Amodiaquine
FFT Medical Adrenaline Pre-clinical
Cancer Pain
Pending/under 
negotiation
Erectile Dysfunction Out-licensed
Migraine Out-licensed
Parkinson’s disease
Under 
development
WO-2013143891 NRT / Nicotine Out-licensed (Wood et al., 2013) 
Aavishkar Tadalafil Tadalafil Launched
Ondansetron Hcl Ondansetron Hcl Launched
Simethicone Simethicone Launched
Dextromethorphan 
Hbr Phenylephrine 
Hcl 2.5 mg Strips 
Dextromethorphan Hbr 
(Cough & Cold)
Phenylephrine Hcl 2.5 
mg 
Vitamin B12 strips Vitamin B12 Launched
Vitamin D3 strips Vitamin D3 Launched
Electrolyte Strips
Vitamin B12 + Vitamin C + 
Sodium + Potassium
Launched
Energy strips
Caffeine + Vitamin B12 + 
Vitamin E + Vitamin B6+ 
Biotin+ Vitamin B5
Launched
Melatonin Strips Melatonin Launched
Teeth Whitening 
Strips
6% Hydrogen Peroxide Launched
Breath Freshening 
Strips
Launched
AVISH-01 ( AIDS) Discovery (Ryoo et al., 2012) 
AVISH-02 (Vaginal 
infections)
R&D completed
SmartFilm® Seoul Pharma Co Ltd
(Choi et al., 2013; 
Jeong et al., 2013; 
Lee, 2013; SK 
Chemicals, 2014; 
Thomson Reuters 
Cortellis, 2013a, b)
Quicksol® SK Chemicals Co Ltd SK Chemicals Co Ltd
(Choi et al., 2013; 
Lee, 2013; SK 
Chemicals, 2014)
Phase 2 Clinical Buccal Pul lulan
(Neurohealing 
Pharmaceuticals, 
2012; NeuroHealing 
Pharmaceuticals 
Inc, 2013; Ron et al., 
2006)
Eluting Bandage 
Platform
Pharmedica
(PharM edica Ltd, 
2014; Ron, 2012)
Thin film
NeuroHealing 
Pharmaceuticals Inc
WO-2006078998 Tropicamide
*
Aoxing 
Pharmaceutical
*
CHA Bio & Diostech 
Co Ltd
Oral thin film CTC Bio Inc
(Jeon et al., 2012; 
Yoo et al., 2013; 
Yoon, 2013)  
Oral thin Film
CURE 
Pharmaceutical Inc
CURE Pharmaceutical 
Inc
PediaSUNATE™ Discovery (PR Newswire, 2012) 
Trans-mucosal 
Drug Delivery
WO-2007073346
Fi lm-forming 
agent 
compris ing an 
a lginate sa l t 
of monovalent 
cation
(Cohen et al., 2012; 
Puri and Zielinski, 
2007; Ryoo et al., 
2012) 
Oral Dispersible 
Film
(Pulliam, 2012) 
Launched
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4. Market overview  
The feverous need of launching on the market renewed drug delivery systems of already 
approved drugs, in order to avoid generic competition, allied with the increased patient’s 
compliance concern, have driven the attention of the industry for the orodispersible 
technology. There are enormous costs and time consumption in the discovery and 
development of new chemical entities and at the same time there is a real need to improve 
the efficacy, safety and compliance of some marketed products (Rekhi, 2009). In fact, almost 
a quarter of the drugs in the market do not provide the expected commercial returns due to 
its poor bioavailability and undesirable pharmacokinetics, demanding the development of 
innovative, better and suitable drug delivery systems (Bajaj and Desai, 2006). Therefore, the 
field of novel drug delivery technologies is highly competitive, but also very rewarding. The 
average cost of a new formulation is considerable lower than the cost involving the 
development of a new chemical entity, in about 40 million dollars, and generally takes also 
less time to develop (approximately 4 to 5 years). Actually, the changing market trends are 
very clear, the FDA approvals revealed a majority of reformulations or combinations of 
current approved products, in contrast with the 25% of new drugs approvals. In 2012, the 
total drug delivery market (DD) worth $142.5 billion (Vasisht and Finn, 2008), and presently, 
for the 10 most-popular DD technologies, its estimated market value of $81.5 billion (Richard 
and W, 2005) and is expected to achieve $92 billion by 2016 (Banbury and MacGregor, 2011). 
The oral formulations are the number-one segment of the drug delivery, retaining more the 
larger sliver of the global market share (Richard and W, 2005). The orodispersible drug 
delivery systems have found its space as mainstream pharmaceutical products. In fact, eight 
in ten patients prefer orodispersible dosage forms over the traditional solid oral dosages. 
Orodispersible films initially emerged as an option for rapid drug delivery, and later with the 
buccal films as an alternative for low bioavailability drugs. From the market standpoint, oral 
films were immediately appointed as a successful delivery system probably fuelled by the 
huge success of Listerine® Pocket Packs®. Actually, oral films proved to be a rewarding 
commercial platform with a growing rate of 500 million dollars by year since 2006 and 
reached the 2 billion dollars in 2010 (Dixit and Puthli, 2009). Recent market analyses 
revealed that the oral film manufacturers have had rapid revenue growth from 2009-2014 
and a similar trend is expected at least until 2019. It was estimated an annual growth of 
17,1% in the same period for this sector (Belanger et al., 2009) 
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In 2001, Pfizer launched the Listerine® Pocket Packs® in the market, the first commercial oral 
film and a blockbuster that in one year exceeded 175 million dollars (Levinson, 2012). 
Nowadays, under new ownership, it still remains a viable business, although it is a shadow 
of its initial success. In 2003, Chloraseptic® Relief Strips, the first drug substance loaded oral 
thin film reached the market (Woolanh, 2003). Chloraseptic® Relief Strips with benzocaine 
provided an immediate and convenient relief of sore throat pain. In 2004, Novartis debuts 
in the oral film market with Triaminic® Thin Strips and Theraflu® Thin Strips to treat the most 
common symptoms of a cold in young children (ages 6-12) and older children (> 12 year old) 
or adults, respectively. These products were considered the "Best Product of 2004" only 
three weeks after their official launch, however, they are no longer available in the shelves 
(Parsippany, 2004). The melts-in-mouth portable delivery platform, with an easy and 
pleasant administration for children was probably the first multi-symptom cough and cold 
medicines that provided a fast and accurate dosing. In the beginning of 2012, Novartis 
decided to discontinue the manufacturing and distribution of Children's Triaminic® Thin 
Strips “after a careful consideration” (Novartis Consumer Health Inc, 2014). Novartis claimed 
that this decision was based upon a business need, but there are some suggestions that the 
removal of these products included production issues and poor sales (Buck, 2013; Cohen, 
2013). The latter may probably be a reflection of the decline in the consumption of cough 
and cold medications due to the implementation of restrictions in 2007 (Freedman, 2014; 
Hampton et al, 2013). 
Nevertheless, Novartis and Pfizer as marketing partners remain as top players in the thin 
film industry, their capitalization in these success brand products allowed them to gain a 
strong position in the field (IBISWorld, 2012). The thin film industry exhibits a high level of 
competition, but until 2010 no prescription oral film product had reached the market. It was 
a slow ride from the over-the-counter (OTC) market until the first prescription has been 
approved.  
It was only in 2010 that the first Rx oral film, the ondansetron Rapidfilm® (Setofilm®) and the 
ondansetron Pharmfilm® (Zuplenz®), received European and FDA approval, respectively. 
Labtec GmBh, APR Applied Pharma Research SA (APR) and MonoSol Rx LLC (MonoSol) 
entered in the market with an ondansetron oral thin film for the prevention of nausea and 
vomiting, staunch that would capture a broad share of an appellative market that generated 
1.9 billion dollars in the same year (Warren, 2011). A month after Zuplenz® launch, MonoSol 
together with Reckitt Benckiser Pharmaceuticals received FDA approval for Suboxone® 
sublingual film (Buck, 2013; Richmond, 2010). This thin film, with two drug substances, 
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buprenorphine and naloxone, approved for the treatment of opioid dependence in adults, 
was a huge success contributing to boost the oral films market. In 2011, Suboxone® thin film 
recorded sales of 513 million dollars and accounted for 96 percent of the oral transmucosal 
film market (PRNewswire, 2013b). In 2012, US sales of Suboxone® sublingual film alone 
exceeded 1.5 billion dollars and continue with gradual growth (BioDelivery Sciences 
International, 2014c). During clinical trial the patients seemed to prefer the Suboxone® 
sublingual film rather than Suboxone® sublingual tablets, due to its fast dissolution and more 
pleasant taste profile (Richmond, 2010). These factors attracted other companies, as 
Alvogen Pine Brook, Actavis, Intelgenx and BioDelivery Sciences International (BDSI) to 
develop similar technologies. In fact, the first three companies have recently filled 
abbreviated new drug applications (ANDA) for generic products of Suboxone® sublingual 
film whereas BDSI submitted a NDA with its own buccal film technology, the BUNAVAIL™. 
BDSI believes that BUNAVAIL™, which adheres to the inside of the cheek, has the potential 
to offer advantages over Suboxone® sublingual film (BioDelivery Sciences International, 
2014c; Raleigh, 2014). 
At the moment, none of these competitors’ products are on the market since a patent 
infringement lawsuit against these applicants was submitted by Reckitt Benckiser (Reckitt 
Benckiser Pharmaceuticals, 2013). The success of the Reckitt Benckiser's prescription thin 
film proved the viability and value of this pharmaceutical form in the Rx market. In the US 
the oral films had come into a strong prominence and the prescriptions confirm the 
preference of these pharmaceutical forms (David S, 2013). 
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5. Market outlook 
It is evident the increasing consumer acceptance of thin films and the market success that 
can be achieved. Generally, for this dosage form the OTC market is the preferred due to the 
close proximity with the consumer and the easily advertising. Additionally, in the USA market 
the convenience store category is extremely important and it has a high sales impact. There 
are more than 140,000 stores across the US, which achieved a gross sale of 708.2 billion 
dollars in 2012, with a continuous sale grew every year. Regarding the OTC products, in the 
Convenience Store News 2013 Industry Report, they are included as health and beauty care 
products, which in overall had an average gross margin of about 46.89 percent in 2012 
(CSNews, 2013; Dixit and Puthli, 2009). It is a very tempting market that may lead to 
precipitated launches that sometimes may fail the expectations. As example of that, the 
Sudafed PE™ Quick Dissolve Strips was launched by Pfizer in the middle of 2005, for the relief 
of sinus pressure and congestion (Drug Store News, 2005; Pfizer, 2005). The brand sales were 
probably lower than expected due to the intense competition in the cough-and-cold 
products segment. In fact, considering only Triaminic® and Theraflu®, launched two years 
earlier, Sudafed PE™ effectively did not leverage a strong point-of-difference, not even in 
the price (Sudafed PE™ approximately 0,45$/film and Triaminic approximately 0,5$/film) 
(Parsippany, 2004; uCan Health LLC, 2014). In addition, it should be mentioned also that this 
segment sale were also off due to the implementation of some constraint measures for 
cough-and-cold medicines administration. 
Nevertheless, all this background experiences are important for planning and develop new 
oral film. It is crucial to consider that the market success of a new oral film depends on its 
capacity of differentiate from its competitive set, beyond an attractive new dosage form. A 
product can achieve a decisive point of difference by its unique characteristics which may 
engage the customer’s attention and bring also some significance. Therefore, considering 
the Rx market, it would be wise to deliver innovative drug substances, or others that bring 
additional value, to the oral film platform, otherwise it will be difficult to achieve success.  
The manufacturing process of the oral films, when comparing with some complex oral 
delivery systems, is cost-effective and generally results in affordable end-products (Dixit and 
Puthli, 2009). However, the majority of the oral films is more expensive than conventional 
oral dosage forms and may not represent a clear benefit for the consumer. It should be 
reminded that once the form novelty wears off, it must be found a way to gain advantage 
over the other competitors / brands that do equal efforts for offering equivalent products.  
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On the other hand, considering the previous discussion, there is still a poorly explored 
market with this delivery platform, the veterinary market. It is well known that in general 
the animals tend to reject, spit out or vomit conventional dosage forms. In fact, giving oral 
medications to pets can be sometimes a dangerous practice, which can also reduce even the 
owner compliance, and compromise the treatment. It was evaluated the overall owner-
perceived acceptability and the easiness administration of an orodispersible film compared 
with gelatin capsules in cats. Although there were no significant differences in the general 
acceptability of the owners, it was shown that the orodispersible films facilitated 
significantly the administration of the medication (Acton, 2011; Traas et al., 2010). Currently, 
few companies have developed oral films applied to this segment, and the available products 
are scarce and limited to OTC products based on blends of herbal extracts (Pace Wellness, 
2015; Vet Guru, 2013). Additionally, IntelGenx presents in its pipeline the VetaFilm which 
rapidly hydrate and adheres upon contact with the tongue. It cannot be spit out and offers 
appealing flavours and scents to increase the acceptability in pets (IntelGenX Corp., 2006). 
The veterinary industry includes several health products such as biologicals, medicated feed 
additives and veterinary pharmaceuticals that deals with a wide range of products: 
metabolic drugs, anti-infectives, reproductive aids, feed additives, vaccines, imaging 
diagnostics, topical solutions, parasite controls, oncologic, cardiovascular, and osteoarthritis 
drugs (ReportLinker, 2014). 
It is estimated that the global animal health care market is worth between 92 and 102 billion 
dollars (Luke M, 2013). Regarding pets, there is an evident trend of the owners spending 
more money each year on their pets’ health. In the US, it is expected that pet-owners 
spending will reach 33 billion dollars in 2014. This market segment will always be far from 
recession, driven by the idea that pets are considered family members. Besides that, the 
farm animals’ health has been in the spotlight as a result of growing awareness of the impact 
that animal health may have in the human food safety and public health. The current unmet 
animal health needs, especially in animal disease surveillance, vaccines and lack of drugs in 
the senior animal veterinary care market (oncology, cognitive dysfunction syndrome, 
antidepressants) may also fuel the veterinary market growth (ReportLinker, 2014). Although, 
US remain the largest regional market for animal medication, Asia-Pacific is the fastest 
growing regional market. Regarding the products segment, the nutritional chemicals and 
parasiticides have the majority share in the total dollar sale, whereas vaccines and 
diagnostics are the fastest growing products segments (Freedonia, 2013; Global Industry 
Analysts, 2012).  
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It is clear that animal health is far to be little and insignificant health care niche. Actually, 
keeping pets and farm animals healthy might be a huge business. Therefore, innovative 
delivery platforms such as the orodispersible films, that quickly dissolve and become sticky 
in contact with saliva, can easily become valued by pet owners and animal caregivers. 
Another unexplored market with these technology platforms is the biologics products. There 
are some references and efforts in the development of these type of products especially in 
immunotherapy, but at the moment no product had already reached the market. For 
example, vaccines in oral film formulations may have significant advantages. Despite of the 
needle free delivery, which may increase patient compliance, the higher stability may 
simplify the worldwide storage and distribution. The simplification of the logistic would also 
favour the mass immunization campaigns (Levine, 2010; Wang and Coppel, 2008). In fact, 
this type of small and stable vaccines could be easily sent by mail. Furthermore, it is expected 
that the human vaccine industry forecast reaches 41.85 billion dollars by 2018 (Lucintel 
insights that matter, 2013), with a CARG growth of 62.81 percent from 2013 to 2018 
(Business Wire, 2014). 
In addition to the quick-dissolving oral film influenza vaccine, under development by 
BiondVax - MonoSol Rx, others had already reported the development of oral film vaccines. 
During 2007, Johns Hopkins students had reported the development of an oral film vaccine, 
the rotavirus thin film delivery system which may surpass the drawbacks of the liquid 
vaccine. The original idea came from Aridis Pharmaceuticals that owns the rotavirus vaccine 
stable at room temperature and gave the challenge to the researchers from the Johns 
Hopkins School of Medicine. The oral film system is composed by a FDA-approved 
biocompatible polymer, which is pH-responsive. This composition design avoids the 
degradation of the vaccine in the stomach acid, allowing its release in the small intestine, 
triggering the immune response. According to their patent application these pH-sensitive 
microparticles are composed by a complex polymeric mixture, a copolymer of methacrylic 
acid or acrylic acid, as an Eudragit®- like copolymer, a pluronic polymer, a chitosan or a 
derivative or a combination thereof; and possible additional components as a surfactant, a 
sugar, a buffering salt and or a combination thereof (Mao et al., 2010). The Eudragit® 
polymers are an Evonik Industries AG trademark that offer a full flexibility of pH-dependent 
drug release (Evonik Industries AG, 2014). In fact, the manufacture method to prepare these 
microparticles includes the blend of two different grades of Eudragit®, possibly to accurately 
define the pH release of the drug. An anionic copolymer of methacrylic acid with ethyl 
acrylate is balanced with an anionic copolymer of methacrylic acid with methyl 
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methacrylate, so the drug release pH may be achieved somewhere between 5.5 and 7. The 
oral film composition is based on water-soluble polymers, as PVP or PVA, mucoadhesive 
polymers, as PEO and / or sodium alginate. Therefore, this composition allows that 
RotavaxTM vaccine melts quickly in a children’s mouth, prompting them to swallow it. 
Unfortunately, no additional developments had been reported since then (Dixit and Puthli, 
2009; Sneiderman, 2007). Currently, the Johns Hopkins School of Medicine also has a clinical 
trial ongoing to evaluate the Safety and Efficacy of a sublingual dissolving film for Peanut 
Allergy. The estimated date for the completion of the study is in the beginning of 2015 and 
it is expected that this sublingual immunotherapy with a dissolving peanut extract film has 
the potential to improve the efficacy of this type of treatment (Clinicaltrials.gov, 2013; Wood 
et al., 2013). 
It has been an increasing interest in the development of micro- and / or nano- drug delivery 
systems associated to buccal polymeric matrices for a transmucosal delivery (Cavallari et al., 
2013; Dott et al., 2013; Giovino et al., 2012; Jones et al., 2014; Morales et al., 2013; Rana 
and Murthy, 2013; Shen et al., 2014). These nanoparticle systems for oral absorption have 
been recently explored to incorporate poorly soluble drugs, to extend and improve the 
buccal release, to provide an improvement in the drug targeting and also to increase drug 
stability. These systems generally include nanosuspensions (Cavallari et al., 2013; Rana and 
Murthy, 2013; Shen et al., 2014), nanofibrous matrix system (Dott et al., 2013), solid lipid 
nanoparticles (Giovino et al., 2012; Jones et al., 2014), PEG-b-PLA nanoparticles (Giovino et 
al., 2012), submicron and nanosized particles of lysozyme (Lys)-loaded d , l –valine (Val) 
(Morales et al., 2013). The majority of these studies were initially applied to the proteins, 
especially due to its large size, low oral bioavaibility and poor stability, but they are currently 
extended to non-biologic drugs. Nevertheless, for the development of this type of systems 
it is important to consider the size of the coating particles. The size and shape of the particles 
may lead to undesirable aggregation and loss in the homogeneity, which could compromise 
the physical stability of the films in terms of both mechanical and mucoadhesive properties. 
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6. Conclusion 
The main catalysts of the drug-delivery market are the patent cliff and more informed and 
autonomous consumers (Vasisht and Finn, 2008). Therefore, the demand side for 
pharmaceutical treatments has been changing and nowadays the approach is more patient 
- centred and quality- based.  
Recent reports refer that in the next five-year period, many oral film drug producers will 
focus on extend their drug pipeline through other therapeutic classes (Belanger et al., 2009). 
At the same time it is expected that the formulation complexity may contribute to technical, 
manufacturing and regulatory barriers that may lessen the growth of the oral film market 
(Vasisht and Finn, 2008). So, it is critical that the value added by any new delivery platform 
boosts its own growth by the continuous improvement of consumer compliance and by 
enticing new consumers. 
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Chapter II 
Oral Films Characterization and Critical Quality 
attributes outline 
 
There are no standardized methods for characterization or analysis of the oral films. The 
absence of guidance leads to the application of several and alternative techniques and 
statistical tools based on a Quality by Design approach that contributed to the development 
of extensive knowledge about this technological platform. Critical quality attributes (CQAs) 
were stablished to be used as reference and facilitate the identification of critical process 
parameters (CPPs).  
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Chapter II.1 
Orodispersible films (ODFs): overall analysis with a 
multivariate Chemometric approach 
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Abstract  
The main goal of the present work concerned the use the fundamentals of Chemometrics to 
analyse commercial orodispersible films (ODFs) aiming to develop basic understanding of 
the interplay between their main components, possible interactions and influence in the 
final product properties. GAS-X ® and Listerine ® ODFs were evaluated regarding their 
residual water content (Rwc), disintegration time (Dt), as well as chemical, thermal and 
mechanical properties. Reconstituted formulations were prepared based on a Mixture 
Design and the data were analysed by Principal component analysis (PCA) and Partial Least 
Squares regression (PLS). PCA analysis allowed the identification of fourier transform 
infrared spectroscopy (FTIR) spectra differences: all the reconstituted formulations are very 
different from each other and particularly dissimilar from the commercial formulation. PLS 
showed the effect of each excipient in the final polymer matrix: Pullulan, sweeteners, 
propylene glycol and menthol were found to have a high influence in the mechanical and 
thermal properties; the molecular weight (Mw) of cellulose derivatives effect on the Rwc 
and Dt and simethicone may affect greatly the thermal properties.  
Although ODFs present a very complex composition the use of these tools allows the 
development of important knowledge about the system and the identification of the 
influence of each excipient in the final product properties as well as the major interactions 
in the polymeric matrix.  
 
Keywords 
Chemometrics; orodispersible films; galenical development 
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1. Introduction  
In the past few years there has been an increasing concern to enhance patient compliance 
in order to improve health outcomes. Although, the oral route is the most preferred for the 
general population, several groups of patients have serious swallowing difficulties regarding 
the conventional dosage forms (Kelly et al., 2009). To overcome these problems, several fast-
dissolving drug delivery systems have been developed. The Orodispersible films (ODFs) are 
a type of delivery system especially indicated for dysphagic patients and children. In fact, in 
some cases the ODFs may be acceptable for children below 2-year-old (Zajicek et al., 2013).  
ODFs were introduced in the market by Pfizer in 2001 with Listerine ® Pocket Packs™. Since 
then ODFs have gained popularity in the US and are currently a well-accepted delivery 
system. Pharmaceutical dosage forms must follow strict regulations according to a set of 
quality criteria defined by the regulatory health authorities (Qiu et al., 2009). Although the 
main processes involved in the pharmaceutical development are well known, each 
development may represent a new challenge. Therefore, a regulatory framework based 
mainly on a risk-control and science-based approach has been introduced since 2002 (Qiu et 
al., 2009). These pharmaceutical regulations focusing on the quality by design (QbD) are 
essentially based on careful risk management and quality systems. QbD is a systematic study 
that provides the strategy, methods and tools for developing the data and information 
needed for a good product, process understanding and control (Qiu et al., 2009; Visser et 
al., 2015; Yu et al., 2014). Generally, the unit operations involved in the manufacturing of a 
dosage form have a significant influence on the final product properties. It is important to 
assure that the uncertainty and risk is minimized during all the processes and also assures 
some leeway to freely operate within a well-designed and structured working space. 
Therefore, several chemometric tools have emerged and are intensively used during the 
different stages of pharmaceutical development and manufacture, such as Design of 
Experiments (DoE) and multivariate analysis (El-Gindy and Hadad, 2012; Singh et al., 2013; 
Wesolowski et al., 2012; Yu et al., 2014).  
DoE involves planning, conducting, analysing and interpreting controlled experiments to 
provide a mechanistic understanding of the relationship between critical process 
parameters (CPP), raw material attributes and critical quality attributes (CQA) of the 
product. Therefore, DoE is especially useful when dealing with multiple factors to 
understand and optimize the formulation system to achieve the desired target product 
profile (TPP) (Hwang and Kowalski, 2005; Visser et al., 2015). On the other hand, multivariate 
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data projection, such as Principal Component Analysis (PCA) and Partial Least Squares (PLS), 
may be used in combination with DoE during formulation or process development for the 
screening of a large number of parameters and further optimization. PCA provides an 
overview about the interactions, while PLS quantifies the correlation between excipient 
characteristics and product properties (Singh et al., 2013; Wold et al., 2006). In fact, these 
methods allow us to map different components which may be very useful in mixture design 
studies (Singh et al., 2013). Additionally with PCA, it becomes easier to identify the sources 
of variation in the data set and the patterns or trends in large data matrixes. The use of PCA 
during pharmaceutical development can be quite broad involving  the search of new drugs, 
mapping and patterning closely related drugs’ pharmacological, and chemical properties 
(Konieczna et al., 2012), or to evaluate the incompatibility between formulation 
components, by mapping thermogravimetric analysis (TGA) (Wesolowski et al., 2012). 
Recently PCA analysis was used to evaluate the correlation of several processing parameters 
of ODF solvent casting method in Loperamide and Ibuprofen cellulose based films. The 
analyses allowed to highlight the strongest influence of the thickness and mass in the studied 
systems (Woertz and Kleinebudde, 2015). Regarding the ODFs there is a considerable lack of 
guidance information, namely the influence of each component on the properties of the 
formulations and quality control. Furthermore, for dosage forms with such a complex 
composition, it can be very difficult to retrieve significant and meaningful information using 
conventional analysis only. PCA analysis was used to map the main composition differences 
in two commercial available ODFs, by the individual analysis of each formulation excipient, 
and the prepared formulations based on the correspondent patents. Hierarchical clustering 
was also used as a PCA complement to facilitate the analysis of the TGA data. This test 
allowed the organization of the data into clusters whose values are close to each other 
relative to those of other clusters (Institute, 2015) . The PLS method was used to evaluate 
the impact of each excipient on the final product properties (Leung et al., 2008; Schobel and 
Vangala, 2010).  
This work intended to develop a basic understanding of the interplay between the main 
components of the formulation, possible interactions between them and their influence on 
ODF properties. The commercial ODFs selection was based on their composition, Listerine ® 
Pocket Packs™ composed of Pullulan, described as the most suitable film-forming polymer 
for ODF technology  (Choudhary et al., 2011), and GAS-X ThinStrips® (GAS-X ®), composed of 
more than 50% (%w/w) of drug substance (Simethicone).  
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2. Material and Methods 
 
2.1. Material 
Acessulfame K (Nutrinova, Frankfurt, Germany); Carrageenan k, Gelcarin GP-379NF (IMCD 
UK Ltd, Sutton, UK); FD&C Blue #1 (Colorcon, Harleysville, U.S.); HPMC E5, Methocel E5 
(Colorcon, Harleysville, U.S.); HPMC E15, Methocel E15 (Colorcon, Harleysville, U.S.); HPMC 
E50, Methocel E50 (Colorcon, Harleysville, U.S.); Maltodextrin (MDX) Maltrin M180 
(LEHVOSS UK Limited, Cheshire, UK); Menthol (-)-Menthol (Merck, Darmstadt, Germany), 
Modified starch, Pure Cote B793 (LEHVOSS UK Limited, Cheshire, UK); Polyethylene Glycol 
(PEG), Lutrol 400 (BTC, Ludwigshafen, Germany); Propylene Glycol 1,2-propanediol (Merck, 
Darmstadt, Germany); Pullulan (Hayashibara Co., Ltd, Okayama, Japan); Simethicone (Resil 
chemicals Pvt. Ltd., Bangalore, India); Sorbitol (Colorcon, Harleysville, U.S.); Sucralose, 
Splenda (Merck, Darmstadt, Germany); Polysorbate 80, Tween 80 (Merck, Darmstadt, 
Germany); Hydranal Composite 5 (Sigma-Aldrich co. LLC, U.S.). 
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2.2. Methods 
2.2.1. Preparation of the ODFs 
The ODFs were prepared according to a general procedure displayed in Figure 8. 
 
Figure 8 - Schematic representation of the general preparation procedure of the ODFs. 
The solutions were prepared in two-neck round bottom-flasks (50 mL). The system was kept 
at room temperature or at elevated temperatures (60⁰C - 90⁰C) depending on the excipient 
used in each formulation. The film solutions were cast in polyvinyl chloride (PVC) foils, used 
as release liner / substrate with an Erichsen film applicator (Coatmaster 510, Erichsen, 
Hemer, Germany). To obtain different heights a vertically adjustable doctor knife was used 
and the film solutions were cast with speeds of 18 mm/s. The ODFs were cast with a gap of 
300 (GAS-X ® formulations) or 500 µm (Listerine ® formulations). This height gap was 
selected based on some casts previously performed with each liquid mixture. 
The cast ODFs are dried on the heated table of the Erichsen film applicator at 40 °C until 
dryness. The duration of dryness depends on the composition of each formulation.  
To further characterize the ODFs, individual samples were prepared by cutting strips of 
regular dimension (60 mm2, 2mm x 3mm) with a surgical scalpel.  
  
Polymer film 
Solvents - water or a 
water:ethanol 96% 
mixture 
Add excipients 
Maintained at room temperature 
or heated when required 
High Stirring 
Cooling at room temperature 
(when necessary) 
Low – stirring during 1-2 
hours 
Final film solution 
Casting Drying 
Solution 
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2.2.2. Storage 
The individual ODFs were stored under controlled conditions (43 % RH, room temperature), 
using a saturated solution of potassium carbonate for at least 5 days before testing.  
 
2.2.3. Film mass 
The ODFs were weighed using an analytical balance (Mettler Toledo AGXS, Mettler-Toledo 
Inc., Columbus, US) and the average weight was calculated (n=3). 
 
2.2.4. Film thickness 
The thickness of the ODFs was measured with a micrometer screw (Mitutoyo Digimatic 
Capiler, Mitutoyo Corporation, Japan) (n=3).  
 
2.2.5. Tensile Strength 
The mechanical properties of the ODFs were determined using a tensile testing universal 
apparatus (Zwick, Germany) with a load cell of 10 N. The measurements were performed 
similarly as described elsewhere. Briefly, ODFs with the dimensions of 60x20 mm and free 
from air bubbles or physical imperfections, were held between two clamps positioned at a 
distance of 40 or 50 mm. Firstly, a preload was applied in each assay and then the strips were 
pulled by the top clamp at a rate of 10,0 mm/min. The load automatically applied to the film 
was gradually increased and the corresponding magnitude of elongation was recorded until 
the break point of the film was finally reached. The parameters were directly retrieved from 
the software TestXpert (TestXpert, Zwick, Germany), namely Young’s modulus (Et), tensile 
strength (σB) and elongation (εB). Measurements were run at least in three samples for each 
film.  
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2.2.6. Disintegration time 
The ODFs were laid on a Petri dish and 4 mL of a phosphate buffer pH=6.8 (artificial saliva) 
at 37⁰C was added. The time at the film samples disintegrate was recorded. 
 
2.2.7. Karl-Fisher 
The Karl Fischer Method was used to determine the residual water content of the ODFs. This 
technique basically consists in the quantitative reaction of iodine and sulfur dioxide by the 
addition of water, in the presence of a lower alcohol such as methanol: 
 
   
A sample was added to the titration flask filled with methanol previously dehydrated with a 
Karl Fischer reagent (Hydranal Composite 5, Sigma-Aldrich Co. LLC). Titration was then 
carried out using the Karl Fischer reagent with a known determined titer (mgH2O/ml). Water 
content was determined based on the titration volume (ml). The polarization-current 
potential-difference method was employed as an end-point detection method.  
These tests were performed in a Karl Fisher 787 KF Titrino (Metrohm AG, Herisau, Schweiz). 
 
2.2.8. FTIR 
To investigate any possible interactions between the excipients used in the preparation of 
the ODFs, infrared spectroscopy (IR) was used similarly as described by other authors 
(Alanazi FK 2007). Fourier Transform Infrared (FTIR) spectroscopy was carried out in a FTIR-
4200 spectrophotometer (Jasco) recorded at a wave number comprised between 550 and 
4000 cm-1 and with 4 cm-1 resolution. Attenuated Total Reflection (ATR) mode was used. 
  
                                    CH3OH 
SO2 + I2 + 2H2O                             2HI + H2SO4 
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2.2.9. Thermogravimetric Analysis (TGA) 
Thermogravimetric Analysis (TGA) was used to analyse the thermal stability of the polymer 
samples. TGA technique quantifies the weight variation/loss of the sample as a function of 
temperature. TGA test was performed in a TGA Q500 (TA instruments), at a heating rate of 
10⁰C/min, from 0⁰C to 500⁰C, under a constant nitrogen flow. 
 
2.2.10. Statistical analysis 
The screening and optimization designs were performed with JMP 10 (SAS Institute Inc., 
Cary, NC). The Custom Design platform was used to generate the mixture design performed, 
by introducing the factors as mixture variables and apply a model for the evaluation of the 
main factors and if possible the second interactions. 
The Multivariate analysis (PCA and PLS) was performed with a Demo version of SIMCA 13 
(Umetrics, San Jose, CA, USA) and the hierarchical clusters were performed with JMP11, 
based on Ward’s minimum variance method (SAS Institute Inc., Cary, NC). 
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3. Results and Discussion 
The composition of the evaluated ODFs is described in Table 5. Both commercial 
formulations (Listerine ® and GAS-X ®) are composed by a high number of excipients. Thus, 
to perform an adequate design of experiments, only the some of the excipients were used 
to prepare the test ODFs. This selection was assumed based mainly on the amount and 
functionality of each excipient in the final product. 
 
Table 5 - Main components of Listerine ® and GAS-X ®, the commercial ODFs evaluated. 
Polymers Plasticizers Flavors Colorants Sweeteners Surfactants
Thickening 
agents
Drug substance / 
Strength
Corn Starch 
modified
Polyethyle
noglycol
Menthol FD&Blue#1 Sorbitol
Hypromellose
Maltodextrin
Menthol Green 3 Sucralose
Polysorbate 
80
Chondruscri
spus 
(carrageena
n)
Coppergluconate
Eucalyptol
ceratoniasil
iquagum
Thymol
Aroma
Orange oil
GAS-X ® 
Simethicone / 62,5 
mg
Sorbitol Flavor
Titanium 
dioxide
Sucralose
Xanthan 
gum
Methylsalicilate
Listerine ® Pullulan
Polyethyle
noglycol
Yellow 6
PotassiumA
cesulfame
Glyceryln 
Oleate
 
The omission of some components was necessary to simplify the mixture design study. The 
introduction of several variables would imply a high complexity of the design that could lead 
to inconclusive and misinterpretation of the results.   
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Table 6 - Composition of the different test ODFs based on Listerine ® Pocket Packs composition (List) 
that were prepared and characterized based on a mixture design (%). 
 
Film ID Pullan
Propylene 
Glycol
Menthol Carrageenan Acessulfame Sucralose Tween 80
Selected 
ranges
49-92% 0-17% 0-10% 0-5.5% 0-6% 0-6%, 0.1-7%
List1 65.6 13.4 8.6 1.8 5.2 5.3 0.1
List2 79.0 15.1 3.7 2.0 0 0 0.2
List3 77.4 0 5.9 5.0 5.0 0 6.7
List4 58.4 15.7 9.2 0 5.9 5.9 4.9
List5 91.8 0 3.2 0 0 0 5.0
List6 49.4 15.5 9.6 5.5 6.4 6.3 7.3
List7 88.4 0 9.4 2.1 0 0 0.1
List8 68.3 16.1 0 2.1 0 6.2 7.3
List9 70.2 16.7 0 1.6 6.6 - 4.9
List10 66.5 15.7 3.9 1.1 6.3 6.4 0.1
List11 89.6 0 3.5 0.9 5.9 0 0.1
List12 80.8 0 0 2.1 6.5 3.9 6.6
List13 73.4 16.0 2.0 1.3 3.6 3.6 0.1
 
The ranges used to prepare the mixture design (Tables 6 and 7) were based on the 
formulation examples of the patents (Leung et al., 2008; Schobel and Vangala, 2010). The 
ODFs are singular dosage forms mainly composed by a film-forming polymer, usually the 
main component that allows the formation of the core matrix. In this design a constraint was 
introduced, the usage of Methocel E50 implied the absence of Methocel E15 and vice-versa, 
because it was not clear in the patent the most suitable Methocel grade to use. 
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Table 7 - Composition of the different test ODFs based on GAS-X ® composition (GAS) that were 
prepared and characterized based on a mixture design (%). 
Film ID
Methocel 
E5
Methocel  
E15
Methocel  
E50
Maltrin Starch PEG 400 Sorbitol Sucralose Simeticone
Selected 
ranges
0-60% 0-75% 0-55% 0-35% 0-45% 0-18% 0-11%, 0-4.5% 5-60%
GAS1 43.3 0 0 0 43.5 0 0 0 13.2
GAS2 43.5 43.3 0 0 0 0 0 0 13.2
GAS3 56 0 0 33.7 0 0 0 0 10.3
GAS4 15.7 15.7 0 15.4 15.4 18.2 9.9 4.6 5.1
GAS5 76.6 0 0 0 0 0 0 0 23.4
GAS6 0 41 0 0 24.6 18.1 0 0 16.2
GAS7 0 76.2 0 0 0 0 0 0 23.8
GAS8 41.1 0 10.3 13.7 13.7 0 7.4 0 13.7
GAS9 59.1 0 14.8 0 0 0 11.2 5 10.0
GAS10 59.8 0 15.0 20.1 0 0 0 0 5.2
GAS11 13.7 0 54.4 0 18.1 0 0 0 13.8
GAS12 15.0 0 14.9 0 0 0 10.6 0 59.4
GAS13 12.4 0 33.0 16.5 0 0 9.2 4.2 24.6
GAS14 15.7 0 47.1 0 0 0 8.8 3.9 24.4
GAS15 13.5 0 49.6 0 18.0 0 0 4.5 14.3
GAS16 14.8 0 14.9 0 19.8 0 0 0 50.5
GAS17 12.0 0 47.5 0 0 16.5 0 0 24.0
 
3.1. FTIR analysis 
The direct analysis of the FTIR spectra allows the identification of some specific chemical 
groups (Figures 9 and 10). This analysis is usually employed to evaluate the drug-excipients 
or excipient-excipient interactions (Cilurzo et al., 2008; Kumar et al., 2014). This evaluation 
is normally based on known and characteristic stretching regions of the FTIR spectra that 
usually are missing or diminished in intensity due to electrostatic interactions and / or 
hydrogen bonds between the components. Kumar et al., was able to relate the probable 
drug-polymer interactions present in the FTIR spectra with the drug dissolution parameters 
(Kumar et al., 2014). Others have also used this assay to evaluate the suitability of some 
plasticizers for specific polymers through miscibility evaluation shown by slight 
modifications of the polymer main bands. These may correspond to shift stretching regions 
and/or band intensity (Cilurzo et al., 2008). 
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The prepared ODF formulations present a very complex composition (see Table 5) which 
difficult the FTIR spectra analysis. Nevertheless, specific functional groups were identified. 
The –OH band (band A, Figure 9) was observed in all spectra as expected, since this 
functional group is very characteristic and abundant in hydrophilic polymers, such as 
starches and cellulose. The C-H bonds, very common in organic compounds, are also 
presented in all spectra (band B, Figure 9). The –O- group is detected in different 
formulations and corresponds to the sharp band identified with the letter E. Other 
characteristic bands of some excipients, like C-Cl of Sucralose (band F, Figure 9) can be found 
in Listerine ® and GAS-X ® spectra.  
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Figure 9 - FTIR spectra of the marketed formulation and its main components. (A) Represents GAS-X 
® and Listerine ® Pocket Packs. (B) Represent GAS-X ® and Simethicone. (C) Represent Listerine® and 
Pullulan. Absorption peaks of 2200- 2400 cm-1 region (CO2 band) were not considered in the analysis. 
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Besides the bands identified above there are others specific bands of each formulation. In 
the Listerine ® FTIR spectra (Figure 9), it is possible to identify the C=C band (1680-1600cm-
1), the double bond present in the sweetener acessulfame K and in the surfactants 
polysorbate 80 and glyceryl oleate (band C, Figure 9). The sulfone group (R2SO2) of the 
acessulfame K is identified by letter D (1340-1280cm-1) (Figure 9) (Yadav, 2005). 
It is important to consider that the conformation and hydration of the polymers may 
influence their FTIR bands. These band modifications for the majority of biopolymers are 
usually observed in a specific absorbance region, at 1200-950 cm -1 (Xiao et al., 2014). Xiao 
et al. showed the band changes of pullulan spectrum during drying and film formation. As 
expected, the most prominent changes were verified in the 1200-950 cm -1 region. Briefly, 
the drying time contributed to an overall increase of absorbance probably due to the higher 
vibration of specific pullulan groups, C-O-C, C-O, C-C and C-O-H. It was also shown that the 
drying process contributes to the formation of more-ordered molecular structure, because 
the shape of the peaks continuously became larger and the area ratio increases. This process 
is accompanied by the inter-chain interactions increase between pullulan molecules that 
have a less-ordered conformation in solution (Xiao et al., 2014). There are no clear shift 
variations of the pullulan characteristic bands in our studied formulations and the 
commercial film. This observation may suggest that there are no strong bonding between 
the pullulan molecules and the other excipients, and probably they simply interpose 
between the polymers net without a stronger linkage. The differences in the intensity of the 
bands absorbance are probably due to the different pullulan concentration between 
formulations. 
Regarding GAS-X ® FTIR spectra (Figure 9) it is clear the presence of the bands of general 
aromatic (1600-1430cm-1) and aromatic amine compounds (1340-1250 cm-1) from the 
colorant used in this formulation, FD&Blue#1. Also, the characteristic band of the titanium 
dioxide (TiO2) is represented by letter J (Figure 9A). The simethicone band is identified in all 
spectra, especially in the commercial ODFs due to its high concentration and characteristic 
bond Si-CH3, identified by letter I (Figure 9A) (Alavi et al., 2014; Yadav, 2005). Additionally, 
there is no evident shift of the simethicone bands in the formulations analysed indicating a 
weak interaction of this component with the other excipients.   
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Figure 10 - FTIR spectra of screened GAS-X ® and Listerine ® formulations. Absorption peaks of 2200- 
2400 cm-1 region (CO2 band) were not considered in the analysis. (A and B) Represent the GAS-X ® 
formulations evaluation. (C and D) Represent the Listerine ® formulations evaluation. 
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The analyses of these spectra allow inferring about the possible presence of some 
components in the formulations and their relative concentration, since the band intensity is 
directly proportional to its concentration. This aspect is particularly clear in the dyes bands, 
which due to its lower amount in the formulation have a much lower intensity comparing 
with other components such as Simethicone, for example. Moreover, it becomes difficult to 
distinguish differences between the spectra of the prepared formulations (Figure 10) from 
the commercial ODFs spectra or even the commercial ODFs spectra with the main 
component spectrum (Pullulan in Listerine ® ODFs – Figure 9C and Simethicone in GAS-X ® 
ODFs – Figure 9B) using only to the FTIR spectra bands and frequency shifts. On the contrary, 
using multivariate analysis it is possible to highlight spectra differences related with the 
composition of the formulations (Figure 11).  
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Figure 11 - Scores Scatter Plot: shows the possible presence of outliers, groups, similarities and other 
patterns. (A) Represents the GAS-X ® formulations evaluation. (B) Represents the Listerine ® 
formulations evaluation. The red dots represent the main component of each formulation (Pullulan 
in (A) and Simethicone in (B)) and the blue dots correspond to the Commercial film spectra (Listerine 
® in (A) and GAS-X ® in (B)). The green dots correspond to the screened formulations. t[1] and t[2] are 
the two vectors calculated by the Principal component analysis (PCA) of a data table, which 
summarize all the variables entering the analysis. 
  
B 
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The PCA was used to map the different FTIR spectra. It is clear that there are significant 
differences in the formulations especially when compared to the commercial ODFs and main 
excipient (Figure 11). Regarding Listerine ® formulation (Figure 11 A), it is notorious that the 
Pullulan spectrum is very different from others since it is plotted as an outlier (outside the 
ellipse). Therefore, it can be concluded that the diversity of functional groups of this 
polymer, contributes to several bands along the spectra turning difficult to distinguish 
specific bands that result from excipient-excipient interactions. The Listerine ® spectrum is 
slightly different from the prepared formulations, which can be explained by the reduced 
number of excipients used in the preparation of the film formulations and their percentage.  
The GAS-X ® formulations spectra are all very different from each other and particularly 
different from the commercial formulation, which is plotted almost as an outlier (Figure 11 
B). These results highlight the complexity of the formulations and the importance of each 
excipient in the overall properties of the ODFs. Furthermore, other important aspects to take 
into account that may be related with the differences found, concern the method and 
preparation conditions in a large scale, involving strictly and highly controlled procedure 
conditions (e.g. drying and blending time, etc.). 
The distance between the scattered points in Figure 11 suggests a significant difference from 
each formulation that may be explained by the concept of the experiments purposely 
generated for the analysis. The construction of the mixture design assumes that the 
experiments are designed to cover a surrounding space implying that the formulations tend 
to be representative of the entire system and therefore with a different composition from 
each other. However, probably due to the high concentration of some components, it is 
possible to show some similarities (FTIR spectra).  
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3.2. Disintegration time, Residual water content, 
Mechanical and thermal properties analyses 
 
Figure 12 - Loadings Scatter plot: highlights the relation between the excipients studied, green dots, 
and the characterization parameters evaluated, blue dots. (A) Represents GAS-X ® formulations. (B) 
Represents Listerine ® formulations. Evaluated parameters: σB (MPa) - tensile strength, εB (%) - 
elongation at break, Et (MPa) - Young’s Modulus, H2O (%) - residual water content, Disintegration (s) 
time, Tonset (⁰C), Weight loss at 100⁰C (%), 5% weight loss (⁰C), 10% weight loss (⁰C). The above w*c 
is a superimposition of the w* plot (loading weights that combine the X-variables) and the c plot (Y-
loading weights) of one PLS component against another, 1 and 2. To analyse this plot, imagine a line 
through the origin and project other X- and Y- variables on this line. Variables opposite to each other 
are negatively correlated and positively correlated to variable situated near them. 
 
B 
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The formulations prepared allowed to retrieve some important conclusions about the 
influence of the different components in the ODFs properties (Figure 12). Regarding the 
Listerine ® formulation (Figure 12B), it is clear the strong and direct correlation between 
Pullulan with the mechanical (σB and Et) and thermal (Tonset and Weight loss until 100⁰C) 
properties. Therefore, these properties are highly dependent on Pullulan’s amount in the 
film (also confirmed by PLS regression coefficients, data not shown). Indeed, Pullulan films 
have been already reported as films with high elastic modulus and moderate to high tensile 
strength (Kawahara et al., 2003). On the other hand, menthol affects negatively the elasticity 
modulus and the thermal stability of the films. In fact, the small relative size of the menthol 
molecule, may allow it to interpose between the polymer chains playing also the role of a 
common plasticizer. These compounds are an important class of low molecular weight non-
volatile compounds that are widely used in pharmaceutical industry. These substances are 
mainly used to improve the flexibility, workability or processability of polymers by lowering 
the glass transition temperature (Tg) (Vieira et al., 2011). The possible presence of menthol 
between polymer chains may reduce the polymer-polymer interactions contributing to a 
higher degree of freedom of motion between the polymer strands. Under this condition, 
there is a reduction in the deformation and hardness tension and probably in the 
electrostatic charge of the polymer. Hence, menthol is known to be able to reduce the elastic 
modulus by increasing the polymer matrix flexibility and simultaneously the resistance to 
fracture (Vieira et al., 2011). Similarly the increase of propylene glycol is also associated with 
the decrease of the tensile strength (σB) and the ODF thermal stability (lower Tonset). It 
would be expectable that propylene glycol may influence the film mechanical properties, 
since it is used mainly as plasticizer in the pharmaceutical industry (Vieira et al., 2011). 
Additionally, it is reported by others the effect of this compound as plasticizer, contributing 
to the decrease of  tensile strength and Young’s modulus,  and the increase in the % 
elongation, turning the films from brittle to flexible (Jagadeesh et al., 2013). Curiously, the 
Sucralose seems also to be associated with a decrease in the tensile at break. According to 
these results it may be possible to conjecture that sucralose molecules probably have the 
ability to break some of the secondary bonds associated with the polymers’ crystallinity.  
It was also verified in this polymeric system that the added sweeteners in general tend to 
enhance the polymer thermal stability. Acessulfame increases the temperature required to 
lose 5% of weight and Sucralose increases the temperature necessary to lose 10% of weight. 
This result may be related with the chemical properties of each excipient. The sucralose is 
described as being stable until 119°C (Bannach et al., 2009), whereas Acessulfame does not 
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have a consensus value in literature. However, it is reported that Acessulfame 
decomposition temperature is usually observed at 200⁰C. Even so, it is also reported that 
the surrounding environment, such as the pH, may also influence this property (Mayer, 
1991; O'Brien-Nabors, 2001). The high thermal stability of these excipients at lower 
temperatures may have a positive effect on the polymeric matrix. Contrarily, menthol 
decreases the temperature necessary to lose 5% of the film’s weight. For this excipient, it is 
difficult to find thermal profiles reported in the literature. The melting point described is 
around 34⁰C, which may contribute to the decrease of the matrix mechanical stability at 
room temperature (Rowe et al., 2012). Curiously, sucralose is also associated with a decrease 
of the degradation temperature, similarly to menthol and propylene glycol. This highlights 
that the influence of sucralose is not linear because this compound help to stabilize the 
matrix until a certain temperature but it can also contribute to diminish it. 
The thermal profile of the different formulations were grouped according to their 
similarities, based on clustering statistical analysis (Figure 13) 
 
 
Figure 13 - TGA data profiles analysed by Hierarchical cluster test (A) and TGA data profile (B). (A) 
Represents a dendrogram that lists and group each observation based on its similarity (by Ward’s 
method).of the Commercial film tested. (B) Represents the TGA profiles of the Listerine ® film-forming 
polymer (pullulan) and two relevant formulations tested (List2 and List5).  
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According to Figure 13, the thermal behaviour of List2 is very similar to the commercial film; 
both belong to the same cluster and have analogous TGA curves. This data confirms the 
prepositions assumed before for the effect of each excipient on the thermal stability. Based 
on the List2 and List 5 compositions (Table 6) it is evident that the addition of propylene 
glycol and menthol to the polymeric matrix contributes to a decrease on the thermal 
stability. List 5 is the formulation with the thermal profile more similar to pullulan, which is 
expected since it corresponds to the film formulation with the highest amount of this 
excipient. 
Regarding GAS-X ® formulations (Figure 12 A), it was also clear the influence of the 
plasticizer, PEG 400, in the mechanical properties of the polymeric matrix. The increase of 
PEG 400 contributes for the decrease of Young’s Modulus and tensile strength, due to the 
reasons pointed out above involving the main characteristics of the plasticizers. The 
decrease in the Et is associated with a reduction of the rigidity of polymer matrix due to the 
lower number of polymer-polymer interactions (Wypych, 2012). On the other hand, the 
increase of Methocel E5 seems to have a more significant influence in the increase of Et and 
σB, than the other higher Mw based celluloses (Methocel E15 and E50). In literature, it is 
commonly reported the direct and linear correlation between the Mw and mechanical 
properties (Carstensen, 2000). However, the results obtained for these complex polymeric 
matrices suggest opposite conclusions. Although this result seems surprising, it should be 
pointed out that the elastic modulus also depends on the chain organization and draw ratio. 
The glassy or amorphous nature of the polymer may origin non-linear behaviour of the 
elastic modulus values, being sometimes unpredictable (Swallowe, 1999). For semi-
crystalline polymers, such as HPMC, it is described that its elastic limit (yield strength) may 
at times increase with the Mw, due to second-order effects of crystallinity Mw degree 
(Akinosho, 2012; Swallowe, 1999). These facts may justify the lower polymeric matrix rigidity 
results obtained for high molecular weight Methocel. Hence, the tendency observed may 
not only be associated with Methocel increase but also related with the increase of modified 
starch in the same formulations (GAS9, GAS11, GAS2, GAS3). The interactions between the 
starch and cellulose chains may cause a decrease of their own mobility contributing for an 
increase of the Et. The hydrogen bounds that may be established between starch and 
cellulose hydroxyl groups might contribute to increase the rigidity of the polymeric film 
contributing for the elevated Young’s modulus observed. 
Regarding the thermal properties, the sweeteners, maltodextrins and simethicone may play 
also an important role. The increase of simethicone contributes to a high thermal stability, 
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showed by the higher temperatures for 5% and 10% weight loss. The simethicone is an inert 
mixture of polydimethylsiloxane and hydrated silica gel (Watson, 2014). These polymers are 
very stable, retaining their own properties when exposed during long periods at higher 
temperatures, compared with the majority of organic polymers. In fact, the Tg of 
polydimethylsiloxanes depends on the particular substituent groups to the main -(Si-O)x- 
chain backbone. Generally, Tg values of these polymers vary between -150 to -70°C and the 
onset temperature for irreversible degradation may be up to 300-350 ⁰C. On the contrary, 
the majority of the organic -C-C- type polymers, rarely present Tg values below -70°C and 
the onset temperatures hardly exceed 150-200°C. Therefore, the inclusion of the 
simethicone in the formulation provide to the polymeric matrix desirable properties, higher 
flexibility at room temperatures, due to the low Tg, and higher thermal stability (Jones et al., 
2001). 
On the other hand, the increase of Maltodextrins (Maltrin) (MDX) contributes to a high 
weight loss when the temperature is elevated at 100⁰C and lower temperature are needed 
to achieve 5% or 10% weight loss. These evidences may be related with the hygroscopicity 
of MDX already described in literature and verified by the Karl-Fisher test (data not shown) 
(Embuscado and Huber, 2009). The ability to retain high amount of water in the polymeric 
matrix is associated with the increase of weight loss at lower temperatures, especially up to 
100⁰C. 
The increase of Sorbitol and Sucralose contribute to lower the temperature for 10 % weight 
loss (poor thermal stability). Additionally, the increase of Maltodextrins, sorbitol and / or 
sucralose contributes for a decrease of the degradation temperature (Tonset), also associated 
with poor thermal stability. Generally, it is advisable to store sucralose below room 
temperature, since under high temperatures it may easily break down with the release of 
carbon dioxide, carbon monoxide, and minor amounts of hydrogen chloride (Rowe et al., 
2012). This poor time-temperature resistance of sucralose may be related with the same 
influence in the final polymeric matrix. On the contrary, sorbitol is described as being 
chemically inert and relatively stable at elevated temperatures but when combined with 
other excipients its thermal stability may be altered. In fact, it is known that this 
phenomenon is common in some excipients, as for example liquid polyethylene glycols, like 
PEG400, which alter its melting point from ca. 100⁰C to around 35–40⁰C when added to a 
excipient mixture (Rowe et al., 2012). 
The disintegration time increases with Methocel E50, but tends to decrease with the 
increase of sorbitol. The higher amount of Methocel E50 (Mw 45,000) in the film 
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composition is mainly compensated by a reduction of the Methocel E5 (Mw 10,000) quantity 
used. This fact justifies the high disintegration time, which normally increases with the 
increase of the polymer molecular weight. This assumption is confirmed by the faster 
disintegration time of the formulations in which the Methocel E50 is replaced by Methocel 
E15. The amount of sorbitol can lead to a decrease of the disintegration time, which may be 
related with its ability to interpose between the individual strands of polymer associated 
with breakdown of polymer-polymer interactions. This effect facilitates the entrance of 
water molecules that posteriorly would be favourable to the disintegration of the polymeric 
matrix. In fact, it is already described that the sorbitol molecules are easily inserted between 
the HPMC strands that due to increase of hydrogen bonds leads to the reduction of 
intermolecular forces (Somashekarappa et al., 2013). 
Finally, the residual water content tend to increase with Methocel E50 and Maltodextrins, 
but decreases with the presence of Methocel E15 (Mw 30,000). The higher Mw of Methocel 
E50 implies longer polymer chains with hydrophilic groups (e.g. –OH), which may be related 
to the higher retention of water in the film matrix, when compared with Methocel E15 films. 
In the case of maltodextrins, it is associated with the inherent hygroscopicity as described 
earlier. 
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Figure 14 - TGA data profiles analysed by Hierarchical cluster test (A) TGA data profile (B). (A) 
Represents a dendrogram that lists and group each observation based on its similarity (by Ward’s 
method). (B) Represents the TGA profiles of GAS-X ® and its major component (simethicone). 
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The clustering analysis of the GAS-X ® formulations showed that the prepared formulations 
have very different thermal behaviour compared to the commercial film. The formulations 
with more resemblances with the commercial formulation are presented in the same cluster 
(green cluster, Figure 14) and are the ones that present higher amounts of simethicone as 
described in Table 7. Considering that the GAS-X ® commercial film presents more than 50% 
of simethicone, it is not surprising that the TGA profiles of the formulations with higher 
amounts of simethicone are the most similar to the commercial film. However, the particular 
TGA curve of the GAS-X ® commercial ODFs was not possible to be reproduced with the 
prepared formulations. There are probably specific excipient combinations that may lead to 
the observed profile, which were not possible to achieve in this study. 
It is also interesting to notice that the sweeteners used in the tested formulations seem to 
have opposite effects in the ODFs studied. In the commercial ODFs evaluated, sucralose that 
apparently have a positive effect on the thermal stability of the Listerine ® ODFs, have 
opposite effect on the GAS-X ® ODFs. However, it is important to consider that this 
discrepancy is only observed until certain extent, since sucralose seem to increase thermal 
stability, due to the higher temperature necessary to lose 10% of weight, but is further 
verified that the degradation temperature (Tonset) decreases with the sucralose increase. This 
observation may be related with sucralose structure and interactions. Briefly, sucralose is 
obtained from sucrose by the replacement of the three hydroxyl groups by three chlorine 
atoms. The major stability added by this compound to the formulation may be due to its 
stability until the first endothermic event. Afterwards the molecule modifications decreases 
its stability and the continuous increase of temperature easily conduct to sucralose 
decomposition, which may be linked with the polymeric matrix decomposition at similar 
temperatures (Bannach et al., 2009). 
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4. Conclusions 
To the best of our knowledge only one very recent study (Woertz and Kleinebudde, 2015) 
used PLS and PCA analysis to evaluate ODFs. In the present work, Chemometric multivariate 
analysis was used to extensively evaluate a pharmaceutical dosage form, especially 
marketed ODFs. The analysis performed was very useful to generate wide formulation 
knowledge essential for ODF matrix development.  
The complex composition of the ODFs makes their characterization and standardization of 
their unique parameters very difficult. This work demonstrates the high importance of each 
excipient in the ODF matrix and also highlights their inter-dependence and interaction.  
This work reinforces that each film, depending on the type and concentration of the 
excipients, presents unique characteristics. The sweeteners exhibited an opposite effect in 
both formulations, and propylene glycol, which was proved in the present work as being a 
suitable plasticizer, was already described as having an anti-plasticization effect in chitosan 
films (Suyatma et al., 2005). Moreover, the preparation of ODFs by solvent casting may be 
influenced by several other technical and galenical factors. For instance, it is important to 
consider the concentration of solids in the casting liquid mixture. In fact, the amount of solids 
is critical, to select cast height, which in turn would influence the polymeric matrix 
rearrangement and finally its properties. There are evidences that casting solution 
properties, as viscosity influences reasonably the mechanical properties. It is described that 
the tensile strength of the ODF may decrease with the solution’s viscosity (Dow, 2002). 
Finally, the techniques and analysis performed appears to be a suitable approach to provide 
a comprehensive of the relationship between raw material attributes and critical quality 
attributes of the pharmaceutical product.  
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Abstract  
Polymers have a key role in the pharmaceutical field. Polymeric matrices have been widely 
explored to obtain different and desirable outcomes in drug releasing kinetics. Thin 
polymeric matrices for oral administration, commonly designated by oral films, had been 
developed during the past years. These innovative dosage forms have gained some 
relevance due to their several advantages and application in unmet medical needs. A deep 
analysis of the complex formulation used in the development of oral films is highly desirable 
to facilitate the final product properties prediction and allow its successful development. 
This work is focused in an extensive thermo-mechanical characterization of marketed oral 
films (GAS-X® and Listerine® films) and in-house prepared thin films by solvent casting using 
the available information about these commercial products. The films were stored under 
controlled conditions and evaluated by TGA, DSC and DMTA. Generally, the GAS-X® films are 
thermally more stable than Listerine® as evidenced in TGA profiles. At least, two distinct 
thermal events were observed in both marketed films at similar temperatures, around -50⁰C 
and 10⁰C. The DMTA analyses corroborate the DSC results and provided additional 
information about polymer chains nature and influence of the formulations. These results 
demonstrate the high impact of the composition on the thermal properties of the oral films, 
highlighting the importance of these techniques development this innovative oral dosage. 
 
Keywords 
Thermal analysis, oral films, DSC, DMTA, TGA 
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1. Introduction  
Polymers have a key role in pharmaceutical development. These macromolecules made up 
of repeating units can have several functions in the pharmaceutical dosage forms. Their 
usage may go simply from a tablet binder, to a more complex role such as taste masking, 
modified release matrices, or even as polymeric drug delivery platforms itself (Omidian et 
al., 2011). Polymeric matrices used as drug delivery systems have evolved along the years, 
and their use in oral administration has been extensively explored. Orodispersible films 
(ODFs) were originally introduced in the market as a breath-freshener, gaining very recently, 
a relevant position in the Rx market. However, the complexity of this type of formulations 
hampers the outline of specifications and methods standardization for their proper 
development, characterization and quality control. 
There are different inherent polymer characteristics that may affect the final product 
performance, such as: viscoelasticity, rheology, mechanical properties, swelling as well as 
gelling and adhesive capacity. These properties may be evaluated using a range of 
techniques, specially thermal and / or mechanical analysis (Jones et al., 2012). 
Thermogravimetric analysis (TGA), differential scanning calorimetry (DSC) and dynamic 
mechanical thermal analysis (DMTA) are the most common methods used for studying the 
thermal behaviour of polymers.  
TGA may be used to evaluate the thermal stability of different compositions including 
polymeric film matrices. It allows obtaining decomposition temperatures (Tonset), moisture 
and volatile compounds determination in complex compositions. In pharmaceutical 
development, TGA can be also used to evaluate the incompatibility between formulation 
components (Australian National Fabrication Facility, 2015; Wesolowski et al., 2012).. 
The DSC is widely used in the pharmaceutical industry because this equipment provides 
important information for drug and galenical developments (Bond et al., 2002; Clas et al., 
1999; Feldstein et al., 2003; Giron, 2002; Okhamafe and York, 1985). This technique allows 
the characterization of the components and multicomponent mixtures, regarding to their 
melting points, enthalpy of fusion, purity, crystallinity, polymorphism, degradation, 
decomposition, stability, glass transition and heat capacity (Bond et al., 2002; Clas et al., 
1999). Additionally, DSC is particularly useful for the fast screening of excipients’ 
compatibility, namely those concerning drug–excipient compatibility. In fact, this type of 
study is very advantageous since it does not require long-term stability studies, only small 
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amounts of samples are required for each assay in early formulation studies and to predict 
possible interactions in the final product. 
Another useful technique for thermal analysis of polymers is DMTA. DSC and DMTA are 
perhaps the most used methods to determine the glass transition temperature (Tg), but the 
last is much more sensitive in the detection of this relaxation phenomenon (Jones et al., 
2012). Different Tgs values may be obtained from these two techniques due to different 
operating principles. DSC is essentially based in variation of the specific heat capacity of the 
sample during the analysis, whereas in DMTA, the strain of the material is measured as result 
of an applied sinusoidal stress. This technique is very useful and efficient to evaluate the 
thermos-mechanical behaviour polymers that typically have amorphous and crystalline 
phases (Australian National Fabrication Facility, 2015; Jones et al., 2012; Soutari et al., 2012). 
Although DMTA is an easy, rapid and non-destructive method to evaluate the viscoelastic 
properties of polymers, it has not been widely used in pharmaceutical development 
essentially due to sample preparation issues. Nevertheless, during the last years DMTA has 
gained increasing interest for the characterization of drug delivery systems and biomedical 
platforms (Jones et al., 2012).  
The references available regarding the determination of mechanical properties of polymeric 
films involve mostly the use of standard tensile equipment based in stress-strain, puncturing 
or creep-recovery and stress-relaxation tests. DMTA emerges as a suitable alternative to 
these classical techniques with the advantage of additional information about viscoelasticity 
and temperature induced transitions over a broad range of temperatures and frequencies 
(Cespi et al., 2011; Jones et al., 2012).  
The aim of this work is to perform a comprehensive thermal and mechanical analysis of two 
marketed oral films, GAS-X® and Listerine® pocket packs, as well as ODFs prepared using the 
same excipients in different proportions. A deep understanding of the mechanical and 
thermal properties of these films is very important to develop fundamental knowledge that 
may be critical for future advancements in the development of this novel dosage form.  
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2. Material and Methods 
 
2.1. Material 
Acessulfame K (Nutrinova, Frankfurt, Germany), Carrageenan k, Gelcarin GP-379NF (IMCD 
UK Ltd, Sutton, UK), FD&C Blue #1 (Colorcon, Harleysville, U.S.), HPMC E5, Methocel E5 
(Colorcon), HPMC E15 Methocel E15 (Orpington, UK), HPMC E50 Methocel E50, Maltrin 
M180 (LEHVOSS UK Limited, Cheshire, UK), Menthol (-)-Menthol (Merck, Darmstadt, 
Germany), Modified starch, Pure Cote B793 (LEHVOSS UK Limited, Cheshire, UK), 
Polyethylene Glycol, Lutrol 400 (BTC, Ludwigshafen, Germany), Propylene Glycol 1,2-
propanediol (Merck, Darmstadt, Germany), Pullulan (Hayashibara Co., Ltd, Okayama, Japan), 
Simethicone (Resil chemicals Pvt. Ltd., Bangalore, India), Sorbitol (Colorcon, Orpington, UK), 
Sucralose, Splenda (Merck, Darmstadt, Germany), Polysorbate 80, Tween 80 (Merck, 
Darmstadt, Germany); Hydranal Composite 5 (Sigma-Aldrich co. LLC, U.S.). 
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2.2. Methods 
 
2.2.1. Preparation of the ODF samples 
ODFs were prepared according to a standard procedure as displayed in Figure 15. 
 
Figure 15 - Schematic representation of the preparation procedure of the orodispersible films (ODFs). 
 
The solutions were prepared in two-neck round bottom-flasks (50mL). The system was kept 
at room temperature or at higher temperatures (60-90⁰C) depending on the excipient used 
in each formulation. For formulations kept at high temperatures that contained ethanol as 
solvent, a condenser was used. The film solutions were cast in PVC release liners (substrate) 
with an Erichsen film applicator (Coatmaster 510, Erichsen, Hemer, Germany). To adjust to 
different heights a vertically adjustable doctor knife was used and the film solutions were 
cast at 18 mm/s. The films were cast with a gap of 250-500 µm. The process of film formation 
has been thoroughly described (Alanazi et al., 2007) and is divided into three stages: (a) 
evaporation of the solvent and subsequent concentration of polymer particles, (b) 
deformation and coalescence of polymer particles and (c) further fusion by inter-diffusion 
of polymeric molecules of adjacent polymer particles. The cast films were dried on the 
heated table of the Erichsen film applicator at 40 °C or at room temperature until dryness.  
Polymer film 
Solvents - water or a 
water:ethanol 96% 
mixture 
Add excipients 
Maintained at room temperature 
or heated when required 
High Stirring 
Cooling at room temperature 
(when necessary) 
Low – stirring during 1-2 
hours 
Final film solution 
Casting Drying 
Solution 
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To further characterize the ODF, individual samples are prepared by cutting strips of regular 
dimension (60 mm2, 2mm x 3mm) with a surgical scalpel. 
The mixture designs were performed with JMP 10 (SAS Institute Inc., Cary, NC), to obtain 
experiments that were representative and randomly chosen within the ranges selected. 
 
2.2.2. Storage 
The individual films are stored under controlled conditions (43 % RH, room temperature), by 
means of a saturated solution of potassium carbonate for at least 5 days before testing.  
 
2.2.3. Differential Scanning Calorimetry (DSC) 
DSC measurements were performed in a DSC Q100 (TA instrument). The tests were carried 
out using two heating runs, from 25 to 100oC and -85 to 100oC with the temperature increase 
rate of 10oC/min and with constant nitrogen flow.  
 
2.2.4. Modulated DSC 
Modulated differential scanning calorimetry of each sample was carried out in a TA 
Instruments (Q100 model). The heat flow was calibrated using indium, whereas for the heat 
capacity, a sapphire standard was employed. The samples were analysed in aluminium pans 
with an ordinary aluminium lid loosely placed from 25 to 100oC and -85 to 100oC. A heating 
rate of 10oC/min, a modulation period of 40 s, and a temperature modulation period of 
±0.50o C were used. A dry nitrogen purge flow of 50 mL/min was used in all measurements. 
 
2.2.5. Thermogravimetric Analysis (TGA) 
TGA test was performed in a TGA Q500 (TA instruments), at a heating rate of 10oC/min, from 
0⁰C to 500oC, under a constant nitrogen flow. 
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2.2.6. Dynamic Mechanical Thermal Analysis (DMTA) 
DMTA analyses ware carried out using a DMA 242 E (Netzsch, Germany) under tensile mode. 
All samples (5.29 ×0.04×5,61 mm3 (average value)) were analysed over a temperature range 
from -150°C to 150°C, at frequencies of 1, 5 and 10 Hz, using a heating rate of 3 °C/min.  
 
2.2.7. Data analysis 
The graphs were prepared using GraphPadPrism version 5.01 (GraphPad Software, Inc, San 
Diego California) and the Plotly (Plotly, Inc, Montréal, Canada). 
The screening and optimization designs were performed with JMP 10 (SAS Institute Inc., 
Cary, NC). The Custom Design platform was used to generate the mixture design performed, 
by introducing the factors as mixture variables and apply a model for the evaluation of the 
main factors and if possible the second interactions. 
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3. Results and Discussion 
The composition of the studied films is summarized in Table 8. The components selected to 
be used in the formulations resulted from the information available to the consumer, usually 
presented on the package. In order to perform a suitable set of experiments, only the most 
critical components of both formulations were selected. 
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Table 8 - Main components of the commercial ODFs evaluated, GAS-X and Listerine® Fresh Burst. 
 
 
 
Polymer Plasticizer Flavor Color Sweetener Surfactant
Thickening 
agent
Drug substance
/ Strength
Modified Corn
Starch 
Propylene 
glycol
Menthol FD&Blue#1
Hypromellose
Maltoextrin
Menthol Green 3 Sucralose
Polysorbate 
80
Chondruscrispus 
(carrageenan)
Coppergluconate
Eucalyptol
Ceratoniasiliqua 
gum
Thymol
Aroma Xanthan gum Methylsalicilate
Orange oil
Simethicone /
62,5 mg
Sorbitol Flavor
Titanium 
dioxide
Glyceryl 
Oleate
GAS-X® Sucralose
Listerine® 
PocketPacks
Pullulan
Propylene 
glycol
Yellow 6
Potassium 
Acesulfame
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This information was used to prepare the mixture design experiments presented in Table 9 
and Table 10. 
 
 
Table 9 - Composition of the different test films based on Listerine® Pocket Packs composition (List) 
that were prepared and characterized based on a mixture design (%). 
Film ID Pullan
Propylene 
Glycol
Menthol Carrageenan Acessulfame Sucralose Tween 80
Selected 
ranges
49-92% 0-17% 0-10% 0-5.5% 0-6% 0-6%, 0.1-7%
List1 65.6 13.4 8.6 1.8 5.2 5.3 0.1
List2 79.0 15.1 3.7 2.0 0 0 0.2
List3 77.4 0 5.9 5.0 5.0 0 6.7
List4 58.4 15.7 9.2 0 5.9 5.9 4.9
List5 91.8 0 3.2 0 0 0 5.0
List6 49.4 15.5 9.6 5.5 6.4 6.3 7.3
List7 88.4 0 9.4 2.1 0 0 0.1
List8 68.3 16.1 0 2.1 0 6.2 7.3
List9 70.2 16.7 0 1.6 6.6 - 4.9
List10 66.5 15.7 3.9 1.1 6.3 6.4 0.1
List11 89.6 0 3.5 0.9 5.9 0 0.1
List12 80.8 0 0 2.1 6.5 3.9 6.6
List13 73.4 16.0 2.0 1.3 3.6 3.6 0.1
 
The intervals used to define the different experiments were based on the marketed films 
patent references (Leung et al., 2008; Schobel and Vangala, 2010). 
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Table 10 - Composition of the different test films based on GAS-X® composition (GAS) that were 
prepared and characterized based on a mixture design (%). 
 
Film ID
Methocel 
E5
Methocel  
E15
Methocel  
E50
Maltrin Starch PEG 400 Sorbitol Sucralose Simeticone
Selected 
ranges
0-60% 0-75% 0-55% 0-35% 0-45% 0-18% 0-11%, 0-4.5% 5-60%
GAS1 43.3 0 0 0 43.5 0 0 0 13.2
GAS2 43.5 43.3 0 0 0 0 0 0 13.2
GAS3 56 0 0 33.7 0 0 0 0 10.3
GAS4 15.7 15.7 0 15.4 15.4 18.2 9.9 4.6 5.1
GAS5 76.6 0 0 0 0 0 0 0 23.4
GAS6 0 41 0 0 24.6 18.1 0 0 16.2
GAS7 0 76.2 0 0 0 0 0 0 23.8
GAS8 41.1 0 10.3 13.7 13.7 0 7.4 0 13.7
GAS9 59.1 0 14.8 0 0 0 11.2 5 10.0
GAS10 59.8 0 15.0 20.1 0 0 0 0 5.2
GAS11 13.7 0 54.4 0 18.1 0 0 0 13.8
GAS12 15.0 0 14.9 0 0 0 10.6 0 59.4
GAS13 12.4 0 33.0 16.5 0 0 9.2 4.2 24.6
GAS14 15.7 0 47.1 0 0 0 8.8 3.9 24.4
GAS15 13.5 0 49.6 0 18.0 0 0 4.5 14.3
GAS16 14.8 0 14.9 0 19.8 0 0 0 50.5
GAS17 12.0 0 47.5 0 0 16.5 0 0 24.0
 
3.1. Thermal analysis 
 
3.1.1. TGA 
An overall analysis of Figure 16 indicates that GAS-X® and Listerine® have similar thermal 
profiles regarding the maximum loss of mass because it starts approximately at same 
temperature, about 200⁰C. However, a closer observation (Figure 16) suggests that GAS-X® 
may present better thermal stability than Listerine® visualized by the higher Tonset, and the 
initial sharp decrease of the Listerine® weight. The temperature that corresponds to 5% 
weight loss is around 60⁰C for Listerine®, whereas for GAS-X® is at 211⁰C.  
There is a clear difference in the thermal behaviour of the polymeric matrices until the 
100⁰C. Generally, it is assumed that the weight decrease up to this temperature corresponds 
to the evaporation of volatile substances, such as ethanol, flavours and water. Therefore, 
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the initial weight loss is not related with any polymer degradation but mainly to water 
evaporation, suggesting that Listerine® is more hygroscopic than GAS-X® polymeric matrix. 
 
 
 
 
Figure 16 - TGA profile of marketed formulations, Listerine® (blue line) and GAS-X® (red line). (A) 
Represents the TGA profile up to 100⁰C. (B) Represents the overall TGA profile. 
 
The prepared ODF based on Listerine® composition that have shown similar thermal 
behaviour compared with the marketed product were the ones prepared with propylene 
glycol (plasticizer) and lower % of menthol (flavour) (List 2, List 7 and List 9 in Figure 17). In 
fact, until 200⁰C, all the films with plasticizer present a very similar thermal profile to the 
marketed product (List1, List2, List4, List7, List8, List9 and List11 in Figure 17). 
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Figure 17 - TGA analysis of marketed and prepared films. (A) Represent the films without plasticizer. 
(B) Represent the films with plasticizer. 
 
Pullulan, the main component of the formulations is very stable until 200⁰C, and its 
degradation starts around 300⁰C (Figure 17). Menthol and propylene glycol have very similar 
thermal profiles, with a starting sharp weight loss around 100⁰C (Figure 18). This poor 
thermal stability justifies the modified profile of pullulan when propylene glycol and / or 
menthol are included in the matrix formulation. Moreover, the thermal degradation starts 
earlier for matrices with higher menthol concentration, above 3.7% (List1, List4 and List11). 
Additionally, this pullulan matrices with propylene glycol and high level of menthol in their 
composition present lower thermal stability even compared with the Listerine® marketed 
formulation. On the contrary, List2 present a very similar profile. On the other hand, the 
pullulan - menthol matrices, without plasticizer, tend to have a higher thermal stability than 
the polymeric systems discussed above (List3, List5, List6, List10 and List12). This result is 
probably related to the fact that without plasticizer, the polymeric films have more pullulan, 
contributing for the higher Tonset.  
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Figure 18 - TGA profile of Pullulan, Menthol and Propylene glycol. 
 
The oral films matrices are generally based on hydrophilic polymers, and consequently 
strongly influenced by moisture. The amount of free water molecules in the polymeric matrix 
may be easily analysed by TGA thermal profiles through the weight loss up to 100⁰C (Leung 
et al., 2008). The polymeric matrices with sharper decrease in this region are probably due 
to a higher hygroscopicity (Figure 19). 
 
 
 
 
Figure 19 - TGA profiles of weight loss up to 100⁰C of the prepared formulations compared with 
Listerine®. 
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List3, List 5 and List 6 have a pronounced weight loss until 100⁰C, whereas List7, List8 and 
List9 have the lowest percentage of loss. There is a clear trend that the films with higher 
Pullulan amount in their composition exhibit a sharper decrease in the weight up to this 
temperature, which is probably related with the capacity of this polymer to absorb water. 
However, it is important to notice that up to 100⁰C other volatile substances, such as 
menthol, may also evaporate contributing to the observed weight loss in this region (Zhang 
et al., 2011). The complexity of the formulations in the polymeric matrix difficult the analysis.  
Among the prepared films, List5 is apparently the one with a higher thermal stability with a 
higher Tonset, while, List7 and List11 are the polymeric matrices with lower degradation 
temperature (Figure 17). The high degradation temperature observed for List 5 is probably 
related with the high pullulan concentration (higher than 90%). The lower thermal stability 
of List7 and List 11 is more difficult to ascribe due to the complexity of the formulations. 
According to the previous analysis, it may be possible to corroborate that pullulan 
contributes to improve the thermal stability, while propylene glycol and menthol could be 
the main components responsible for a decrease in the thermal stability of the prepared 
samples. Sucralose is another excipient that is present in the formulations with lower 
thermal stability (Figure 17, List1, List4, List7, List9, List11 and List12). Sucralose is described 
as being thermally stable up to 119°C (Bannach et al., 2009) but an opposite effect was 
observed here.  
TGA thermal profiles of the GAS-X® based formulations is very different from the marketed 
formulation (Figure 20). Despite the complex composition of the GAS-X® formulation, its 
main component is simethicone and accounts for ~60% of the film weight, which was never 
achieved in the prepared formulations due to technical limitations that involved the 
preparation of homogeneous films with this high drug load.  
The hydrophilic polymers present in the composition of GAS-X® films are less hygroscopic 
than the Pullulan polymer matrices evaluated in the Listerine® based formulations. In 
general, up to 100⁰C none of the films lose more than 6.5% of weight and the majority of 
the films, especially the films with HPMC E50, do not reach the 5% of weight loss (Figure 20, 
Gas8 to Gas19). The films with higher weight loss, above 5%, correspond to formulations 
based on HPMC E5 with a modified starch (Figure 20 and Table 10, Gas1 and Gas3). In fact, 
the hygroscopicity of maltodextrins (Maltrin) (MDX) are already described in literature 
(Embuscado and Huber, 2009), and its presence could contribute to 5% or 10% weight loss 
at lower temperatures.  
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Figure 20 - TGA analysis of marketed and prepared ODFs (A) TGA profiles of prepared films with HPMC E15. (B and D)TGA profiles of weight loss up to 100⁰C of the prepared 
formulations compared with GAS-X®and (C) TGA profiles of prepared films with HPMC E50. 
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Additionally, a lower thermal stability is also observed in the thermal profiles of formulations 
with higher amounts of sorbitol (Figure 20, GAS4, GAS13 and GAS14) and sucralose (Figure 
20, GAS4, GAS9, GAS13, GAS14 and GAS17). However, there is a tendency to higher thermal 
stability for formulations with higher HPMC contents, probably related with the high thermal 
stability of this polymer (Figure 20, GAS1, GAS3 and GAS11). Additionally, it is also verified a 
notorious trend to a higher thermal stability with the increase of simethicone content 
confirmed by the small weight loss until temperatures up to 100⁰C (Figure 20, GAS7, GAS11, 
GAS13, GAS16, GAS18 and GAS19). Chemically, simethicone is a mixture of 
polydimethylsiloxane and hydrated silica gel (Watson, 2014). Polysiloxanes are known to be 
very stable and to retain their characteristic properties when exposed during long periods 
to higher temperatures, compared with the majority of organic polymers. Typically, 
polydimethylsiloxanes have degradation temperatures around 300-350 ⁰C. This fact may be 
associated to the higher thermal stability of these formulations (Jones et al., 2001). 
 
3.1.2. DSC 
The thermal behaviour of samples can be a powerful approach to access relevant 
information such as: purity, chiral purification and miscibility issues. 
The absence of interactions in the solid state and immiscibility in the liquid state would result 
in DSC curve profiles correspondent to the combination of each individual thermal curve 
(Giron, 2002). On the other hand, any possible miscibility would result in a single transition 
temperature (Feldstein et al., 2003). 
Figure 21 (blue line) present two thermal events in the GAS-X® DSC trace, approximately at 
-46⁰C and 10⁰C.The first event is an endothermic peak typically ascribed to a melting 
temperature (Tm). The event at 10⁰C may be attributed to a Tg. The form of the peak at 
approximately -46⁰C is characteristic of a Tm event, which according to the GAS-X 
composition that may be attributed to two different substances: simethicone and / or 
polyethylene glycol (PEG) (Tejwani et al., 2000; United States Pharmacopeia, 2013). Both 
substances are referred as having very low Tm, simethicone lower than -50⁰C and PEGs from 
-60⁰C to +40⁰C depending on their Mw. Therefore, such lower Tm for PEG is only valid for 
specific Mw polymers, especially low Mw PEGs. Even for the same grade, low Mw PEGs may 
have slightly different characteristics, due to minor variations on the carbonated chain. The 
Tm ranges found in literature for PEG 200 vary from -60 to -45⁰C (Dow, 2011a; JHD Fine 
Chemicals, 2008). It is not specified on the marketed product the PEG grade used in GAS-X 
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composition. Nevertheless, it should be mentioned that in the patent of the product the 
examples are presented only PEG 400 (Schobel and Vangala, 2010) (Tm~4-8⁰C (Dow, 
2011b)), which was also used for the prepared formulations in the present work. In turn, the 
simethicone is described to have a Tm around -58⁰C (United States Pharmacopeia, 2013). It 
is important to highlight that these characterization temperatures may vary depending on 
the purity and the moisture content of the compounds. The prepared formulations carried 
out to replicate the GAS-X® marketed formulation, have the same endothermic peak 
independently of the PEG presence (Figure 22, GAS1 to GAS5, Gas 13 and GAS17). Hence, 
this endothermic event may be attributed to simethicone, which is also corroborated by 
simethicone DSC profile (Figure 22). There is also another event, not very clear, at 
approximately -36⁰C, that may be related with a Tg. However, there are no components in 
the formulation that could justify this transition at this temperature. PEG 400 is described to 
have a Tg around -70⁰C to -60⁰C (Feldstein et al., 2003; Okhamafe and York, 1985; Pillin et 
al., 2006) and GAS13 and GAS17 also have a similar endothermic profile and are PEG-free 
(Figure 22). As described previously, another subtle endothermic event may be identified at 
10⁰C with a shape coherent with a Tg transition. This event is also observed for other 
formulations. Although, it is not possible to identify a specific component that may justify 
this event, this peak may result from the physical interaction between the polymers in the 
formulation and the other components. As mentioned above, the good miscibility of the 
components would result in a DSC profile with a single Tg. Therefore, despite the high Tgs of 
the polymers used (Table 8) (HPMC Tg=170-180⁰C (Rowe et al., 2012) and modified corn 
starch Tg= 40-50⁰C (Lim et al., 2001)), the plasticization effect of PEG 400 and sorbitol 
(anhydrous Sorbitol Tg= -9 to -1,7⁰C (Netzsch, 2015; Rahman, 2009)) may have depreciated 
the Tg of the mixture to values around 10⁰C. 
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Figure 21 - DSC profile of Listerine ® (orange line) and GAS-X® (blue line) marketed films. 
 
Simethicone is mainly composed by polydimethylsiloxane (PDMS), which presents a very low 
Tg, around -127⁰C (Ringsdorf and Schneller, 1982). Due to technical limitation of the DSC 
equipment, it was not possible to start the tests below -80⁰C, and verify the presence of this 
Tg. Therefore, no conclusions regarding its miscibility within the polymeric matrix can be 
drawn. However, a DSC analysis of the simethicone used in the formulations was performed, 
and a very close profile was obtained, compared to GAS-X marketed film (Figure 22D). This 
result reveals that a similar silicone mixture is probably used to prepare the original GAS-X® 
commercial film. Additionally, the majority of the prepared GAS-X® based formulations 
present the same endothermic event. In fact, the formulations with lower simethicone 
amount, GAS4, GAS10 and GAS15, present also this small variation in the heat flow in the 
same region. On the other hand, the formulations GAS13 and GAS18, which have around 50-
60% of simethicone, have a pronounced endothermic peak at this temperature. The 
possibility of the existence of two simultaneous thermal events with different nature cannot 
be excluded, since each may be related with two independent sub-systems that may be 
formed within the overall polymeric matrix (for example starch-based polymeric system and 
cellulose-based matrix system that are not completely miscible). But, analysing the 
formulations prepared, similar DSC profiles are verified in cellulose based matrices (Figure 
 151 
22, GAS13), which rebuts any of the previous theory. In order to clarify the obtained profiles 
a modulated DSC was performed. 
In Listerine®, two different thermal events were also identified, an apparent exothermic 
event, around -53⁰C, and an endothermic one visible at around 10⁰C (Figure 21). The 
exothermic peaks are usually related with crystallization or oxidative decomposition (Ahuja 
and Scypinski, 2010; Sepe, 1997). However, crystallization peaks are usually preceded by Tg 
events (Sepe, 1997), and the oxidative events are associated with higher temperatures 
(Ahuja and Scypinski, 2010). In turn, the second peak of Listerine® DSC curve has the shape 
of a melting transition. However, within the formulation components, none of them has a 
Tm around 10⁰C. Nevertheless, it is important to consider that miscible blends may 
contribute to lower Tm of each single component (Zhang et al., 1998). Indeed, the 
complexity of the system and the wide range of Tm values of the different components, 
difficult the clear interpretation of the traces. However, as discussed before, it is possible to 
consider the formation of a blend that due to its good miscibility may behave as a single 
component with in-between characteristics of the different components used in the 
formulation. In fact, it is already described in literature that an optimal miscibility between 
the oral film components pullulan-based polymeric matrices is possible (Bhavya, 2013; 
Bumbu et al., 2002; Diab et al., 2001; Prasad et al., 2012; Wesolowski et al., 2012). 
A modulated DSC was also performed for the Listerine® marketed films, in an attempt to 
clarify the thermal events presented. 
The information regarding DSC profiles of pure pullulan available in literature is very scarce 
and contradictory because some references indicate very different Tg values (94⁰C (Bhavya, 
2013) and 160⁰C (Bumbu et al., 2002)). There is an evident discrepancy between the 
reported results and also with the Tg obtained in the present work, around 120⁰C (pullulan 
DSC curve, Figure 23). These differences may be related with the fact that pullulan is a 
natural polymer, and different sources or suppliers, may have influence in the purity of the 
raw material. Additionally, it is important to consider that this biopolymer due to its 
hydrophilic nature, has a high affinity for water, which is known to function as a plasticizer 
that may contribute to lower the Tg values.  
Regarding the prepared Listerine® formulations, the differences to the commercial film DSC 
profile are clear. In fact, in the prepared formulations, it is very difficult to identify clearly 
specific thermal events, only very slight changes in the heat flow curves are observed, except 
in formulation List6. This last formulation presents an unexpected DSC profile with two 
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endothermic events. In this specific formulation the profile obtained may be related with 
the high content of menthol. Therefore, a part of the menthol interacting with the polymeric 
matrix may functioning as a plasticizer, as previously described, and may contribute for the 
matrix-endothermic peak event observed around 50⁰C; whereas the menthol that remains 
free in the polymeric matrix may contribute for the first-endothermic peak, which could 
correspond to its Tm, around 40⁰C (Rowe et al., 2012).
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Figure 22 - DSC traces of GAS-X® prepared formulations compared with GAS-X® marketed film. (A), (B) and (C) Represent DSC profile of GAS-X® formulations. (D) Represents 
DSC profile of marketed GAS-X® and Simethicone.
C 
A 
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Figure 23 - DSC traces of Listerine® prepared formulations compared Listerine® marketed film. (A) 
DSC profile of Listerine® prepared formulations. (B) Represents DSC profile of Listerine® marketed 
film and pullulan.  
  
B 
A 
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3.1.3. Modulated DSC 
Modulated DSC allows the separation of reverse and non-reverse thermal events. This 
approach allows the separation of specific events into individual signals, which can be very 
helpful to identify peaks that are overlapped. The reverse component allows highlighting 
important transitions as crystal melting and glass transition, whereas the non-reversing 
component may allow identify, recrystallization and enthalpy relaxation (Artiaga et al., 2011; 
Sepe, 1997).  
 
 
Figure 24 - Modulated DSC for GAS-X® (A) and Listerine® (B) marketed products (Exothermic events 
Up).  
A 
B 
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In the GAS-X® analysis, it is possible to verify the presence of a melting event around -44⁰C 
(Figure 24A, orange line). The slight elevation at the same temperature in the non-reverse 
heat flow curve (Figure 24A green line) may also indicate a Tg. However, this last is not so 
obvious and is difficult to assure this event due to the very slight variation. Similarly, the 
possible Tg identified in the previous DSC results, at 10⁰C, is also not so evident in this profile. 
No significant change is verified in the non-reverse heat flow curve that represents a Tg at 
this temperature. As already discussed the event at negative temperatures probably results 
from simethicone melting.  
In the Listerine® profile, it is easier to identify the transition events, two possible Tms, 
around -52⁰C and 5⁰C (Figure 24B, orange line). The peak form is related with the enthalpy 
energy, since the overlapping of events contributed to an energy release, masking the real 
genesis of the event. At this negative temperature it is possible that the Tm results from the 
propylene glycol, which is described to melt at -59⁰C (Rowe et al., 2012). However, to 
present an unchanged Tm profile compared with the pure substance, in such complex 
system, it may have to be immiscible with the other components and / or have an excess 
amount non-linked / interaction-free with the polymeric matrix.  
The DSC analysis is very useful to evaluate and characterize galenical formulations, but the 
interpretation of the thermal data is not always simple and several external / environmental 
factors may lead to results’ misinterpretation and misleading. In fact, it should be considered 
that if the DSC experiment is performed in non-equilibrium conditions, some interactions 
may not be predicted and confirmation methods should be used (Clas et al., 1999). In 
addition, the complexity of the formulations highlights the limitation of this technique to 
obtain structural-properties characteristics in these matrices. Therefore, a dynamical 
mechanical thermal technique (DMTA or DMA) was also used to evaluate the oral thin films 
in attempt to discriminate some of the dubious thermal events verified in DSC traces. 
  
 157 
3.1.4. DMTA 
DMTA analyses were carried out to complement the previous thermal analyses. Thermal 
relaxation events as Tg and secondary transitions (β and γ) can be accurately identified with 
this technique.  
The tests were performed in a multifrequency mode (1, 5 and 10Hz) and the results are 
presented at 1 and 10 Hz for the marketed formulations and at 1Hz for the others. The 
viscoelastic properties (elastic modulus - E’, viscous modulus - E’’ and damping - Tan δ) are 
represented for both commercial films (Figure 25). The DMTA analysis was performed for 
the developed formulations that apparently present some similarities with the commercial 
form (Figure 25). 
The complexity of the DMTA traces is obviously associated with the blending complexity of 
the polymeric matrix. However, there are some basic features that can be always retrieved 
from the profiles obtained. The Tg value may be estimated assuming the events combination 
in the same region: maximum peak of the Tan δ curve and elastic modulus (E’) sharp 
decrease (Jones et al., 2012). 
Regarding the Listerine®, there is an unusual profile of the viscoelastic properties of the films 
in the beginning of the thermal profile, around -100⁰C, with an evident peak of the viscous 
modulus (E’’) along with a slight decrease of the storage modulus (E’). The next thermal 
transition evident assumes the profile of a Tg, at approximately at 10⁰C (not observed in the 
DSC). This event is shown by very intense transitions, a Tan δ peak and a sharp decrease of 
the storage modulus. Above this temperature the samples becomes too soft avoiding the 
analysis to continue. 
The Listerine® developed formulations have similar behaviour when compared with 
commercial Listerine® films. In fact, in the Tg region (0-25⁰C), a sharp decrease in the E’ is 
observed for all formulations. However, this phenomenon occurs slightly earlier in the 
developed formulations than in commercial Listerine®. Therefore, the Tg is lower in these 
formulations. Actually, the Tg is around 0⁰C for the majority of the formulations, except for 
List7, in which the E’ curve starts to decrease at negative temperatures, indicating a higher 
flexibility of this polymeric matrix at lower temperatures. The complexity of the formulations 
that involve the use of different compounds/quantities turn extremely difficult to ascribe 
the differences observed. 
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The majority of the Listerine® formulations prepared has half of the E’ values compared with 
the commercial films and present a longer rubbery plateau. In general higher storage 
modulus is indicative of higher crystallinity or lower plasticization of the polymer chains. The 
storage modulus of a semi crystalline polymer is always higher than the modulus of a similar 
amorphous polymer above the Tg (Menard, 1999; Menczel and Prime, 2014). 
The differences of E’ observed between the commercial and the prepared formulations can 
be also ascribed to the number of excipients used that in the latter case are smaller.  
The analysis of the GAS-X® DMTA show two regions with major E’ drops. This unusual profile 
has been already reported for some complex film matrices, due to thermal events overlap 
(Menard, 1999). The first sharp decrease of E’ occurs around -125⁰C. This event is ascribed 
to the presence of simethicone that has a Tg around -127⁰C (Ringsdorf and Schneller, 1982). 
This thermal transition was not observed in the DSC profile, since the equipment could not 
be used at such low temperatures. The very slight transition observed at -50⁰C is consistent 
with the results observed in DSC regarding the presence of Tm of this simethicone, which 
has been reported at -50⁰C. 
The second Tanδ peak is at 30⁰C that depends on the frequency of analysis may be related 
to the thermal event that was observed at about 10⁰C in the DSC trace. This transition 
corresponds to the main Tg of the film resulting from the formulation used. Several reports 
in the literature describe differences between the Tg values obtained by DSC and DMTA that 
can be between 10-20⁰C (Menard, 1999). Also, the mentioned difference is usually higher in 
the DMTA assays because the differences on the time scale of the methods and frequency 
effect of the DMTA (Cheng, 2002).  
The prepared GAS-X® formulations present a DMTA profile different from the commercial 
film (Figure 25). In fact, comparing their storage modulus it is easier to identify the thermal 
event at - 50⁰C, which probably corresponds to simethicone Tm. In the GAS6 formulation it 
is also possible to identify a second Tg around 10⁰C that corresponds to the film resulting 
from the formulation used. The E’ peaks above Tg transition are well-marked in GAS6 and 
more subtle in GAS13. This formulation presents significantly higher values of E’ in negative 
temperatures, however with the temperature increase these values rapidly drop. In fact, 
around -50⁰C, presumably the simethicone’s Tm, a sharp decrease is verified in formulation 
GAS6.
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Figure 25 - DMTA analysis traces of the marketed films (1Hz, full line and 10Hz, dashed trace) of the prepared formulation and marketed films. (A) and (C) Represent DMTA 
profile of marketed films Listerine® and GAS-X®; (B) and (D) Represent Storage modulus (E’) of prepared formulations, top Listerine® formulations and bottom GAS-X® 
formulations.
C D 
B 
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4. Conclusion 
A complete thermo-mechanical analysis was performed in a novel dosage form (ODFs) in an 
attempt to relate its composition to the final product characteristics. This data may be 
extremely relevant to retrieve information that may be helpful to the development of new 
oral films platforms. Currently, to the best of our knowledge, it is not available any similar 
approach or such complete thermo-mechanical study in highly complex polymeric systems. 
Despite of the formulations’ composition complexity, very simple curve profiles were 
observed, which may be related with the optimal interaction between the components or 
thermal events overlapping. It was also obvious that the fewer amount of components in 
the prepared formulations diminished the overlap events in the thermal analysis methods 
allowing the easier identification of some events. 
The TGA analysis was very useful to evaluate the thermal stability profile of the different 
components, which may be very useful to predict the formulations stability subjected to 
different temperatures.  
The DSC analyses allow retrieving some relevant information about some components 
interactions and behaviour in the polymeric matrix. But, the complexity of the formulations 
hampered a complete understanding of role of the different components used in the 
formulations, and highlighted the limitation of this technique to obtain structural-properties 
characteristics in these matrices. Therefore, the DMTA evaluation was very helpful to obtain 
additional information about matrix-composition and product properties. Despite of some 
differences observed regarding the values obtained by DSC, both results are consistent and 
coherent regarding the Tg determination.  
Although DMTA application is still limited in pharmaceutical industry its application in this 
polymeric film systems would be very useful to understand the performance, stability 
behaviour and some quality attributes of the final product (Jones et al., 2012; Perfetti et al., 
2010). 
In the present work it was shown that the main polymers / components presented in the 
film are responsible by the majority of the characteristic trends verified in the final product. 
Even the minimal amount of other excipients can change greatly the matrix film properties. 
It was also demonstrated that there is no need to have a perfect miscible system to obtain 
marketed viable products, with suitable handling, stability and performance properties. 
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Therefore, the compatibility or immiscibility of the components may be sometimes desirable 
depending on the drug delivery system under development (Mura et al., 1995).  
Finally, in the development of these systems each excipient’s properties added to the matrix 
should not be considered individually or independently. Several complex interactions may 
occur and each component of the oral film functions as a fingerprint for final product 
identification and behaviour. 
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Abstract 
Oral films have gained increasing relevance as a novel dosage form the pharmaceutical 
market. Associated to their particular processing and multicomponent composition, there 
are a vast number of reasons to establish helpful development guidance, gathering 
simultaneously the recent pharmaceutical regulatory trends. This study aimed at 
characterizing marketed oral films in order to provide essential information about a clear 
definition of product CQAs. Several commercial oral films were evaluated in terms of 
thickness, residual water content, disintegration time and mechanical and thermal 
properties. The oral films exhibit a very broad range of thickness values [40-140µm], which 
is probably associated with the height gap used on the cast of oral films production. The 
majority of oral films dissolved within 60 seconds [32-105s]. In general, a broad range of 
values were found for all the properties studied, residual water content [2.91- 9.75 %], 
Young’s Modulus [51.25 – 1827 Mpa], tensile strength [1.47 - 33.91Mpa] and tensile strain 
[0.32 – 38.2 %]. Despite the oral films’ complex composition, it was possible to establish 
some important correlations about the impact of the main excipients on the final product 
characteristics. Additionally, it was also defined a range of acceptable values for the CQAs 
evaluated that may work as an acceptance criterion in the development of new oral film 
formulations. 
 
Keywords 
Orodispersible films, Quality by Design, Critical Process parameters, Critical Quality 
Attributes 
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1. Introduction 
Oral drug delivery still holds the major share in the drug delivery market (Borges et al., 2015; 
De Robertis et al., 2015; Research, 2010). This fact is mainly driven by the convenience of 
the administration and lower production costs. Therefore, innovative oral dosage forms for 
very fast or controlled release, have been developed, with the focus on patient’s compliance 
by addressing swallowing problems, multi-dose prescriptions, and for improving safety and 
/ or efficacy (Kelly et al., 2009; Patel et al., 2010; Yang et al., 2010). 
Orodispersible films (ODF) are a pharmaceutical dosage form that may be developed to have 
a fast or tailor drug release profile, and the interest of the pharmaceutical industry in this 
dosage form has significantly increased during the past years. ODFs were firstly introduced 
in the market as breath fresheners with the Listerine Pocket Packs®. This important 
landmark was followed by other OTC ODFs and later by the Rx products, in 2009 with the 
launch of Onsolis® and in 2010 with Zuplenz® (Borges et al., 2015; CenterWatch, 2015). 
Currently, ODFs already have a solid and growing presence in the pharmaceutical market. 
However, there is still some lack of guidance for the development and manufacture of ODFs 
with suitable properties, particularly for medical use. These difficulties are mainly driven by 
the inexistence of well-defined characterization procedures, standard evaluation 
parameters, guidance on appropriate final product properties and specifications. 
In literature, several techniques are described for the characterization of this dosage form. 
Garsuch et al. tested a set of very convenient techniques for oral films characterization with 
high relevance for the development phase, such as morphological characterization (scanning 
electron microscopy, near-infrared chemical imaging) as well as other techniques more 
indicated for the evaluation of product performance, tensile strength (based on DIN EN ISO 
527), disintegration (thermomechanical analysis, contact angle measurement), and 
dissolution profile (fibre-optic sensor, common and adapted dissolution apparatus) (Garsuch 
and Breitkreutz, 2009).  
Gaisford et al. also described a very interesting technique based on near-infrared chemical 
imaging (NIR-CI) to investigate the expected crystallization of the drug substances in the 
polymeric matrix (Gaisford et al., 2009). This non-invasive approach allows the analysis of 
the drug substances distribution within the matrix, after previous calibration with pure 
substances. As result, vibrational bands for selective imaging are obtained. The verification 
may be performed visualizing the possible substance crystallization by a homogeneous or 
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nonhomogeneous appearance (Gaisford et al., 2009). This information may have extreme 
importance during formulation development and optimization to evaluate possible 
incompatibilities between the drug substance and the polymeric matrix and to evaluate the 
product long-term stability. 
Although these advanced techniques may be very helpful during formulation development, 
they are not easily carried out during routine procedures like in-process control and quality 
control. On the other hand, there is a lack of standard methods to evaluate relevant critical 
properties that are mandatory to control the product quality and at the same time are 
appropriate to evaluate such relative small-size dosage form. In this context, alternative 
methods have been studied and developed to be specifically applied to ODFs. For example, 
texture analyzer (TA) instruments enable the determination of ODFs’ mechanical strength 
based on puncture tests (Preis et al., 2014b). This equipment has a holder clamp systems, 
special weights, an electronic end-point detection that enable the determination of the 
disintegration time (Preis et al., 2014a). Also, millifluidic continuous flow-through dissolution 
devices to mimic more closely mouth physiological conditions (the place where the 
disintegration and dissolution of oral films occurs) have been developed (Adrover et al., 
2015).  
Currently, scarce information is still available on the Pharmacopeia’s regarding ODFs. The 
USP presents a complete definition for the characterization of films depending on its 
application site (European Pharmacopoeia Commission, 2015), but has no specific tests or 
any dedicated monograph requirements to apply (European Pharmacopoeia Commission, 
2015). On the other hand, the European Pharmacopeia (EP) present a brief description of 
the dosage form and also mention that oral films should have an adequate drug release and 
mechanical strength (European Pharmacopoeia Commission, 2015). Therefore, there is an 
urgent need to study techniques and characteristics that may be critical to obtain ODFs 
products with optimal quality and performance properties, during the development and 
product quality control stages. Visser et al. recently enumerated some critical quality 
attributes (CQAs) that ODFs should present to be easily handled and quickly dissolved in the 
oral cavity, those include: tensile strength, elongation at break, Young’s modulus and 
disintegration time (Visser et al., 2015). 
Nevertheless, besides the brief guidance provided by EP (suitable mechanical strength and 
appropriate dissolution method), it was not possible to find more detailed information 
regarding advisable procedures for oral films characterization /quality control or to define 
suitable specification limits (Preis et al., 2014). For this reason, there is still much work to be 
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done in this area aiming to contribute to the knowledge and understanding of the CQAs of 
this new pharmaceutical dosage form. 
The aim of this work was to perform an extensive characterization of several different 
commercial films, using different techniques, in order to correlate their main properties with 
major composition components and to evaluate the possibility of defining acceptance 
criteria for oral films’ CQAs that may constitute valuable information to boost the 
development of new ODF formulations.  
ODFs were evaluated regarding their structure, disintegration time, residual water content, 
mechanical and thermal properties. The methods used to characterize the films were 
selected based on the most widely described in literature and their suitability for the specific 
purpose. 
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2. Material and methods 
 
2.1. Materials 
Ten marketed products with orodispersible films technology were investigated: Gas-X®, 
Novartis Consumer Health, Inc; Snoreeze, Passion For Life Healthcare (International) Ltd; 
Re:balance, Boots Pharmaceuticals; Stop Snoring, Essential Health Products Ltd; Zentrip, 
Sato Pharmaceutical Co., ltd; B12 strips, Essencial Source, Inc; Hunger Strips, Now Slim Ltd; 
Listerine® Fresh Burst and Listerine® Cool Heat, Johnson & Johnson Healthcare Products; 
Snore Relief, CNS Inc. 
 
2.2. Methods 
 
2.2.1. Film mass 
The films were weighed using an analytical balance (Mettler Toledo AGXS, Mettler-Toledo 
Inc., Columbus, US) and the average weight was calculated (n=3). 
 
2.2.2. Film thickness 
The thickness of the films was measured with a micrometer screw (Mitutoyo Digimatic 
Capiler, Mitutoyo Corporation, Japan) (n=5).  
 
2.2.3. Tensile Strength 
The mechanical properties of the films were determined using a tensile testing universal 
apparatus (Zwick, Germany) equipped with a load cell of 10 N. Briefly, oral films were held 
between two clamps positioned at a distance of 15 mm. Firstly, a preload was performed in 
each assay and then the strips were pulled by the top clamp at a rate of 10,0 mm/min. 
The load automatically applied to the film is gradually increased and the corresponding 
magnitude of elongation is recorded until the break point of the film is finally reached. The 
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parameters are directly retrieved from the software TestXpert (TestXpert, Zwick, Germany), 
namely Young’s modulus, tensile srength and elongation. Measurements were run at least 
in three replicates for each film. 
 
2.2.4. Disintegration time 
A simple test was used to evaluate the time needed until the disintegration starts. The oral 
films were laid on a Petri dish and 4 mL of water at room temperature or a phosphate buffer 
pH=6.8 (artificial saliva) was added. The time until the film samples started to disintegrate 
was recorded. 
 
2.2.5. Karl-Fisher 
The Karl Fischer Method was used to determine the residual water content in the oral films. 
This technique basically consists in the quantitative reaction of iodine and sulfur dioxide by 
the addition of water, in the presence of an alcohol (methanol). 
 
 
A sample was added to the titration flask filled with methanol previously dehydrated with a 
Karl Fischer reagent (Hydranal Composite 5, Sigma-Aldrich Co. LLC). Titration was carried out 
using Karl Fischer reagent with a known determined titer (mgH2O/ml). Water content was 
determined based on the titration volume (ml). The polarization-current potential-
difference method was employed as an end-point detection method.  
These tests were performed in a Karl Fisher 787 KF Titrino (Metrohm AG, Herisau, Schweiz). 
 
2.2.6. Differential Scanning Calorimetry (DSC) 
DSC measurements were performed in a DSC Q100 (TA instrument). The tests were 
performed in two heating runs, from 50 to 100oC and -90 to 100oC with a heating rate of 
10oC/min under constant nitrogen flow.   
       CH3OH 
SO2 + I2 + 2H2O                             2HI + H2SO4 
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2.2.7. Thermogravimetric Analysis (TGA) 
TGA was used to analyse the thermal stability of the sample by measuring the weight loss of 
the sample as a function of temperature, when the sample is submitted to a significant 
temperature variation. Generally, the TGA derivative, known as DTG curve, is used to mark 
the different peaks associated to each TGA steps, which represents the maximum rate of 
mass loss. 
TGA test was performed in a TGA Q500 (TA instruments), at a heating rate of 10oC/min, from 
0oC to 500oC, under a constant nitrogen flow. 
 
2.2.8. Statistical analysis 
The number of samples tested was too small (n<7) to perform the normality test. Therefore, 
it was used the Kruskal-Wallis test to compare the different groups, or the Mann-Whitney 
test to compare 2 groups. The values in tables and graphs are presented as median (25% 
quartile – 75% quartile). These analyses were performed with GraphPadPrism version 5.01 
(GraphPad Software, Inc, San Diego California). 
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3. Results and discussion 
The compositions of the different marketed products were taken from the available 
information on the packaging boxes and are presented in Table 11. Excluding Listerine® oral 
films, all the products have modified hydrophilic cellulose. The complexity of their 
composition is well illustrated by the significant number of excipients used in each 
formulation. 
The samples were kept at room conditions in their primary packaging material until the 
moment to perform the different characterization tests. 
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Table 11 - Main components of the commercial oral films evaluated - Gas-X, Re:balance, Stop Snoring, Zentrip, B12 strips, Hunger Strips, Listerine Fresh Burst and Listerine Cool Heat and Snore Relief. 
.
Corn Starch 
modified
Polyethyleno
glycol
Menthol FD&Blue#1 Sorbitol
Hypromellose Maltodextrins
Maltoextrin Sucralose
Menthol Green 3 Sucralose Polysorbate 80
Chondruscrispus 
(carrageenan)
Coppergluconate
Eucalyptol
Ceratoniasil iquagu
m
Thymol
Aroma xanthangum Methylsalicilate
Sodium alginate Sucralose sorbitol
Modified starch
Modified 
cellulose
Hypromellose Peppermint Flavor
Sodium 
Carboxymethyl 
Cellulose
ModifiedStarch Menthol
Microcrystall ine 
Cellulose
Menthol
Orange oil
Hypromellose Menthol FD&Blue#1 Polydextrose
Polyethylene 
Oxide
Pectin
Cornstarch Maltitol
Cellulose Acessulfame K
Sorbitan
Stearate
Sodium saccharin Hyaluronicacid
Potassiumsorbate 
(preservative)
Citricacid
Pectin Peppermintoil Aspartame Sorbitan Stearate Tocopherylacetate
Sodiumsaccharin Hyaluronicacid
Potassiumsorbate 
(preservative)
Citricacid
Thickening agent Desintegrant Anti-oxidant Drug substance / Strength
Gas-X Simethicone / 62,5 mg
Polymers Plasticizers Flavors Color Sweetener Surfactant
Sorbitol Flavor
Titaniumdioxid
e
ListerinePocket 
Packs
Pullulan
Propylenogl
ycol
Stop Snoring Oral
Strips
Glycerol
Essential oils of 
peppermint, lemon, 
pine, fennel, lemon 
balm, eucalyptus, 
lavander, mastic, 
sage, thyme, clve
FDC Blue Soylecithin
Yellow 6
Potassium 
Acesulfame
Glyceryl Oleate
Potassium 
Acesulfame
Polysorbate 80
GumArabic B12 / 1000mcg
Zentrip Hypromellose
Polyethylene
glycol 400
Ferric Oxide Mannitol
Sucrose esters of 
fatty acids
B12 Strips Glycerol Stevia Polysorbate 80
Butylatedhydroxytoluene
MeclizineHCl 25mg
Peppermintoil
Blue FCF
Hunger Strips Glycerol Natural MintFlavour Bril l iantBlue
Cellulose
Guargum
Guargum
GuaranaSeedextract
Tocopherylacetate
Cellulose Menthol Polysorbate 60
Acessulfame K
Commercial Name
Re:Balance Glycerol Blue FCF
Aspartame
AlginicAcid 
(stabilizer)
Menthol Polysorbate 60
Acessulfame K
Snoreeze
Pectin
Glycerol
Wintergreenflavour FD&Yellow#5 Sucralose
SnoreRelief
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3.1. Tensile Strength 
The mechanical properties were analysed in commercially available films in order to 
evaluate the possibility of defining standard ranges for these properties. These tests were 
restricted to the original shape of the films. The tests performed provided important insights 
about their mechanical characteristics. 
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Table 12 - Mechanical properties of commercially available oral films. The values are presented as 
median (25% quartile – 75% quartile). ϬB - tensile stress at break; εB - tensile strain; Et– Young’s 
modulus.  
Commercial 
films 
Et (MPa) εB (%) ϬB (Mpa) Thick. (µm) Nature
692.5 7.815 33.78
(554.3-803.9)  (6.4-10.07)  (31.43-35.45)
51.25 3.160 1.470
(45.89-56.54) (3.160-3.710)  (1.440-1.610)
1003 0.3200 4.570
 (956.4-1437)  (0.3100-0.3400) (3.830-5.450)
1077 4.485 33.91 
(797.7-1440) (2.595-5.955) (29.45-43.01)
1724 3.380 27
(1677-1729)  (2.940-3.710) (26.89-27.20)
236.2 6.340 10.39 
(145.0-277.2) (4.943-6.958) (9.032-13.17)
1827 3.810 29.94 
(1753-1871) (2.990-4.420) (24.04-31.87)
223.8 2.485 3.960
(218.7-228.4)  (2.288-2.570) (3.953-4.103)
90.47 38.20 14.84
(39.42-91.77)  (32.80-44.44)  (12.94-17.06)
186.2 31.59 12.44 
(157.3-204.2)  (25.01-33.38) (10.62-13.65)
B12 Strips 60 Soft - Tough
Gas-X 110 Soft- Weak
Hunger 
strips
40 Hard - Brittle
ListerineFre
shBurst
40 Hard - Tough
Listerine 
Cool Heat
40 Hard - Tough
Stop 
Snoring
60 Soft - Tough
SnoreRelief 60 Hard - Tough
Zentrip 140 Soft - Weak
Snooreze 80 Soft - Tough
Re:balance 80 Soft - Tough
 
 
The Young’s modulus (Et) of the marketed ODFs varied between 51.25MPa and 1827 MPa 
(Table 12 and Figure 26). In the present study, it was not possible to correlate the Et with 
the films thickness, due to the high variability and multicomponent complexity of the studied 
films. The GAS-X® samples correspond to the less stiffeness films (lower Et) but are the 
second samples in terms of thickness, whereas the SnoreRelief samples correspond to the 
most rigid films (higher Et) and are the second thinner films. Although the elastic modulus is 
affected by the cross sectional area of the sample, the gauge length of the test specimen 
was maintained constant in order to minimize the impact of having samples with different 
cross sectional areas, since samples with higher cross sectional area tend to be stiffer. 
Therefore, the main differences observed between the different oral films are probably 
related with the different nature of the polymeric matrices (Table 11). Interestingly, the 
majority of the films are based on modified cellulose, despite the discrepancy of results. This 
observation suggests that besides the polymeric matrix, the other components used in the 
formulation have also an important role on the mechanical properties.  
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Listerine® films, mainly based on Pullulan are clearly stiffer than the majority of cellulose 
based films, except for Snorerelief® and Hunger strips®. Considering the structures of 
hypromellose and pullulan, the latter presents more available hydroxyl groups to establish 
intra-and inter-polymer chains hydrogen bonds, which could justify the higher rigidity of the 
Pullulan based films.  
It is also interesting to notice that Listerine® films with distinct flavours (Listerine® Fresh 
Burst menthol flavour, and the Listerine® Cool Heat, cinnamon flavour) present slight 
differences in the elastic modulus. Their mechanical properties are probably mainly affected 
by Pullulan and propylene glycol, but the differences found may indicate that components 
present in very small amounts can also have some influence on the product properties, in 
this case, different flavours. Nevertheless, the mechanical properties of Listerine films 
evaluated are consistent with the mechanical properties of Pullulan films reported: higher 
elastic modulus and moderate to high tensile strength (Kawahara M, 2003). The tensile 
strain at break reflects the elongation ability of the products. Regarding this property, a wide 
range of possible values were observed from 0.32 % to 38.20% for Hunger strips® and 
Snooreze®, respectively (Table 12 and Figure 26).  
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Figure 26 - Mechanical properties of commercially available oral films (Gas-X, Re:balance, Stop Snoring, Zentrip, B12 strips, Hunger Strips, Listerine Fresh Burst and Listerine 
Cool Heat and Snore Relief). (A) Represent Et, Young’s modulus. (B) Represents ϬB, tensile stress at break. (C) Represents εB, tensile strain. * p<0.05; ** p<0.01.
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The tensile stress at break (Breaking force, σB) also varies significantly between the tested 
products (Table 12 and Figure 26). Gas-X® tears easily with 1.47 MPa while Listerine Fresh 
Burst requires 33.91 MPa to break. It was also verified that the majority of the films with 
high rigidity (high Et) tend to have higher tensile stress to break (Listerine®, Snore Relief® 
and B12 strips®). However, this is not observed for the Hunger strips®, that are hard (high 
Et) and brittle (low σB). Snooreze ® and Rebalance® films are less stiffness (low Et) but also 
though (medium σB values).  
In general, the results demonstrate that the several marketed films studied have a wide 
variation of the mechanical properties. Moreover, it is clear that the overall composition 
should be the main reason for the observed differences.  Therefore, it would be very 
important to evaluate the role of each component and its influence in the matrix. It is 
expected that the major contributors to the mechanical properties are due to the film 
forming polymers, the plasticizer and the drug substance (Cilurzo et al., 2010; Mishra and 
Amin, 2009). 
Hydrophilic modified cellulose compose the majority of the films studied, being 
hydroxypropylmethyl cellulose (HPMC or hypromellose) and hydroxypropyl cellulose (HPC)  
the most widely used, since these polymers have a fast dissolution in aqueous media 
(Bourtoom, 2008).  
Generally, HPMC is referred as a strong polymer with good physical integrity and as a film-
former (Chen M, 2006; Meenu Dahiya, 2009). Thus, these properties are highly dependent 
on HPMC grade and also can be influenced by formulation characteristics, e.g. concentration 
of HPMC used or possible excipients blends. In fact, it is reported that the maximum 
puncture strength of HPMC increases with the molecular weight, E3 (Mw 9,000) < E5 (Mw 
10,000) < E15 (Mw 30,000) < E50 (Mw 45,000) (Cherukuri and Ravella, 2009; Meenu Dahiya, 
2009). It is also known that HPMC E-15 has better film forming properties when blended 
with other polymers such as microcrystalline cellulose or synthetic polymers (PVA and PVP) 
(Kulkarni et al., 2010), while solutions with lower HPMC concentration became thin, brittle 
and non-peelable (Mahesh et al., 2010).  
The films evaluated that have cellulose as film-former are mainly soft (moderate Young’s 
modulus) and tough (moderate tensile strength). However, there are some exceptions such 
as Zentrip® and Gas-X® that are soft and weak (low elongation and very low tensile strength). 
Hunger strips® are hard and brittle (high Et and very low elongation), whereas Snore Relief® 
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is hard and tough (high Et). One half of the films under study have hypromellose as matrix 
component, while the other half have solely cellulose or modified cellulose. Therefore, 
based on the moderate Et that favours the softener handling properties observed, 
hypromellose may be the polymer used. The exceptions are Snore Relief® and the Hunger 
strips®, that normally are tougher. This fact may be related with different cellulose grades 
used or excipient-excipient interactions between different components. For example, HPC 
based films were shown to be stiffer than HPMC films, due to the high elastic modulus, and 
were found to have a brittle fracture and a very low elongation (Priyanka et al., 2011). The 
higher rigidity could be explained by the relatively high glass transition temperature (Tg) of 
HPC comparing to hypromellose. Low substituted HPC presents a Tg of 220⁰C, whereas 
HPMC may vary typically between 170-198⁰C (Gómez-Carracedo et al., 2003). The 
hydroxypropyl side groups on both celluloses increase the interactions (via hydrogen 
bonding) between substituents, raising the Tg, whereas the methoxyl groups presented on 
the hypromellose reduce the ability of the polymer to form hydrogen bonds. This fact 
increases the amorphous content of the polymer, resulting in the mentioned Tg differences. 
Therefore, HPC has a relatively strong intermolecular force and consequently a higher 
crystallinity which results in tougher but brittle materials. Additionally, it has been 
demonstrated that in thin films both mechanical and thermal properties have a strong 
dependence, and the Young’s modulus and Tg are likely to follow a similar trend (S. Rivero, 
2010). Furthermore, hypromellose thin films demonstrated different mechanical properties 
when blended with other film-forming polymers. As referred before, Snore Relief® films, 
contrarily to the other hypromellose based films, present a significantly higher Et (p< 0.01: 
Snore Relief® / Gas-X®) (Figure 26) that is comparable with the Pullulan based films 
(Listerine® films) (Figure 26). These results can be explained by the presence of the poly 
(Ethylene Oxide) (PEO) that is known as a polymer with good film-forming properties (Chen 
M, 2006; Myers, 2008; Myers et al., 2013), with the additional and valuable characteristic of 
being a self-plasticizing polymer. This PEO feature eliminates the need of adding a plasticizer 
to the film formulation, which is absent in Snore Relief® films, and enables the incorporation 
of a higher percentage of the drug substance (Chen M, 2006; Myers, 2008). It is worth to 
mention that the commonly used plasticizers, are small molecules that easily embed 
themselves between the polymer’s chains, increasing the free volume and chains’ 
movements, lowering significantly the Tg and turning the polymer matrix softer. On the 
contrary, despite of the sufficient plasticizing effect of PEO in the film, due to its high 
molecular weight (Mw) that can range from around 100,000 (Polyox WSR N-10) to 4,000,000 
(Polyox WSR 301) (Myers, 2008; Rowe R, 2009), probably do not interlace between 
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hypromellose chains so easily, and therefore work essentially as an additional film-forming 
polymer. Consequently, the addition of another polymer restricts the polymer chain motions 
in the polymer-polymer complex, particularly due to the hydrogen bonds established 
between the primary hydroxyl groups on cellulose with the oxygen in the ether groups of 
PEO (Pawar et al., 2013), contributing to the higher rigidity and tensile strength. 
Regarding Gas-X® films, the mechanical behaviour can be ascribed to the high percentage of 
drug substance (Simethicone) presented on the film (at least 60 % w/w). This high amount 
of drug contributes to a weaker structure of the polymer matrix that has a deleterious effect 
on the mechanical parameters. The Zentrip® soft and weak mechanical performance can be 
related to the mannitol presence, which has demonstrated the ability to increase the 
crystallinity of polymeric films turning the structures more brittle (Lakshmi et al., 2011). 
 
3.2. Disintegration 
It is important to consider that this test is used only for comparison purposes, because it 
does not mimic properly the in-use conditions, namely: the complex saliva composition, the 
physiological temperature, the possible tongue movements and the pressure. Nevertheless, 
the results are very consistent with the literature (Borges et al., 2015). Briefly, the pullulan 
and HPMC based films tend to dissolve faster comparing to the films that contain Pectin as 
film forming agent (Snooreze, Boots and Snore Relief) (Borges et al., 2015). 
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Figure 27 - Disintegration time of commercially available oral films (Gas-X, Re:balance, Stop Snoring, 
Zentrip, B12 strips, Hunger Strips, Listerine Fresh Burst and Listerine Cool Heat and Snore Relief). 
 
At least half of the marketed tested films dissolved within 60 seconds (Figure 27). Pullulan 
based films (Listerine® films) present fast disintegration time compared with HPMC based 
films (Chen M, 2006). Boots® and Snoreeze® films showed higher disintegration time 
probably due to pectin, which is known by its mucoadhesive properties and slowly 
dissolution, even in oral cavity (Dahiya et al., 2009). Zentrip® films do not completely 
dissolve; instead they rapidly disintegrate in small pieces. This behaviour could be explained 
by the presence of Mannitol, which facilitates the fast disintegration times (Kadajji and 
Betageri, 2011) and the insoluble components presented in the formulation including the 
drug substance, Meclizine HCl (approximately 34% w/w film). Regarding the hypromellose 
based films, the difference observed between samples is not statistically significant, being 
the slight variations probably related to the different hypromellose grades used (Chen M, 
2006). 
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3.3. Residual Water content 
The evaluation of the residual water content is important parameter to establish an optimal 
amount that would allow obtaining flexible films. Higher water contents are known to induce 
the formation of tacky films (Hoffmann et al., 2011).  
 
Figure 28 - Residual water content of commercially available oral films (Gas-X, Re:balance, Stop 
Snoring, Zentrip, B12 strips, Hunger Strips, Listerine Fresh Burst and Listerine Cool Heat and Snore 
Relief). % H2O, residual water content. * p<0.05. 
 
All commercial films analysed exhibited residual water content below 10% and the majority 
below 5% (Figure 28). There were no significant differences between the films, except for 
Snoreeze® and Zentrip® (p<0.05). In fact Snoreeze®, Boots® and Stop Snoring® films are the 
ones with higher water content. This observation could be explained by the high hydrophilic 
nature of sodium alginate and pectin used in the formulation of these films, or eventually 
due to the use of glycerol as plasticizer. In fact, all formulations with more than 5% of water 
content (with no exceptions) have glycerol as a plasticizer: Stop Snoring®, B12 strips®, 
Hunger Strips®, Snoreeze® and Rebalance®; whereas the others have poly(ethylenoglycol) 
or propylene glycol as plasticizer (Table 1, Figure 3). In addition, it is described that the water 
retention depends not only on hygroscopicity of the polymer but also on the amount and 
type of plasticizer. In fact, polymers plasticized with hydrophilic compounds tend to absorb 
more water from surrounding medium. For instance, an increase on the plasticizer content, 
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from 1 to 3 %, can induce an increase of about 68% of the water retention by the polymer 
(Meenu Dahiya, 2009). 
 
3.4. TGA and DSC Analysis 
TGA and DSC allow the characterization of individual components and multicomponent 
mixtures (Bond et al., 2002; Clas et al., 1999) and also a fast screening excipients’ 
compatibility, specially concerning to drug–excipient compatibility (Feldstein et al., 2003; 
Giron, 2002; Wesolowski et al., 2012). These techniques are very advantageous since they 
can be used for quick stability screening evaluation that may be performed in early 
development stage and with small amount of sample. 
Probably due to the complex composition of the films analysed very different thermal 
profiles were obtained (Figure 29 and Figure 30) because the TGA thermogram is not only 
dependent on the polymer’s degradation mechanism but also on oral film components, such 
as water content, plasticizers and volatile substances. 
 
3.4.1. TGA 
TGA in the pharmaceutical development is mainly used for the characterization of excipients 
and drug substances. This method essentially evaluates the thermal decomposition 
reactions, dehydrations as well as the nature of excipient-water interactions (Craig and 
Reading, 2006). Thereby, it is also an useful test to evaluate the phenomenon of adsorption 
and desorption of water (Gabbott, 2008). 
TGA consists in the continuous measurement of the sample weight with increasing 
temperature. The weight loss is easily quantified and associated with degradation or 
transition processes (Gabbott, 2008; Stuart, 2004).  
In this particular case, TGA was very helpful to evaluate the composition in volatile 
substances, including water molecules, and the thermal stability of the oral films studied.  
The Hunger strips were apparently the more unstable formulation avoiding valid assays, 
whereas the Snore Relief seems to be more thermal stable composition, with higher Tonset.. 
However, considering the weight loss percentage, Gas-X would be the more thermal stable 
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oral films. Temperatures above 200⁰C are needed for 5% or 10% of weight loss in GAS-X 
films. 
 
Table 13 - TGA results of the commercial films: Gas-X, Re:balance, Boots Pharmaceuticals, Stop 
Snoring, Zentrip, B12 strips, Hunger Strips, Listerine Fresh Burst and Listerine Cool Heat and Snore 
Relief. T(5%), represents the temperature at each oral dispersible film have 5% of weight loss. T(10%), 
represents the temperature at each oral dispersible film have 10% of weight loss. Tonset, is the 
maximum tolerated temperature before degradation. (* - the film swelled during the analysis, it was 
not possible to perform valid assays). 
T(5%) T(10%) Tonset
B12 51.44 145.61 158.85
Snore Relief 78.60 202.31 297.94
Zentrip 125.24 201.52 236.40
Snoreeze 56.82 101.89 157.86
Listerine 62.62 168.61 210.38
Gas-X 210.02 231.05 207.59
Hunger Strips* - - -
Re Balance 60.61 109.25 159.98
Stop Snoring 58.55 132.54 188.06  
 
The weight decrease observed in the beginning of the curve (until 100°C) corresponds 
essentially to the evaporation of volatile substances, such as ethanol, flavours and water. 
Gas-X®, Zentrip® and Snore Relief® are the films with lower weight loss in this region, which 
is consistent with the previous results (% of residual content) (Figure 29). In fact, Gas-X® is 
the film with lower % of residual water, followed by Zentrip® and Snore Relief® (Figure 28). 
On the other hand, the highlighted decrease of weight observed in the Re balance® (Boots) 
and Snoreeze® curves indicate that these films have higher residual water content as already 
demonstrated by Karl-Fisher results (Figure 29). 
Above the 200°C, there is an accentuated weight loss that corresponds to the decomposition 
of the polymers that are the main components of the oral films.
 
 
 
Figure 29 - TGA analysis of commercially available oral films (Gas-X, Re:balance, Stop Snoring, Zentrip, B12 strips, Hunger Strips, Listerine Fresh Burst and Listerine Cool Heat 
and Snore Relief). 
.
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Finally, it is possible to conclude that, despite the very different thermal profiles, Gas-X® is 
the most thermal stable film, followed by Zentrip® (Table 13 and Figure 29). This result can 
be explained taking into account the film composition, which influences the polymer-
polymer and polymer-plasticizer interactions. 
 
3.4.2. DSC 
As can be observed in Figure 30, two distinct thermal events are identified: one from Stop 
Snoring® and other from Snore Relief®. However, even these events are hard to disclose due 
to the complexity of the formulations. Stop Snoring® is composed by a complex polymer 
matrix: a modified cellulose (Tg~ 100 °C (Gómez-Carracedo et al., 2003)), a modified starch 
and sodium alginate (Tg ~ 95-158°C (Roger et al., 2007)). The Tg of these polymers are very 
high compared to the possible Tg event observed for this film (Figure 30), suggesting that 
this event may occur due to complex interactions between the film components. The Snore 
Relief® films have as main components HPMC (Tg ~ 170-198°C (Gómez-Carracedo et al., 
2003)), PEO (Tg ~ -67°C (Meenu Dahiya, 2009)) and pectin (Tg ~95°C) without any plasticizer. 
The endothermic event observed at 60°C, may correspond to the PEO melting temperature 
(Tm), as reported by others (Money and Swenson, 2013). 
 
 
Figure 30 - DSC analysis of commercially available oral films (Gas-X, Re:balance, Stop Snoring, Zentrip, 
B12 strips, Hunger Strips, Listerine Fresh Burst and Listerine Cool Heat and Snore Relief).  
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Regarding the other marketed films analysed it is not possible to draw any effective 
conclusion. Despite of formulations’ composition complexity, very simple curve profiles are 
observed, which may be related with the optimal interaction between the components or 
overlapping of some thermal events.  
 
3.5. Critical Quality attributes (CQAs) 
The data presented above allowed defining acceptance criteria for CQAs that may be used 
to develop oral film platforms with appropriate properties for the intended use (Table 14). 
These ranges of values were defined considering that a wide selection of polymeric matrixes 
may be done to prepare this dosage form and each may be singular with its own 
performance behaviour. Although the broad range values determined, all the studied films 
present acceptable features to be processed, manufactured, marketed and handled.  
 
Table 14 - Critical Quality attributes acceptance criteria for ODF development. 
CQA Acceptance criteria 
ϬB (Mpa) 15-35
εB (%) 5-40
Et (Mpa) 100-1500
Residual water content (%) 3-6%
Disintegration time (s) <60 seconds (target 30 seconds)
 
 
The difficulty to establish thermal specifications is mainly related with the inherent 
characteristics of the assays and the complex formulation of the polymeric matrices. These 
are very specific tests used to characterize materials normally with completely different 
parameters compared to oral films (Craig and Reading, 2006; Gabbott, 2008; Stuart, 2004). 
In turn, this pharmaceutical dosage is a multicomponent matrix that may behave as a new 
material depending on the components miscibility (Bond et al., 2002; Clas et al., 1999). 
Therefore, the results obtained are a very own feature of each formulation, which turns 
difficult a universal standardization. The thermal stability may be assumed and extrapolated 
for higher stabilization through time by assessing a kinetic degradation model for each 
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system (Clas et al., 1999; Yoshida et al., 2010). Additionally a good excipient-excipient or 
drug-excipient compatibility would correspond to a good miscibility, and the 
multicomponent matrix would behave as a single component. Therefore, this information 
would be related with a suitable dispersion of the drug substance within the polymeric 
chains that may avoid possible instability of the drug and also its premature crystallization. 
In fact, polymers that may inhibit the crystallization if drug-polymer interactions are more 
favourable than those present in the crystalline drug (Shah et al., 2014).  
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4. Conclusions 
To the best of our knowledge there is no study that enabled the definition of acceptance 
criteria for oral films CQAs. The relative wide range of values determined for each CQA are 
justified by the variety oral films composition, especially regarding the additives. 
Nonetheless, the definition of acceptance criteria for these quality attributes can be 
translated into a very important contribution to the future development of new oral films 
formulations.  
This work highlights the complexity involving the characterization of oral films and the 
urgent need of have development guidance and suitable quality standards. Although it was 
not possible, with this approach, to define a strict correlation between a single component 
and the selected CQAs, the general analysis allowed to conclude that the same polymer 
based films may have significantly different behaviours. However, it is also important to 
consider that these differences may be caused not only by the composition but also by the 
processing and manufacturing methods. 
Finally, the acceptance criteria values should be preferentially used for initial screening tests 
during the development of a new, soft and tough oral film. Nevertheless, based on a pre-
defined polymeric matrix composition, optimization tests should be performed in order to 
define less broad acceptance criteria for each specific oral film formulation in order to obtain 
a desirable and robust final product.  
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Chapter III 
Hydrophobic polymers for oral films: Development 
and Optimization 
 
This Chapter is dedicated to the preparation of a novel and versatile oral film technological 
platform. The Quality by Design approach was applied to screen the different formulations 
developed based on the previous critical quality attributes established and selection of 
appropriate critical process parameters. The optimization was only performed in one 
formulation that apparently demonstrated more promising results. 
This study led to a patent application entitled “Orodispersible films”.  
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Abstract 
Orodispersible films (ODF) for fast oral disintegration are generally based on hydrophilic 
polymers, which when exposed to ordinary environmental humidity conditions may become 
sticky, with low stability, undesirable texture and appearance. The aim of present study was 
to develop ODF based on hydrophobic polymers with a fast disintegration time. A quality by 
design (QbD) approach was applied to screen three different formulations each one based 
on a different hydrophobic polymer: polyvinyl acetate (PVAc), methacrylate based 
copolymer and shellac.  
The screening formulations were characterized regarding their mechanical properties, 
residual water content, disintegration time and appearance, in order to find a suitable ODF 
formulation according to established critical quality attributes (CQAs). The selected critical 
process parameters (CPP) for the selection of appropriate ODF formulations were the 
percentage of the different excipients and the plasticizer type. Three hydrophobic based 
matrices with fast disintegration were developed. These were generically composed by a 
hydrophobic polymer, a stabilizer, a disintegrant and a plasticizer. Interestingly, it was found 
that the same component may behave differently depending on the overall system 
composition. It was shown that it is possible to develop oral films based on hydrophobic 
polymers with fast disintegration time, good texture and appearance, breaking a paradigm 
of the ODF research field. 
 
Keywords 
Oral Films; Hydrophobic Polymers; Critical Quality Attributes; Critical Process Parameters, 
Polyvinyl acetate; Methacrylate copolymer; Shellac 
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1. Introduction 
Orodispersible films (ODF) have been introduced in the market as an alternative to 
conventional oral dosage forms. The fast dissolution in the oral cavity is useful to overcome 
the swallowing problems associated with capsules or tablets and for non-cooperative 
patients, promoting patient compliance.  
The majority of the oral films available in the market and under development are based in 
hydrophilic film forming polymers (Borges et al., 2015; Dixit and Puthli, 2009; Hoffmann et 
al., 2011; Irfan et al., 2015). By definition, hydrophilic substances have higher affinity to 
water when compared to hydrophobic components. Therefore, mechanical and physical 
properties of hydrophilic polymeric matrices may vary significantly with the water presence 
in the surrounding environment, which could lead to the premature disintegration of the 
polymeric matrix (Ping et al., 2001). In fact, these structures tend to become sticky over time 
when exposed to ordinary environmental humidity conditions, leading to low stability ODFs, 
undesirable texture and bad appearance. Nevertheless, additional changes at molecular 
level may occur, since small or less perfect crystalline polymeric structures might be lost 
contributing to a decrease of the glass transition temperature (Tg) (Ping et al., 2001). In turn, 
it is known that hydrophobic polymers tend to absorb very small quantities of water at 
equilibrium even at high moisture contents at room temperature.  
Polyvinyl acetate (PVAc) is an atactic, non-crystalline and non-ionisable polymer, synthesized 
by a free radical polymerization. It presents high flexibility and low toxicity, making it very 
appropriate to use in the food and pharmaceutical industry (BASF, 2010; Kolter et al., 2013). 
PVAc is available in a 30% w/w aqueous colloidal dispersion by BTC, known as Kollicoat® SR 
30 D, with an optimal low minimum film forming temperature (MFT) of 18⁰C (BASF, 2010). 
This characteristic may allow the application of the suspension to form a polymeric matrix 
without the need of a plasticizer when above 35⁰C (BASF, 2010). Additionally, this polymer 
is an interesting choice for the development of film matrices with low tendency to absorb 
water when exposed to the environment RH (Ping et al., 2001). The high molecular weight 
(Mw) of the polymer (around450 kDa), contributes to the formation of films with suitable 
mechanical polymeric properties (Kolter et al., 2013). 
Ammonium Methacrylate Copolymers are acrylic polymers widely used as film forming 
polymers in modified drug release dosage formulations due to their hydrophobic properties 
(Qiu et al., 2009), and are also available as aqueous suspensions, e.g. Eudragit RL or RS from 
Evonik®. These copolymers of poly(ethylacrylate), poly(methyl methacrylate) and 
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poly(trimethyl aminoethyl methacrylate chloride) are insoluble in water, but easily 
permeable to drugs’ incorporation, depending on the relative proportion of the quaternary 
ammonium groups. The increase of these charged chemical groups may enhance the 
amount of loaded drug. Eudragit RL (10%) has twice the amount of this functional quaternary 
ammonium groups when compared to Eudragit RS (5%) (Derakhshandeh and Soleymani, 
2010). 
In opposition to the previous synthetic polymers, shellac is a purified product of lac, a natural 
resinous oligomer (Mw ≈ 1000 D) secreted by an insect. Shellac is composed by polyesters 
of mainly aleuritic acid, shellolic acid, and a small amount of free aliphatic acids (Leopold, 
2009). In its pure form this polymer is insoluble in water. The development of shellac 
aqueous ammoniacal solutions turned this polymer very important for pharmaceutical 
dosage forms, being commonly used as an enteric coating material (Farag and Leopold, 
2009). Shellac ammonium salt solutions are easy to handle even at high concentrations and 
present higher stability than its acid form (Farag and Leopold, 2009). It is described that 
shellac-coated tablets have lower water uptake than HPMC-coated systems, indicating 
higher shellac’s moisture protection, especially at high RH (Pearnchob et al., 2003). 
Hydrophobic polymers usually origin insoluble matrices widely used for controlled drug 
release formulations due to their inertness and high drug loading capacity. Although, the 
hydrophobic nature seems to be incompatible with oral fast disintegration, the association 
of a channelling agent may facilitate the liquid penetration and consequently the 
disintegration (Derakhshandeh and Soleymani, 2010).  
The development process of pharmaceutical preparations has changed in recent years. A 
systematic approach for the optimization of pharmaceutical dosage forms and processes 
able to improve the quality prediction and control has been amply adopted (Quality by 
Design) (ICH Harmonised Tripartite, 2009). A very common tool used in the QbD is the 
definition of a quality target product profile (QTPP), a dynamic product description that 
summarizes the quality characteristics expected to guarantee the product performance, 
stability, safety and efficiency. Generally, the QTPP includes the different dosage form 
characteristics (e.g. route of administration, strength, therapeutic indication, drug release 
profile, pharmacokinetics, the critical quality attributes (CQAs) and the critical process 
parameters (CPPs) (Rathore and Winkle, 2009; Visser et al., 2015). The CQAs may be 
resumed as the characteristics that define the product quality, and CPPs refers to the process 
variables that can influence these characteristics (Rathore and Winkle, 2009). Therefore, the 
combination of the CQAs and CPPS allow the definition of the design space (Rathore and 
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Winkle, 2009; Visser et al., 2015). The construction of an oral film QTPP may be roughly 
structured based on the available literature describing the suitable oral films requirements 
and the characterization methods available to access the film properties (Borges et al., 2015; 
Dixit and Puthli, 2009; Hoffmann et al., 2011; Irfan et al., 2015). An ideal oral film should be 
handled without being damaged, should be physically stable and provide an easy and 
pleasant administration. These properties may be translated into product quality attributes, 
such as appropriate mechanical properties and organoleptic evaluation (Visser et al., 2015). 
In the present work, three different hydrophobic polymers (polyvinyl acetate, methacrylate 
copolymer and shellac), generally regarded as safe (GRAS) and suitable for oral 
administration were selected for the development of ODFs, based on a QbD approach. The 
main aim of this work was to demonstrate that hydrophobic polymers can be used in the 
manufacture of ODFs with suitable mechanical properties and higher resistance to moisture 
conditions without compromising the rapid disintegration time, which breaks a paradigm in 
the ODF research field. 
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2. Material and methods 
 
2.1. Material 
Polyvinyl acetate (PVAc) (Kollicoat® SR 30D) (BTC, Ludwigshafen, Germany), Polyvinyl alcohol 
4-88 (Merck, Darmstadt, Germany), Ammonium Methacrylate Copolymer, Type A (Eudragit® 
RL 30D) (Evonik Nutrition & Care GmbH, Essen, Germany), Shellac (HARKE Pharma GmbH, 
Mülheim an der Ruhr, Germany), Hydroxypropylmethyl cellulose, Methocel E5 (Colorcon, 
Harleysville, U.S.), Sodium Carboxymethylcellulose (Aqualon France BV, Alizay, France), 
Maltodextrins (Grain Processing Corporation, Iowa, USA), Monoammonium glycyrrhizinate 
(Mafco, NJ, USA), Citric acid (Merck, Darmstadt, Germany), Glycerol (Merck, Darmstadt, 
Germany), Triethyl citrate (Merck, Darmstadt, Germany), Polyethylene Glycol 400, Lutrol 
400 (BTC, Ludwigshafen, Germany), Polyethylene Glycol 4000, Macrogol 4000 (Clariant 
Burgkirchen, Deutschland GmbH), Polyethylene Glycol 6000, Macrogol 6000 (Clariant 
Burgkirchen, Deutschland GmbH), Propylene Glycol 1,2-propanediol (Merck, Darmstadt, 
Germany), Polysorbate 80, Tween 80 (Merck, Darmstadt, Germany), Red Iron Oxide 
(Huntsman Pigment S.p.A, Torino, Italy), 
 
2.2. Methods 
 
2.2.1. Choice of design and experimental Layout 
The software JMP 10 (SAS Institute Inc., Cary, NC) was used to construct custom designs. 
This platform was used instead of classical designs, since different types of factors were 
studied, including mixture and categorical variables. The defined experiments carried out in 
this work are presented on Tables 15, 16 and 17. They were run in random order within each 
formulation type. The analysis was performed using the screening designer platform, so the 
software adds automatically the interactions and crossed effects.  
The selection of the ranges for the CPPS (factors) (e.g. amount of excipients and plasticizer 
type) was based on preliminary tests and theoretical intervals for each excipient-function 
described in literature (Dixit and Puthli, 2009; Hoffmann et al., 2011). The continuous factors 
were introduced as mixture factors in order to identify the proportions within the different 
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components that maximize the defined responses (CQAs). The factors are constituent 
proportions of a mixture which sums to 1 (100%) and the last component percentage is 
determined by the sum of all the others. Therefore, factors are not independent, but the 
software methodology for this type of designs is the same as for classical designs. The 
Plasticizer type is a categorical factor and was introduced as a nominal variable. 
The screening platform used to evaluate the results basically uses the n values in the 
response vector and rotates them into n new values. The rotated values are then mapped 
by the space of the factors and their interactions. The screening report generated shows a 
list of coefficients with their contrasts and p-values. Mathematically, the contracts are: 
Contrasts = T’ × Responses. T is an orthonormalised set of values which starting with the 
intercept and goes in descendent order through the main effects, two-way, three-way 
interactions, and so on, until n values have been obtained. T is orthogonal, the contrasts are 
the parameters estimated in a linear model. The significant terms are usually associated with 
low p-values, which are generated based on Lenth t-ratios that are created through a Monte 
Carlo simulation of 10,000 runs of n – 1 purely random value. The t-ratios are obtained from 
the Lenth Pseudo Standard Error (PSE) by the Lenth’s method that identifies inactive effects 
and constructs an estimate of the residual standard error. The most significant terms that 
may lead to the best Model to explain the variable in study are selected.  
The best fit Model was selected based on the higher and proximal RSquare and RSquare 
Adjusted, the overall F-value and the associated p-value of the Analysis of Variance for the 
entire model (Goupy and Creighton, 2007; SAS Institute, 2013). 
 
2.2.2. Design Selection and experimental layout 
The QTPP was constructed with previous knowledge of the dosage form, acquired from 
previous laboratorial work on marketed oral films; but also based on literature support 
(Hoffmann et al., 2011; Preis et al., 2014; Visser et al., 2015) (Figure 31). The QTPP includes 
the outline of the CQA that should be carefully selected and evaluated to establish limits 
that allow obtaining suitable oral films without compromising its performance. In turn, the 
CPPs are subsequently chosen according to its influence and effect on the CQAs. Figure 31 
summarizes the CQAs and CPPs selected in the present work. The aim of the work, screening 
and develop innovative oral film platforms, lead to a careful and limited selection of the 
quality parameters and attributes. Therefore, the CQAs were restricted to features that are 
characteristic and essential of this dosage form: mechanical properties, due to the handling 
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and manufacturing process; disintegration time, the slow or fast disintegration of the dosage 
form determines its performance; residual water content, may determine the stability of the 
product. 
Subsequently, the most critical process parameters (CPPs) that may influence the attributes 
described were chosen: film forming polymer amount, %weight /weight (%w/w) per film 
(PVAc, methacrylate copolymer or shellac); stabilizer amount, %w/w per film (PVA, HPMC 
and / or tween 80); disintegrant amount, %w/w per film (NaCMC); plasticizer amount, %w/w 
per film (triethyl citrate, 1,2 -propanediol, glycerol, polyethylene glycol 400, polyethylene 
glycol 1000 and / or polyethylene glycol 6000); plasticizer type. 
 
 
Figure 31 - Control Quality Attributes (CQA) and Control Process Parameter (CPP) selected. QTPP - 
Quality Target Product Profile; Et – Young’s modulus; εB –Elongation at break; σB – tensile strength. 
 
2.2.3.  Selection of excipients 
The selection of other excipients, in particular the plasticizers and stabilizers (PVA and 
HPMC), was mainly based on manufactures indication and some literature available (BASF, 
2010; Evonik, 2011; Freed et al., 2007; Kolter et al., 2013). Based on this information some 
preliminary tests were performed, in which the main concern was to confirm the ability of 
these systems to form suitable films (PVAc – system A; Ammonium Methacrylate – system 
B; Shellac – system C). In these screening tests the selection was based on a qualitative 
analysis according to their ability to form films. In summary, within the 6 disintegrant tested 
(sodium carboxymethyl starch, croscarmellose sodium, crospovidone, microcrystalline 
cellulose, sodium alginate, NaCMC), NaCMC revealed to be compatible with all systems and 
is the only common excipient in the 3 different types of polymeric matrixes. PVA and HPMC 
were tested as stabilizer in the three systems. Although, it was possible to obtain ODF with 
HPMC and PVA in the three systems, PVA was selected as stabilizer for methacrylate and 
CQA 
Mechanical properties 
(Et, σB, εB) Disintegration time 
Residual water 
content 
CPP 
Excipients type 
(categorical nominal 
factors) 
Excipients amount 
(continuous factors) 
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PVAc formulations and HPMC as stabilizer for Shellac ODF because they contributed to 
formulations with a better visual appearance than the other alternatives.  
 
2.2.4.  ODF Appearance characterization 
ODFs were evaluated by a test panel based on their appearance and handling properties. 
The appearance parameters evaluated were the existence of lumps, phase segregation and 
the visual homogeneity of the oral films. The handling properties considered were the 
detachment ability from the release liner, the touch sensitivity, and the mechanical integrity 
to allow further characterization. It was used a 1 to 5 scale, where the global evaluation 
value corresponds to the average of the referred parameters, all with equivalent degree of 
importance (14% of importance) except for the detachment from the release liner (30% of 
importance). 
 
2.2.5. Preparation of the ODFs 
The liquid mixtures were prepared in two-neck round bottom-flasks (50mL). The system was 
kept overnight at room temperature under slow agitation to obtain free-bubble-liquid. Each 
excipient was added after ensuring that a homogeneous liquid mixture was formed. The 
liquid mixtures were cast in PVC release liners (substrate) with an Erichsen film applicator 
(Coatmaster 510, Erichsen, Hemer, Germany). To adjust different heights a vertically 
adjustable doctor knife was used and the film mixtures are cast with speeds of 6 mm/s. The 
casted films were dried on the heated table of the Erichsen film applicator at 40 °C or at 
room temperature until dryness. The drying time depended on the composition of each 
formulation evaluated.  
To further characterize the films, individual samples were prepared by cutting strips of 
regular and equal dimension with a bench manual press (Tinius Olsen, Horsham, USA). 
 
2.2.6. Storage 
The individual films were stored under controlled conditions (43 % RH, room temperature), 
by means of a saturated solution of potassium carbonate for at least 5 days before testing.  
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2.2.7. Film mass 
The films were weighed using an analytical balance (Mettler Toledo AGXS, Mettler-Toledo 
Inc., Columbus, US) and the average weight was calculated (n=3). 
 
2.2.8. Film thickness 
The thickness of the films was measured with a micrometer screw (Mitutoyo Digimatic 
Capiler, Mitutoyo Corporation, Japan) (n=5).  
 
2.2.9. Tensile Strength 
The mechanical properties of the films were determined using a tensile testing universal 
apparatus (Zwick, Germany) with a load cell of 10 N. The measurements were performed 
similarly as described elsewhere (11, 12). Briefly, ODFs with the dimensions of 60x20 mm 
and free of air bubbles or physical imperfections, were held between two clamps positioned 
at a distance of 40 or 50 mm. Firstly, a preload was applied in each assay, and then the strips 
were pulled by the top clamp at a rate of 10.0 mm/min. The load automatically applied to 
the film was gradually increased and the corresponding magnitude of elongation was 
recorded until the break point of the film was finally reached corresponding magnitude of 
elongation was recorded until the break point of the film was finally reached. The 
parameters were directly retrieved from the software TestXpert (TestXpert, Zwick, 
Germany), namely Young’s modulus (Et, MPa), tensile strength (σB, MPa) and elongation at 
Break (εB, %). Measurements were run at least in three samples for each film. 
 
2.2.10. Disintegration time 
Approximately 4 mL of a phosphate buffer pH=6.8 (artificial saliva) was added on a Petri dish 
and the ODFs were laid on. The time at which the film samples disintegrate was recorded. 
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2.2.11. Karl-Fisher 
The Karl Fischer Method was used to determine the residual water content in the ODFs. This 
technique basically consists in the quantitative reaction of iodine and sulfur dioxide by the 
addition of water, in the presence of methanol: 
 
 
A sample was added to the titration flask filled with methanol previously dehydrated with a 
Karl Fischer reagent (Hydranal Composite 5, Sigma-Aldrich Co. LLC). Titration was then 
carried out using the Karl Fischer reagent with a known determined titer (mgH2O/ml). Water 
content was determined based on the titration volume (ml). The polarization-current 
potential-difference method was employed as an end-point detection method.  
These tests were performed in a Karl Fisher 787 KF Titrino (Metrohm AG, Herisau, Schweiz). 
 
2.2.12. Contact angle 
Drop shape analysis was used to determine contact angles. Time-dependent contact angles 
were measured by an optical contact angle meter (OCA20 Dataphysics equipment, 
Filderstadt, Germany) at room temperature. An approximate volume of 10 µL of distilled 
water was dropped onto the film surface, initially fixed in a slide on a planar position. The 
contact angle was determined right after the drop addition (t=0s) and after 20 or 30 seconds 
(t=20s or t=30s, depending of the film characteristics) by using the supplied software (SCA20 
Dataphysics software, Filderstadt, Germany). 
  
                                    CH3OH 
SO2 + I2 + 2H2O                           2HI + H2SO4 
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3. Results 
The information regarding the different components of each systems were introduced in the 
DoE software and a custom design was generated. In total, 58 oral films were prepared with 
different percentages of main film-forming polymer (PVAc, system A; methacrylate 
Copolymer, system B; and shellac, system C), stabilizer (PVA or HPMC), disintegrant (NaCMC) 
and plasticizer (triethyl citrate, propanediol, glycerol, polyethylene glycol 400, polyethylene 
glycol 1000, and polyethylene glycol 6000). The different runs are presented on the CPPs 
columns of Tables 15, 16 and 17, whereas the results of their evaluation are on the CQAs 
columns on the same tables. Even though the excipients were previously selected in the 
screening tests described previously, 9 of the films prepared exhibited very poor 
characteristics that hampered the characterization of these samples (samples marked with 
an * on Tables 15, 16 and 17).
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Table 15 - Disintegration time, % of H2O, qualitative evaluation, Et, εB and σB. Ranges of CPPs (amount of PVAc, PVA, NaCMC, tween 80, plasticizer and plasticizer type) for formulations based on PVAc. . The amount of each excipient is presented as rational 
values where the sum of the components is 1. The missing values are identified (*) and are related with the poor films characteristics t hat prevented the execution of valid characterization tests. The median values of the CQAs were introduced in 
the software to perform the analysis. TEC - Triethyl citrate; PG - Propylene glycol; H2O - Residual water content; Et – Young’s modulus; εB –Elongation at break; σB – tensile strength. 
 
Run
PVAc PVA NaCMC Tween 80 Plasticizer 
Plasticizer 
Type
Global 
evaluation
(1-5)
Range 
tested 
0,5-0,75 0,1-0,40 0,05-0,2
0,001-
0,05
0,05-0,2
A1 0,469 0,248 0,053 0,05 0,18 TEC 25 ( 24 - 26 ) 4,6 ( 4,5 - 4,8 ) 81,4 ( 53,7 - 83,1 ) 113,2 ( 101,8 - 129,5 ) 1,9 ( 1,7 - 2,8 ) 3
A2 0,726 0,093 0,134 9,00E-04 0,046 TEC 49,5 ( 47,3 - 51,8 ) 220,8 ( 208,3 - 233,3 ) 46,0 ( 38,3 - 53,8 ) 6,3 ( 5,2 - 7,3 ) 3,8
A3 0,224 0,374 0,139 0,06 0,201 PG 14,5 ( 14,3 - 14,8 ) 7,8 ( 7,6 - 8,0 ) 171,2 ( 158,1 - 184,2 ) 19,1 ( 18,3 - 19,9 ) 7,0 ( 7,0 - 7,0 ) 3,5
A4 0,443 0,405 0,051 0,05 0,051 TEC 10 ( 9,5 - 10,5 ) 6,4 ( 6,2 - 6,6 ) 41,5 ( 33,4 - 49,6 ) 80,7 ( 76,6 - 84,7 ) 3,2 ( 2,7 - 3,6 ) 3,5
A5 0,464 0,103 0,184 0,05 0,199 PG 60 ( 60 - 60 ) 8,0 ( 7,9 - 8,1 ) 328,6 ( 315,3 - 341,9 ) 1,3 ( 1,3 - 1,4 ) 8,1 ( 7,9 - 8,4 ) 2,5
A6 0,34 0,406 0,203 1,00E-03 0,051 TEC 9 ( 8,5 - 9,5 ) 7,3 ( 7,1 - 7,4 ) 433,7 ( 381,6 - 485,8 ) 27,8 ( 26,4 - 29,3 ) 19,1 ( 19,1 - 19,2 ) 3,5
A7 0,512 0,282 0,05 1,00E-03 0,154 PG 60 ( 60 - 60 ) 5,3 ( 5,1 - 5,4 ) 99,2 ( 85,3 - 105,0 ) 85,5 ( 80,6 - 99,9 ) 4,8 ( 3,3 - 5,7 ) 3
A8 0,752 0,099 0,05 0,05 0,049 PG 60 ( 60 - 60 ) 4,1 ( 4,0 - 4,2 ) 71,1 ( 69,4 - 72,8 ) 5,6 ( 5,4 - 5,8 ) 7,1 ( 6,9 - 7,3 ) 2,5
A9 0,367 0,253 0,17 0,04 0,167 TEC 7,5 ( 7,25 - 7,75 ) 7,3 ( 7,3 - 7,3 ) 325,8 ( 316,7 - 337,5 ) 11,4 ( 11,0 - 12,5 ) 11,2 ( 10,1 - 11,3 ) 4
A10 0,636 0,146 0,073 0,07 0,072 TEC 60 ( 60 - 60 ) 4,1 ( 4,1 - 4,1 ) 34,2 ( 33,8 - 34,6 ) 55,2 ( 41,6 - 68,8 ) 1,8 ( 1,3 - 2,3 ) 3
A11 0,395 0,23 0,164 0,05 0,165 PG 34 ( 33,5 - 34,5 ) 6,8 ( 6,3 - 7,3 ) 38,6 ( 38,3 - 42,0 ) 28,0 ( 26,9 - 30,5 ) 5,8 ( 5,5 - 6,0 ) 2
A12 0,255 0,426 0,053 0,05 0,213 PG 16,5 ( 16,3 - 16,8 ) 6,5 ( 6,4 - 6,6 ) 47,2 ( 42,6 - 51,9 ) 170,9 ( 168,4 - 173,3 ) 9,1 ( 8,7 - 9,5 ) 1,5
A13 0,494 0,102 0,202 1,00E-03 0,201 TEC 17 ( 17 - 17 ) 5,4 ( 5,4 - 5,5 ) 238,3 ( 231,5 - 245,1 ) 20,8 ( 20,2 - 21,3 ) 3,7 ( 3,1 - 4,3 ) 3
A14 0,3 0,4 0,051 0,05 0,2 TEC 29 ( 28 - 30 ) 5,1 ( 5,0 - 5,2 ) 50,9 ( 47,9 - 55,8 ) 141,9 ( 139,9 - 145,5 ) 5,7 ( 5,2 - 5,7 ) 3,5
A15 0,304 0,398 0,199 0,05 0,05 PG 9 ( 9 - 9 ) 7,3 ( 7,2 - 7,5 ) 269,1 ( 237,1 - 291,5 ) 13,0 ( 12,5 - 13,0 ) 12,1 ( 10,9 - 12,9 ) 2
A16 0,49 0,407 0,051 1,00E-03 0,051 PG 21 ( 20,5 - 21,5 ) 5,3 ( 5,2 - 5,4 ) 78,8 ( 76,6 - 80,9 ) 178,0 ( 177,6 - 178,5 ) 10,5 ( 10,4 - 10,6 ) 4
A17 0,239 0,355 0,202 1,00E-03 0,203 TEC 10 ( 9 - 11 ) 7,5 ( 7,5 - 7,6 ) 326,3 ( 323,3 - 333,1 ) 20,2 ( 18,5 - 20,8 ) 14,0 ( 13,3 - 14,0 ) 3,8
Selected 
range
0,50-0,57 0,07-0,17 0,07-0,17 0-0,01 0,06-0,10 TEC
σB
 (%)
CQACPPs
Disintegration 
time (s)
H2O 
(%)
Et 
(MPa)
εB 
(MPa)
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Table 16 - Disintegration time, % of H2O, qualitative evaluation, Et, εB and σB. Ranges of CPPs (amount of PVAc, PVA, NaCMC, tween 80, plasticizer and plasticizer type) for formulations based on Methacrylate Copolymer. The amount of each component is 
presented as rational values where the sum of the components is 1. The range used to delineate the design is present on the excipients row. The missing values are identified (*) and are related with the poor films characteristics that does not allowed to perform 
some valid tests. The value in the CQAs column corresponds to the median value introduced in the software to perform the analysis. H2O - Residual water content; Et – Young’s modulus; εB –Elongation at break; σB – tensile strength. 
 
Run
Ammonio 
Methacrylate 
Copolymer 
Glycerol NaCMC PVA 
Global 
evaluation
 (1-5)
Range 
tested
0,5-0,65 0,1-0,2 0,07-0,2 0,1-0,2
B1 0,559 0,14 0,1 0,201 >60 ( 60,0 - 70,0 ) 6,48 ( 6,3 - 6,7 ) 115,2 ( 90,6 - 139,9 ) 3,9 ( 3,3 - 4,5 ) 3,6 ( 3,1 - 4,0 ) 4,28
B2 0,55 0,152 0,149 0,148 51 ( 48,0 - 54,0 ) 7,27 ( 7,1 - 7,4 ) 227,5 ( 227,5 - 227,5 ) 8,1 ( 8,1 - 8,1 ) 12,4 ( 12,4 - 12,4 ) 3,38
B3 0,597 0,205 0,099 0,099 * * * * * 2,66
B4 0,498 0,205 0,099 0,198 35 ( 30,0 - 40,0 ) 7,355 ( 7,1 - 7,6 ) 85,6 ( 82,0 - 92,0 ) 3,7 ( 3,6 - 3,9 ) 12,1 ( 11,1 - 13,1 ) 4,56
B5 0,545 0,204 0,101 0,149 46 ( 44,0 - 48,0 ) 8,34 ( 8 - 8,7 ) 107,7 ( 101,1 - 114,2 ) 4,7 ( 4,7 - 4,7 ) 13,0 ( 12,0 - 14,0 ) 3,66
B6 0,497 0,101 0,201 0,201 43 ( 38,0 - 48,0 ) 7,815 ( 7,8 - 7,8 ) 251,9 ( 245,6 - 458,4 ) 14,4 ( 8,3 - 14,8 ) 6,5 ( 5,4 - 8,2 ) 4,28
B7 0,606 0,152 0,142 0,1 51 ( 49,0 - 53,0 ) 6,62 ( 6,6 - 6,7 ) 226,8 ( 226,8 - 226,8 ) 8,4 ( 8,4 - 8,4 ) 7,7 ( 7,7 - 7,7 ) 3,38
B8 0,51 0,196 0,197 0,098 25 ( 10,0 - 36,0 ) 6,74 ( 6,5 - 7,4 ) * * * 2,54
B9 0,547 0,153 0,15 0,15 >60 7,07 ( 6 - 7,8 ) 236,3 ( 220,5 - 252,1 ) 7,0 ( 6,1 - 7,9 ) 3,8 ( 2,6 - 5,1 ) 3,38
B10 0,598 0,105 0,198 0,098 33 ( 32,0 - 70,0 ) 6,45 ( 6,1 - 6,8 ) 488,2 ( 488,2 - 488,2 ) 4,0 ( 4,0 - 4,0 ) 0,6 ( 0,6 - 0,6 ) 4,28
B11 0,6 0,1 0,12 0,179 25 ( 21,0 - 29,0 ) 6,44 ( 6,3 - 6,6 ) 239,5 ( 228,2 - 270,9 ) 6,5 ( 6,4 - 6,8 ) 2,5 ( 2,5 - 3,6 ) 3,66
B12 0,499 0,152 0,198 0,151 26 ( 24,0 - 28,0 ) 6,68 ( 6,7 - 6,7 ) 151,3 ( 123,7 - 178,8 ) 7,1 ( 6,7 - 7,5 ) 8,6 ( 8,0 - 9,3 ) 3,38
B13 0,5857 0,1136 0,143 0,1578 35 ( 30,0 - 40,0 ) 7,045 ( 6,9 - 7,2 ) 407,3 ( 407,3 - 407,3 ) 11,8 ( 11,8 - 11,8 ) 2,8 ( 2,8 - 2,8 ) 4,28
B14 0,6299 0,1019 0,0679 0,2002 23,5 ( 17,0 - 30,0 ) 6,455 ( 6,3 - 6,6 ) 423,1 ( 379,5 - 466,8 ) 6,0 ( 4,9 - 7,0 ) 1,1 ( 0,8 - 1,3 ) 3,66
B15 0,6206 0,2083 0,0688 0,1023 * * * * * 2,66
B16 0,5404 0,2144 0,1417 0,1035 7,5 ( 5,0 - 10,0 ) 8,25 ( 8,2 - 8,4 ) 78,6 ( 78,6 - 78,6 ) 6,8 ( 6,8 - 6,8 ) 14,4 ( 14,4 - 14,4 ) 2,96
B17 0,6285 0,1526 0,0682 0,1507 23,5 ( 23,0 - 24,0 ) * * * * 3,1
B18 0,5812 0,1053 0,1032 0,2103 19 ( 16,0 - 22,0 ) 5,975 ( 6,0 - 6,0 ) 450,7 ( 445,5 - 455,8 ) 11,7 ( 11,2 - 12,2 ) 3,0 ( 2,5 - 3,5 ) 4,56
B19 0,5309 0,1133 0,142 0,2139 >60 6,17 ( 5,9 - 6,8 ) 473,1 ( 458,1 - 488,1 ) 14,7 ( 14,1 - 15,2 ) 6,9 ( 5,9 - 7,9 ) 4,56
B20 0,6487 0,1074 0,1402 0,1037 >60 6,00 ( 5,6 - 6,4 ) * * * 3,12
B21 0,5163 0,2057 0,0674 0,2106 19 ( 6,0 - 21,0 ) 5,95 ( 5,9 - 6 ) 161,2 ( 147,3 - 175,1 ) 7,0 ( 6,5 - 7,5 ) 31,6 ( 28,1 - 35,1 ) 4,56
B22 0,5235 0,2173 0,1087 0,1505 51 ( 42,0 - 60,0 ) 7,13 ( 6,9 - 7,4 ) * * * 3,4
B23 0,526 0,1549 0,1064 0,2128 44,5 ( 37,0 - 52,0 ) 5,285 ( 5,2 - 5,4 ) 219,5 ( 188,4 - 220,1 ) 7,5 ( 6,3 - 8,0 ) 7,3 ( 6,0 - 7,8 ) 4,42
B24 0,5896 0,1638 0,1434 0,1031 >60 5,825 ( 5,8 - 5,9 ) * * * 4
Selected 
range 
0,52-0,58 0,10-0,15 0,15-0,17 0,15-0,20
Et 
(MPa)
εB
 (MPa)
σB
 (%)
CPPs
H2O 
(%)
Disintegration 
time
(s)
CQA
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Table 17 - Disintegration time, % of H2O, qualitative evaluation, Et, εB and σB. . Ranges of CPPs (amount of Shellac, HPMC, NaCMC, plasticizer and plasticizer type) for formulations based on Shellac. The amount of each component is presented as rational values 
where the sum of the components is 1. The range used to delineate the design is present on the excipients row. The missing values are identified (*) and are related with the poor films characteristics that does not allowed to perform some valid tests. The value 
in the CQAs column corresponds to the median value introduced in the software to perform the analysis. H2O - Residual water content; Et – Young’s modulus; εB –Elongation at break; σB – tensile strength; PG - Propylene glycol.  
 
Run
Shellac HPMC NaCMC 
Plasticizer 
Amount
Plasticizer 
Type
Global 
evaluation
 (1-5)
Range 
tested
0,4-0,8 0,2-0,5 0,01-0,2 0,01-02
C1 0,4 0,389 0,011 0,2 PEG 1000 >60 3,51 ( 3,3 - 11 ) 315 ( 309 - 321 ) 13,7 ( 14 - 14 ) 10,5 ( 10 - 11 ) 4,14
C2 0,585 0,202 0,011 0,202 Glycerol >60 5,46 ( 5 - 5,9 ) 56,9 ( 55,8 - 58,1 ) 24,6 ( 25 - 25 ) 5,04 ( 4,8 - 5,3 ) 3,44
C3 0,575 0,196 0,218 0,011 PG 7 ( 4 - 10 ) 4,64 ( 3 - 5,6 ) 997 ( 946 - 1048 ) 0,48 ( 0,3 - 0,6 ) 5,39 ( 3,6 - 7,2 ) 2,84
C4 0,393 0,498 0,098 0,011 PEG 6000 18,5 ( 17 - 20 ) 4,7 ( 4,2 - 5,2 ) 1181 ( 1142 - 1220 ) 0,57 ( 0,5 - 0,6 ) 7,29 ( 6,9 - 7,7 ) 3,54
C5 0,778 0,2 0,011 0,011 PEG 6000 >60 2,98 ( 2,7 - 3,2 ) * * * 2,26
C6 0,462 0,244 0,077 0,217 PEG 400 >60 4,24 ( 4,2 - 4,3 ) 541 ( 496 - 556 ) 1,22 ( 1 - 1,3 ) 7,12 ( 6 - 8,6 ) 2,84
C7 0,398 0,197 0,209 0,195 PEG 6000 >60 4,69 ( 3,6 - 5,5 ) 875 ( 776 - 912 ) 1,04 ( 1 - 1,2 ) 11,3 ( 8,9 - 12 ) 3,72
C8 0,516 0,303 0,095 0,087 Glycerol >60 5,01 ( 4,6 - 5,4 ) 570 ( 563 - 577 ) 0,96 ( 1 - 1 ) 6,39 ( 6,3 - 6,5 ) 3,72
C9 0,398 0,488 0,096 0,018 Glycerol 50,5 ( 47 - 54 ) 3,94 ( 3,8 - 4,1 ) 1254 ( 1221 - 1287 ) 0,85 ( 0,8 - 0,9 ) 12,3 ( 11 - 14 ) 3,26
C10 0,398 0,389 0,011 0,202 PG >60 4,58 ( 4,4 - 4,7 ) 125 ( 121 - 130 ) 27 ( 23 - 31 ) 5,98 ( 5,6 - 6,3 ) 4,28
C11 0,598 0,189 0,205 0,008 PEG 1000 6,5 ( 5 - 8 ) 5,26 ( 3,5 - 5,6 ) 774 ( 683 - 930 ) 0,48 ( 0,5 - 0,6 ) 3,81 ( 3,5 - 5,7 ) 3,26
C12 0,783 0,197 0,011 0,009 PEG 400 >60 3,3 ( 3,2 - 3,4 ) * * * 2,28
C13 0,639 0,198 0 0,163 PEG 400 >60 3,16 ( 3,1 - 3,2 ) 139 ( 124 - 155 ) 12,6 ( 11 - 14 ) 6,59 ( 6,2 - 7 ) 3,72
C14 0,641 0,199 0 0,16 PEG 1000 >60 3,61 ( 3,5 - 3,8 ) 324 ( 324 - 324 ) 1,55 ( 1,6 - 1,6 ) 7,05 ( 7,1 - 7,1 ) 3,44
C15 0,646 0,199 0 0,155 PEG 6000 >60 3,41 ( 3,2 - 3,7 ) 391 ( 386 - 396 ) 1,22 ( 1,2 - 1,3 ) 7,29 ( 7 - 7,5 ) 4,56
C16 0,646 0,199 0 0,156 Glycerol >60 5,38 ( 5,1 - 5,6 ) 87,1 ( 81,4 - 88,7 ) 19,9 ( 20 - 22 ) 6,92 ( 6,2 - 7 ) 3,58
C17 0,657 0,196 0 0,148 PG >60 4,32 ( 3,9 - 4,6 ) 30,7 ( 29,5 - 33,1 ) 37,7 ( 32 - 42 ) 1,65 ( 1,6 - 2,6 ) 3,3
Selected 
range
0,50-0,57 0,16-0,20 0,10-0,20 0,01-0,15
PG or 
glycerol
σB
 (%)
CQACPPs
εB 
(MPa)
Et 
(MPa)
H2O
 (%)
Disintegration 
time 
(s)
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The obtained results were examined via DoE study according to the CQAs acceptance criteria 
defined by the analysis and evaluation of several marketed products in a previous study (see 
Table 18).  
 
Table 18 - Critical Quality attributes acceptance criteria. 
σB (MPa) 15-35
εB (%) 5-40
Et (MPa) 100-1500
Residual H2O content (%) [3-6%]
Disintegration time (s) <30
Global evaluation (1-5) >3,5
Desirability
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3.1. Screening results: model selection and profiler 
creation 
The JMP screening platform was used to analyse the data of the set of experiments designed 
before. The best Fit models were selected and generated based on their statistical 
significance. This information was based on the analysis of variance (ANOVA) F-test. The 
results are depicted on Figures 32, 34 and 35.  
The prediction profiler is a simplified way of representing the response surface and gives the 
settings that according with the software origin the best formulation composition based on 
the target response (see Figures 32, 33 and 34). The main advantage of the prediction 
profiler concerns the ability of the user to predict the values which were not actually 
examined as long as they are within the experimental space. The individual plots in each row 
of plots show the prediction traces for each CPP. This prediction trace shows the expected 
variance of the response according to the change in each variable while the others are 
constant (SAS Institute, 2013). Therefore, parallel lines to the x-axis represent the absence 
of parameter’s influence in the correspondent y-variable (response). On the other hand, 
nonlinear traces indicate the influence of the x-variable in the response that may be more 
or less complex depending on the shape of the line. The profile visualization presented in 
Figures 32, 33 and 34 is related with the defined acceptance criteria for CQAs referred before 
and with the range that allows a better visualization of the curves. 
Next to each prediction profiler a summary of the model significance is presented for each 
CQA. The ANOVA through the p-value allowed to evaluate the whole model, and a 
significance probabilities of 0.05 or less are often considered evidence that there is at least 
one significant regression factor in the model (SAS Institute, 2012). The RSquare (R2) that 
estimates the proportion of the variation in the response around the mean and the Rsquare 
Adj which adjusts R2 (to make it more comparable over models with different numbers of 
parameters) are also presented (SAS Institute, 2012). The RSquare also represents the 
square of the correlation between the actual and predicted response, meaning that if equal 
to 1, a perfect fit (errors are all zero) is observed, whereas 0 means that the fit predicts the 
response no better than the overall response mean. In this way, an ideal model should 
present a p value lower than 0.05 (for 95% of confidence), the RSquare closer to 1 and an 
RSquare Adj value similar to the RSquare (SAS Institute, 2012). 
Therefore, the analysis of the models should be done carefully (Tables 15, 16 and 17, first 
row). In theory, models with very low p-value and high and similar Rsquare are very robust 
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(Figures 32, 33 and 34 with green boarder evaluation). On the contrary, more caution should 
be take when analysing models with high p-values and low Rsquare (Figures 32, 33 and 34 
with yellow and red boarder evaluation). 
 
3.2. PVAc based films 
PVAc formulation models seem to be less complex than the other tested systems (B and C). 
The plasticizer amount seems to have very little influence in the parameters tested since it 
was not included in any model and consequently does not appear in the profiler (Figure 32).  
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Figure 32 - Prediction profiler of PVAc screened formulations. It is represented the effect of each CPP in the CQAs. Parallel lines to the x-axis mean that there is no effect of the 
parameter on the evaluated attribute. The significance of the selected model for each CQA evaluated is summarized and presented in the correspondent row. The border colour 
of each summary is related with the model significance. Green solid border means very good fit models p value <0.01) and high (>0.6) and proximal Rsquare; Yellow dashed 
border means good fit models (p value <0.05) and Rsquare values between 0.4-0.6; Red square dotted border means poor fit models, (p-value >0.05) and very low Rsquare 
values. 
Model ANOVA 
RSquar
e 
RSquare Adj 
Et 
p=0.005
8 
0.790 0.664 
σB 
p=0.002
9 
0.648 0.566 
εB 
p=0.000
9 
0.894 0.812 
% H2O 
p=0.007
9 
0.854 0.725 
Disintegrat
ion time 
p=0.004
1 
0.544 0.479 
Global 
evaluation 
p=0.017
8 
0.785 0.617 
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The majorities of the models present a more linear profile and are generally very good 
models (Figure 32), with very small p-values, p≤0.01. Only, disintegration time has a less 
robust model, but even though, the p-value is very low, and the RSquare indicates that there 
is more than 55% of possibilities that the response effect observed is correct (Figure 32). In 
addition, the models for the other CQAs are more robust, with very low p-values and higher 
Rsquare values.  
General views of the models are presented in Table 5.
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Figure 33 - Plasticizer type influence in the Young’s modulus, Residual water content and disintegration time on the PVAc polymeric matrices. The influence of the plasticizer 
may be visualized based on the two main components of the formulation, PVA and PVAc. The grade of colours range from the desirable (green) to the unsuitable (red) effect in 
each CQA evaluated.
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The plasticizing effect on the Young’s modulus, residual water content and disintegration 
time of the PVAc formulation was also evaluated according with the type of plasticizer 
evaluated. The two main components of the formulation were selected, and the effect of 
each plasticizer was analysed (Figure 33).  
As previously described the grade of colours is related with the CQA limits defined in Table 
18. Briefly, green is the desirable zone, yellow-orange correspond to values close to the 
limits and the red zone out of the CQAs acceptance criteria (out of limit data). 
Young’s modulus varies in a similar way with both plasticizers (Figure 33, column 1). 
Independently, of the PVAc-PVA ratio a yellow-orange is obtained. However, there is also a 
trend to be out of the limits with the increase of PVAc, above 55% (% w/w), with medium 
values of PVA, between 20 to 30%. Regarding the other properties, it is verified that TEC 
origins larger green areas, but the trend of the effect is similar with both plasticizers. The 
use of TEC demonstrates that there is a higher probability of having films within the CQAs 
limits. However, for both, higher PVAc contents in all the range of PVA amount contribute 
to desirable values of residual water content, whereas lower amount of PVAc within almost 
all PVA ranges used contributed to lower disintegration times. 
The plasticizer effect that allows obtaining green areas based on PVA-PVAc proportion 
within the limits studied (coloured area) is summarized in table 20. 
According to the obtained results, PVAc based films should be preferentially composed by: 
PVAc (50-57%), PVA (7-17%), NaCMC (7-17%) and Tween 80 (0-1%) (Table 15). 
Unfortunately, it was not possible to define a definite range for the triethyl citrate with this 
model, but from the literature is possible to retrieve a probable range of concentration for 
triethyl citrate (6-10%) (Kolter et al., 2013)). 
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3.3. Methacrylate Copolymer based films 
The different CPPs evaluated using methacrylate copolymer based films influence all CQAs 
under analysis (Figure 34).  
 
 
 
 
Figure 34 - Prediction profiler of methacrylate screened formulations. It is represented the effect of 
each CPP in the CQAs. Parallel lines to the x-axis mean that there is no effect of the parameter on the 
evaluated attribute. The significance of the selected model for each CQA evaluated is summarized 
and presented in the correspondent row. The border colour of each summary is related with the 
model significance. Green solid border means very good fit models p value <0.01) and high (>0.6) and 
proximal Rsquare; Yellow dashed border means good fit models (p value <0.05) and Rsquare values 
between 0.4-0.6; Red square dotted border means poor fit models, (p-value >0.05) and very low 
Rsquare values. 
  
Model ANOVA 
RSquar
e 
RSquare 
Adj 
Et 
p=0.001
2 
0.731 0.614 
σB 
p=0.025
4 
0.483 0.340 
εB 
p=0.001
3 
0.728 0.609 
% H2O 
p=0.042
0 
0.617 0.411 
Disintegrat
ion time 
p=0.196
9 
0.507 0.204 
Global 
evaluation 
p=0.001
1 
0.934 0.832 
 218 
For the methacrylate copolymer model the majority of the variations are nonlinear, although 
according with the shape of the prediction profiler fit models, the effect seems to be less 
complex when compared to shellac fit models (Figure 34). However, 3 excellent models were 
obtained (Et, εB and global evaluation) with very low p-values, 2 models with reasonable 
characteristics (p-values closer to 0.05) and a non-significant statistical model (disintegration 
time) (Figure 34). Regarding the elongation, despite the significant p-value (p<0.05) the 
RSquares are very low and different (Figure 34). Therefore, there are less than 50% of chance 
of having a reliable model (RSquare<0.5) where the response (CQA) is attributed to the 
factors (CPPs) included in the model rather than to random error.  
A general view of the models obtained can be visualized in Table 19. 
Finally, based on the results obtained a methacrylate based films should be preferentially 
composed by: methacrylate copolymer (52-58%), PVA (15-20%), NaCMC (7-17%) and 
glycerol (10-15%) (Table 16).  
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3.4. Shellac based films 
In the Shellac formulation the CQAs (y-variables) are influenced by the majority of all the 
CPPs tested except by the plasticizer type that seems to influence only the mechanical 
properties in the range of concentration used (Figure 35).  
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Figure 35 - Prediction profiler of Shellac based formulations. It is represented the effect of each CPP in the CQAs. Parallel lines to the x-axis mean that there is no effect of the 
parameter are on the evaluated attribute. The significance of the selected model for each CQA evaluated is summarized and presented in the correspondent row. The border 
colour of each summary is related with the model significance. Green solid border means very good fit models p value <0.01) and high (>0.6) and proximal Rsquare; Yellow 
dashed border means good fit models (p value <0.05) and Rsquare values between 0.4-0.6; Red square dotted border means poor fit models, (p-value >0.05) and very low 
Rsquare values. 
Model ANOVA 
RSquar
e 
RSquare 
Adj 
Et 
p=0.000
2 
0.929 0.875 
σB 
p=0.056
7 
0.992 0.933 
εB 
p=0.038
7 
0.791 0.582 
% H2O 
p=0.046
9 
0.724 0.509 
Disintegrat
ion time 
p<0.000
1 
0.974 0.948 
Global 
evaluation 
p=0.003
1 
0.767 0.661 
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It is easily seen by the curves of the prediction profile that the fit models are complex and 
non-linear. Nevertheless, some very good prediction models were obtained (Figure 35, 
green border). Some of the values predicted by the model should be analysed with more 
caution (Figure 35, yellow and red border), e.g.the ones related with tensile strength, 
elongation at break and residual water content.  
An overall summary of the model is presented in Table 19. 
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Figure 36 - Plasticizer type influence in the mechanical properties of the Shellac polymeric matrices. 
The influence of the plasticizer may be visualized based on the two main components of the 
formulation, HPMC and Shellac. The grade of colours range from the desirable (green) to the 
unsuitable (red) effect in each CQA evaluated. Only the coloured area represents the range of the 
CPPs studied. The white zone is out of range values that were not studied. 
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The effect of the different plasticizers on the mechanical properties of the Shellac based 
formulations was also evaluated. However, to facilitate the analyses, only the two main 
components of the formulation were considered (Figure 33).  
The grade of colours is related with the CQA limits defined previously, and used in the 
screening evaluation of the formulations (Table 18). The green area corresponds to the 
desirable zone that allows obtaining suitable response effect for the correspondent CQA: 
Young’s modulus, tensile strength or elongation (Figure 36). In turn, the yellow-orange area 
is related with values close to the limits and the red zone out of limit data. 
Acceptable Young’s modulus values are possible to obtain with the majority of the 
plasticizers, except with PEG 400. The values obtained for Young Modulus with PEG 400 for 
any HPMC-Shellac combination are always on the boarder limits of the acceptance criteria 
(100-1500MPa, Table 18). By the contrary with PEG 6000 a large green area is obtained and 
only with high shellac concentration (above 55%) a smaller yellow-orange zone is verified. 
Regarding the tensile strength effect this plasticizer is associated with poor characteristics 
(big red zone, Figure 36). For this property, glycerol and 1,2 propanediol are the only 
plasticizers that allow obtaining green areas. In turn, any plasticizer allowed obtaining a 
green area for the elongation, but mainly orange zones. 
The percentage of each plasticizer that allows obtaining green areas based on HPMC-Shellac 
proportion within the limits studied (coloured area) are in Table 20. 
Therefore based on the obtained results a proper selection to obtain suitable shellac films 
seems to be: Shellac (50-57%), HPMC (16-20%), NaCMC (10-20%), PG or glycerol (1-15%) 
(Table 17). 
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Table 19 - Summary of the influence of the tested components on the different system evaluated. 
Only the major effects are presented. 
 
CQA PVAc formulations
Methacrylate Copolymer 
formulations
Shellac formulations
↑ PVAc ↑ Methacrylate Copolymer ↓ Shellac
↑ NaCMC ↑ NaCMC ↑celluloses (NaCMC and HPMC)
↓ PVA ↑ PVA from 16% (%w/w per fi lm) Choose PG or PEG 400
PG ↓ Glycerol
↑ Methacrylate Copolymer
↑ Shellac up to 60% (%w/w per 
fi lm)
↑ PVA
↑ celluloses (NaCMC and 
HPMC) from 30% (%w/w per 
fi lm)
Choose PG or PEG 400
↓ NaCMC ↓ Methacrylate Copolymer
↑ PVA ↑ PVA 
↑ tween 80 ↑ Glycerol
↓ PVAc ↓ Methacrylate Copolymer
↑ Shellac up to 60% (%w/w per 
fi lm)
↑ NaCMC
↑ NaCMC from 15% (%w/w per 
fi lm)
↑ celluloses (NaCMC and 
HPMC) from 30% (%w/w per 
fi lm)
↓ tween 80 ↓ PVA Choose PG or PEG 400
PG ↑ Glycerol
↓ PVAc ↓ Methacrylate Copolymer ↓ Shellac
TEC ↑ NaCMC ↑celluloses (NaCMC and HPMC)
↓ PVA ↓ Shellac
↑celluloses (NaCMC and 
HPMC)
↑ Glycerol
↓ PVAc ↑ Methacrylate Copolymer ↓ Shellac
↑ NaCMC
↓ NaCMC from 15% (%w/w per 
fi lm)
↑celluloses (NaCMC and HPMC)
↓ PVA ↑ PVA ↓ plasticizer amount
TEC ↓ Glycerol
↑ celluloses (NaCMC and 
HPMC) 
Higher residual 
water content
Fast 
disintegration
Better 
appearance
Stiffer films 
(higher Et)
Resilient films 
(higher σB)
↑NaCMC
Deformable 
films 
(higher εB)
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Table 20 - Desirable zones (green areas) obtained from the plasticization effect on PVAc and Shellac 
based films. The clear cells indicate that there are no green zones for the referred properties. 
 
PVAc based films Shellac based films
Glycerol: Shellac < 50% and HPMC >30%
PEG 1000: Shellac < 60% and HPMC <30%
PEG 6000: Shellac < 55% and HPMC <45%
1,2 – Propanediol (Propilenoglicol): Shellac < 60% 
and HPMC <25%
Glycerol: Shellac < 65% and HPMC <25%
1,2 – Propanediol (Propilenoglicol):: 60% <Shellac < 
65% and HPMC <30%
1,2 – Propanediol (Propilenoglicol): 
PVAc > 65% 
Triethyl citrate: PVAc > 55% 
1,2 – Propanediol (Propilenoglicol): 
30% < PVAc < 50% 
Triethyl citrate: 35% < PVAc < 65% 
Disintegration 
time
Tensile 
Strength
Green areas
Young’s 
modulus
Residual water 
content
 
3.5. Contact angle evaluation in the best screened 
formulations 
Based on the screening results, 3 additional formulations of each hydrophobic polymer with 
a composition within the ranges determined to be appropriate for ensuring ODFs with good 
properties, to test and evaluate the contact angle (Table 21). The contact angle assay was 
used to determine the hydrophobicity of the systems when compared with a well-known 
commercial hydrophilic polymeric matrix oral film (Listerine Pocket Packs).  
Based on the previous results, the PVAc system was apparently the most promising. 
Therefore, this polymer was used to prepare more complex formulation (additives addition) 
to test the film-forming ability of this system with complex composition (Table 21). 
Additionally, optimized formulations of system B and C were also prepared and 
characterized. 
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Table 21 - Optimized ODF formulations with hydrophobic behavior.  
 
A18 A19 A20 B25 B26 B27 C18 C19 C20
PVAc 52,80% 58,90% 59,90%
Methacrylate 
Copolymer
58,10% 51,60% 52,60%
Shellac 51,40% 57,40% 57,50%
PVA 16,80% 7,00% 15,20% 21,00% 21,10% 21,30%
HPMC 19,60% 17,00% 19,60%
NaCMC 17,40% 14,50% 6,90% 10,30% 6,70% 10,60% 17,60% 10,10% 21,80%
Triethylcitrate 6,90% 10,60% 10,00%
Glycerol 10,50% 20,60% 15,50%
1,2 - Propanediol 11,40% 15,50% 1,10%
Citric acid 6,00% 5,00% 5,00%
Mono-
ammonium 
glycyrrhizinate
0,50%
Maltodextrins 3,00% 3,00%
Red Iron Oxide 0,40%
Young's 
Modulus (Mpa)
457,4 330,2 901,4 450,7 161,2 219,5 306,46 106,75 997,1
Elongation (%) 25,68 38,65 6,795 11,67 6,98 7,49 1,01 2,69 0,475
Tensile Strength 
(Mpa)
10,07 2,44 23,39 2,99 31,58 7,25 4,31 4 5,39
Water Content 
(%)
4,66 3,73 4,255 5,98 5,95 5,29 5,15 4,69 4,64
Disintegration 
time (s)
13,5 17,06 46,22 19 19 44,5 4 18 7
Contact Angle (°) 58,8 64,2 74,4 61,12 61,24 63,54 66,28 41,48 50,31 38,34
PVAc formulations
Methacrylate 
formulations
Shellac formulations
Listerine 
Pocket 
Packs ®
 
Contact angles higher than 65⁰ are characteristic of hydrophobic surfaces (Vogler, 1998). All 
the prepared formulations had revealed contact angles significantly superior to the ones of 
the pullulan hydrophilic films (Listerine® marketed films). The PVAc based films (Table 20, 
A18-A20) exhibited values between 58.8 - 74.4⁰, the methacrylate copolymer based films 
(Table 20, B25-B27) presented angles between 61.12 - 63.54⁰ and shellac based films within 
41.48 – 66.28⁰.  
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4. Discussion 
Each polymeric matrix has its own inherent properties that affect greatly the CQAs of the 
final product. Each system depending on its composition exhibits different behaviour. 
Nevertheless, these Designs with smaller number of experiments are useful to screen a high 
number of process parameters in order to find which ones have a significant effect on the 
responses evaluated (in this case CQAs) such the one used in this study (fractional factorial 
design). These designs are commonly designated by screening designs. Three independent 
screening designs, one for each system, were performed in attempt to have an overall view 
of the influence of each process component in the CQAs of the 3 systems (Goupy and 
Creighton, 2007).  
The number of experiments depended on the number of CPP (x-variables) being evaluated. 
 
4.1. Critical Quality Attributes 
The CQAs of the oral films have been already described by others (Preis et al., 2014; Visser 
et al., 2015). The most studied characteristics are the mechanical properties and the 
disintegration time. Since the free water molecules in the polymeric matrix are known to 
have a plasticizing effect, the percentage of the residual water content was also evaluated 
in this work. In solvent casting method the remaining percentage of water is dependent on 
the formulation composition, the drying temperature and drying time during films’ 
preparation, but may also change depending on the storage environment and primary 
packaging material. For that reason, these parameters were controlled. 
In previous works, it was demonstrated the difficulty to define with precision the ideal 
mechanical properties for ODF (Preis et al., 2014). Even so, considering ODFs usage and 
purpose, the polymeric matrix should be soft (moderate Young’s modulus) to avoid 
becoming uncomfortable and difficult to handle. On the other hand, it should be though 
enough to resist during the entire manufacturing process and also handling at the moment 
of administration (moderate to high tensile strength and elongation).  
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4.2. PVAc based films 
The PVAc based films present a peculiar pattern concerning the influence of each excipient 
in the CQAs studied (Figures 32 and 33). Interesting to notice is the small influence of the 
amount of plasticizer in these films in the range of concentration evaluated. The plasticizer 
amount is not included in any model justifying its absence on the profiler (Figure 32). 
Theoretically, this situation occurs when the factor being studied does not have any 
significant effect in the responses evaluated. Even so, it is well known that plasticizer amount 
influences greatly the films properties. This result is contrary to the results of other authors 
that described a significant influence of the plasticizer nature and amount in PVAc matrices 
(Kolter et al., 2013).  
The PVAc aqueous suspension used (Kollicoat® SR 30 D) is known by its low film forming 
temperature (MFT), that allows the formation of film matrices without plasticizers (Kolter et 
al., 2013). Most probably due to the presence of the disintegrant in the formulation it was 
impossible to obtain a suitable film without a plasticizer and a stabilizer (PVA). Two different 
plasticizers were tested, triethyl citrate (TEC) and 1,2 – propanediol (propilenoglicol). As 
already described by others, more lipophilic plasticizers, such as TEC, contributed to obtain 
PVAc films with better characteristics (Kolter et al., 2013). Although, the plasticizer amount 
was not included in the profiler, it is described that the plasticization of PVAc films 
contributes to the decrease of MFT (especially for medium lipophilic plasticizers) and to 
increase sharply the flexibility (εB) even in small amounts (Kolter et al., 2013). Nevertheless, 
the recommended amount of plasticizer for PVAc based films is 5–10% w/w based on 
polymer mass (Kolter et al., 2013). 
NaCMC demonstrated a strong and positive influence in the Young’s modulus (Figure 32, 1st 
row). Hence, also in the PVAc based films the increase of the percentage of charged polymer 
chains in the matrix contributes to increase the rigidity of the films. Similarly, NaCMC-PVA 
films are already described as being stiffer with the NaCMC increase (Knyazeva et al., 2006). 
The COO- groups and non-substituted OH groups of NaCMC promote the chemical 
interaction with other chemical groups, especially OH and COCH3 groups through hydrogen 
bonding (Xiao et al., 2001). Therefore, the increase of NaCMC in this system leads to the 
formation of stronger linkages that are associated with more resilient (higher tensile 
strength) and non-deformable films (lower elongation at break) (Figure 32, 1st row). 
Apparently, these results seem to contradict some literature references describing that 
NaCMC may increase elongation and flexibility and decrease the tensile strength when 
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blended with polymers more brittle than NaCMC (Kundu et al., 2011). However, this effects 
were more prominent and significant for  NaCMC concentrations on the films above 30% 
(%w/w per film) (Kundu et al., 2011). Nevertheless, it is also referred by others that the 
mechanical properties effect of NaCMC on polymeric binary systems is nonlinear (Xiao et al., 
2001). Therefore, NaCMC addition effectively changes the mechanical properties of the 
matrices, creating new materials with different behaviour. Both stabilizers, tween 80 and 
PVA, contribute to increase the elongation and decrease the tensile strength and rigidity 
(Figure 32, 2nd and 3rd rows). In literature, it is found that tween 80 in starch based films at 
2% (%w/w per film) may behave as a plasticizer (Brandelero et al., 2010), which is in 
accordance with the obtained results (Figure 32, 3rd column). PVA has a different behaviour 
in this system compared to the methacrylate based films (Figure 32, 2nd column). Although 
the elongation increases, the elasticity and toughness of the polymeric matrix decreases 
with PVA augmentation (Figure 32, 2nd column). This profile corresponds to a plasticizing 
effect, which may be possible considering the low molecular weight of the PVA used 
(approximately 31 kDa (Clariant, 1999)) and the optimal miscibility between PVA-PVAc 
chains (Jelinska et al., 2010).  
Regarding the plasticizer nature, in accordance to the results described above, the higher 
lipophilicity of the plasticizer, such as triethyl citrate compared to propylene glycol, lead to 
the formation of more elastic films (Figure 32, 4th column, 1st row). The other mechanical 
properties did not changed significantly with the nature of the plasticizer (Figure 32, 4th 
column, 2nd and 3rd row). However, the predominant red zone in Figure 33 for Young’s 
Modulus, crossed with the profiler trace (Figure 32, 1st row), indicates that both plasticizers 
contribute to low Et values, close to the CQAs limits defined. 
The residual water content is affected in a similar manner in the other polymeric systems. 
The hydrophobic polymer (PVAc) diminishes significantly the free water molecules in the 
polymer matrix, and the disintegrant increases it sharply (Figure 32, 4th row). Triethyl citrate, 
probably due to its lipophilicity and the absence of polar groups available for water retention 
(Rowe et al., 2009), contributes to lower the residual water content when compared to 
propylene glycol (Figure 32, 4th row). In addition, the residual water content (Figure 33) 
column presents a higher green zone when TEC is used, meaning that a larger operational 
space for these attribute may be obtained using TEC as plasticizer. 
The interposition of tween 80 amphiphilic molecule between the polymer chains contribute 
to increase the free volume between the polymer chains, which besides the plasticizing 
effect, could also increase the water sorption capacity due do tween 80 polar region 
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(Brandelero et al., 2010). However, this effect was not observed in this system, where the 
increase of tween 80 decreases the residual water content (Figure 32, 4th row). This result is 
probably due to the hydrogen bond interactions between the surfactant polar groups and 
the hydrophilic groups of the matrix, reducing the number of polar groups available to retain 
water molecules (Villalobos et al., 2006). 
Curiously, the disintegration time was only significantly affected by the main polymer and 
the nature of the plasticizer used (plasticizer type) (Figure 32, 5th row, Figure 33 column 3). 
The increase of PVAc contributes to delay the disintegration time and triethyl citrate origins 
fast disintegrating films when compared to propylene glycol. The slower disintegration 
behaviour with the increase of the % PVAc may be easily explained by its hydrophobic 
nature, which difficult the water permeation to the polymeric matrix breaks. Considering 
the triethyl citrate, although it is more lipophilic than propilenoglycol, the faster 
disintegration may be explained by the higher efficiency of triethyl citrate to interpose 
between the PVAc chains. This effect may lead to higher free volume that may function as 
channels allowing a more efficient water penetration and faster matrix disintegration. In 
Figure 36, it is also shown that using TEC as plasticizer allows to have a larger operational 
range for these attribute, demonstrated by the larger green area. 
In this system, the films with better appearance have triethyl citrate, higher amount of 
disintegrant and lower concentration of PVA and PVAc (Figure 32, 6th row). 
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4.3. Methacrylate based films 
In the Methacrylate based films there is an evident influence of the excipients (CPPs) in all 
the studied CQAs (Figure 34). Young’s modulus is affected in a nonlinear way by the main 
polymer, the disintegrant (NaCMC) and the stabilizer (PVA) (Figure 34, 1st row). The higher 
concentration of charged polymers such as NaCMC and the ammonium methacrylate 
copolymer, could be associated with the higher rigidity and stiffness of the material. On the 
other hand, a tensile strength decrease is observed with an increase of Methacrylate %, 
which may be related with the concomitant PVA proportion decrease in the polymeric matrix 
(Figure 34, 2nd row). In fact, the results show that PVA increase contributes to higher tensile 
strength and elongation (Figure 34, 3rd row). This behaviour is commonly verified in other 
PVA based films reported (Clariant, 1999).  
The glycerol increase origins polymeric matrices with a peculiar behaviour (Figure 34, 3rd 
column). As described above, the plasticizers would contribute to more deformable films, 
with higher elongation and lower tensile strength. The opposite profile was observed in this 
work within the range of concentration tested (Figure 34, 3rd column). Glycerol is a small 
molecule with three hydroxyl groups, which may facilitate the interposition between the 
polymeric chains. It should be mention that higher concentration of hydroxyl groups may 
also promote hydrogen bonding. In fact, the behaviour observed indicates a probable strong 
interaction between the chemical groups, which may explain the tougher and less 
deformable films. However, the free space available between the polymer chains by the 
glycerol interposition also originated less rigid films, lower Et (Figure 34, 3rd column, 1st row).  
Regarding the residual water content variation, more hydrophilic substances (glycerol and 
NaCMC) tend to increase this parameter, although in a nonlinear way (Figure 34, 4th row). 
Glycerol is a very hygroscopic substance (Rowe et al., 2009), and its increase in the matrix 
increases significantly the retention of water, as already described by others (Baldwin et al., 
2011). The matrix moisture increase is not so evident with the NaCMC variation and 
surprisingly, below 15% of NaCMC there is also a decrease on the residual water content 
(Figure 34, 4th column, 4th row). This result may be justified by the diffusion or dilution of this 
polymer in a more concentrated methacrylate/PVA matrix, wrapping NaCMC chemical 
hygroscopic groups responsible for water molecules retention. In turn, NaCMC increase may 
lead to a higher accessibility of these groups and more residual water content is present in 
the films (Figure 34, 4th column, 4th row). Contrarily, methacrylate copolymers and PVA 
contribute to diminish the water retention in the polymeric matrix (Figure 34, 4th row). 
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Methacrylate copolymers are considered hydrophobic, which by definition do not tend to 
absorb water (Derakhshandeh and Soleymani, 2010; Qiu et al., 2009), and PVA based films 
are also described as non-hygroscopic (Clariant, 1999). Hence, the same components have 
opposite effects in the disintegration time: PVA and methacrylate copolymers increase 
sharply the time to disintegrate the films whereas glycerol and NaCMC contribute to a faster 
disintegration of the films (Figure 34, 5th row). Curiously, a similar pattern is verified in the 
qualitative evaluation of the appearance (Figure 34, 6th row). The appearance of the film 
tends to ameliorate significantly with methacrylate and PVA increase but diminish with the 
augmentation of the plasticizer and NaCMC (Figure 34, 6th row). 
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4.4. Shellac based films 
Although other works related with shellac based films are scarce, it was possible to find some 
information regarding their properties and behaviour. Increasing amounts of shellac, 
particularly above 45%, contributes to a sharp decrease of the young’s modulus (Figure 35, 
1st row) whereas the addition of celluloses, NaCMC and HPMC, as well as their interaction, 
significantly contributes to its increase (Figure 35, 1st row). The Young’s modulus translates 
the elasticity of the polymeric matrix that also depends on the polymeric chain orientation 
and interactions. Therefore, considering the usage of shellac ammonium salts, it would be 
expectable that some ionic interactions may occur contributing to the stiffness of the films 
(higher Et). The opposite effect was verified in the present study, probably due to the 
formation of less ionized shellac films during the process. Ammonium ion is a weak acid, 
therefore a possible explanation for this result, is that during the drying time the ammonium 
ions protonate the carboxylate anion of the shellac (Al-Gousous et al., 2015). Consequently, 
more protonated shellac films are formed and the resulting ammonia evaporates, during the 
process (Al-Gousous et al., 2015). A possible evidence of the carboxylate protonation is the 
lightly yellow films obtained, similar to the shellac free acid films (Al-Gousous et al., 2015). 
Nevertheless, the increase of shellac is associated with the reduction on the proportion of 
HPMC (Table 17) and consequently more elastic films were obtained. In fact, it is already 
described that the addition of HPMC may contribute to stiffer films (Borges et al., 2015). 
Additionally, the increase of the films rigidity with the NaCMC increase may also be related 
with its ionic nature and possible interactions with other polymer matrix components 
leading to a higher stiffness of the matrix (Figure 35, 1st row). 
The tensile strength is strongly affected by all the CPP tested, and the majority exhibits a 
nonlinear influence. The Shellac effect on the tensile strength (Figure 35, 2nd row, sharp 
increase up to 60% Shellac followed by an accentuated decrease) may be related with the 
Shellac / HPMC ratio in the matrix composition, since HPMC concentration has the opposite 
effect on the films.  Cellulose values up to 30% contribute to brittle films (Figure 35, 2nd row) 
although for higher amounts of stiffer films are obtained probably due to the augment of 
chemical interactions that turn the polymeric matrix less deformable and stiffer (Figure 35, 
2nd row).  
The elongation is also negatively influenced by the main polymer but tends to increase 
slightly with the increase of celluloses concentration (Figure 35, 3rd row). The addition of the 
celluloses, which also implies the decrease of shellac in the matrix (Table 17) may increase 
 234 
the free volume between shellac chains contributing to higher mobility and higher 
elongation. On the other hand the increase of hydrophilic polymers, particularly NaCMC, in 
the polymeric matrix may promote the increase of the moisture content. The water 
molecules are known to act as external plasticizers, promoting an elongation rise and a 
decrease in the tear strength (Figure 35, 3rd row) (Clariant, 1999). 
Among the plasticizers tested (Glycerol, PEG 400, PEG 1000, PEG 600, 1,2 Propanediol) 
(Figure 35, 3rd column), PG and PEG 400 contribute to higher tensile strength values (Figure 
35, 2nd row), but low and unsuitable elongation values (Figure 35, 3rd row). A deeper analysis 
of the plasticizing effect is presented in Figure 36. It is easily seen by the orange and red 
zones, that suitable elongation values are hard to obtain with any of the plasticizers tested 
(Figure 36, column 3) and ODF with PG or PEG 400 have predominant red zones compared 
to the other plasticizers for this attribute.  
Amongst the plasticizers tested, glycerol and PG are probable the most alike (chemically and 
in structure), and it is notorious their different effects (Figure 35, column 3 and Figure 36, 1st 
and 5th rows). The additional hydroxyl group of the glycerol is probably enough to interpose 
more efficiently between the polymeric matrix chains. In fact, the good miscibility of glycerol 
with shellac was already described due to the thermal and mechanical properties 
modifications with glycerol increase (e.g. reduction of melting temperature, elasticity 
improvement) (Stummer et al., 2010). It is also described that glycerol plasticizing effect on 
shellac films is due to its diffusion within the polymer chains and hydrogen bonds formation 
(Stummer et al., 2010).  
Regarding the PEGs, the differences found are probably related with their different 
molecular weight (Figure 35, column 3 and Figure 36, 2nd, 3rd and 4th rows). Higher Mw PEGs 
present long carbonated chains (Al-Nasassrah et al., 1998; Rowe et al., 2009) that may be 
more prone to entangle within the polymer matrix chains, increasing the free volume 
between them and consequently diminish the tensile strength and increase the elongation.  
Nevertheless, considering the overall results of the plasticizer type analysis (Figure 35, 
column 3 and Figure 36), it is possible to select Glycerol and PG as the most appropriate 
plasticizers for the shellac based films within the group studied. This conclusion is mainly 
retrieved from the major green areas presented in Figure 33 for this two plasticizers 
compared with the others. However, Figure 36 should be analysed with caution since it is 
not presented the whole system, but only the plasticizing effects considering only the two 
main components (Shellac and HPMC). On the other hand, the results obtained are in 
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accordance with the literature, which describes that plasticizers with lower Mw and more 
hydrophilic functional groups have better plasticizing effect on shellac films (Stummer et al., 
2010). Glycerol and 1, 2 - propanediol have lower Mw (Glycerol Mw is 92.09 g/mol and 1,2 
Propanediol 76.09 g/mol (Rowe et al., 2009)) compared to the lowest Mw PEG (PEG 400 Mw 
380-420 g/mol (Rowe et al., 2009)).  
Surprisingly, in this system the type of plasticizer appears to have no significant impact on 
the residual water content and disintegration time, in the range of concentrations tested 
(Figure 35, 4th and 5th rows). However, Shellac and HPMC have a nonlinear and predictable 
influence in these properties, considering their chemical nature (Figure 35, 4th and 5th rows). 
Higher shellac concentration is associated with smaller residual water content and a sharp 
increase of the disintegration time, whereas the modified celluloses have the opposite effect 
(Figure 35, 4th and 5th rows).  
The overall appearance of the film seems to be related with every component tested except 
with the plasticizer type (Figure 35, 6th row). The amount of polymers affects greatly the film 
appearance (Figure 35, 6th row). High amount of shellac has a deleterious effect on the oral 
films appearance, whereas high cellulose amount origin films with better appearance (Figure 
32, 6th row).  
  
 236 
4.5. Hydrophobicity of maximized desirability 
formulations 
The contact angle (CA) is a parameter that may be used to measure the hydrophobicity of a 
surface (Oun and Rhim, 2015). A marketed oral film with a hydrophilic polymer was used as 
reference.  
It is described that the addition of hydrophilic polymers to the matrix usually contributes to 
lower the CA due to the increase of the hydrophilicity of the film surface. This may be 
chemically explained by the exclusion of non-polar components of the hydrophobic 
polymers and the exposure of hydroxyl groups from the hydrophilic structures (Oun and 
Rhim, 2015). Therefore, the polar groups are more prone to absorb and retain water that 
may favour the polymeric matrix disintegration. 
The PVAc based films had higher contact angles with the PVAc increase, as expected. The 
major proportion of non-polar groups of PVAc tend to repel the water contributing to the 
higher contact angles verified. However, at the same time the disintegration time increases. 
The contact angles obtained for the methacrylate polymer films were very consistent, and 
had very slightly variations with the increase of glycerol. This is probably due to the 
compensation with NaCMC decrease, also known by being hygroscopic when dried (Rowe 
et al., 2009). 
The shellac based films presented the lower contact angles. This result is probably due to 
the usage of the shellac as an ammonium salt. Although during the drying the majority of 
these ammonium salts may be converted in shellac non-ionic form, some of the ionic forms 
may still remain and contribute to increase the water affinity of the films. Additionally, these 
films are prepared with HPMC as stabilizer of the main polymer instead of PVA, which is 
known to have better moisture protection (Edsall et al.).  
The contact angle of the marketed pullulan film (Listerine® pocket packs) is in accordance to 
values available in literature, lower than 35⁰ (Farris et al., 2011; Garsuch and Breitkreutz, 
2009). Therefore, the majority of the tested formulations present a contact angle 
significantly higher, representative of a more hydrophobic nature of the polymeric matrix 
that was one of the aims of the present work. 
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4.6. Systems overall comparison 
It is not clear if the different hydrophobic behaviour of each system was due to the specific 
hydrophobic polymer used or mainly due to the overall system composition. However, it was 
possible to verify that the same component may have a different influence on the ODF 
properties depending on the overall system composition (Table 22).  
As a general evaluation, considering the previous discussion and the compositions studied, 
it was possible to observe that PG is probably a more efficient plasticizer for PVAc based 
films than for shellac (medium-low Et and medium σB), whereas glycerol is better for shellac 
than methacrylate copolymer formulations (medium Et, low σB and higher εB) (Table 22, 
columns propylene glycol and glycerol). Theoretically, the plasticizers interpose between the 
polymer chains increasing their free volume, which contributes to a more freely motion and 
rotation of the chains. This phenomenon would be associated to a higher flexibility and more 
prone to deformation ODF. Therefore, lower tensile strength, lower Young’s modulus and 
higher elongation are expected (Lim and Hoag, 2013). However, these effects are completely 
dependent on the plasticizer nature and its miscibility with the main polymer (Boateng et 
al., 2009). It is likely that the effects described above, occur mainly if the plasticizer is fully 
miscible or compatible with the polymeric matrix. Ideally, the plasticizers should be 
compatible with the polymer to plasticize, hydrophilic polymers usually are well plasticized 
by hydroxyl-containing compounds, which may not be valid for hydrophobic polymers. 
Therefore, the distinct effects of the plasticizers on the polymeric matrix reflect the different 
interactions that each have with the polymeric matrix. 
Additionally, the influence of NaCMC and PVA on PVAc and methacrylate copolymer 
formulations was also evaluated and summarized in Table 22. The most evident influences 
are on Et, σB and disintegration time. NaCMC contributes to stiffer, resilient and fast 
disintegration films in PVAc systems. These observations are probably related with chemical 
interactions between the polymer chains. NaCMC and Methacrylate are charged polymers, 
and chemical bounds between them may be related with the different results obtained 
when compared to the neutral PVAc.  
PVA allows obtaining more elastic and deformable films using methacrylate copolymers 
based formulations. This effect may not be strictly related with the PVA addition but also 
with the film-forming polymer characteristics. PVAc is known to form high flexible films 
(Kolter et al., 2013) whereas methacrylate copolymers are described to origin brittle films in 
the dry state (Bodmeier and Paeratakul, 1994). Therefore, these significant differences may 
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be also related with the PVAc and methacrylate copolymers inherent film-forming 
properties.
 239 
Table 22 - Summary of the influence of common excipients used in the different systems. This information is retrieved form the profilers, considering the excipients increase (a 
right to left reading of each square of the profilers). 
Shellac PVAc Shellac Methacrylate Shellac Methacrylate PVAc Methacrylate PVAc
Medium-
high
Medium-
low
Medium Medium-low ↑↑ ↑ ↑↑ ↓ ↓↓
~900MPa ~450MPa ~600MPa <500MPa
10-
400MPa
40-100MPa 0-300MPa
200-40 MPa 
(up to 16 % 
PVA) 
<300MPa
↑
40-200MPa 
(from 16% 
PVA)
Medium Medium Medium ↑↑ ↓↓ ↑ ↓↓ ↓
~25MPa <20MPa <20MPa 10-40MPa
40-0 MPa (up 
to 12 % 
NaCMC) and 
<20MPa 
(from 18 % 
NaCMC)
12-18MPa
20-0 MPa (up 
to 12 % PVA) 
<15MPa
↑↑ ↑↑
0-20MPa (12-
18% NaCMC)
0-30MPa 
(from 12% 
PVA)
Low Low Low Low ↑ - ↓↓ ↑↑ ↑↑
<10% <10% <10% <5% 0-5% ~5% <5% 5-10% > 0%
High High ↑ ↑ ↑ ↓ ↓
> 6 % > 6 % 3-4% >7% >7% 7 - 6 % 8 - 7 %
Low Medium ↓↓ ↓↓ ↓ ↑↑ ↓
~20s <40s 100-40s 60-20s <10s 20-60s 20-60s
Disintegration - -
Propilenoglycol Glycerol
Et
σB
Low 
<5MPa
PVA
εB
%H2O - -
NaCMC
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5. Conclusions 
This work demonstrates that orodispersible films can also be prepared based on 
hydrophobic polymers, and not only hydrophilic polymers, breaking a paradigm of the 
research of this novel dosage form. Three different formulations were developed, which may 
be optimized and used to embed drug substances for oral delivery. Additionally, there is a 
similar pattern in the three formulations: a hydrophobic polymer, a stabilizer, a disintegrant 
and a plasticizer. Despite the need of a disintegrant, for the fast disintegration, it was also 
shown that other components may also contribute to this property. In fact, the DoE 
approach for initial screening was very useful to determine the influence that each excipient 
could have in the overall system. The generation of the profilers and counter graphs is 
helpful for the graphic visualization of these influences.  
In general, it was not possible to clearly define if the differences in the hydrophobic nature 
of the 3 systems was due to the specific hydrophobic polymer used alone or due to the 
overall system composition. However, it was possible to determine the effect of each 
component in the different polymeric matrices CQAs and to detect some common trends.  
In the future, the incorporation of drug substances in this type of ODFs (more hydrophobic 
in nature) should be performed as well as stability studies as the final proof of concept.
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Abstract 
Orodispersible films (ODFs) emerged as an effective alternative for conventional oral dosage 
forms. ODFs, based on a hydrophobic polymer were developed and optimized. The quality 
by design approach was applied to a pre-defined polyvinyl acetate (PVAc) formulation to 
perform three different studies: evaluation of the influence of the plasticizer type, 
determination of the maximum drug loading capacity (Pramipexole) and optimization design 
to obtain an ODF with the target product profile. The formulations were characterized 
regarding their mechanical properties, residual water content, disintegration time, contact 
angle, organoleptic and appearance characteristics in attempt to find out a suitable ODF that 
could meet the critical quality attributes (CQAs) defined. The selected critical process 
parameters (CPP) for the formulation screening were the percentage of the different 
excipients and the plasticizer type. It was found that the plasticizing effect is critical for the 
overall performance and stability of the product. Also, a binary taste-masking system, based 
on a flavour and a sweetener, to obtain agreeable ODFs was accomplished. Additionally, the 
drug substance effect may be very significant and greatly dependent on its concentration. 
Finally, an ODF with suitable characteristics, such as: very fast oral disintegration; easy to 
handle and manufacture; pleasant taste and appearance; and likely to become appropriate 
for drug delivery, was developed. 
 
Keywords 
Orodispersible Films; Hydrophobic Polymers; Critical Quality Attributes; Critical Process 
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1. Introduction 
Orodispersible films (ODF) have been introduced in the market as a patient centric 
alternative to conventional oral dosage forms. ODFs are a pharmaceutical dosage form 
based on a polymeric matrix that may be developed to disintegrate almost immediately in 
the oral cavity. This dosage may be very helpful for some patients that refuse conventional 
oral dosage forms due to swallowing disorders (dysphagia) or fear of chocking. Therefore, 
the development of an ODF orientated for diseases associated with dysphagia, such as 
Parkinson’s disease (PD), will most likely improve patient compliance due to the easier 
administration. PD is the second most common neurodegenerative disorder and is 
estimated that may affect 7 to 10 million people worldwide (Ballard et al., 2015; Foundation, 
2015; Miller and O’Callaghan, 2015; Olanow et al., 2009; Sapir et al., 2008). PD is progressive 
and it is characterized by motor disabilities including bradykinesia, hypokinesia, muscle 
rigidity, resting tremor, speech and swallowing disorders (dysphagia), autonomic 
dysfunction and, non-motor symptoms such as olfactory disturbances, oral cavity problems, 
fatigue, pain, sleep fragmentation, depression, and dementia (Sapir et al., 2008; Zlotnik et 
al., 2015). Nearly 90% of individuals with PD suffer from dysphagia during the course of the 
disease, which is becoming a major problem in patient compliance to therapy (Sapir et al., 
2008; Zlotnik et al., 2015). Therefore, unmet needs in PD therapy include improved efficacy, 
tolerability and ease of drug use/compliance due to the problems associated to swallowing 
of drug dosage forms available in the market. 
For the development and optimization of every novel dosage form, a deep knowledge of the 
product and its process parameters should be established very early stage of the 
development process of the product, essentially to build quality in. This understanding is the 
base of the Quality by design (QbD) concept, a systematic approach that allows controlling 
and improving the quality of the product. The most common tool used for pharmaceutical 
development is the definition of the quality target product profile (QTPP), which is critical to 
describe the desired product performance, delimit the CQAs and then identify the critical 
process parameters (CPPs) (Rathore and Winkle, 2009; Visser et al., 2015).  
In the case of ODF, the mechanical characteristics, the water molecules retained, the 
disintegration and dissolution time are all critical quality attributes (CQAs) that may affect 
the drug release and bioavailability of the drug as well as the stability of the final product. 
Additionally, the mechanical resistance of the ODF is also associated with its ability to be 
properly processed and manufactured; and with its handling capacity, that allied to 
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appropriate organoleptic characteristics, may compromise the patient compliance 
(Hoffmann et al., 2011; Visser et al., 2015).  
The aim of the present work was to use the QbD approach for the optimization of an ODF 
for the treatment of PD. The CQAs considered to obtain a suitable ODF were the mechanical 
properties, residual water content and disintegration time. The critical process parameters 
were outlined based on the variables that may influence the previous parameters, such as 
the type of plasticizer, the amount of excipients and drug substance. From a pre-defined 
PVAc formulation (Borges et al., 2015) three independent, but consecutive tests were 
performed: an initial screening design, a second screening study to evaluate the ability of 
the matrix to incorporate a PD drug and, finally, an optimization study to obtain a pleasant 
and moisture resistant polymeric matrix. 
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2. Material and methods 
 
2.1. Materials 
Polyvinyl acetate (PVAc) (Kollicoat® SR 30D) (BTC, Ludwigshafen, Germany), Polyvinyl alcohol 
4-88 (PVA) (Merck, Darmstadt, Germany), Sodium Carboxymethylcellulose (NaCMC) 
(Aqualon France BV, Alizay, France), Maltodextrins (Grain Processing Corporation, Iowa, 
USA), Glycerol (Merck, Darmstadt, Germany), Triethyl citrate (TEC) (Merck, Darmstadt, 
Germany), Polyethylene Glycol 400, Lutrol 400 (BTC, Ludwigshafen, Germany), Polyethylene 
Glycol 6000, Macrogol 6000 (Clariant Burgkirchen,  Deutschland GmbH), 1,2-Propanediol 
(PG) (Merck, Darmstadt, Germany), FD&C Blue #1 (Colorcon, Harleysville, U.S.), Red and 
Yellow Iron Oxide (Huntsman Pigment S.p.A, Torino, Italy), Indigotine Lake (Colorcon, West 
Point, US), Menthol (-)-Menthol (Merck, Darmstadt, Germany), Lemon Flavour, Passion Fruit 
Flavour, Wildberry Flavour (IFF, Haverhill, UK), Mannitol (Merck, Darmstadt, Germany), 
Sucralose, Splenda (Merck, Darmstadt, Germany), Monoammonium glycyrrhizinate (MAG) 
(Mafco, NJ, USA), Citric acid (Merck, Darmstadt, Germany), Pramipexole Dihydrochloride 
(Crystal Pharma S.A.U, Boecillo, Spain). 
 
2.2. Methods 
 
2.2.1. Choice of design and experimental layout 
The software JMP 10 (SAS Institute Inc., Cary, NC) was used to construct Custom designs. 
This platform was used instead of classical designs, since different types of variables were 
studied including mixture and nominal variables. The defined experiments to run are 
presented in Table 23. The experiments were carried out following a random order within 
each formulation type. The analysis was performed using the screening designer platform, 
meaning that the software adds automatically the interactions and crossed effects.  
The selection of the ranges for the CPPs (process variables, the amount of excipients and 
plasticizer type) was based on preliminary tests and ranges of concentration for each 
excipient-function described in literature (Dixit and Puthli, 2009; Hoffmann et al., 2011). The 
continuous variables were introduced as mixture factors in order to identify the proportions 
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within the different components that maximize the defined responses (CQAs). The factors 
are constituent proportions of a mixture which sums to 1 (100%) and the last component 
percent is determined by the sum of the others. Therefore, the factors are not independent, 
but the software methodology for this type of designs is the same as for classical designs. 
The nominal factor evaluated was the plasticizer type.  
The screening platform used to evaluate the results basically uses n values in the response 
vector and rotates them into n new values. The rotated values are then mapped by the space 
of the factors and their interactions. The screening report generated shows a list of 
coefficients with their contrasts and p-values. Mathematically, the contracts are: Contrasts 
= T’ × Responses. T is an orthonormalized set of values that starts at the intercept and goes 
in descendent order through the main effects, two-way, three-way interactions, etc., until n 
values have been obtained. T is orthogonal and the contrasts are the parameters estimated 
in a linear model. The significant terms are usually associated low p-values, which are 
generated based on Lenth t-ratios that are created through a Monte Carlo simulation of 1- 
runs of n – 1 purely random value. The t-ratios are obtained from the Lenth Pseudo Standard 
Error (PSE) by the Lenth’s method that identifies inactive effects and constructs an estimate 
of the residual standard error. The most significant terms that may lead to the best fit model 
to explain the variable in study were manually selected. The best fit model was selected 
based on the higher and proximal RSquare and RSquare Adjusted, the overall F-value and 
the associated p-value of the Analysis of Variance for the entire model (Goupy and 
Creighton, 2007; SAS Institute, 2013). 
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2.2.2. Design Selection and experimental layout 
The QTPP implies the definition of the CQAs, which stablish the limits to obtain suitable ODFs 
without compromising product’s performance, and the CPPs that should be selected 
according to the effect that may have on the CQAs. The CQAs and CPPs outlined for this work 
are summarized in Figure 37.  
 
 
Figure 37 - Control Quality Attributes (CQA) and Control Process Parameter (CPP) selected. QTPP - 
Quality Target Product Profile; Et – Young’s modulus; εB –Elongation at break; σB – tensile strength. 
 
In general, this work consists mainly in the optimization of an ODF platform for the 
treatment of PD. Therefore CQAs and CPPs were selected based on the main features and 
characteristics essential for this dosage form, these include: mechanical properties; 
disintegration time; residual water content; appearance and organoleptic evaluation and 
contact angle. 
Successively, the most critical components and parameters (CPPs) that would influence the 
CQAs above were selected, such as: the film forming polymer (PVAc) amount, %weight 
/weight (%w/w) per film; stabilizer amount (PVA), %w/w per film; disintegrant amount 
(NaCMC), %w/w per film; plasticizer amount, %w/w per film  and plasticizer type (triethyl 
citrate, 1,2 -propanediol, glycerol, polyethylene glycol 400, polyethylene glycol 1000 and / 
or polyethylene glycol 6000).  
Excipients type 
(categorical nominal 
factors) 
Excipients amount 
(continuous factors) 
Mechanical properties 
(Et, σB, εB) 
Appearance and 
Organoleptic evaluation 
Disintegration time 
Contact angle 
Residual water content 
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2.2.3. Preparation of the oral films 
The formulation used as starting point for this work was previously described (Borges et al., 
2015). The liquid mixtures were prepared in two-neck round bottom-flasks (50mL). The 
system was kept overnight at room temperature under agitation to obtain free-bubble-
liquid. Each excipient was added only after assuring that a homogeneous liquid mixture had 
been formed. The PVA and NaCMC were added as pre-prepared solutions of 25% w/w and 
7% w/w, respectively. In the more complex mixtures, involving the use of flavours, MAG, 
colourant and sucralose, these compounds were previously solubilized in the PVA solution 
before being added to the mixture. The PVAc was always the last compound to be added in 
the mixture. The liquid mixtures were cast in PVC release liners (substrate) with an Erichsen 
film applicator (Coatmaster 510, Erichsen, Hemer, Germany). To adjust to different heights 
a vertically adjustable doctor knife was used and the film mixtures were cast with speed of 
6 mm/s. The films were cast with a gap of 300 µm. The process of film formation has been 
thoroughly described (Alanazi et al., 2007) and it is divided into three stages: (a) evaporation 
of the solvent and subsequent concentration of polymer particles, (b) deformation and 
coalescence of polymer particles and (c) further fusion by interdiffusion of polymeric 
molecules of adjacent polymer particles. The cast films were dried on the heated table of 
the Erichsen film applicator at 40 °C or at room temperature until dryness. The drying time 
depended on the properties of each polymer.  
To further characterize the films, individual samples were prepared by cutting strips of 
regular and equal dimension with a bench manual press (Tinius Olsen, Horsham, USA). 
 
2.2.4. Film mass 
The films were weighed using an analytical balance (Mettler Toledo AGXS, Mettler-Toledo 
Inc., Columbus, US) and the average weight was calculated (n=3). 
 
2.2.5. Film thickness 
The thickness of the films was measured with a micrometer screw (Mitutoyo Digimatic 
Capiler, Mitutoyo Corporation, Japan) (n=5) 
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2.2.6. Tensile Strength 
The mechanical properties of the films were determined using a tensile testing universal 
apparatus (Zwick, Germany) with a load cell of 10 N. The measurements were performed 
similarly as described elsewhere (11, 12). Briefly, ODFs with the dimensions of 60x20 mm 
and free from air bubbles or physical imperfections, were held between two clamps 
positioned at a distance of 40 or 50 mm. Firstly, a preload was applied in each assay and 
then the strips were pulled by the top clamp at a rate of 10.0 mm/min. The load 
automatically applied to the film was gradually increased and the corresponding magnitude 
of elongation was recorded until the break point of the film was finally reached. The 
parameters were directly retrieved from the software TestXpert (TestXpert, Zwick, 
Germany), namely Young’s modulus (Et, MPa), tensile strength (σB, MPa) and elongation at 
Break (εB, %). Measurements were run at least in three samples for each film. 
 
2.2.7. Disintegration time 
Approximately 4 mL of a phosphate buffer pH=6.8 (artificial saliva) was added on a Petri dish 
and the ODFs were laid on. The time at which the film samples disintegrate was recorded. 
 
2.2.8. Karl-Fisher 
The Karl Fischer Method was used to determine the residual water content in the ODFs. This 
technique basically consists in the quantitative reaction of iodine and sulfur dioxide by the 
addition of water, in the presence of a lower alcohol such as methanol. 
 
 
A sample was added to the titration flask filled with methanol previously dehydrated with a 
Karl Fischer reagent (Hydranal Composite 5, Sigma-Aldrich Co. LLC). Titration was then 
carried out using Karl Fischer reagent with a known determined titer (mgH2O/ml). The water 
                                    CH3OH 
SO2 + I2 + 2H2O                           2HI + H2SO4 
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content is determined based on the titration volume (ml). The polarization-current 
potential-difference method is employed as an end-point detection method.  
These tests were performed in a Karl Fisher 787 KF Titrino (Metrohm AG, Herisau, Schweiz). 
 
2.2.9. Contact angle 
Drop shape analysis is used to determine contact angles. Time-dependent contact angles 
were measured by an optical contact angle meter (OCA20 Dataphysics equipment, 
Filderstadt, Germany) at room temperature. An approximate volume of 10 µL of distilled 
water was dropped onto the film surface initially fixed in a slide on a planar position. The 
contact angle was determined right after the drop addition (t=0s) and after 20 or 30 seconds 
(t=20s or t=30s, depending of the film characteristics) by using the supplied software (SCA20 
Dataphysics software, Filderstadt, Germany). 
 
2.2.10. Storage 
The individual films were stored under controlled conditions (43 % RH, room temperature) 
by means of a saturated solution of potassium carbonate for at least 5 days before testing.  
 
2.2.11. Appearance and handling characterization  
The oral films obtained from each run were also evaluated by a test panel based on their 
appearance and handling properties. The test panel was created to select appearance and 
handling properties of the films that allow its evaluation and classification. The appearance 
parameters evaluated were the existence of lumps, phase segregation and the homogeneity 
of the oral films. The handling properties considered were: the detachment ability from the 
release liner; the touch sensitivity; and the integrity of the sample to be characterized. It was 
used a 1 to 5 scale, where the Global Evaluation value corresponds to the average of the 
referred parameters, all with equivalent degree of importance (14% of importance) except 
for the detachment from the release liner (30% of importance). 
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2.2.12. Organoleptic characterization  
The placebo ODF obtained from each run were also evaluated by a test panel based on taste 
and mouthfeel characteristics. The initial taste sensation, aftertaste and mouthfeel were 
evaluated based on a 0 to 5 scale, 0-bad, 1-unconfortable, 2-indiferent, 3-reasonable, 4-
agreeable and 5- very agreeable. It was also evaluated if the triethyl citrate taste was 
detectable or uncomfortable in the prepared oral films based also in a 0 to 5 scale, where 0 
– too uncomfortable, 1- uncomfortable with aftertaste, 2 - uncomfortable without 
aftertaste, 3- detectable and still a bit uncomfortable, 4- detectable but not uncomfortable, 
5- not detectable. The final evaluation value corresponded to the average of the referred 
parameters, all with equivalent degree of importance (20% of importance) except for the 
aftertaste (40% of importance). 
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3. Results  
3.1. Screening results: experimental design with CPPs 
range and CQAs studied 
A QbD approach was followed essentially by using the Design of Experiments (DoE) tool. The 
QTPP was constructed based on practical knowledge of the dosage form, from previous 
works and from literature support (Hoffmann et al., 2011; Preis et al., 2014; Visser et al., 
2015). 
The different factors under study (CPPs) were introduced in the DoE software and a custom 
design was outlined for each different test. In total, 123 oral films were prepared with 
different percentages of main film-forming polymer (PVAc), stabilizer (PVA), disintegrant 
(NaCMC) and plasticizer (triethyl citrate and / or propanediol, glycerol, polyethylene glycol 
400, polyethylene glycol 1000, polyethylene glycol 6000) (Table 23). For the taste masking 
optimization (Table 24) and DS incorporation (Table 25) additional additives were tested: 
mannitol, citric acid, sweeteners (sucralose, MAG), flavour (strawberry flavour) and /or 
colourant (iron oxide). The different runs are presented on the CPPs columns of Tables 23, 
24 and 25, whereas the results of their evaluation are on the CQAs columns on the same 
tables.
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Table 23 - Ranges of CPPs (amount of PVAc, PVA, Plasticizer, NaCMC and Plasticizer type) for plasticizer selection formulations. The amount of each compound is presented 
as rational values where the sum of the components is 1. The range used to delineate the design is present on the excipients row. The missing values are identified (*) 
and are related with the poor films characteristics that did not allowed to perform some valid tests. The value in the CQAs column corresponds to the median value 
introduced in the software to perform the analysis.  
 
 
Run
PVAc PVA Plasticizer NaCMC 
Plasticizer 
type
Global 
evaluation
 (1-5)
Range 
tested
0,25-
0,80
0,1-
0,40
0,01-0,2
0,01-
0,20
A1 0,5 0,2 0,2 0,1 PEG 400 9,42 ( 8,6 - 10,23 ) 2,41 ( 2,3 - 2,5 ) 80,8 ( 75 - 87 ) 6,16 ( 5,7 - 6,6 ) * 3,4
A2 0,67 0,2 0,01 0,12
Propylene 
glycol
* * * 5,03
( 4,2 - 5,8 )
* 1,98
A3 0,67 0,01 0,2 0,12
Propylene 
glycol
* * * 5,19
( 4,7 - 5,7 )
>60 1,98
A4 0,69 0,11 0,01 0,19 Glycerol * * * 5,82 ( 5,5 - 6,1 ) >60 1,86
A5 0,6 0,01 0,2 0,19 Glycerol * * * * * 1,54
A6 0,69 0,01 0,1 0,2 PEG 6000 621 ( 618,7 - 622,8 ) 6,47 ( 5,5 - 7,4 ) 0,66 ( 0,6 - 0,7 ) 6,89 ( 6,4 - 7,4 ) >60 2,42
A7 0,82 0,06 0,1 0,01 PEG 400 3,19 ( 2,39 - 3,98 ) 6,96 ( 6,9 - 7 ) 391 ( 380 - 402 ) 2,99 ( 2,7 - 3,3 ) >60 3,16
A8 0,82 0,01 0,06 0,12 PEG 400 58,2 ( 44,16 - 72,16 ) 4,22 ( 3,2 - 5,3 ) 58,8 ( 55 - 63 ) 5,02 ( 4,9 - 5,2 ) >60 2,68
A9 0,95 0,03 0,01 0,01
Propylene 
glycol 656 ( 653,9 - 669,8 ) 9,84 ( 9,8 - 24 ) 1,19 ( 1,1 - 3,6 )
3,11
( 2,9 - 3,3 )
>60 3,96
A10 0,93 0,01 0,01 0,05 PEG 6000 3,91 ( 3,5 - 4,3 ) >60 2,42
A11 0,72 0,06 0,06 0,16 PEG 6000 1366 ( 990,6 - 1552 ) 13,2 ( 12 - 28 ) 0,76 ( 0,7 - 1,9 ) 4,56 ( 4,2 - 4,9 ) >60 2,98
A12 0,67 0,09 0,2 0,04 Glycerol * * * 2,1
A13 0,46 0,2 0,15 0,2 Glycerol * * * 2,12
A14 0,68 0,14 0,14 0,05 PEG 6000 939 ( 829 - 1049 ) 6,6 ( 5,6 - 7,6 ) 0,58 ( 0,6 - 0,6 ) 3,14 ( 2,7 - 3,5 ) >60 3,58
A15 0,67 0,18 0,01 0,14 Glycerol 0,5 ( 0,5 - 0,5 ) 0,01 ( 0 - 0 ) 0,01 ( 0 - 0 ) 5,32 ( 5 - 5,6 ) >60 2,42
A16 0,7 0,19 0,07 0,04 PEG 6000 1361 ( 1128 - 1473 ) 4,36 ( 3,7 - 8,8 ) 0,3 ( 0,3 - 0,5 ) 3,49 ( 3,3 - 3,7 ) >60 2,98
A17 0,4 0,2 0,2 0,2 PEG 6000 833 ( 692,9 - 973,9 ) 8,81 ( 8,2 - 9,4 ) 0,69 ( 0,7 - 0,7 ) 7,19 ( 6,7 - 7,7 ) 26 ( 15 - 31 ) 3,58
A18 0,68 0,11 0,11 0,1 PEG 400 23,9 ( 23,33 - 24,54 ) 6,9 ( 6,1 - 7,7 ) 221 ( 187 - 255 ) 5,34 ( 5,3 - 5,4 ) >60 2,6
A19 0,79 0,01 0,01 0,19
Propylene 
glycol 1521 ( 1513 - 1529 ) 16,5 ( 16 - 17 ) 0,88 ( 0,9 - 0,9 )
5,12
( 4,8 - 5,5 )
>60 3,58
A20 0,9 0,03 0,07 0,01 Glycerol 696 ( 696,3 - 696,3 ) 10 ( 10 - 10 ) 1,42 ( 1,4 - 1,4 ) 3,68 ( 3,6 - 3,7 ) 2,54
A21 0,49 0,17 0,18 0,17 PEG 400 0,5 ( 0,5 - 0,5 ) 0,01 ( 0 - 0 ) 0,01 ( 0 - 0 ) 6,28 ( 6,3 - 6,3 ) >60 1,42
A22 0,64 0,2 0,15 0,01
Propylene 
glycol
*
0,47 ( 0,3 - 0,7 ) 49,5 ( 16 - 83 )
4,32
( 4 - 4,6 )
>60 1,98
A23 0,78 0,01 0,2 0,01 PEG 6000 1766 ( 1766 - 1766 ) 11,2 ( 11 - 11 ) 2,08 ( 0,6 - 3,6 ) 2,53 ( 2,5 - 2,6 ) >60 2,84
A24 0,82 0,12 0,02 0,05
Propylene 
glycol
* * * >60 2,42
A25 0,57 0,19 0,23 0,01
Propylene 
glycol
* * * 6,14
( 6,1 - 6,2 )
>60 1,42
A26 0,8 0,01 0,14 0,05
Propylene 
glycol
* * * 4,78
( 4,6 - 4,9 )
>60 1,42
A27 0,58 0,22 0,01 0,2 PEG 6000 1488 ( 1168 - 1543 ) 16,6 ( 13 - 30 ) 0,93 ( 0,9 - 2,3 ) 5,92 ( 5,9 - 5,9 ) 60 ( 19 - 67 ) 3,58
A28 0,59 0,11 0,19 0,12
Propylene 
glycol 0,5 ( 0,5 - 0,5 ) 0,01 ( 0 - 0 ) 0,01 ( 0 - 0 )
*
( - )
>60 1,7
A29 0,6 0,16 0,08 0,16 PEG 400 228 ( 224,4 - 240,5 ) 10,8 ( 11 - 12 ) 11 ( 11 - 13 ) 6,75 ( 6,7 - 6,8 ) >60 3,44
A30 0,7 0,1 0,12 0,08 Glycerol * * * * * 1,68
CPPs CQAs
Young's modulus (Et) 
(Mpa)
Tensile Strength 
(σB)
 (Mpa)
Elongation (εB) 
(%)
Residual water 
content
 (%)
Disintegration 
time 
(s)
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Table 24 - Ranges of CPPs (amount of PVAc, PVA, Triethyl citrate, NaCMC, Mannitol, Citric acid, Sucralose, MAG, Flavour and colourant) for taste masking optimization formulations. The amount of each compound is presented as rational values where 
the sum of the components is 1. The range used to delineate the design is present on the excipients row. The missing values are identified (*) and are related with the poor films characteristics that did not allowed to perform some valid tests. The value 
in the CQAs column corresponds to the median value introduced in the software to perform the analysis.  
Run
PVAc PVA 
Triethyl 
citrate 
NaCMC Mannitol 
Citric 
acid 
Sucralose MAG Flavour Colorant 
Global 
evaluation
 (1-5)
Range 
tested
0,45-
0,60
0,1-
0,20
0-0,1
0,05-
0,20
0-0,10
0-
0,20
0-0,05
0-
0,05
0-0,05 0-0,005
B1 0,435 0,2 0,174 0,196 - - - - - - 577,3 ( 484 - 655 ) 7,04 ( 6,07 - 8,13 ) 9,53 ( 9,14 - 14,7 ) 6,88 ( 6,42 - 7,33 ) 5 ( 5 - 5 ) 88,01 ( 87,5 - 90,2 ) 0 4
B2 0,552 0,17 0,107 0,171 - - - - - - 678,5 ( 667 - 682 ) 9,8 ( 7,71 - 12,9 ) 45,8 ( 44,6 - 49,3 ) 5,47 ( 5,14 - 5,8 ) 7 ( 7 - 7 ) 69,05 ( 68,6 - 75 ) 0,2 ( 0 - 0,2 ) 3,6
B3 0,46 0,19 0,163 0,188 - - - - - - 743 ( 712 - 972 ) 14,6 ( 11,8 - 16,3 ) 2,42 ( 2,29 - 2,47 ) 5,01 ( 5,01 - 5,01 ) 6,5 ( 6 - 7 ) 54,41 ( 53,1 - 56,5 ) 0 4,3
B4 0,426 0,21 - 0,199 - 0,17 - - - - 1401 ( 1337 - 1465 ) 13,6 ( 4,49 - 22,6 ) 0,68 ( 0,27 - 1,09 ) 3,22 ( 3,14 - 3,3 ) 26 ( 25 - 26 ) * 2,8 ( 2,2 - 3,4 ) 3,7
B5 0,543 0,15 - 0,201 - 0,11 - - - - 2285 ( 2244 - 2327 ) 17 ( 14,5 - 19,4 ) 0,63 ( 0,55 - 0,71 ) 4,49 ( 3,77 - 5,19 ) 25 ( 25 - 25 ) * 2,2 ( 2,2 - 2,4 ) 3,7
B6 0,587 0,16 - 0,201 - 0,05 - - - - 2537 ( 2463 - 2610 ) 13,1 ( 7,41 - 18,7 ) 0,47 ( 0,28 - 0,66 ) 5,27 ( 4,88 - 7,06 ) 19 ( 16 - 21 ) * 2,2 ( 2,2 - 2,8 ) 3,7
B7 0,498 0,15 0,056 0,149 0,085 0,05 - 0,01 - - 73,1 ( 69,1 - 81,8 ) 8,69 ( 7,61 - 8,74 ) 42,6 ( 42,2 - 50,4 ) 3,91 ( 3,87 - 3,95 ) 17 ( 17 - 17 ) 63,44 ( 62,3 - 63,7 ) 1,8 ( 1,8 - 2,6 ) 3,6
B8 0,528 0,17 0,069 0,174 - 0,06 - - - - 457,4 ( 435 - 460 ) 10,1 ( 7,99 - 10,1 ) 25,7 ( 16,9 - 32,1 ) 4,66 ( 4,07 - 5,25 ) 14 ( 13 - 14 ) 59,48 ( 58,1 - 59,9 ) 1 ( 1 - 2,6 ) 1,5
B9 0,491 0,15 0,056 0,174 0,058 0,01 - 0,01 - - 488,3 ( 383 - 515 ) 16 ( 12,3 - 17,6 ) 15,3 ( 14 - 25,5 ) 3,97 ( 3,59 - 4,34 ) 13 ( 12 - 14 ) * 2,4 ( 2,4 - 3,4 ) 2,3
B10 0,529 0,15 0,072 0,144 0,058 0,02 - 0,03 - - 274,8 ( 266 - 354 ) 8,47 ( 7,91 - 9,09 ) 21,4 ( 16,8 - 22,4 ) 4,54 ( 4,34 - 4,73 ) 5,5 ( 5 - 6 ) 68,02 ( 64,9 - 68,2 ) 2,2 ( 2,2 - 2,2 ) 3,2
B11 0,553 0,15 0,071 0,151 0,04 0,01 - 0,01 - - 172,3 ( 148 - 197 ) 4,75 ( 3,44 - 6,05 ) 61,2 ( 54,1 - 68,3 ) 4,41 ( 4,25 - 4,56 ) 7 ( 7 - 13 ) 59,36 ( 59,3 - 60,4 ) 1 ( 1 - 2,8 ) 4,3
B12 0,494 0,16 0,052 0,133 0,049 0,01 0,02 0,01 0,043 0,005 824,1 ( 684 - 952 ) 20,4 ( 14,4 - 21,6 ) 24,8 ( 21,5 - 25,9 ) 5,33 ( 5,22 - 5,44 ) 4 ( 4 - 4 ) 65,08 ( 59,6 - 65,8 ) 4,4 ( 4 - 4,4 ) 4,6
B13 0,511 0,15 0,05 0,147 0,026 0,01 0,039 0,01 0,051 0,005 897,3 ( 692 - 1049 ) 16,9 ( 16,2 - 25,8 ) 12,7 ( 7,06 - 17,1 ) 4,94 ( 4,9 - 4,98 ) 3,5 ( 3 - 4 ) 67,37 ( 63 - 67,5 ) 4 ( 3 - 4 ) 4,6
B14 0,477 0,13 0,099 0,143 0,048 0,01 0,041 0,01 0,039 0,005 607,7 ( 551 - 724 ) 11,5 ( 4,19 - 11,8 ) 28,2 ( 25,1 - 37,8 ) 5,23 ( 5,18 - 5,28 ) 6,5 ( 5 - 8 ) 61,84 ( 61,7 - 62,4 ) 3,2 ( 3,2 - 3,2 ) 4,6
B15 0,544 0,14 0,017 0,144 0,048 0,05 - - 0,048 0,005 629,6 ( 345 - 914 ) 24,6 ( 24,6 - 24,6 ) 10,4 ( 9,76 - 11,1 ) 4,02 ( 3,9 - 4,13 ) 29 ( 23 - 34,4 ) 65,93 ( 65,4 - 68,6 ) 3 ( 3 - 3 ) 4,3
B16 0,49 0,15 0,103 0,082 0,051 0,05 0,04 0,01 - - 154,6 ( 110 - 199 ) 10 ( 9,32 - 10,7 ) 106 ( 104 - 108 ) 3,97 ( 3,75 - 4,18 ) 21 ( 18 - 22,8 ) 64,78 ( 63,7 - 65,7 ) 2 ( 1,8 - 2 ) 3,9
B17 0,563 0,15 0,104 0,084 0,049 - - 0,01 0,049 - 206,4 ( 130 - 256 ) 6,34 ( 1,98 - 7 ) 61,1 ( 37,6 - 101 ) 3,82 ( 3,49 - 4,78 ) 20 ( 15 - 24,8 ) 56,8 ( 56 - 58,7 ) 0,8 ( 0,4 - 0,8 ) 3,6
B18 0,492 0,15 0,083 0,147 - - 0,04 0,01 0,05 0,005 748,5 ( 660 - 837 ) 3,92 ( 3,59 - 4,25 ) 23,4 ( 23,3 - 23,4 ) 4,18 ( 4,07 - 4,29 ) 9,7 ( 9,3 - 10,1 ) 59,98 ( 59,4 - 60 ) 2,6 ( 2,4 - 2,6 ) 4,6
B19 0,45 0,14 0,094 0,138 0,047 0,05 0,037 - 0,047 - 405,6 ( 388 - 424 ) 10,1 ( 7,63 - 12,5 ) 22,6 ( 19,8 - 25,3 ) 2,76 ( 2,6 - 2,91 ) 13 ( 13 - 13,3 ) 65,82 ( 62,3 - 69,9 ) 3,8 ( 2,6 - 3,8 ) 4,6
B20 0,6 0,14 0,012 0,149 - 0,05 0,04 0,01 - - 2282 ( 2282 - 2282 ) 12,4 ( 12,4 - 12,4 ) 0,48 ( 0,48 - 0,48 ) 3,28 ( 3,11 - 3,45 ) 35 ( 31 - 38,4 ) 56,53 ( 56 - 58,1 ) 3,2 ( 3,2 - 3,2 ) 3,7
B21 0,599 0,09 0,012 0,068 0,05 0,05 0,04 0,01 0,05 0,005 421,5 ( 341 - 502 ) 6,42 ( 4,39 - 8,45 ) 0,6 ( 0,48 - 0,71 ) 3,93 ( 3,91 - 3,95 ) 22 ( 20 - 24,8 ) 61,86 ( 60,4 - 64,1 ) 3,8 ( 3,8 - 4 ) 3,7
B22 0,599 0,15 0,1 0,069 - 0,05 - - - - 292,4 ( 277 - 355 ) 3,54 ( 2,55 - 7,22 ) 81,9 ( 71,6 - 85,4 ) 3,1 ( 3,03 - 3,16 ) 17 ( 16 - 18,7 ) 58,84 ( 56,2 - 59,4 ) 1 ( 0,8 - 1 ) 4,3
B23 0,599 0,07 0,013 0,145 0,051 - 0,04 - 0,05 - 901,4 ( 870 - 933 ) 23,4 ( 22,2 - 24,6 ) 6,8 ( 5,89 - 7,7 ) 4,26 ( 4,15 - 4,36 ) 46 ( 25 - 100 ) 77,54 ( 72,4 - 78 ) 3,6 ( 2,8 - 3,6 ) 4,3
B24 0,6 0,07 0,105 0,08 - 0,05 0,039 0,01 0,049 0,005 438,9 ( 415 - 463 ) 2,89 ( 2,06 - 3,71 ) 59,5 ( 37,7 - 81,2 ) 3,02 ( 2,65 - 3,92 ) 30 ( 30 - 31,2 ) 57,83 ( 56,2 - 59,2 ) 2,8 ( 2,2 - 3,6 ) 4,3
B25 0,582 0,15 0,106 0,067 0,05 - 0,04 - - 0,005 286,5 ( 218 - 292 ) 3,35 ( 3,24 - 3,64 ) 94,4 ( 93,6 - 111 ) 3,31 ( 3,03 - 3,59 ) 15 ( 12 - 17,6 ) 59,43 ( 58,7 - 62,1 ) 2,4 ( 0,8 - 2,6 ) 4,3
B26 0,589 0,07 0,106 0,145 0,05 - - 0,01 - 0,004 330,2 ( 310 - 339 ) 2,44 ( 2,36 - 2,49 ) 38,7 ( 23,9 - 41,7 ) 3,73 ( 3,33 - 4,13 ) 17 ( 17 - 17,5 ) 63,72 ( 62,5 - 65,6 ) 1,8 ( 1,8 - 2,4 ) 3,6
B27 0,432 0,15 - 0,145 0,095 0,09 0,039 0,05 - 0,005 585,9 ( 568 - 604 ) 9,44 ( 9,38 - 9,5 ) 1,12 ( 1,05 - 1,18 ) 5,45 ( 5,3 - 5,59 ) 29 ( 20 - 37 ) 79,84 ( 79,8 - 79,8 ) * 2,7
B28 0,483 0,18 - 0,075 0,107 0,05 - 0,05 0,054 - 528,6 ( 514 - 543 ) 4,91 ( 4,27 - 5,55 ) 0,66 ( 0,56 - 0,75 ) * * * * 1,7
B29 0,554 0,16 - 0,142 0,093 - - 0,05 - 0,005 * * * * * * * 1,5
B30 0,624 0,16 0,019 0,131 - - - 0,01 0,054 0,005 627,2 ( 601 - 668 ) 14,8 ( 11,1 - 16,8 ) 34,1 ( 30,9 - 39,7 ) 5,52 ( 5,39 - 5,64 ) 28 ( 25 - 30 ) 63,78 ( 63,7 - 65,2 ) * 3,6
B31 0,638 0,19 0,006 0,051 - 0,11 - 0,01 - - 420,4 ( 364 - 477 ) 7,15 ( 3,42 - 10,9 ) 0,74 ( 0,46 - 1,01 ) * * * * 2,7
B32 0,64 0,07 0,006 0,071 0,038 0,11 0,043 0,01 0,016 - 270,2 ( 238 - 302 ) 7,78 ( 5,68 - 9,87 ) 19,8 ( 1,37 - 38,2 ) 4,39 ( 4,38 - 4,4 ) 100 ( 100 - 100 ) 58,45 ( 56,6 - 59,2 ) * 2,7
B33 0,537 0,05 0,058 0,15 0,099 - 0,049 0,05 - 0,005 231,2 ( 187 - 255 ) 11,9 ( 11,3 - 12,9 ) 42,1 ( 35 - 55,1 ) 5,32 ( 4,83 - 6,19 ) 6 ( 6 - 6 ) 60,7 ( 59,4 - 63,2 ) * 3,6
B34 0,567 0,05 0,095 0,145 - - 0,048 0,05 0,048 - 439,7 ( 426 - 447 ) 3,92 ( 2,84 - 5,88 ) 33,7 ( 30,8 - 36,4 ) 5,82 ( 5,72 - 5,91 ) 9 ( 9 - 9 ) 61,66 ( 60,7 - 61,7 ) * 3
B35 0,595 0,17 0,035 0,05 - - 0,048 0,05 0,05 - 633,3 ( 631 - 635 ) 10 ( 4,9 - 15,1 ) 44,9 ( 23,9 - 66 ) 4,05 ( 4,04 - 4,06 ) 20 ( 18 - 21 ) 61,66 ( 61,5 - 61,8 ) * 4
B36 0,456 0,17 0,036 0,055 0,1 0,08 - 0,05 0,05 0,005 * * * 4,79 ( 4,73 - 4,85 ) 7,5 ( 6 - 9 ) 68,36 ( 64,6 - 69,4 ) * 3,7
B37 0,452 0,05 0,082 0,139 0,099 0,07 0,05 - 0,05 - 91,3 ( 90,7 - 91,9 ) 9,33 ( 9,25 - 9,41 ) 93,3 ( 89,4 - 97,1 ) 4,18 ( 4,09 - 4,27 ) 10 ( 9 - 11 ) 58,08 ( 55,4 - 59,6 ) * 3,6
B38 0,504 0,21 0,089 0,044 0,085 0,06 - - - 0,004 203,5 ( 154 - 253 ) 3,08 ( 2,83 - 3,33 ) 60,7 ( 56,2 - 65,1 ) 2,41 ( 2,31 - 2,5 ) 100 ( 100 - 100 ) 62,78 ( 62,5 - 64,7 ) * 4,6
B39 0,443 0,06 0,1 0,15 0,099 0,05 0,049 0,01 0,049 - 172,4 ( 161 - 180 ) 9,78 ( 9,34 - 10,1 ) 50,8 ( 47,6 - 53,7 ) 4,55 ( 4,3 - 4,79 ) 7,5 ( 6 - 9 ) 60,5 ( 60,2 - 63,2 ) * 3,9
B40 0,467 0,18 0,048 0,164 - 0,08 0,052 0,01 - 0,005 1054 ( 1002 - 1114 ) 28,3 ( 27,2 - 30,7 ) 6,78 ( 5,12 - 9,32 ) 3,55 ( 3,39 - 3,7 ) 16 ( 12 - 19 ) 64,51 ( 60,5 - 64,9 ) * 3,6
Organoleptic 
evaluation
 (1-5)
CQAs
Disintegration 
time 
(s)
Contact angle 
(⁰)
CPPs
Young's modulus (Et) 
(Mpa)
Tensile Strength (σB)
 (Mpa)
Elongation (εB) 
(%)
Residual water 
content
 (%)
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Table 25 - Ranges of CPPs (amount of PVAc, PVA, Triethyl citrate, NaCMC, Mannitol, Citric acid and Pramipexole) for formulations with drug substance incorporated. The amount of each compound is presented as rational values where the sum of 
the components is 1. The range used to delineate the design is present on the excipients row. The missing values are identifi ed (*) and are related with the poor films characteristics that did not allowed to perform some valid tests. The 
value in the CQAs column corresponds to the median value introduced in the software to perform the analysis.  
Run
PVAc PVA
Triethyl 
citrate 
NaCMC Mannitol Citric acid Pramipexole 
Global 
evaluation
 (1-5)
Range 
tested
0,5-0,6 0,1-0,17
0,025-
0,075
0,1-0,15 0-0,06 0,01-0,05 0,004-0,5
C1 0,593 0,099 0,045 0,099 0,03 0,05 0,084 70,8 ( 68 - 73,54 ) 5,55 ( 4,2 - 6,9 ) 37,3 ( 34,6 - 40,1 ) 4,87 ( 4,81 - 4,92 ) 34 ( 33 - 35 ) 2,54
C2 0,6 0,102 0,03 0,139 0,05 0,05 0,03 260 ( 246 - 274,8 ) 14,7 ( 14 - 16 ) 22,1 ( 12,9 - 31,4 ) 4,45 ( 4,2 - 4,7 ) 39 ( 27 - 40 ) 2,96
C3 0,597 0,151 0,048 0,1 0,05 0,01 0,045 102 ( 89 - 104,2 ) 10,2 ( 7,7 - 10 ) 61,4 ( 47 - 77,1 ) 4,85 ( 4,51 - 5,92 ) 11 ( 10 - 25 ) 3,72
C4 0,526 0,131 0,031 0,141 0,031 0,01 0,131 260 ( 223 - 296,3 ) 12,9 ( 12 - 14 ) 8,9 ( 4,14 - 13,7 ) 5,76 ( 5,57 - 5,95 ) 24 ( 24 - 24 ) 3,52
C5 0,531 0,131 0,063 0,135 0,065 0,045 0,031 89,4 ( 80,4 - 98,44 ) 10,1 ( 9,6 - 11 ) 42,6 ( 40,3 - 44,9 ) 4,75 ( 4,45 - 5,04 ) 12,5 ( 12 - 13 ) 4,56
C6 0,536 0,141 0,075 0,138 0,031 0,046 0,032 134 ( 119 - 149,2 ) 4,94 ( 3,8 - 6 ) 43,7 ( 39,2 - 48,2 ) 4,03 ( 4,03 - 4,03 ) 21 ( 18 - 24 ) 3,58
C7 0,509 0,1 0,03 0,1 0,03 0,05 0,181 * * * * * 2,66
C8 0,598 0,149 0,03 0,102 0,03 0,01 0,081 193 ( 191 - 194,5 ) 10,2 ( 9 - 11 ) 31,2 ( 28,1 - 34,4 ) * * 2,52
C9 0,53 0,132 0,062 0,135 0,064 0,045 0,032 51,5 ( 50,5 - 52,48 ) 8 ( 6,4 - 9,6 ) 90,1 ( 69,6 - 111 ) 4,69 ( 4,68 - 4,7 ) 17 ( 15 - 19 ) 2,84
C10 0,553 0,091 0,042 0,092 0,028 0,009 0,186 38,2 ( 37,6 - 38,8 ) 3,68 ( 3,4 - 3,9 ) 65,6 ( 64,3 - 66,8 ) 6,75 ( 6,74 - 6,76 ) 13,5 ( 11 - 16 ) 3,58
C11 0,574 0,149 0,045 0,141 0,03 0,05 0,01 211 ( 209 - 214,1 ) 10,8 ( 9,7 - 12 ) 34,8 ( 33,1 - 36,6 ) 4,04 ( 3,81 - 4,26 ) 15 ( 10 - 22 ) 4,28
C12 0,511 0,149 0,03 0,1 0,05 0,05 0,11 90 ( 74,8 - 105,2 ) 8,43 ( 7,6 - 9,3 ) 41,9 ( 38,7 - 45,1 ) 5 ( 4,84 - 6,08 ) 12,5 ( 11 - 14 ) 4,56
C13 0,556 0,109 0,039 0,153 0,055 0,011 0,077 123 ( 103 - 125,6 ) 8,85 ( 8,7 - 9,8 ) 21,1 ( 19,5 - 33,9 ) 4,68 ( 4,47 - 4,89 ) 17,5 ( 16 - 19 ) 2,98
C14 0,569 0,15 0,046 0,142 0,045 0,045 0,004 131 ( 106 - 131,9 ) 9 ( 8,1 - 9,2 ) 43,4 ( 39,6 - 46,4 ) 4,43 ( 4,35 - 4,5 ) 13,5 ( 11 - 16 ) 3,44
C15 0,275 0,075 0,025 0,075 0,025 0,025 0,5 * * * * * 1,54
C16 0,535 0,146 0,045 0,151 0,045 0,045 0,033 103 ( 102 - 109,1 ) 8,91 ( 8,1 - 9,1 ) 20 ( 14,8 - 20,1 ) 4,56 ( 4,39 - 4,73 ) 8 ( 7 - 9 ) 3,3
C17 0,548 0,147 0,046 0,153 0,045 0,045 0,017 115 ( 96,5 - 122,4 ) 8,08 ( 7,9 - 8,9 ) 19,7 ( 19,6 - 25,7 ) 5,88 ( 5,67 - 6,08 ) 6 ( 5 - 7 ) 3,44
C18 0,513 0,148 0,047 0,152 0,045 0,045 0,05 87,4 ( 70,4 - 94,54 ) 7,45 ( 6,3 - 8,2 ) 23,6 ( 17 - 27,5 ) 5,78 ( 5,57 - 5,98 ) 7 ( 7 - 7 ) 3,58
C19 0,514 0,15 0,044 0,151 0,045 0,045 0,05 67,4 ( 160 - 169,7 ) 7,33 ( 7,5 - 7,6 ) 26,2 ( 28,4 - 34,6 ) 5,43 ( 5,4 - 6,19 ) 8 ( 14 - 15 ) 4,14
C20 0,562 0,149 0,046 0,15 - 0,045 0,05 165 ( 202 - 221 ) 7,56 ( 8,6 - 10 ) 31,5 ( 13,9 - 19,5 ) 5,45 ( 5,2 - 5,51 ) 14,5 ( 9 - 13 ) 3,58
C21 0,557 0,151 0,042 0,15 - 0,05 0,05 218 ( 215 - 221,1 ) 10 ( 8,3 - 12 ) 16,3 ( 10,3 - 14,7 ) 5,36 ( 6,04 - 6,28 ) 11 ( 4 - 6 ) 3,12
C22 0,534 0,168 0,046 0,153 - 0,05 0,05 218 ( 63,9 - 82,52 ) 10,3 ( 6,4 - 7,8 ) 12,5 ( 23,1 - 29,3 ) 6,16 ( 5,14 - 5,72 ) 5 ( 8 - 8 ) 3,3
C23 0,55 0,155 0,041 0,155 - 0,05 0,05 208 ( 200 - 212,5 ) 12 ( 10 - 12 ) 20,6 ( 10,2 - 20,7 ) 5,62 ( 5,59 - 5,65 ) 10,5 ( 8 - 13 ) 3,58
CPPs CQAs
Disintegration 
time
 (s)
Residual water 
content
 (%)
Elongation (εB) 
(%)
Tensile Strength 
(σB) 
(Mpa)
Young's modulus 
(Et)
 (Mpa)
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The components used in each experiment are presented in its rational value being their sum 
always equal to 1. The oral films were prepared by solvent casting and tested with the 
appropriate techniques to evaluate the CQAs (target vales on Table 26). The obtained results 
were evaluated according to the CQAs limits previously defined. The global and organoleptic 
evaluations, as well as the contact angle, were added and the limits were stablished 
according to the test panel used and literature reference (Vogler, 1998). 
 
Table 26 - Critical Quality attributes acceptance criteria defined for the initial screening studies. * - 
Not applicable in all the optimization design. 
σB (MPa) 15-35
εB (%) 4-50
Et (MPa) 100-1500
Residual H2O content (%) [3-6%]
Disintegration time (s) <30
Global evaluation (1-5) >3,5
Organoleptic evaluation (1-5)* >3,5
Contact Angle (⁰)* >65⁰
Target values
 
 
The JMP screening platform was used to analyse the data of the set of experiments designed 
before. The models selection was based on their statistical significance, p-value and RSquare 
analysis. The p-value was obtained through the analysis of variance (ANOVA) and allows 
evaluating the whole model. Significance probabilities of 0.05 or less were considered to be 
an evidence that there is at least one significant regression factor in the model (Institute, 
2012). In turn, the RSquare (R2) estimates the proportion of the variation in the response 
around the mean. Additionally, the Rsquare Adj was also considered because it corresponds 
to the adjustment of R2 to make it more comparable with other models with different 
numbers of parameters (Institute, 2012). The RSquare is also the square of the correlation 
between the actual and predicted response. If R2 = 1 (errors are all zero) a perfect fit is 
observed, whereas R2 = 0 occurs when the response prediction of the model is not different 
from the mean response. Nonetheless, a good model should present a low p-value (lower 
than 0.05 for 95% of confidence), a RSquare closer to 1 and an RSquare Adj similar to the 
RSquare (Institute, 2012). 
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The analysis of the models should be carefully performed considering the statistical data 
obtained for the parameters presented above. Theoretically, models with very low p-value 
and high and similar Rsquare are very robust models (Figures 38, 39 and 40 with green 
border evaluation), whereas higher p-values and low RSquare models indicate that more 
caution should be taken in their analysis (Figures 38, 39 and 40 with yellow and red boarder 
evaluation). In addition, the results should only be considered reliable if within the real range 
studied (Tables 23, 24 and 25, first row).  
The model selection lead to the creation of prediction profilers that show graphically the 
influence of each excipient on the CQAs tested (Figures 38, 39 and 40). The prediction 
profiler is a simplified way of representing the response surface and verifies the settings that 
may origin the best response target (see Figures 38, 39 and 40). The individual plots in each 
row of plots show the prediction traces for each CPP. This prediction trace shows the 
predictable variance of the response according to the change in each variable while the 
others are constant (SAS Institute, 2013). Therefore, parallel lines to the x-axis represent the 
absence of parameter’s influence in the correspondent y-variable (response). On the other 
hand, nonlinear traces indicate the influence of the x-variable in the response that may be 
more or less complex depending on the shape of the line. The profile visualization presented 
in Figures 38, 39 and 40 is related with the defined limits for CQAs and / or with the range 
that allows to obtain better curve variations. 
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3.2. Screening of possible alternative plasticizers  
Although the optimal formulation was obtained using TEC in previous work, its bitter flavour 
was considered and screening tests with alternative plasticizers were performed (Shimizu et 
al., 2003; Taylor and Linforth, 2009). The tested plasticizers were chosen based on the 
previous knowledge that they would not present unpleasant taste: glycerol(Koseki et al., 
2004), polyethylene glycols (Clariant, 2014) and propylene glycol (Todd, 1992). 
Approximately 60 test solutions were prepared and the results are summarized in the 
profiler graph (Figure 38).  
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Figure 38 - Prediction Profiler of different types of plasticizers. It is represented the effect of each CPP in the CQAs. Parallel lines to the x-axis mean that there is no effect of the 
parameter on the evaluated attribute. The significance of the selected model for each CQA evaluated is summarized and presented in the correspondent row. The border colour 
of each summary is related with the model significance. Green solid border means good fit models, with very low p value (<0.01) and high (>0.6) and proximal Rsquare; Yellow 
dashed border means reasonable fit models, with low p value (<0.05) and medium Rsquare values (0.4-0.6); Red square dotted border means poor models, with no significant 
p-value (>0.05) and very low Rsquare values. The vertical axis present the evaluated properties in function of the amount and type of component tested in each formulation 
(horizontal axis). 
Model ANOVA RSquare 
RSquare 
Adj 
Et p<0.0001 0.660 0.498 
σB p=0.0008 0.673 0.464 
εB p<0.0137 0.883 0.570 
% H2O p<0.0001 0.885 0.822 
Disintegratio
n time 
p<0.0001 0.907 0.828 
Global 
evaluation 
p=0.0014 0.558 0.379 
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The majority of the effects obtained do not have a linear trend and it was possible to obtain 
essentially good models (Figure 38 green border summary). However, two weaker models, 
that should be carefully analysed (Elongation and Global evaluation, Figure 38 yellow 
summary), were also obtained.  
Briefly, an overall summary of the model is presented in Table 27, column 1.  
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Table 27 - Summary of the influence of the components on the different testes performed. Only the most evident influences are presented. 
 
Plasticizers evaluation Organoleptic optimization Pramipexole incorporation
↑PVAc from 65% (%w/w per
film)
↓TEC ↑PVAc
↓ Plasticizer ↑NaCMC ↓PVA
Choose PEG 600 or PEG
1000
↓Mannitol ↓TEC
↑NaCMC from 12% (%w/w
per fi lm)
↓Citric Acid ↑NaCMC 
↑Sucralose ↓Pramipexole
↓PVAc ↑TEC ↑PVAc
↓PVA ↓NaCMC ↓TEC
↓ Plasticizer ↑Mannitol ↑NaCMC 
Choose PEG 600 or PEG
1000
↓Flavor
↑Citric acid from 3% (%w/w
per fi lm)
↓Colorant
↓Pramipexole up to
20%(%w/w per fi lm)
↑PVAc ↓PVAc ↑PVAc
↓PVA ↑PVA ↑TEC
↑ Plasticizer ↑TEC ↓NaCMC 
Choose PEG 400 or PG ↑NaCMC ↑Mannitol
↑NaCMC ↑Sucralose ↓Citric acid
↑Flavor up to 3% (%w/w per
film)
↓Pramipexole 
↓PVAc ↓PVAc ↓PVAc 
↑PVA ↑PVA ↑PVA
Choose Glycerol, PEG 400 or 
PEG 100
↓TEC ↓TEC
↑NaCMC ↑NaCMC ↑Mannitol 
↑Sucralose ↑Pramipexole
↑MAG
↓PVAc ↓PVAc ↓PVAc 
↑PVA ↑PVA ↑PVA
Choose PEG 1000 or TEC ↑TEC ↑TEC
↑NaCMC ↑NaCMC ↑NaCMC
↓Citric acid ↑Mannitol
↑MAG ↑Citric acid
↑PVA ↓PVAc ↓PVAc 
Choose PEG 1000 or TEC ↑PVA ↑PVA
↑TEC ↑ Mannitol 
↑Sucralose
↓Pramipexole from 20%(%w/w
per fi lm)
↑Colorant up to 0.03% (%w/w
per fi lm)
↓TEC 
↑NaCMC
↑Mannitol
↑Citric acid
↑Sucralose up to 3% (%w/w
per fi lm)
↑MAG
↑Flavor
↑Colorant
↑PVAc from 52.2% (%w/w per
film)
↑PVA from 10% (%w/w per fi lm)
↓Citric acid
Better appearance
Stiffer films 
(higher Et)
Resilient films
 (higher σB)
Deformable films
 (higher εB)
More hygroscopic
(Higher residual water
retention)
Fast disintegration
Better organoleptic
characteristics
- -
More Hydrophobic 
(higher contact angle)
- -
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Figure 39 - Plasticizer type influence in the studied CQAs. The influence of the plasticizer may be visualized based on the two main components of the formulation, 
PVA and PVAc. The grade of colours range from the desirable (green) to the unsuitable (red) effect in each CQA evaluated. Only the coloured area represents the 
range of the CPPs studied. The white zone is out of range values that were not studied. 
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The effect of each plasticizer was also analysed through counter plots (Figure 39). In order 
to facilitate the analyses only the two main components of the formulation were considered 
(Figure 39).  
The grade of colours is related with the CQAs limits defined (Table 26). The green area 
corresponds to the desirable zone, yellow-orange area is related with values that are close 
to the limits and the red zone is out of limit range. 
In general, almost every plasticizer allows obtaining acceptable values for the majority of the 
CQAs tested, except for disintegration time. Only TEC, PG and PEG 6000 allow to afford ODF 
that quickly disintegrate (in less than 30 seconds). Nevertheless, a more suitable operational 
range was obtained with TEC (no red areas, Figure 39), whereas with PEG 6000 there is an 
elevated risk to be out of the limits (small yellow-orange area, when PVAc<50% and PVA> 
15%, Figure 39). 
It is also possible to retrieve that both glycerol and PEG 400 are the worst plasticizers for this 
system according to the outlined CQAs. This conclusion was taken based on the large and 
predominant red areas in Figure 39. 
Briefly, the plasticizer effect for each plasticizer tested that allows obtaining green areas 
based on PVAc-PVA proportion within the limits studied (coloured area) are summarized in 
Table 28. 
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Table 28 - Desirable zones (green areas) obtained from the plasticization effect on PVAc-PVA system. 
 
Green areas
Glycerol: PVAc > 85% and PVA < 5%
PEG 6000: 40% < PVAc < 90% and 5% <PVA < 20%
PEG 1000: 75% > PVAc > 90% and PVA < 10%
1,2 – Propanediol (Propilenoglicol): 40% < PVAc < 50% and 30% < PVA
< 40%; plus 75% < PVAc < 80% and PVA < 10%
PEG 6000: 55% < PVAc < 60% and PVA > 20% plus 70% < PVAc < 80%
and PVA < 5%
PEG 1000: PVAc < 80% and PVA < 10%
1,2 – Propanediol (Propilenoglicol): 30% < PVAc < 50% and PVA > 30%
Triethyl citrate: 30% < PVAc < 40% and PVA > 25%
PEG 400: Diffuse zones when PVAc < 60% and PVA > 10% with very
narrow operational ranges
PEG 6000: 50% < PVAc < 70% and 8% < PVA < 18%
PEG 1000: PVAc < 80% and PVA > 5% plus PVAc > 80% and 2,5% < PVA <
5%
1,2 – Propanediol (Propilenoglicol): Diffuse zones within all the range
evaluated, but with very narrow operational ranges
Triethyl citrate: Diffuse zones in all  PVA range when PVAc < 60%
Glycerol: 75% < PVAc < 90% and PVA > 5%
PEG 400: 70% < PVAc < 82,5% and 5% < PVA < 12,5%
PEG 6000: 65% < PVAc < 90% and 5% < PVA < 20%
PEG 1000: 75% < PVAc < 90% and 5% < PVA < 20%
1,2 – Propanediol (Propilenoglicol): 65% < PVAc < 90% and 5% < PVA <
40%
Triethyl citrate: 45% < PVAc < 70% and 10% < PVA < 35%
1,2 – Propanediol (Propilenoglicol): 35% < PVAc < 55% and PVA > 40%
Triethyl citrate: PVAc < 50% and PVA > 25%
Young’s modulus
Elongation
Residual water content
Disintegration time
Tensile Strength
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3.3. Optimization complexes to ameliorate the 
organoleptic characteristics 
Another important goal of this work concerned the development of a formulation with a 
pleasant taste. For that purpose, additional screening tests were performed with specific 
sweeteners and flavours. 
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Figure 40 - Prediction Profiler of different sweeteners / flavours for taste masking. It is represented the effect of each CPP in the CQAs. Parallel lines to the x-axis mean that there is no effect of the parameter on the evaluated attribute. The significance of the 
selected model for each CQA evaluated is summarized and presented in the correspondent row. The border colour of each summary is related with the model significance. Green border means good fit models, with very low p value (<0.01) and high (>0.6) and 
proximal Rsquare; Yellow border means reasonable fit models, with low p value (<0.05) and medium Rsquare values (0.4-0.6); Red border means poor models, with no significant p-value (>0.05) and very low Rsquare values. The vertical axis present the evaluated 
properties in function of the amount and type of component tested in each formulation (horizontal axis).
Model ANOVA RSquare RSquare Adj 
Et p<0.0001 0.789 0.713 
σB p=0.001 0.711 0.542 
εB p<0.0001 0.845 0.745 
% H2O p=0.0022 0.662 0.492 
Disintegration 
time 
p=0.008 0.641 0.502 
Global 
evaluation 
p=0.010 0.618 0.405 
Oraganoleptic 
evaluation 
p<0.0001 0.946 0.910 
Contact angle p=0.0405 0.453 0.270 
 270 
The majority of the models present a linear profile and in general are good models, except 
for the contact angle (Figure 40). However, despite the relatively moderate RSquare, the 
model is still statistically significant, since the possibility of 45% of the response effect 
observed not being by chance remains (Figure 40). The models for the other CQAs are 
relatively robust, with very low p-values and moderate to high RSquare values.  
A general graphical analysis of the models are presented in Table 27 column 2. 
 
3.4. Incorporation in the ODF of a drug used in the 
treatment of Parkinson’s disease (PD) 
It was verified previously that an ODF formulation with suitable organoleptic characteristics 
was possible to achieve with the PVAc-NaCMC-PVA-triethyl citrate system when a taste 
masking complex is incorporated. The suitability of this system to incorporate a drug 
substance was also evaluated. 
Several formulations were tested and the results are summarized in a profiler graph (Figure 
41).
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Figure 41 - Prediction Profiler of PD drug loaded films. It is presented the effect of each CPP in the CQAs. Parallel lines to the x-axis mean that there is no effect of the parameter on the evaluated attribute. The significance of the selected model for each CQA 
evaluated is summarized and presented in the correspondent row. The border colour of each summary is related with the model significance. Green solid border means good fit models, with very low p value (<0.01) and high (>0.6) and proximal Rsquare; Yellow 
dashed border means reasonable fit models, with low p value (<0.05) and medium Rsquare values (0.4-0.6); Red square dotted border means poor models, with no significant p-value (>0.05) and very low Rsquare values. The vertical axis present the evaluated 
properties in function of the amount and type of component tested in each formulation (horizontal axis). 
Model ANOVA RSquare RSquare Adj 
Et p<0.0001 0.941 0.892 
σB p<0.0001 0.851 0.752 
εB P=0.0082 0.639 0.422 
% H2O p<0.0001 0.921 0.828 
Disintegration 
time 
p<0.0001 0.931 0.900 
Global 
evaluation 
p=0.0014 0.614 0.449 
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The majority of the models obtained are linear and the more peculiar traces are obtained by 
pramipexole influence (Figure 41). All the models obtained were considered good models, 
since the p-value was always low (<0.01) and the RSquare above relatively high (>0,6). 
A general view and effect of each component in the model is presented in Table 27, column 
3. 
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4. Discussion 
 
4.1. Screening of possible alternative plasticizers  
Although an optimal formulation was obtained with TEC in a previous work, its unpleasant 
taste could affect patient compliance (Shimizu et al., 2003; Taylor and Linforth, 2009). 
Therefore, screening tests with other plasticizers were performed in an attempt to find a 
suitable alternative. The tested plasticizers were chosen based on the available references 
that suggested compounds with no unpleasant taste: glycerol (Koseki et al., 2004), 
polyethylene glycols (Clariant, 2014) and propylene glycol (Todd, 1992). 
Sixty test solutions were prepared and the results are summarized in the profiler graph 
(Table 23 and graphically in Figures 38 and 39). It is clear the influence of the type of 
plasticizer in the general properties of the films (Figure 38, 3rd column and Figure 39), as well 
as the amount of plasticizer used (Figure 38, 4th column). According to the CQAs defined, the 
most suitable mechanical properties were obtained with polyethylene glycol of higher 
molecular weight (Mw): PEG 6000 and PEG 1000 (larger green areas in Figure 39). The 
polymeric matrix with these polyethylene glycols are more rigid (higher Young’s modulus) 
are tougher (higher tensile strength) but less deformable (lower Elongation) (Figure 38, 3rd 
column). It should be mentioned that this behaviour is unexpected for a plasticizer (Lim and 
Hoag, 2013). In general, plasticizers are molecules that may interpose between the polymer 
chains allowing them to tilt and rotate freely. This is commonly observed by the achievement 
of films with high elongation, low tensile strength and young’s modulus (Lim and Hoag, 
2013). The high Mw PEGs have a reverse behaviour, which could be justified considering the 
complexity of the system. It is already described that for simpler binary system with 
microcrystalline cellulose or gelatin, the increase of PEGs molecular weight contribute to a 
less efficient plasticizing effect (Cao et al., 2009; Turhan et al., 2001). This effect is explained 
by the decrease of the polar (hydroxyl) groups per mole influenced by the increase non-polar 
substitutes of the PEG skeletal related with the higher Mw. This leads to solubility and 
polarity decrease and consequently to a decrease in the number of hydrogen bound 
interactions and their ability to interpose and interact easily with hydrophilic polymer chains 
(Cao et al., 2009; Turhan et al., 2001). The same authors also refer that low polarity PEGs 
may be easily included in these systems when an interface (e.g. amphiphilic molecule) 
between both is created (Laboulfie et al., 2013). Additionally, the large polymer chains of 
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the high Mw PEGs may also have a block effect that may difficult other polymer-polymer 
interactions (Turhan et al., 2001). 
The PVAc based formulation proposed in this work is mainly hydrophobic, due to the 
hydrophobic nature of the film-forming polymer (PVAc) and represents a significant content 
of the formulation composition. PVAc is known to have an elevated flexibility and plasticity 
(Kolter et al., 2013). Therefore, the inclusion of high Mw PEGs in the PVAc matrices probably 
exert a blocking effect due to the interposition of its long carbonated skeletal between the 
non-polar polymeric chains contributing to increase the matrix rigidity and lack of resilience 
(Figure 38, 3rd column).  
On the other hand, PEG 400, the lower Mw PEG tested in this system, originate matrices 
with very high elongation values (Figure 38, 3rd column). The smaller carbonated skeletal of 
this PEG probably facilitates its penetration between the polymer matrix, leading to a more 
freely chains movement and consequently easier deformable films. This characteristic 
makes the films less suitable to process and/or manufacture. 
Glycerol revealed to be a very weak plasticizer to this system, probably due to its small size 
and hydrophilic nature (Figure 38, 3rd column and Figure 39). In turn, the additional methyl 
groups in the PG backbone seems to be sufficient to increase the non-polar properties of the 
molecule and to ameliorate its plasticizer properties in this hydrophobic polymeric matrix 
(Figure 38, 3rd column and Figure 39). Similarly, the triethyl citrate non-polar groups can also 
easily interpose between the polymeric matrix and origin suitable mechanical properties 
(Figure 38, 3rd column and Figure 39). Additionally, it is described in literature that triethyl 
citrate is one of the most suitable plasticizers for PVAc matrix systems (Kolter et al., 2013).  
The influence of the polymers (PVAc, PVA and NaCMC) in the matrix mechanical properties 
is essentially nonlinear (Figure 38, 1st, 2nd and 5th column). The rigidity of the film tends to 
increase with high PVAc concentration (higher young’s modulus), starting at 65% (% w/w per 
film) (Figure 38, 1st column, 1st row) and decrease with lower concentration of NaCMC in the 
matrix, up to 12,5% (%w/w per film) (Figure 38, 5th column, 1st row). The higher rigidity of 
the samples with higher PVAc concentrations in the polymeric matrix is probably related to 
proportional decrease of the other compounds in the formulation, especially PVA (Figure 38, 
2nd column, 1st row). On the other hand, the initial decrease of the rigidity with NaCMC 
increase may be due the hygroscopic nature of this polymer that enhances the water 
absorption and retention. The water molecules have high affinity for polar and charged 
groups, and when diluted in the macromolecules decrease its intermolecular interactions 
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and increase their free volume. These factors turn the water molecules good plasticizers 
(Blum et al., 2011). On the contrary, saturation of NaCMC groups probably contributes to 
the further increase of the matrix rigidity. The influence of these compounds in the other 
mechanical properties is also complex and somehow difficult to explain (Figure 38, 1st, 2nd 
and 5th column).  
The residual water content decrease is associated with the lower polarity of the tested 
plasticizers, as expected (Figure 38, 4th row). The less polar components are associated with 
lower affinity for water molecules, which may contribute to a decrease in the water 
retention (Blum et al., 2011). According to the chemical structures of the hydrophilic 
plasticizers tested, and their polar groups per mole (mainly hydroxyl groups), glycerol is 
probably the most hygroscopic component followed by propylene glycol, PEG 400, PEG 1000 
and then PEG 6000. Therefore, the residual water content behaviour obtained for the 
different compounds follow the same order, more hygroscopic and polar components 
contribute to retain more water molecules in the polymeric matrix (Figure 38, 4th row and 
Figure 39). Triethyl citrate a lipophilic compound, presents a similar behaviour compared to 
the high Mw PEGs tested regarding water retention in this polymeric matrix, probably due 
to their nonpolar characteristics (Figure 38, 3rd column, 4th row and Figure 39). Glycerol 
presents a limited green area which only occurs when there is a higher concentration of the 
hydrophobic polymer in the composition, at least 85% (%w/w per film). Regarding the other 
plasticizers PEG 6000 has the larger green zone, highlighting its non-hygroscopic properties. 
The residual water content sharply increases with the disintegrant concentration (NaCMC), 
whereas the PVAc concentration origins a sharp decrease (Figure 38, 4th row). This effect is 
easily explained by the nature of the components. The increase of PVAc in the polymeric 
matrix contributes to higher non-polar groups that tend to repel the water, whereas the 
increase of the charged and polar (NaCMC) promote the water adsorption and retention. 
Curiously, regarding the disintegration time, the more hydrophilic plasticizers (Glycerol and 
low Mw PEGs), except PG, contribute to increase this parameter (Figure 38, 5th row). This 
observation may be related with a more efficient ability of the less polar components to 
interpose between the PVAc chains that may contribute to form channels that facilitate the 
water movement and the disruption of the hydrophobic polymeric matrix (Emeje et al., 
2006; Tajrin et al., 2015). Additionally, high Mw PEGs, as PEG 6000, are usually used as 
channeling agents either in hydrophilic or hydrophobic matrices to improve the fast release 
profile (Emeje et al., 2006; Tajrin et al., 2015). The PG may promote easily the disintegration 
compared to glycerol, possibly due to its apolar group, and to PEG 400, probably due to PG 
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lower Mw (PG=76.09 g/mol; PEG400 = 380-420 g/mol) (Rowe et al., 2009) that may ease its 
interposition between the PVAc chains. Nevertheless, only for TEC or PG was possible to 
obtain suitable working zones (green areas, Figure 39). In fact with TEC, the probability of 
being out of the limits (red area, Figure 39) is very low, and may only happen for very high 
PVAc concentrations (> 65% (%w/w per film)). 
The disintegration time is slightly affected by NaCMC and PVA, and both contribute to 
originate fast dissolving films. Moreover, the PVAc augment is related with sharp increase of 
the disintegration time. This result is associated with the high concentration of non-polar 
groups in the polymeric matrix that tend to repel the water molecules, delaying the 
disintegration time. 
The general appearance of the films do not vary significantly with compounds’ amount, but 
mainly with plasticizer type. High Mw PEGs and the triethyl citrate led to films with an 
acceptable appearance. 
Finally, it is easily verified that the plasticizer type influences greatly the overall system and 
the defined CQAs. However, among the plasticizers tested, TEC showed to be the most 
suitable plasticizer to use considering the general performance of the obtained films, 
especially due to larger operational working ranges (it presents less red areas than the 
others, Figure 39) and the fast disintegration time (<30s). 
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4.2. Optimization complexes to ameliorate the 
organoleptic characteristics 
The plasticizer screening allowed us to verify the different profiles of the system when 
diverse plasticizers were used. It was obvious that the modification of a single component 
may be critical and can change completely the polymeric matrix behaviour. Triethyl citrate 
remains the plasticizer that allowed meeting more efficiently the CQAs defined for the ODF 
developed, especially regarding the fast disintegration time. Therefore the unpleasant 
triethyl citrate aftertaste has to be masked.  
Around sixty formulations were tested and the results are summarized in a profiler graph 
(Figure 40). 
An efficient taste masking complex to improve the organoleptic properties of a formulation 
may be composed by a combination of sweeteners and flavours (Preis et al., 2015). However, 
the choice of flavour should not be random and some criteria must be considered: the target 
population, its application and the unpleasant taste to mask (Marriott, 2010). The bitter 
taste is preferably masked by anise, chocolate, mint, passion fruit and wild berry (Marriott, 
2010). Additionally, the bitter aftertaste may also be reduced by the addition of flavour 
enhancers. Other additives, such as citric acid, may also be used to mitigate some bitter taste 
(Marriott, 2010). The correct combination of flavours and sweeteners may origin interesting 
masking profiles that might function as suitable palatable and pleasant taste. An attempt to 
mask the bitter and unpleasant taste with a masking system was carried out, which was not 
intended only to cover the initial bitter taste but also to be protracted over the tasting 
experience (Roger E. Stier, 2007). A two-fold approach was followed: sweetness profiling 
and flavour creation. The first was achieved using sucralose for initial sweetness burst and 
monoammonium glycyrrhizinate (MAG) as natural sweetener enhancer. A citrus flavour 
combining lemon flavour, citric acid and mannitol was studied. The mannitol was added 
because of the cooling effect that may be used to mitigate the organoleptic effects involving 
a bitter taste (Rowe et al., 2009; Stier, 2007).  
The impact of these flavours on the mechanical properties was not evident for most of the 
molecules tested. The absence of evidences of influence in these parameters might be 
related with the complexity of the system. Such complex formulation may demand the 
preparation of more experiments to obtain more data to be analysed. The components that 
showed more prominent influence on the mechanical characteristics were the plasticizer 
(triethyl citrate) and the disintegrant (NaCMC). Both present antagonistic effects, except for 
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the elongation at break (Figure 40, 1st - 3rd row). Triethyl citrate contributes to a reduce the 
rigidity of the matrix (Et decrease), in a non-linear way (Figure 40, 3rd column, 1st row) 
probably by an increase in the free volume between the polymer chains. However, at the 
same time triethyl citrate seems to increase the film toughness, probably its interposition 
between the polymer chains contributes to the formation of a more organized structure 
(Figure 40, 3rd column, 2nd row). NaCMC contributes to increase the Young’s modulus (Figure 
40, 4th column, 1st row), perhaps due to the augment of charged and long polymer chains. 
On the other hand, the influence on the tensile strength and elongation is very similar to 
that of a plasticizer (Figure 40, 4th column, 2nd and 3rd row). This effect may be due to the 
hygroscopicity of this polymer that promote the absorption of water molecules absorption 
that is then responsible for this plasticizing effect. In this system, it is showed that PVA may 
also contribute to a more deformable matrix, as expected (Clariant, 1999). In turn, the PVAc 
leads to a less resilient structure, probably due to proportional reduction of NaCMC and PVA 
(Figure 40, 1st column, 2nd row).  
Regarding the taste-masking complex, some influences were possible to identify with the 
design performed (Figure 40, 5th  - 9th column, 1st - 3rd row).  
MAG seems to have a slight influence on the mechanical properties of the films, especially 
on their ability to be deformed (Figure 40, 8th  column, 3rd row). The MAG used in this system 
is a MAG-glycerol solution. Previously, it was seen that glycerol contributed to diminish the 
elongation of the matrix, therefore the similar behaviour observed may be due to its effect. 
Mannitol seems to influence the rigidity and the hardness of the structure (Figure 40, 5th 
column, 2nd row). The small molecule of mannitol (Rowe et al., 2009), with several hydroxyl 
groups, might facilitate its interposition between the polymer chains, enhancing the free 
volume that contributes to increase the flexibility of the matrix. However, this interposition 
may occur in a way that, at the same time, a more organized chain orientation and probable 
chemical bounding would also contribute to harder matrices. The increase of sucralose 
content also presents a peculiar pattern (Figure 40, 7th column, 1st and 3rd row) with a slight 
non-linear increase of the matrix rigidity that tends to a plateau for higher sucralose 
concentrations. At the same time, an increase of elongation is observed. This result could be 
related with sucralose complex structure with a closed ring structure and chlorine groups. 
The flavour exerts a non-linear effect on the matrix deformability (Figure 40, 9th column, 3rd 
row). Initially contributes to the elongation increase but, above 3%, it seems to decrease this 
property. Usually, flavours correspond to complex compound mixtures, which may be the 
reason for observed effect. At low concentrations the interposition of some components in 
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the matrix contribute to an increase in the free volume between chains and exert its effect 
as plasticizer, whereas at high concentrations these components begin to have a reverse 
effect turning the matrix more weak and less robust.  
The colourant has a peculiar influence on the polymeric matrix toughness (Figure 40, 10th 
column, 2nd row). At lower concentrations of pigment it is possible to obtain more flexible 
films but with the increase of its concentration, the polymeric matrix starts to become 
harder. This observation is probably related with the insolubility of the colourant used, 
higher concentrations lead to poor dispersions that contribute to its precipitation within the 
matrix. 
The residual water content has a similar pattern to the previous results (Figure 40, 4th row). 
The lipophilicity of some molecules, such as triethyl citrate and PVAc, contribute to diminish 
the residual water content. Their non-polar groups tend to repel the water molecules, 
contributing for less water absorption. Other components (such as NaCMC, Sucralose, PVA 
and MAG) contribute to increase the residual water content probably due to their 
hydrophilic nature. Citric acid does not tend to increase this parameter probably because its 
hydrophilic groups are not available to absorb water molecules. 
Regarding the disintegration time triethyl citrate contributes to fast disintegrating matrices, 
possibly by the reason already pointed. The NaCMC (super disintegrant) also leads to a 
decrease of the disintegration time. Additionally, PVA also have a significant impact on this 
parameter contributing to its decrease. Despite its hydrophilic nature, the observed effect is 
probably related with the lower proportion of PVAc in the matrix with the PVA increase. The 
PVAc increase contributes to higher disintegration time, as expected considering its 
lipophilicity. MAG and citric acid seem to have a strong impact on this property, although 
with opposite effects. The MAG contributes to boost the matrix disintegration, probably 
functioning as a channelling agent on the polymeric structure. On the other hand, citric acid 
exerts a non-linear influence with an increase trend of this parameter. Some authors showed 
that elevated concentrations of citric acid in polymer structures may lead to free citric acid 
molecules (non-linked molecules within the matrix). These free molecules are then able 
interact with other compounds in the formulation even at room temperature. Additionally, 
it was shown that non-bonded citric acid may react with the hydroxyl groups through time, 
leading to the formation of esters bonds. These bonds are susceptible to suffer hydrolysis at 
low pH (Ortega-Toro et al., 2014). Both effects are associated to disintegration time increase 
through the formation of more hydrophobic component or crystalline structures. The PVA 
polymer chains are also known to undergo esterification reactions with citric acid, and may 
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also go through hydrolysis by pH decrease. PVA esterification is commonly used to improve 
films properties and / or to ameliorate polymers compatibility (Park et al., 2005; Wang et al., 
2014). Although, it is not very common at lower temperatures, this type of chemical 
reactions should not be discarded, considering the limited knowledge of the system under 
study, and the observation of this chemical reaction during storage at room temperature 
between HPMC-citric acid (Ortega-Toro et al., 2014). In turn, the higher degree of PVA 
hydrolysis is probably associated with an increase of crystallinity due to a greater extent of 
hydrogen bounding (Chanda and Roy, 2006; Koo et al., 2011). This phenomenon is similar to 
what occurs in the natural unmodified cellulose. The abundant hydrophilic groups, lead to a 
polymer chain conformation that promotes hydrogen bonding systems increasing tendency 
to form crystalline aggregates, which are responsible for its insolubility in water (Wertz et 
al., 2010). Additionally, the pH decrease may also lead to the protonation of the NaCMC, 
decreasing its hydrophilicity, and consequently slowing the disintegration time (Akar et al., 
2012).  
The organoleptic evaluation tends to ameliorate with the addition of sweeteners and 
flavours but becomes worse with increasing amounts of triethyl citrate (Figure 40, 6th row). 
However, it was shown that sucralose may perform a dual effect on this parameter, but 
besides triethyl citrate and sucralose, the other components linearly contributed to improve 
the organoleptic characteristics. The increase of triethyl citrate concentration in the 
polymeric matrix contributes to enhance the unpleasant taste. Interestingly, sucralose has a 
non-linear influence in the system: smaller amounts, up to 3% (%w/w per film), contribute 
to an improvement of the taste, while higher sucralose amounts contribute to unpleasant 
flavour (Figure 40, 7th column, 6th row). Sucralose is widely used as a sweetening agent in the 
pharmaceutical industry. It is strongly sweet, approximately 600 times more than sucrose 
and has no aftertaste (Magnasweet, 2015; Rowe et al., 2009), but it seems to present an 
upper limit to origin pleasant tasteful films. All the other components have a more linear 
and slight influence on this parameter (Figure 40, 6th row). Nevertheless, it is observed that 
mannitol also tend to ameliorate the organoleptic characteristics, which may be associated 
with its negative heat of solution, sweetness, and ‘mouth feel’ (Rowe et al., 2009).  
Regarding films appearance (Figure 40, 7th row), the most evident influence is associated 
with the colourant concentration. Its non-linear and abrupt influence on this property is 
probably related with the usage of an insoluble colourant. At low concentrations it is easy to 
disperse within the liquid mixture, contributing to improve the films appearance, whereas 
higher concentrations may lead to deficient dispersions and poor films appearance.  
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The contact angle presents an interesting pattern varying mainly with the polymers used, 
PVAc, PVA and NaCMC, with the plasticizer, mannitol and citric acid (Figure 40, 8th row). 
Oddly, the NaCMC seems to increase the contact angle in this system despite its known 
hygroscopicity. This result may indicate that the polar groups of NaCMC polymer chains are 
not available at the surface, which could contribute to the lower contact angles. The PVA 
and PVAc present a non-linear influence on this parameter but with a trend to increase it 
with their concentration on the matrix. Up to 50% of PVAc (%w/w per film) it is clear a 
decrease on the contact angle. Probably above this concentration, the polymer chains 
disposition do not allow the prevalence of the non-polar groups of PVAc at the matrix 
surface. Therefore, this polymer matrix rearrangement with more available polar groups on 
the exterior do not favour the water repelling and smaller contact angles are obtained. 
Above 50%, the apolar concentration would be sufficiently high to contribute to the increase 
of the angle between the water drop and the polymeric matrix surface. The PVA and 
mannitol contribute to higher contact angles (Figure 40, 8th column). Both are known as non-
hygroscopic substances, and the influence on this parameter would also be associated with 
the non-disposition of the polar groups at the matrix surface (Rowe et al., 2009). 
The high number of variables tested increased the complexity of the system, which may be 
the reason for the observed differences obtained for each component that fall outside of 
the initial prediction. In order to have more details and robust models, more experiments 
would be required. However, it should be stressed that the formulations tested had 
organoleptic properties good enough to obtain a final ODF with satisfactory properties. 
 
4.3. Incorporation in the ODF of a drug used in the 
treatment of Parkinson’s disease (PD) 
An ODF formulation based on a PVAc-NaCMC-PVA-triethyl citrate with an additional taste 
masking complex was developed with suitable organoleptic characteristics. In addition, it is 
also important to evaluate if this system is suitable to embed a drug substance for the 
treatment of PD and its impact on the properties of the film.   
Several formulations were tested and the results are summarized in a profiler graph (Figure 
41). 
Different amounts of a PD drug were incorporated in the ODF formulation (Table 25, Figure 
41). It is interesting to observe the influence of the PD drug in PVAc polymeric matrix. There 
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is a complex interaction of this between the drug and the polymer matrix (Figure 41). In 
general all the CQAs evaluated are affected significantly by the PD drug (Pramipexole) 
incorporated in the matrix. This substance tends to decrease the rigidity, the deformability 
and the toughness until 20% w/w. However, above this value it starts to have an opposite 
effect that is the rigidity, toughness and the deformity starts to increase (Figure 41, 7th 
column). The residual water content increases sharply with the increase in the % of the drug 
substance, whereas the disintegration time tends to decrease with a particular behaviour. It 
is observed a short and fast increase of the disintegration time up to 2,5% of Pramipexole, 
then a fast decrease up to 12% and a small plateau until de 15%, followed by a slight increase 
up 20% of drug substance. The global appearance of the films had a slightly increase up to 
20% of DS incorporation, but tends to worsen sharply for higher amounts. 
Regarding the other components, the majority have similar profiles to the other systems DS-
free analysed (Figure 41). The higher differences are observed in the PVA, NaCMC and citric 
acid, which may be related to the higher interaction of these components with the drug 
substance. Other important feature concerns the ranges that were narrowed in this system, 
based on the previous screening results. The rigidity and deformability of the film varies in 
completely different way with NaCMC and in an opposite direction of the drug substance 
(Figure 41, 4th column). In PVA there are opposite differences when compared to the 
previous systems regarding lower rigidity and more rigid polymeric matrices (Figure 41, 2nd 
column). The citric acid presents a completely different behaviour than the previous study 
(Figure 41, 6th column). This observation may related with the narrow ranges values selected 
that would influence the pH and the surrounding environment, which may also contribute 
to the other differences verified. 
It is expectable that drug substance incorporated in the film can contribute to the alteration 
of the matrix behaviour, due chemical interactions. As any other used compound, it was 
obvious the effect of the DS in the polymeric system, which in this case may be more evident 
considering the high content used. Additionally, it was already described that Pramipexole 
tend to modify the polymeric systems characteristics, e.g. the decrease of glass transition 
temperature (Tg) with the increase of its concentration (Papadimitriou et al., 2008). 
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5. Conclusions 
The overall analyses emphasized, once more, the complexity of the ODFs’ formulations and 
their impact on the properties of the film. However, it was shown that each film, depending 
on the type and concentration of the excipients, presents unique characteristics. Finally, all 
the techniques and methodologies of analysis used allowed the generation of an extensive 
knowledge of this type of formulation that lack in the available literature. This type of know-
how is essential for ODF matrix research, development and manufacturing, according to the 
Quality by Design principles. 
Three main conclusions were possible to retrieve from these tests:  
 Specific functional excipients have significant effect on the overall polymeric matrix;  
 Binary taste-masking complex (sweetener and flavour) allows to obtain ODFs with 
satisfactory taste; 
 There are Complex interactions of the drug substance with the polymeric matrix that 
may be critical for the ODFs properties.  
It was also verified that the addition of pH modifiers may be critical and influence 
considerably the product characteristics, since parallel reactions may interfere with film 
performance and chemical stability. 
Nonetheless, it is difficult to assume that a single excipient combination can be defined to 
incorporate any different drug substance. Modifications and adjustments to the formulation 
composition must be performed for each different DS to incorporate, due to different 
physic-chemical properties and its specific behaviour in the matrix.  
Although these types of studies are laborious and time consuming, they give a deep 
knowledge of the system and the influence that each component and drug substance may 
have in the polymer matrix and the film properties. This type of information becomes very 
useful to predict and overcome eventual problems in the product production and will 
certainty facilitate the scale-up process. 
Finally, a new, soft and tough oral dispersible film with PD DS was developed. However,  to 
evaluate its suitability as an optional drug delivery system, additional in vitro (e.g. 
dissolution, content uniformity, accelerated stability) and in vivo (e.g. pharmacokinetic tests) 
tests should be performed in future work. 
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Chapter IV 
Product formulation overview and development of an 
Orodispersible Film (ODF) with a Neurodegenerative 
Disorder drug  
 
This chapter is focused in the problems and challenges found during the research and 
development of this new dosage form, in a perspective to discuss and suggest solutions that 
may allow surpassing similar difficulties 
It also reports the development of an oral film for fast oral disintegration, aiming to become 
suitable and feasible alternative for oral Neurodegenerative Disorder therapy. 
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Abstract 
The oral films emerged as an alternative dosage form for old and new prescription drugs in 
the pharmaceutical field. There are relevant advantages of this dosage form, mainly due to 
its portability, handling and administration easiness. Additionally, from the industrial 
standpoint it is also favourable, since diverse formulations may allow different bioavailability 
and pharmacokinetic profiles. Recently, there is a concern to use research and development 
(R&D) equipments that are similar to the industrial production to avoid some main critical 
challenges and to facilitate the scale up. Additionally, the Quality by Design (QbD) arose as 
an assisting approach to facilitate the scale-up process, through the definition of the quality 
product profile. This includes the delineation of the critical quality attributes (CQAs), which 
are influenced by the critical process parameters (CPPs). The CQAs include the main 
characteristics that may interfere with product performance, especially focused on the 
efficiency and safety. The CPPs are defined based on the process unit operations and the 
critical attributes previously outlined. A focused overview about oral films preparation and 
manufacturing challenges is presented and discussed. Furthermore, some suggestions are 
pointed out but, generally, the correct application of QbD concepts and usage of equivalent 
manufacturing processes may lead to an efficient and successful scale-transposition. 
 
Keywords 
Orodispersible films; scale-up; Quality by Design; critical quality attributes; critical process 
parameters; quality target product profile; solvent-casting 
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1. Introduction 
The oral route is the most popular and usually the preferred administration route of the 
patients (Sastry et al., 2000). Recently, orodispersible films (ODF) have gained relevance as 
a patient centric formulation. 
ODF are complex multicomponent matrixes, mainly composed by a plasticized film-forming 
polymer with additional additives to improve the product performance in terms of patient 
acceptance / compliance (Borges et al., 2015). Moreover, ODF may be developed in order to 
obtain different release profiles, to obtain single or multi-layer dosage forms and to achieve 
gastro-intestinal or mucosal drug absorption (Borges et al., 2015).   
Changes in formulation composition including solvents, thickeners, main polymer matrix, pH 
environment and also the DS may have a significant impact in the dosage form 
characteristics and performance. For this reason, the influence and variability of the 
formulation components should be early investigated and understood and a better 
understanding and more knowledge associated with quality issues, scale up hurdles and 
other specificities regarding this particular dosage form are fundamental to advance in the 
development of new products.  
Scale-up is commonly defined as the process to increase the batch-size. The control of this 
process generally demands a deep understanding of the critical quality attributes (CQA) and 
the critical process parameters (CPP). It is crucial the control of these critical variables, as 
well as the definition of in process control tests and final product quality control tests in 
order to obtain a reproducible product with the highest standard of quality (Levin, 2001; 
Swarbrick and Boylan, 2000).  
In this short report, the most critical points to consider during the development of ODF 
manufactured using the solvent-casting method are reviewed, based on practical experience 
and literature revision.  
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2. Formulation variables 
Generally, ODFs may be roughly categorized in different types including (Borges et al., 2015; 
Garg et al., 2010):  
 fast disintegrating films;  
 non-disintegrating mucoadhesive films;  
 slow disintegrating (mucoadhesive) films.  
Normally, ODFs are composed by water-soluble polymers matrices and are usually designed 
to dissolve or disintegrate in the oral cavity. Additionally, the polymeric matrix is also 
composed by other excipients that may also be critical for the oral film performance, such 
as plasticizers, fillers, thickeners, pH modifiers and stabilizers (Dixit and Puthli, 2009; 
Hoffmann et al., 2011).  
All excipients used in the formulation should be Generally Regarded as Safe (GRAS) (i.e. 
GRAS-listed) and should be listed in the FDA Inactive Ingredients list as being used in the 
same pharmaceutical dosage form if the medicine is intended to get a Marketing 
Authorization.  
The main parameters to consider during the excipients selection and product development 
are:  
 Drug delivery profile (fast or controlled release); 
 Drug absorption (local or systemic absorption and mechanism of drug absorption);  
 System design (simple or multi-layer, size, thickness, strength, combination with 
other drug delivery strategies); 
 Local tolerability; 
 Moisture content; 
 Packaging requirements and characteristics; 
 Mechanical properties under demanding climate zones (e.g., tropical climates, WHO 
Zones IVa and IVb).  
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Also, the proportion between the components cannot be neglected in particular the % of 
drug load. The % of drug load is dependent on 3 main factors:  
 minimal amount (%w/w) of polymer required to create a matrix with appropriate 
mechanical strength;  
 % w/v of polymers in the coating suspension, which is limited by the desired viscosity 
range. 
 Drug / excipients interactions. 
 
2.1. Polymers 
The ideal properties of the film forming polymer are: film-forming ability, safe and non-
irritant, without leachable impurities, good wetting and spreadability, acceptable peel / 
shear / mechanical properties and inexpensive to manufacture and package.  
Since the film-forming polymer has a significant impact the product’s performance 
(mechanical strength, disintegration time, stability, compatibility / miscibility with the drug 
substance), all the polymer characteristics must be considered, from its chemical nature to 
single and slight modifications of polymer’s molecular weight, during the selection process.  
 
2.2. Plasticizers 
Many polymers used form rigid and brittle matrix which require the addition of plasticizers. 
These additives are essential to provide flexibility, appropriate tensile properties and also to 
ensure an acceptable texture. Oral films should be tough enough to avoid damages while 
manufacturing, packaging, handling and during transportation. Nevertheless, inappropriate 
use of plasticizers may lead to film cracking, splitting and peeling. Additionally, it is important 
to consider that the plasticizer type may also influence the disintegration time, the drug 
absorption rate, the water absorption capacity and the final product stability. 
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2.3. Additives 
Depending on the Quality Target Product Profile (QTPP) different additives may be necessary 
in order to achieve the desired product performance. For example, disintegrants can be used 
to reduce the disintegration time of the final product(Garg et al., 2010) and cross-linked and 
/ or swellable polymers may be used to delay the drug substance release.  
The pH modifiers may be incorporated for several reasons including stability improvement, 
promotion of specific pH environments related with drug release and / or drug absorption, 
enhancement of organoleptic or to control / fine-tune the extent of the drug substance 
absorption. That is the case in Suboxone® sublingual film and in the fast-onset sublingual 
bilayer film from Cynapsus Therapeutics (Borges et al., 2015; Myers et al., 2011; Silva et al., 
2015). In the first product, a specific buffer system is used to maintain a local pH 
environment that ensures appropriate buprenorphine absorption while reducing for the 
mucosal absorption of naloxone. In the case of the Cynapsus technology, the pH modifier is 
used to deionize the Apomorphine and, in this way, promote its mucosal absorption (Myers 
et al., 2011; Silva et al., 2015). Moreover, pH modifier substances may be used to mask 
unpleasant tastes or promote fast disintegration profiles through saliva stimulation (Dixit 
and Puthli, 2009). Acidic substances, such as citric acid, may be used as saliva stimulant 
agents and to mask  bitter tastes (Marriott, 2010). 
Taste masking complexes, based on sweeteners, flavours and coating or competitors taste 
receptors substances (Stier, 2007) should be used. Although it may increase the formulation 
complexity, the product’s residence time in the oral cavity demands ODF with pleasant taste 
and good mouthfeel. This aspect becomes critical considering that a high number of DS have 
bitter taste. For ODF, liquid flavours should be preferentially used rather than powder 
flavours to avoid its sedimentation that may originate poor film appearance and texture and 
may induce disruption of particles during drying.  
Some drug substances, depending on their chemical characteristics, may need stabilizers 
such as surfactants or pH modifier agents, to achieve an appropriate shelf-life. 
It should also be considered that not all drugs can be incorporated into this dosage form, 
smaller and potent drugs are preferred, since the loading capacity and cross-sectional area 
available are limited. Additionally, physicochemical properties of the DS should be critically 
evaluated, including: heat and shear sensitivity (but may not be a critical factor) (Garg et al., 
2010), polymorphic form, stability at the local pH, compatibility with solvent and other 
excipients and non-irritant to the mucosa.   
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2.4. Manufacturing process 
The additives added to the formulation may not only be critical to the product performance, 
but also to the processing method. There are two main manufacturing processes used to 
prepare oral films, solvent casting and hot-melt extrusion (HME), but valuing the 
experimental practice only the first method will be addressed (Borges et al., 2015).  
Solvent-casting involves the preparation of liquid mixtures in which some thickeners, gelling 
agents, fillers and / or thixotropic agents may be added, to stabilize and or to give enough 
consistency / density to the liquid mixture. Viscosity must be high enough to avoid the 
precipitation of suspended solids during liquid preparation and coating operation, essential 
to achieve uniformity of drug content. On the other hand, the viscosity should not be too 
high to avoid mixing problems and film defects due to poor spreadability.  
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3. Process variables 
Oral films preparation involves several unit operations (see table 29) and vary depending on 
the manufacturing process used. Nevertheless, the DS and excipients are usually dissolved 
or dispersed in a liquid and the final liquid mixture is then coated on a platform substrate 
(commonly designed by release liner) to be dried. Normally, in oral films this release liner is 
removed before packaging and is not used as backing layer like in the case of transdermal 
drug delivery systems. However, the development of multilayer ODFs is common, and in this 
case the one-layer coated release liner can be used again as raw material for another casting 
before punching and pouching. 
In each unit operation some key variables must be controlled and specific parameters 
determined (quantification / measure to access control). Some are summarized in table 29. 
Considering the industrial process perspective the unique manufacturing method of the oral 
films may be advantageous, but from the development perspective the singular 
manufacturing process may become challenging (Garg et al., 2010).  
In sum, the oral films manufacturing process might include the following steps:  
 Preparation of the liquid mixture,  
 Coating or casting process,  
 Drying,  
 Cutting,  
 Packaging. 
 
3.1. Liquid mixture 
The preparation of the liquid mixture is more complex and challenging than it could seem at 
a first glance. Firstly, the components of the mixture, including the solvents, need to be well 
characterized to predict and easily understand the impact that each may have on the system 
performance. In the same way, their interaction (e.g. compatibility, solubility) should also be 
considered since it is likely the possible occurrence of chemical interaction. Therefore, the 
individual components may start to behave as mixture with singular properties and 
characteristics (e.g. eutectic mixtures, crystallization, gel structures) due to specific 
modifications (e.g. plasticization, cross-linking, hydration, (de)protonation, gelification) that 
could have significant impact on product performance (e.g. drug release, swelling, adhesion, 
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tensile strength). On the other hand, the preparation method parameters may also influence 
greatly the mixture characteristics which are summarized in table 29. 
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Table 29 - Oral films manufacturing process summary by unit operation. The critical process 
parameters (CPPs) are identified.  
Unit 
operation
CQAs of output 
materials
Challenges
· mechanical · drug content · shear stress
· magnetic stirring · homogeneity
· correct formulation 
ratio
· temperature · viscosity
· excipients 
incompatibil ity
· time · solids content
· air bubbles inside the 
mixture
· speed · flowability · agglomerates
mixing device · mixer or homogenizer · homogeneity
mixture accessory
head and blade 
· shape, design, size (e.g.
propeller, U-paddle)
· shape
· size
· occupancy
· polymer hydration 
· order of addition
· proportion
· inherent characteristics
· compatibil ity
· appearance · drug loss
· coat weight per unit 
area
· excipient loss
· coat uniformity · air entrapment
feeding
· speed, nozzle
characteristics
· control of fi lm 
thickness
micrometer accuracy · gap height precision
release liner
· coating mass and dried
film adherence,
interaction, compatibil ity
air temperature · residual solvents · moisture control
air circulation · impurities profile · water activity
line speed · fi lm thickness
time
type gradual or continuous
· dimensional 
accuracy
· yield
· appearance · roll  tension
·  unit weight 
variation
· storage time effect
die shape, size · defects detection
pressure · pouch integrity
· stability
· shelf l ife
· target market
· moisture control
material
composition, number of
layers 
· selection of the 
appropriate container
Critical Process Parameters (CPPs)
Mixture
mixing type 
mixing conditions
mixture vessel
components 
Package
type single- or multi-unit
· external conditions 
tolerability 
Casting
speed
Drying
Cut
degree of precision 
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The liquid mixture parameters are very important and should be tightly controlled. 
Depending on the conditions (e.g. pH, order and velocity of addition) there are some 
chemical and/or physical interactions that may be favoured as well as molecular 
modifications. It is also important to have a tight control of room’s temperature and 
moisture in the manufacturing area to prevent their incorporation into the product and 
avoid possible interferences that might impact on the final product quality attributes.  
 
3.2. Casting and drying 
The casting process is a critical step in ODF manufacturing process, since the initial coating 
mass feeding (e.g. speed, nozzle characteristics) to the selection of the film substrate 
(release liner). The release liner should allow the formation of an optimal web in order to 
avoid delamination during handling and, at the same time, allow its easy separation prior to 
packaging. The micrometer precision, which promotes the coating mass spreadability, has a 
direct impact in the DS dose accuracy since the oral films weight and strength are generally 
low. The speed of casting should be optimal to assure appropriate levels for commercial-
scale throughput and obtain thickness uniformity. In addition, the thickness of the coated 
mass and the physicochemical properties of the liquid mixture affect the scale-up by limiting 
the drying speed of product and final thickness of the dried film. These properties should be 
carefully adjusted to enable efficient commercial scale production.  
The type of drying process also affects the final product performance. The dryness could be 
performed from the bottom, from the top or both, depending on the machine used. 
Therefore, the parameters adjustment should be performed according to type of 
equipment, the minimum-film-forming-temperature of the liquid mixture developed and 
thermal stability of its components. If necessary, the drying time can be shorten by 
incorporating extra dryers into the line and by temperature gradients along the process.  
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3.3. Cutting and Package 
The oral films should be cut and packed immediately, ideally right after its preparation. If 
this is not possible, the casted and dried film should be properly conditioned in specific 
rooms with controlled and monitored conditions. The packaging of the oral films may be 
done in single-unit or multiple-unit dosage packaging. The majority of the Rx products are in 
single unit packaging, usually in individual pouches, to ensure higher product stability, being 
more suitable for severe climate zones. Curiously, the multiple dose packaging tends to be 
more expensive to develop but it is less expensive to manufacture in large quantities (Garg 
et al., 2010). Nevertheless, it demands the use of a more robust secondary package to 
provide larger shelf life stability, until the first-opening. Still, the product stability during 
usage becomes more critical with the multi dosage packaging. (Garg et al., 2010). The 
packaging container should have suitable mechanical strength to protect the film during 
shipping and it has to provide protection from external factors such as temperature and 
moisture. Therefore, the selection of the type of packaging material and their specific 
characteristics should not be neglected. The packaging could be critical for product stability 
and should be treated as part of the formulation.  
Although there is no specific guidance for the parameters discussed above, their control is 
important, since the working components are usually hygroscopic. Therefore, companies are 
increasingly adopting continuous-coating equipment and dryers in their research and 
development (R&D) laboratories that are similar to the commercial scale production 
technology. This strategy allows the proper simulation of the process and turns easier the 
later scale-up. Moreover, it allows the initial interplay with machine controllers that give the 
necessary information for high-capacity production. In fact, the major challenges of 
switching from R&D to commercial-scale production generally results from coating speeds 
and drying operations (Greb, 2009). 
In resume, the manufacturing techniques must be deeply understood and exceptionally tight 
tolerances through the process should be established, in such way that the scale-up would 
not be more challenging compared to other conventional dosage forms.  
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4. In vitro tests for Oral films 
In vitro tests are important tools to guide the product development, for quality control of 
the final product and to study the product stability. These tests may also be used as in 
process control (IPC) for process monitoring and control and / or alternatively as integrant 
part of the Process Analytical Technology (PAT) (De Beer et al., 2011). These tests may be 
differentiated in physical, mechanical, and chemical characterization and the number os 
tests used depend on the product’s development stage, formulation type (e.g. 
orodispersible, mucoadhesive, single- or multilayer) and the characterization purpose. The 
physical tests usually include size, shape, appearance, weight and thickness. The mechanical 
characterization usually includes tensile strength, % of elongation, Young’s modulus (Preis 
et al., 2014) and might be completed with additional determinations of tear resistance, fold 
endurance and peel strength (Dixit and Puthli, 2009; Garg et al., 2010). The chemical 
evaluation could include swelling index, bioadhesion, drug release / permeation, dissolution 
profile, drug content uniformity, impurities content, residual water content, disintegration 
time, thermal stability and components compatibility (Garg et al., 2010).  
It is important to consider that good experimental data require a proper number of 
replicates. Additionally, the delineation of algorithms to confirm properties determinations 
and predict toxicity, bioactivity, safety and efficacy assessments could be developed and 
used (Garg et al., 2010). The in vitro release and / or in vitro absorption (when applicable) 
should be used to evaluate probable correlations with in vivo bioavailability. 
Finally, the success of the products development may be related with detailed 
characterization. On this matter, in early stages, a careful characterization should be 
performed to gain a broad knowledge of the system, but in a later stage only the most critical 
and representative are possible to carry out as routine procedure (Garg et al., 2010). 
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5. Summary 
Due to the complexity of ODF drug delivery systems several points must be considered 
during product development. During the scale-up, adjustments in the percentage of the 
different compounds may be made in order to maintain the products stability and 
performance. During the development, it should be clearly distinguished and identified the 
excipients that have minor impact and those that are critical for the product quality and 
performance. The operational ranges should be defined for all the components of the 
formulation. The operational ranges must be outlined by experimental data showing the 
impact and effects of any change and its effecton the CQA or CPP (e.g. mechanical 
properties, disintegration time, residual water content, crystallinity, solubility, adhesion, 
dissolution profile, stability). In this line, the Quality by Design (QbD) emerged as an optimal 
approach to predict the product’s quality, performance and stability.  
The most common tool used in the QbD is the description of a quality target product profile 
(QTPP) that includes all the dosage form characteristics (e.g. route of administration, 
strength, therapeutic application, drug release profile, pharmacokinetics), the 
characterization of the CQAs and the CPPs (Rathore and Winkle, 2009; Visser et al., 2015). 
The CQAs may be resumed as the characteristics that define the product quality, whereas 
the CPPs are the process variables that could influence these characteristics (Rathore and 
Winkle, 2009). In table 30 a generic resume of a possible QTPP for an oral film is presented 
and possible CQAs are listed and explained by critical level in table 31. In turn, the CPPs are 
discriminated in table 29. 
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Table 30 - Quality Target product profile (QTPP) for an oral film. OTR, oxygen transmission rate. WTR, 
water transmission rate. 
Features Target Observations
Dosage form Oral Film
Fast or slow disintegration 
Single- or multi-layer
Sublingual / Mucoadhesive
Route of administration
Oral – systemic, local or
through GI
Drug release profile:
Immediate
Controlled / delayed
25-40 mm in length and 20-
30 mm in width (stamp
size)
Rectangular /square /
round fi lm
Dry thickness 50 – 200 µm
Unit weight ≤ 150 mg
It should have the same
strength as the reference (if
applicable)
New manufacturing
technologies or
formulations may allow
higher % per fi lm
Upper limit for drug loading
Usually 60-80 mg (max.
120 mg)
< 30 s for orodispersible
films
> 30-60 s for others
Stability / shelf life in
package 
At least 24-month shelf-l ife
at room temperature
Ideally equivalent to or
better than the reference
Needed to achieve the
target shelf-l ife
Preferentially with Low OTR
and WTR
Therapeutically target
Indications to correct use
Meet the reference
characteristics (if
applicable)
Dosage form design
Pharmacokinetics
Dimensions / shape
Dosage strength
0.01 up to 60%, %w/w per
film
Oral 
disintegration/dissolution
Container closure system
Triple laminated aluminum
child resistant pouch
Administration /
Accordance with labeling
Pharmaceutical 
equivalence requirement
 
 
In-process and / or in-real-time control may be used during the manufacturing as an 
assurance mechanism of finish product consistency and reproducibility. The use of PAT tools 
allows the manufacturing control in real-time on the identified CPPs during a specific or 
across the span of unit-operations of the process. Therefore, the PAT tools can be used as 
part of the quality control strategy for the manufacturing process if the impact of the CPPs 
on the CQAs is already understood (Çelik, 2011). 
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Table 31 - Critical quality attributes for an oral film. 
CQA Target Critical level Rationale
Suitable color and 
shape 
No visual fi lm defects
Ensure patient
acceptability
Odor No unpleasant odor Medium
Size
Suitable for the site
application and target
population
Low
For ease of
administration to oral
cavity
No unpleasant taste
Suitable for the target
population
Suitable for the
therapeutically target
Appropriate to the
application site
Must comply with 
pharmacopoeia
specification 
100 % (95-105%)
%w/w per fi lm 
Uniformity of
Must comply with 
pharmacopoeia
weight and content specification
Dissolution profile
Should be
characterized and
defined according to
the therapeutically
target and application
site
High
May have direct 
impact in the safety 
and efficacy due to 
influences in the 
products’ 
bioavailability
Must comply with 
pharmacopoeia
specification or ICH
requirements
The water content may 
interfere with the 
product performance
May alter the stability 
and the physical 
characteristics of the 
fi lm
Suitable properties to 
handle and process
Should be defined 
according to the 
system characteristics
Appearance Low Not directly l inked to 
safety and efficacy
Flavor and taste Medium
May influence patient
compliance
Disintegration time High
May have direct
impact in the safety
and efficacy due to the
onset action
Assay High May have direct 
impact in the safety 
and efficacy due to the 
inaccuracy of dosage
High
Mechanical Properties High
Unappropriated 
mechanical properties 
may lead to fi lms that 
may easily break or 
may difficult the cut 
and packaging
Degradation products High
May have direct 
impact in the safety 
and efficacy due to the 
presence of 
Residual water
content
Should be defined 
according to the 
system characteristics
High
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This chapter is presented separately for confidentiality 
reasons. 
 
 
 
 
 
Figure 42 - Scheme of ND drug ODF preparation. 
Table 32 - Pre-stability design of the pre-pilot batch prepared. * Limited number of films just to verify 
the dissolution profile of these batches after submitted to these extreme conditions. 
Table 33 - Experimental runs performed to test the stability of the ND drug HCl when incorporated in 
the ODF base formulation using different manufacturing processes and composition. NR - Not 
recorded. NA - Not applicable. N - Absence. Y - Presence. * - additives include sweetener, sucralose, 
and lemon flavour. 
Table 34 - Component and percentages to prepare a suitable ND drug ODF. 
Table 35 - Liquid mixture characterization: content uniformity of 3 distinct points with and without 
agitation and liquid mixture density. (mean ± standard deviation). RSD, relative standard deviation. 
Table 36 - Summary results of the stability tests of ND drug ODFs individually packaged in OPA 
pouches. Each point represents the average point of two test solutions. 
Figure 43 - Stability of the ND drug ODF after storage under long term conditions (25⁰C / 60% HR and 
30⁰C / 75 % HR) or accelerated condition (40⁰C / 75 % HR) up to 12 weeks. Each point represents the 
average point of two test solutions. 
Figure 44 - Dissolution profile of ND drug ODFs during the stability assay up to 12 weeks. (A) and 
(B)Long term conditions. (C) Accelerated conditions. Each point represents the mean ± SD of 3 
experiments.  
Figure 45 - Disintegration time (blue line), Surface pH (green line) and residual water content (%H2O, 
orange line) determined for each stability point studies. The solid line corresponds to the long term 
condition 25°C / 60%, the dashed line is the long term condition 30°C / 75% and the stippling 
represents the accelerated conditions 40°C / 75%.  
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Main conclusions and Future 
perspectives 
Chapter I: Introduction to the Oral Films concept 
Oral films are a relatively new and very promising drug delivery system. Their versatility offer 
future potential for expanded applications across different delivery routes in multiple 
pharmaceutical, biopharmaceutical, and medical markets. Although, it is already included in 
the Pharmacopeias, there is still a lack of information regarding their development, 
characterization and quality features.  
 
Chapter II: Oral Films Characterization and Critical Quality 
attributes outline 
The results showed that the multivariate analysis may be very useful to generate wide 
formulation knowledge essential for ODF matrix development. It was also clear that the 
complex composition of the ODFs makes their characterization and standardization very 
challenging. In this thesis, it is demonstrated the high importance of each excipient in the 
ODF matrix and also highlighted their inter-dependence and interaction. Moreover, it was 
seen that the manufacturing process should be deeply known and carefully controlled, since 
slight variation in the process parameters may also influence the polymeric matrix 
rearrangement and product properties.  
Thermo-mechanical analysis was also found very useful to generate relevant data to the 
development of new oral films platforms. The TGA may be very useful to predict the 
formulations stability, whereas the DSC analyses allow retrieving relevant information about 
some components interactions and behavior in the polymeric matrix. In turn, DMTA 
evaluation was very helpful to obtain additional information about matrix-composition and 
product properties, especially to understand the performance, stability behavior and some 
quality attributes of the product.  
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The second approach of this chapter allowed defining a range of acceptable values for the 
CQAs that could be used as acceptance criteria for the development of new oral film 
formulations.  
In sum, during the development of oral film systems each excipient property should not be 
considered individually, since complex interactions may occur and each component may 
function as a fingerprint in the polymeric matrix. The characterization and analysis 
techniques appeared as a suitable approach to provide a mechanistic understanding of the 
relationship between raw material attributes and critical quality attributes of the 
pharmaceutical product. Nevertheless, based on a pre-defined polymeric matrix 
composition, optimization tests should be performed in order to define less broad 
acceptance criteria for each formulation aiming obtain a desirable and robust oral film. 
 
Chapter III: Hydrophobic polymers for oral films: 
Development and Optimization of novel formulations 
The results of the present thesis revealed the successful design of ODFs based on 
hydrophobic polymers with fast disintegration. Three different formulations with a similar 
pattern (a hydrophobic polymer, a stabilizer, a disintegrant and a plasticizer) were 
developed. These could be posteriorly optimized and used to embed drug substances for 
oral delivery.  
It was also demonstrated, once more, that each film depending on the type and 
concentration of the excipients, presents unique characteristics. In fact, specific functional 
excipients and complex interactions of the drug substance could have significant effect on 
the overall product’s performance. Therefore, it may be presumed that each film may be 
designed with singular and focused specific desirable target (e.g fast / slow disintegration, 
mucoadhesive) depending mainly on the excipients, proportions and possibly processing 
parameters.  
Nonetheless, it is difficult to assume that a single excipient combination can be defined to 
incorporate any different drug substance, some adjustments would be necessary due to 
different physico-chemical properties and peculiar behavior within the matrix.  
This work also revealed that the initial usage of QbD principles and tools may be laborious 
but rewarding. The use of specific statistical platforms such as the Design of Experiments 
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was very useful for initial screening and optimization. This methodology of analysis allowed 
the generation of an extensive know-how essential for ODF matrix research, development 
and manufacturing. Moreover, this type of information is very scarce in the literature.  
Finally, this data becomes very useful to predict and overcome eventual problems in the 
product production and will certainty facilitate the scale-up process. 
 
Chapter IV: Product formulation overview and development 
of an Orodispersible Film (ODF) with a Neurodegenerative 
Disorder drug  
Finally, the work of the present thesis allowed obtaining a stable ND drug ODF, apparently 
with good uniformity and fast oral disintegration. This constitutes an alternative for MS 
patients with swallowing issues, being helpful to ameliorate patients’ compliance and life’s 
quality. 
This thesis work also endorses the major challenges of the solvent casting, mainly focused 
in the liquid mixture preparation and process parameters. The main issues are pointed, 
critically discussed and circumvent alternatives or solutions were suggested.  
 
Future perspectives 
Numerous features regarding characterization (by several methods and distinct analysis), 
formulation development (based on QbD tools) and final product production (including 
stability and a small scale-up tests) were discriminated in this thesis.  
The oral films market is an emergent area, a newborn field that still needs to be spread and 
be more explored. Additionally, it is notorious some unawareness or probably some 
reluctance of European consumers regarding the usage of this dosage form. Therefore, it is 
important that the oral films technology breakthrough the health market, probably through 
a properly caregivers’ approach, which may incite and easily gain consumers acceptance. 
Eventually, it would only be necessary to evidence properly their peculiar valuable 
advantages as portable and exceptionally convenient pharmaceutical form.  
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There is a need to surpass some technical, manufacturing and regulatory barriers to avoid 
the downturn growth of the oral film’s market. The correct application of the QbD approach, 
as well as, the specific characterization and analysis techniques may be helpful for this goal. 
This thesis aimed to propose the application of potential characterization tests and statistical 
tools that may be used to evaluate available products and support the development of new 
oral films. Thus, it is highlighted the crucial need of standardized procedures and reliable 
guidelines to promote a more efficient and feasible development, processing and quality 
evaluation. 
Considering formulation development it is expected that some common guidance may be 
outlined to facilitate the technical hurdles. Regarding product performance, hopefully, in a 
near future, it is expected to have defined and standardized solutions for the mechanical 
strength evaluation, suitable and consistent methods / equipment for disintegration and 
dissolution evaluation. In time, it would also be needed the development of reliable and 
standard adhesive testing techniques (e.g novel synthetic material, new equipment 
accessories – Texture analyzer) and organoleptic assessment test (e.g. electronic tongues). 
The demand side for pharmaceutical treatments has been changing and nowadays the 
approach is more patient-centered and quality- based. One of the main goals of this thesis 
was to develop successfully an ODF that could meet and fulfil specific patients’ needs. This 
objective was materialized by the conception of one ODF product that answers an unmet 
therapeutic need, which expectably could be soon on the market; and hopefully would be 
the first of many.  
 
 
